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Cardiovascular disease (CVD) is an important cause of morbidity and mortality world-
wide. Due to factors such as the aging population and an increased number of people 
with overweight, the incidence and prevalence of CVD are increasing. This constitutes 
a considerable disease burden and major health challenge for prevention and treat-
ment.1,2 CVD frequently co-exists with other diseases such as type 2 mellitus (T2DM) 
and non-alcoholic fatty liver disease (NAFLD). These diseases are strongly related to the 
metabolic syndrome, a disease entity which consists of the components dyslipidemia, 
insulin resistance, hypertension, and abdominal obesity.3-5 The metabolic syndrome is a 
strong risk factor for the occurrence of CVD, and CVD is an important cause of death in 
NAFLD and T2DM patients.3,6
A broad spectrum of cardiovascular drugs is available for the prevention and treat-
ment of CVD, and often, a patient receives a combination of drugs. The intention for 
using these drugs is to treat risk factors for CVD, such as hypertension and hypercholes-
terolemia, or the symptoms of CVD, such as heart failure and rhythm disorders. At the 
beginning of this thesis, we wrote an inventory on the current state of knowledge on the 
pharmacogenetics of response to cardiovascular drug therapy.7 Thereafter, we decided 
to focus this thesis on one particular drug group: the frequently prescribed cholesterol 
lowering statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in-
hibitors. Statins have proven to be beneficial in the primary and secondary prevention 
of CVD, and act primarily by lowering serum low-density lipoprotein (LDL)-cholesterol 
levels through inhibition of HMG-CoA reductase, the rate-limiting step in the cholesterol 
biosynthesis pathway.8-13 Independent of this cholesterol lowering effect, statins have 
pleiotropic effects, including anti-inflammatory, immunomodulatory, and anti-oxidants 
effects, and improvement of endothelium viability.14
With the pharmaco-epidemiological studies described in this thesis, we aimed to 
gain more insight into the use of statins in an ageing population. We focused on statins 
because several topics with regard to these drugs are important and interesting to 
consider, and there were many more interesting research hypotheses than we could 
investigate during this PhD research period. Therefore, we had to restrict our choices to 
the following ones. First, current statin therapy is not optimal for all patients, and some 
individuals do not respond adequately to statins. This ranges from lack of therapeutic ef-
fect to the occurrence of adverse drugs reactions (ADRs).15,16 This difference in response 
between individuals can partly be explained by genetic variation, and insight into 
underlying genetic variation that predicts drug response could be useful in tailoring 
treatment for individual subjects or certain patient subgroups, so-called ‘personalized 
medicine’.14 Second, in 2013, the American guidelines on primary prevention of CVD 
lowered the threshold for the indication for statin treatment, and thereby widened the 
target population for these already frequently prescribed drugs.17 This might have impli-
cations for current clinical practice, certainly since one may not ignore the potential risk 
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of overtreatment or unintended effects that may go with this increased use. Moreover, 
in observational studies it is a challenge to investigate the association between statin 
exposure and outcome measures, since these studies are often subject to bias and 
confounding.
The first part of this introduction is the inventory on the current state of knowledge on 
the pharmacogenetics of response to cardiovascular drug therapy, which was published 
in 2012.7 The second part describes the aim and outline of this thesis.
1.1 PhArmACoGEnEtiCS of rESPonSE to CArdiovASCUlAr drUG 
thErAPy: whAt iS thE CUrrEnt StAtE of KnowlEdGE?
Catherine E de Keyser, Mark Eijgelsheim, André G Uitterlinden, Bruno H Stricker. Dia-
logues in Cardiovascular Medicine 2012; 17(4): 281-292
CVD is a major cause of morbidity and mortality in developed countries. Besides well-
known environmental factors such as smoking and overconsumption of saturated fat, 
genetic factors contribute to the risk of developing CVD. In addition, genetic factors 
may modify both the pharmacokinetics and pharmacodynamics of cardiovascular 
drugs (pharmacogenetics). The most important genetic polymorphisms that influence 
response to cardiovascular treatment are highlighted, with regard to effectiveness and 
risk of adverse reactions. Insight into individual genetic risk factors for disease and treat-
ment response could lead to ‘personalized medicine’ in the future.
CVD is an important cause of morbidity and mortality in developed countries, and insight 
into the underlying risk factors for the occurrence of CVD and response to treatment 
are major topics for the understanding and improvement of current clinical practice. 
CVD consists of a range of predominantly cardiac syndromes that are often caused by 
atherosclerosis of the vascular system, but may also be of other origin (e.g., idiopathic 
cardiomyopathy, congenital long QT syndrome).
A broad spectrum of cardiovascular drugs are available for the treatment of CVD. They 
are all intended to treat risk factors for CVD, such as hypertension and hypercholester-
olemia, or the symptoms of CVD, such as heart failure and rhythm disorders. Often, a 
patient receives a combination of drugs, acting on different pathways or transporters, 
or acting synergistically on one pathway. According to the World Health Organization 
(WHO)18, in the Anatomical Therapeutical Chemical (ATC) classification system, cardio-
vascular drugs are divided into 9 different subclasses of drugs, namely, cardiac therapy, 
antihypertensives, diuretics, peripheral vasodilators, vasoprotectors, β-blocking agents, 
calcium channel blockers, agents acting on the renin-angiotensin system, and lipid-
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modifying agents. Every drug subclass contains several different chemical groups, each 
of which in turn contains a large number of different drugs, each with its own ATC 
code. Although this underscores the large number of different cardiovascular drugs, 
it should be emphasized that the number of unique pharmacological entities is rather 
limited and that many drugs on the market are merely slightly changed copies of each 
other. Fortunately, research is going on to develop new drugs, acting on other targets/
biological systems. Here, pharmacogenomics (i.e., the whole-genome application of 
pharmacogenetics) plays a pivotal role in the discovery of new drug targets.
There is a large interindividual variability in response to cardiovascular drugs, which is 
not simply explained by differences in daily doses. Variability in response despite similar 
dosage can be explained by individual differences in pharmacokinetics, for instance, 
by comorbidities such as a decrease in hepatic or renal function. However, it may also 
result from concomitant medication interacting with the cardiovascular drug, e.g., if two 
drugs are both metabolized by the same cytochrome P450 (CYP450) isoenzyme or if 
another drug is an inducer or inhibitor of the enzyme by which the cardiovascular drug 
is metabolized. Interindividual differences in pharmacodynamics response may occur 
via a difference in the molecular structure of a drug receptor or a smaller number of 
receptors. Although it is assumed that aging is associated with a decrease in numbers of 
receptors, determinants for differences in pharmacodynamics are less well documented.
Probably the most important factor that can explain interindividual variability in phar-
macokinetics and pharmacodynamic response to drug therapy is genetic variation.19,20 
Pharmacogenetics focuses on genetic variants and polymorphisms that influence 
response to drug therapy. A single nucleotide polymorphism (SNP) is a DNA sequence 
variation, in which one single nucleotide differs between individuals. If this variation 
occurs in 1% or greater of the population, it is called a genetic polymorphism or vari-
ant.21 A SNP or a combination of SNPs (haplotype) can help predict susceptibility to 
environmental factors and the risk of developing a particular disease, but also the phar-
macokinetic and pharmacodynamics response of individuals to certain drugs. Other 
reasons for genetic variation may be the presence (“insertion”) or absence (“deletion”) 
of a series of DNA bases or the presence of “copy number variations” (CNV). In case of 
genetic variation that modifies pharmacokinetics, the SNP is located in a gene involved 
in the absorption, distribution, metabolism, or excretion of a drug. For example, genetic 
variation in one of the important CYP450 isoenzymes, such as CYP2C9 or CYP2D6, or 
genetic variation in a liver transporter that is involved in the active uptake or excretion 
of a particular drug, modifies the pharmacokinetics of a drug. As a consequence of this 
variation, the plasma concentration of the drug changes, which alters efficacy or toxicity 
risk, because less or more drug, respectively, is available at the receptor site. Regulatory 
variation in the gene encoding the drug uptake receptor at its target organ can influ-
ence the active uptake of the drug to its main organ where it is acting. In this case, the 
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plasma concentration of the drug has not changed, but the concentration in the primary 
organ of acting  is diminished or increased, depending on whether the SNP increases or 
decreases the number of uptake transporters, respectively.22-24 A pharmacodynamic ex-
ample of a potential genetic variation is the encoding for the structure of cardiovascular 
and respiratory β-adrenoceptors, which is supposed to lead to differences in response 
to drugs.
Over the past decades, many studies have focused on identifying genetic determi-
nants that influence response to therapy, using different techniques for analysis. Candi-
date gene studies investigating SNPs in “biologically plausible” genes, e.g., SNPs in genes 
involved in the biological pathway of a disease, and genome-wide association studies 
(GWAS) without an a priori hypothesis of the underlying genetic variation involved 
in treatment response, are two often used methods.25 Furthermore, new analyzing 
techniques, “next-generation sequencing” like exome sequencing and whole-genome 
sequencing, are currently upcoming and promising techniques to unravel rare coding 
variants involved in the genetics of complex traits.26 In future perspective, markers that 
are predictive of drug efficacy or the occurrence of adverse drug reactions could be use-
ful in tailoring treatment for individual subjects or certain patient subgroups, so-called 
‘personalized medicine’.
In the following paragraphs, we discuss the most important pharmacogenetic as-
sociations that were discovered in the past years for the different cardiovascular drugs, 
regarding treatment response. This includes both the efficacy of drugs, and the risk of 
developing adverse reactions. Although there are many drugs with cardiovascular ad-
verse effects, the discussion will be restricted to drugs with a cardiovascular indication, 
notably antiarrhythmics, diuretics, angiotensin-converting enzyme (ACE) inhibitors, 
and angiotensin blockers, β-blockers, lipid-lowering drugs, and anticoagulants. Im-
portantly, we restricted ourselves to those associations that were confirmed in other 
studies because many incidental findings in the pharmacogenetic literature have not 
been confirmed by others.
Antiarrhytmics: prolonged Qt interval duration, calcium antagonists, and digoxin
Several drugs are associated with prolongation of the electrocardiographic QT interval 
duration, but only some of them have cardiovascular indications. The QT interval is a 
measure of myocardial repolarization time, and prolongation of the QT interval dura-
tion is associated with a higher risk of drug-induced arrhythmias and sudden cardiac 
death (SCD). In particular, in individuals with the congenital long QT syndrome (a term 
encompassing more than 10 different mutations, for instance, in the genes KCNQ1, 
KCNH2, and SCN5A), it is associated with an increased risk of torsades de pointes (TdP), a 
specific type of ventricular arrhythmia. Although the risk of TdP might also be increased 
in cases of drug-induced QT prolongation, this seems to be less well documented. 
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Moreover, there are rare and more common genetic loci for QT prolongation. In 2009, a 
meta-analysis of three GWAS in 13 685 individuals of European ancestry discovered 14 
independent variants at 10 loci, together explaining 5.4% to 6.5% of the variation in QT 
interval.27 The results of this meta-analysis are represented in Figure 127, the Manhattan 
plot for the QT interval association results for the three cohorts combined. Other studies 
also detected several genetic variants in multiple genes associated with prolongation 
of the normal QT interval duration, and with that provide candidate genes that might 
predispose to modifying the QT-prolonging effect of drugs.28,29 A study showed that the 
minor alleles of two genetic variants (rs10494366 T>G and rs10918594 C>G) in the nitric 
oxide synthase 1 activating protein (NOS1AP) gene potentiate the QTc prolonging effect 
of the calcium antagonist verapamil.30 Another study showed that the minor allele of 
the NOS1AP rs10494366 polymorphism was associated with increased all-cause and 
cardiovascular mortality in users of dihydropyridine calcium channel blockers.31 Pos-
sibly, genetic variation modifies cardiac contractility and repolarization, by influencing 
calcium and potassium ionic transport in the cardiomyocyte. Although these findings 
are interesting, studies revealing the underlying biological mechanism are needed.
Not only studies on QT interval duration, but also GWAS in different opulations 
showed genetic variation that was associated with other electrocardiographic measures 
such as PR-interval and QRS interval.32-34 Also, genetic variants associated with the risk of 
atrial fibrillation were discovered in GWAS.34,35 Testing these polymorphisms on interac-
figure 1 Manhattan plot for the QT interval association analysis, a meta-analysis of three GWAS in 13,685 
individuals from three independent cohorts
QT interval association results for 2,543,686 imputed SNPs in 13,685 individuals from 3 cohorts. Results are 
shown on the −log10(P) scale and are truncated at −log10(P) = 18 for display purposes. The solid bar corre-
sponds to the genome-wide significance threshold of 5 × 10−8.
Abbreviations: CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; GWAS, genome-wide as-
sociation study; RS, Rotterdam Study; SNP, single nucleotide polymorphism.
After reference 27: Newton-Cheh et al. Nat Genet. 2009; 41(4): 399-406.
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tion with drugs used in atrial fibrillation, such as calcium channel blockers, would be an 
interesting topic for future research.
Digoxin is most frequently used in chronic heart failure with atrial fibrillation. It is a 
known substrate for the ATP-binding cassette B1 (ABCB1) transporter (P-gp, P-glycopro-
tein), encoded by the ABCB1 gene, formerly known as multidrug resistance 1 (MDR1) 
gene. A study showed that three common variants in the ABCB1 gene—1235C>T, 
2677G>T, and 3435C>T—and the associated TTT haplotype were associated with in-
creased digoxin serum concentrations.36 Other studies also showed that TTT haplotype 
and the 3435TT genotype were associated with higher digoxin serum concentrations.37,38 
Thereby, the effect of haplotype analysis seemed superior to single SNP analysis in the 
prediction of digoxin pharmacokinetics.
diuretics
Thiazide diuretics are the most commonly used diuretics in the treatment of hyper-
tension. However, large differences in blood pressure lowering response between 
individuals exist.39 In 2008, a GWAS discovered a region of chromosome 12q15 that was 
significantly associated with blood pressure-lowering response in black individuals us-
ing hydrochlorothiazide (HCTZ).40 After fine mapping of the three genes in the region 
(FRS2, YEATS4, LYZ), the variation in YEATS4 appeared to be most strongly associated with 
blood pressure response. This gene is involved in the regulation of the initiation of tran-
scription, and a priori this gene was not expected to be involved in thiazide response.
The study was replicated in an individual population, and variation in the YEATS4 
rs7297610 polymorphism contributed most to the variation in response to HCTZ. In ex-
pression analyses, HCTZ-treated African-Americans showed different YEATS4 expression 
patterns post-treatment between the rs7297610 genotypes, which could explain the 
HCTZ response variability.41
Other candidate gene studies on the blood pressure–lowering response to thiazides 
revealed several polymorphisms at different loci. Two polymorphisms in the sodium 
channel γ-subunit promoter gene (SCNN1G, rs5729, and rs5723), and a polymorphism in 
the endothelial nitric oxide synthase gene (eNOS, rs1799983) were significantly associ-
ated with blood pressure response to HCTZ.42 A combination of genetic variation in the 
alpha adducin (ADD1) gene (Gly460Trp) and NEDD4L gene (rs4149601, G>A), both genes 
regulating renal sodium absorption, was associated with a modified antihypertensive 
response to thiazides.43 This effect has also been demonstrated for the two polymor-
phisms separately.44-46
Regarding pharmacogenetics of response to loop diuretics, there are several candi-
date genes possibly relevant for interindividual variability in drug pharmacokinetics 
and pharmacodynamics, such as genetic variation in the organic anion transporters 
OAT1 (SLC22A6 gene) and OAT3 (SLC22A8 gene), and the primary target of loop diuret-
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ics, the Na+-K+-2Cl– cotransporter (NKCC2, SLC12A1 gene).47 Some associations were 
described48; however, there is little evidence and more research is needed.
drugs involved in the renin-angiotensin-aldosterone system (rAAS): ACE-inhibitors 
and angiotensin receptor blockers
The most frequently investigated polymorphism in the treatment response to ACE 
inhibitors is the ACE gene insertion/deletion (I/D) polymorphism (rs1799752). This 
polymorphism is strongly associated with serum ACE levels, and accounts for almost 
50% of the phenotypic variance of serum ACE levels. This suggests that the polymor-
phism might be a good candidate for modifying the response to ACE-inhibitor therapy. 
However, studies on this topic show conflicting results on blood pressure lowering ef-
fect, cardiovascular events, and mortality risk, and currently no final conclusions can be 
drawn on an association with therapeutic response.49-52
A recent review on the effect of genetic variants in the RAAS system on the blood 
pressure lowering response to RAAS-blocking drugs (ACE inhibitors, angiotensin recep-
tor blockers) also failed to show an association between the ACE I/D polymorphism and 
antihypertensive effects from RAAS blockade.53
Another frequently investigated variant in the RAAS system is the Met235Thr poly-
morphism in the angiotensinogen (AGT) gene, which is associated with elevated serum 
levels of angiotensinogen. But after review, again no association with antihypertensive 
effects of RAAS blockade could be demonstrated.53 Furthermore, in the Rotterdam 
Study, both the ACE I/D polymorphism and the AGT Met235Thr polymorphism did not 
significantly modify the risk of atherosclerosis.54
Several other genetic variation involved in the RAAS system (AT1 A1166C and haplo-
type, AT2 variants, AGT rs7079, REN and ACE2 variants) might be involved in the response 
to ACE inhibitors and angiotensin receptor blockers, but as confirmative studies are 
lacking or conflicting, further evaluation within larger populations is needed to confirm 
associations before definite conclusions can be drawn.
β-blocking agents
β-Adrenoreceptor antagonists or β-blockers have an important role in the treatment of 
cardiovascular diseases. Major indications are heart failure, hypertension, angina pec-
toris, and myocardial infarction (MI). β-Blockers can selectively act on the β1-adregenic 
receptor (ADRB1) or on the β2-adregenic receptor (ADRB2), or on both receptors.
Regarding the efficacy of β-blocker treatment, ADRB1 and ADRB2 are potentially 
interesting candidate genes for investigation. Within the ADRB1 gene, the linked poly-
morphisms rs1801252 (Ser49Gly) and rs1801253 (Arg389Gly) are clinically relevant, and 
for the ADRB2 gene three clinically relevant polymorphisms were described: rs1042713 
(Arg16Gly), rs1042714 (Gln27Glu), and rs1800888 (Thr164Ile). Many studies have inves-
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tigated these polymorphisms and the results are extensive and diverse. For instance, 
ADRB1 polymorphisms have been associated with blood pressure reduction55,56, with 
overall the largest blood pressure–lowering response for users with the homozygous 
Arg389 genotype or Ser49/Arg389 haplotype. Furthermore, they have been associ-
ated with mortality in heart failure patients on the β-blocker carvedilol57, and the 
homozygous Arg389 genotype is associated with significantly better improvement of 
left ventricular ejection fraction (LVEF) during β-blocker therapy within heart failure 
patients.58-62 However, other studies did not find an association, and further investiga-
tion in larger populations or studying the combination of different alleles is needed. 
Regarding the ADRB2 polymorphisms, these are described in relationship with survival, 
and the Glu27 allele of the rs1042714 polymorphism seems associated with improved 
LVEF in response to β-blocker therapy in heart failure patients, compared with the Gln27 
allele.63 Patients heterozygous for the Ile164 rs1800888 genotype may have impaired 
heart failure survival during β-blocker treatment.64 No association with blood pressure 
response is found.65,66 Also, for these ADRB2 polymorphisms, results of studies are incon-
sistent and more research should be performed.
Many β-blockers are metabolized by the polymorphic isoenzyme cytochrome P450 
2D6 (CYP2D6), encoded by the CYP2D6 gene. To date, more than 70 genetic variants 
within this gene have been described. Several of these variants lead to diminished or 
absent function of the enzyme. Patients with two inactive alleles are associated with 
the so-called “poor metabolizer” phenotype, which includes 5% to 10% of the white 
population. Poor metabolization results in higher plasma concentrations of β-blockers, 
with a higher risk of toxicity, but also a potentially increased efficacy of the drug. Studies 
showed that poor metabolizers have a lower heart rate than extensive metabolizers in 
response to β-blockers that are metabolized by CYP2D6 (e.g. metoprolol), but not in 
non-metabolized β-blockers such as atenolol.67 Also, the blood pressure reduction was 
larger in individuals with the poor metabolizing phenotypes, reflecting a better efficacy 
of the drug.67-69 An example of a study in which poor metabolizers showed a stronger 
lowering of the heart rate than extensive metabolizers is given in Figure 2. A stronger 
heart rate lowering response increases the risk of adverse reactions: a study showed 
an almost fourfold increased risk of bradycardia with metoprolol in poor metabolizers 
compared with extensive metabolizers.67 Another study demonstrated that CYP2D6 
poor metabolizers had a fivefold increased risk for the development of adverse reac-
tions during metoprolol treatment in comparison with patients who were not poor me-
tabolizers.70 The consequences of genetic variation in the CYP2D6 gene and their clinical 
effect were mainly demonstrated for metoprolol, which could be explained from the fact 
that this β-blocker is most extensively metabolized by CYP2D6.71 As the CYP2D6 gene 
may demonstrate copy number variations with ultraextensive metabolism, high doses 
of metoprolol might be required for a clinical effect in some individuals. Since there is 
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a large difference between β-blockers in their receptor specificity, and in their affinity 
for metabolizing enzymes and transporters, it is difficult to draw definitive conclusions 
about the pharmacogenetics of β-blocker response. Currently, genetic testing for the 
CYP2D6 poor metabolizing genotype is performed only occasionally. In many patients, 
the dosage will be titrated downward if needed on clinical grounds. According to some, 
dose adjustments should be considered in certain patients, depending on the particular 
drug or underlying disease.72
figure 2 The CYP2D6 genotype has an influence on heart rate in metoprolol users, but not in atenolol users
Association between CYP2D6 genotype and adjusted heart rate in users of (a) metoprolol and (b) atenolol. 
The data are adjusted for age, sex, β-blocker dose, and use of other antihypertensives. The adjusted heart 
rate in metoprolol users was 8.5 bpm lower in PMs than in EMs (P<0.0001). In *4 heterozygotes, the heart 
rate was 2.5 bpm lower (P = 0.013).
Abbreviations: *1/*1 – *1/*4 – *4/*4, genotypes; bpm, beats per minute; EMs, extensive metabolizers; PMs, 
poor metabolizers.
After reference 67: Bijl MJ et al. Clin Pharmacol Ther 2009; 85(1): 45-50.
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lipid-lowering therapy with statins: cholesterol-lowering effect and muscle toxicity
The HMG-CoA reductase inhibitors, or statins, have a beneficial effect on the primary 
and secondary prevention of cardiovascular morbidity and mortality, primarily by low-
ering the concentration of circulating LDL.73 Statins exert their effect by inhibition of 
HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the cholesterol biosynthesis 
pathway. Therefore, the HMGCR gene is a good candidate for studies on genetic varia-
tion influencing the cholesterol lowering effect of statin therapy. Studies have showed 
that polymorphisms in the HMGCR gene are associated with a lower reduction in levels 
of total and LDL-cholesterol, within different populations and settings.74-76Another 
important candidate gene is the LDL receptor (LDLR) gene, since statins increase LDLR 
expression. Studies on genetic variation in this gene showed a decreased response to 
statin therapy.77,78 Furthermore, cytochrome P450 3A4 (CYP3A4) metabolizes simvas-
tatin, atorvastatin, and lovastatin, and in a recent study the CYP3A4 intron 6 C>T SNP was 
associated with an increased total and LDL-cholesterol lowering response to simvastatin 
therapy.79 Other studies investigating CYP3A4 polymorphisms also showed an improved 
LDL-cholesterol lowering response to atorvastatin therapy.80,81 On the other hand, within 
the CYP3A4 gene, polymorphisms showing a diminished lipid-lowering response to 
statin therapy were also described.80-82 Regarding the apolipoprotein E (APOE) ε2/ε3/ε4 
variants (a combination of genetic polymorphisms rs429358 and rs7412) and response 
to statin therapy, in several studies the ε2 variant seemed to be associated with better 
cholesterol lowering response to statin therapy and a reduction in cardiovascular out-
comes, while in other studies this was not found.83 The first GWAS on genetic variation 
and statin response showed an association for variation in APOE84, but in a meta-analysis 
this was not confirmed.85 Therefore, the question remains whether APOE polymorphisms 
are associated with a modified statin response. In recent GWAS, 95 new loci that influ-
ence lipid concentrations were identified.86,87 These loci are interesting candidates for 
pharmacogenetic associations with statin treatment response.
In general, statins are well-tolerated and safe drugs, although adverse reactions do 
occur. A relatively common adverse reaction is myopathy, which in its severe form may 
evolve into rhabdomyolysis with muscle necrosis and release of myoglobin. This serious 
condition can lead to renal failure and death.88 In 2008, the SEARCH Collaborative Group 
(Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) 
published a GWAS on the development of myopathy in simvastatin users and identified 
a strong significant association for the rs4363657 variant in the solute carrier organic an-
ion transporter family 1B1 (SLCO1B1) gene, as shown in Figure 3.89 This polymorphism was 
in almost complete linkage disequilibrium with the rs4149056 c.521T>C polymorphism, 
which had already been described in the literature in relation to statin metabolism. 
Patients homozygous for the minor allele had a 17 times higher risk of myopathy than 
patients homozygous for the major allele. It is established that the homozygous minor 
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allele genotype of this polymorphism is associated with a higher risk of simvastatin-
induced adverse reactions, since other studies also find an association.90,91 However, the 
question remains whether there is a class effect, since currently no association could be 
found between the SLCO1B1 rs4149056 polymorphism and adverse reactions during use 
of other statins such as atorvastatin.90-92
Anticoagulant therapy with coumarin derivatives and platelet-inhibiting therapy 
with clopidogrel
Although in a strict sense one might question whether anticoagulants and platelet in-
hibitors can be considered as cardiovascular drugs, they are often used in combination 
with such drugs. In this topic, we mention the most important polymorphisms in the 
response to oral anticoagulants and platelet inhibitors.
Coumarin derivatives (vitamin K antagonists) are widely used in the prevention and 
treatment of venous thromboembolism. In models for dose prediction of the coumarin 
derivative warfarin, polymorphisms in the cytochrome P450 2C9 (CYP2C9) and vitamin 
K epoxide reductase complex subunit 1 (VKORC1) gene substantially contribute to the 
prediction of stable warfarin dose. Prediction models with CYP2C9 polymorphisms, 
VKORC1 polymorphisms, and clinical factors together included, explained approximately 
50% to 60% of the interindividual variability in response to warfarin therapy.93-95 A study 
demonstrated that genetic variation in the VKORC1 gene has a stronger influence on 
international normalized ratio (INR) response to warfarin therapy at a particular dos-
figure 3 GWAS on myopathy cases and matched controls, using 80 mg simvastatin daily, showed a ge-
nome-wide significant association for a SNP in the SLCO1B1 gene
Results of tests for a trend in the association between myopathy and each SNP (single nucleotide polymor-
phism) measured in the genome-wide association study (GWAS). P values are shown for each SNP mea-
sured among 85 participants with myopathy and 90 matched controls who were taking 80 mg of simvas-
tatin daily. Analyses are based on 316,184 of the 318,237 SNPs (99.4%) on the Sentrix HumanHap300-Duo 
BeadChip (Illumina). A result above the horizontal red line indicates strong evidence of an association.
After reference 89: SEARCH Collaborative Group. N Engl J Med. 2008; 359(8): 789-799.
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age, than genetic variation in the CYP2C9 gene.96 These results are also represented in 
Figure 4. The variant alleles of the VKORC1 polymorphisms – 1639A>G (rs9923231) and 
1173T>C (rs9934438) – result in patients with this genetic trait being less sensitive to 
warfarin therapy.96 Vitamin K epoxide reductase complex subunit 1, encoded by VKORC1, 
is responsible for converting inactive vitamin K back to its active form, and coumarins 
are in competition with vitamin K for receptors that activate vitamin K-dependent clot-
ting factors. Therefore, genetic variation in the VKORC1 gene that decreases the function 
of the VKORC1 enzyme requires higher doses of warfarin to elicit the same effect as in 
patients with the major genotype.
Cytochrome P450 2C9 (CYP2C9) is the most important enzyme for the elimination 
of warfarin. The CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) alleles are associated 
with diminished effect of the enzyme, and therefore patients with one or two of these al-
figure 4 Genetic variation in the VKORC1 gene has a stronger effect on variability in response to warfarin 
therapy, than genetic variation in the CYP2C9 gene
Association between specific genetic variants and study outcomes. The graphs show the association be-
tween the time to the first international normalized ratio (INR) within the therapeutic range and the time to 
the first INR of more than 4 for patients carrying genetic variants for vitamin K epoxide reductase (VKORC1) 
(Panels A and B) and for cytochrome P450 2C9 (CYP2C9) (Panels C and D).
After reference 96: Schwarz et al. N Engl J Med. 2008; 358(10): 999-1008.
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leles require lower warfarin doses for a particular target INR according to an allele-effect 
relationship.97,98 Also for acenocoumarol therapy, a coumarin derivative which is mostly 
used in several European countries, it has been demonstrated that genetic variation 
within the VKORC1 and CYP2C9 genes play an important role in the response to therapy. 
In a GWAS within 1451 whites, besides other significant polymorphisms in other genes, 
polymorphisms within VKORC1 (most significant polymorphism: rs10871454, chromo-
some 16, P=2.0 × 10−123) and CYP2C9 (most significant polymorphism: rs4086116, chro-
mosome 10, P=3.3 × 10−24) contributed to the variance in acenocoumarol dosage. It was 
established that besides age, sex, body mass index, and target INR, one polymorphism 
within each of the VKORC1, CYP2C9, CYP4F2, and CYP2C18 genes could explain 48.8% of 
the variation in acenocoumarol dosage.99
For platelet-inhibiting agents, most genetic studies have focused on clopidogrel. 
Clopidogrel is an inactive prodrug and the cytochrome P450 2C19 (CYP2C19) enzyme 
is involved in the conversion of clopidogrel into its active metabolite. The CYP2C19*2 
polymorphism (rs4244285) results in a decreased activity of the CYP2C19 enzyme, lead-
ing to diminished plasma concentrations of the active metabolite of clopidogrel. This 
decreases the therapeutic effect of clopidogrel and higher doses are needed to reach 
their optimal effect.100-104 Whether these lower plasma levels also lead to increased risk 
of cardiovascular events due to inefficiency of the drug is questionable: large studies or 
reviews find an increased risk of cardiovascular events in carriers of a reduced-function 
allele101,102, but other studies could not demonstrate an association with cardiovascular 
events.103,104
overview and future challenges
In this paper, we have summarized current knowledge concerning the most important 
genetic associations in the response to cardiovascular drug therapy. There is also much 
literature about pharmacogenetic determinants of cardiovascular effects by drugs 
with other indications, such as by tricyclic antidepressants, which may prolong the QT 
interval duration, but these associations were not covered in this paper.105 A couple of 
conclusions can be made.
First, it is clear that despite abundant literature we know relatively little about 
pharmacogenetic determinants of drug response. Much pharmacogenetic literature 
is contradictory and gives a scattered picture of the topic. Probably, many apparently 
contradictory results come from lack of power in candidate gene studies, lack of stan-
dardization, and lack of collaboration between studies within a large consortium. Also, 
the likelihood that for complex phenotypes the contribution of pharmacogenetic deter-
minants may be difficult to disentangle from other risk factors may have contributed to 
the relative lack of consistency between studies. Consequently, most clinically relevant 
knowledge pertains to pharmacogenetics of drug metabolism by the cytochrome 
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P450 system, where a relative wealth of clinical pharmacological literature facilitates 
the performance of candidate gene studies with blood levels as an outcome. Second, 
despite the fact that during the past decades much effort has been put into pharma-
cogenetic research and many studies have been published, the pharmacogenetics of 
cardiovascular drug therapy has not had substantial clinical consequences. Apart from 
the abovementioned argument of contradictory literature, this is explained by the fact 
that most drugs can be titrated on clinical symptoms (e.g., digoxin) or biomarkers such 
as the INR (e.g., warfarin). Although health authorities such as the US Food and Drug 
Administration give dose recommendations based on genetic polymorphisms for some 
drugs (e.g., warfarin), there is no indication that this has led to substantial implementa-
tion in clinical practice. Although this might seem to be a negative appraisal, it does 
not mean that pharmacogenetic research was a waste of time, effort, and resources. 
Pharmacogenetic research provided us with important scientific insights into drug 
metabolism and actions. For instance, pharmaceutical companies will be reluctant to 
develop a drug that is metabolized by CYP2D6 because of the high prevalence of “poor 
metabolizers.” Moreover, pharmacogenetic research is only at an early stage because 
progressive cost reduction of DNA analyses, and increasing international cooperation in 
study consortia such as CHARGE (Cohorts for Heart and Aging Research in Genomic Epi-
demiology),106 are leading to discovery of important polymorphisms in candidate genes 
studies as well as in GWAS. Moreover, new genetic approaches, the “next-generation 
sequencing,” will undoubtedly have an important role in revealing new and also rare loci 
of genetic variation. Especially, pharmaceutical companies should play a more active 
role than they currently do by focusing on variations of known pharmacological enti-
ties. New genetic associations, and their synergism with patient characteristics, should 
be investigated more proactively to determine specific groups of patients for whom 
genetic testing is relevant. Hopefully, future findings will make it possible that, based 
on a pharmacogenetics profile, drug therapy can be individualized. This would improve 
efficacy of therapy, reduce the risk of ADRs, and minimize costs. However, before we 
reach that point, if ever, there is still a long way to go.
1.2 Aim And oUtlinE of thiS thESiS
The aim of this thesis was to gain more insight into the pharmaco(genetic) epidemiol-
ogy of statins in an ageing population. The main purposes were 1) to identify genetic 
determinants that modify the response to statin therapy, 2) to investigate unintended 
effects of the use of statin therapy in clinical practice, and 3) to investigate different 
methodological techniques to estimate the effect of time-dependent statin use in 
observational studies. All studies in this thesis are embedded in the Rotterdam Study, a 
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prospective population-based cohort study among 14,926 inhabitants of Ommoord, a 
suburb of Rotterdam, aged 45 years and older. The objectives and design of the Rotter-
dam Study were described in detail previously.107,108 Since the start of the study in 1990, 
follow-up examinations were conducted periodically. Blood samples were obtained 
from which genomic DNA was extracted, medication dispensing data were available on 
a daily basis through linkage with pharmacies in the Ommoord suburb, and the cohort is 
continuously monitored for major morbidity and mortality through linkage with general 
practitioner’s records.
In chapter 2, we describe genetic factors that modify the efficacy, effectiveness, and 
risk of ADRs of statins in clinical practice. We used the GWAS approach to discover new 
genetic markers without a priori hypothesis of the underlying genetic variation, and 
the candidate gene approach to replicate genetic variation that has previously been 
associated with a modified statin response or occurred in a pathway that relates to statin 
pharmacokinetics. Chapter 3 covers general (non-genetic) epidemiological studies on 
unintended effects of the use of statins in clinical practice. Use of statins is studied in 
relation with NAFLD, a disease which is frequently associated with dyslipidemia, and in 
which statins are frequently prescribed. Moreover, the influence of statins on the levels 
of total and non sex hormone-binding globulin-bound testosterone is investigated. 
Cholesterol is a precursor in the formation of testosterone, and since statins lower cho-
lesterol, these drugs may also influence testosterone levels. In chapter 4, we investigate 
whether marginal structural modeling (MSM) produces different effect estimates from 
more traditional Cox-proportional hazards models in estimating the effect of time-de-
pendent drug use in observational studies. Statin use in the primary prevention of CVD 
is investigated as an example. Studies can be biased when a time-dependent covariable 
is simultaneously 1) a reason for prescribing or dose-changing (often termed ‘confound-
ing by indication’), 2) influenced by the drug under study, and 3) a potential cause of the 
outcome of interest. This can be adjusted for by MSM. Chapter 5 investigates whether 
serum SHBG can serve as a biomarker for the risk of NAFLD. Previous cross-sectional 
studies have demonstrated an inverse association between serum SHBG levels and 
NAFLD prevalence, but no statements on causality could be made. Finally, chapter 6 will 
provide a general discussion, in which we discuss the main findings of this thesis, discuss 
the consequences of widespread statin use, evaluate several methodological issues, and 
discuss the implementation of personalized medicine in future clinical practice.
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AbStrACt
Introduction: The objective of this study was to investigate whether common variation 
in genes involved in lipid metabolism modify the effect of statins on serum total choles-
terol concentration.
Methods: Statin users were identified in the Rotterdam Study, a prospective population-
based cohort study of subjects >55 years of age. We studied the association between 
single nucleotide polymorphisms (SNPs) in genes involved in lipid metabolism and total 
cholesterol response to statin therapy, using linear regression analysis and adjusting for 
potential confounders. Replication was performed in an independent extended cohort 
of the Rotterdam Study.
Results: Genotype data and total cholesterol concentrations after start of statin therapy 
were available for 554 newly started statin users. Two SNPs were associated with a 
significantly higher cholesterol concentration under statin therapy: SNP rs1532624 in 
the CETP gene (β 0.141 mmol/L, P 0.004 per additional allele) and SNP rs533556 in the 
APOA1 gene (β 0.138 mmol/L, P 0.005 per additional allele). In the replication sample, 
only the CETP rs1532624 SNP again showed a significant association. The SNPs were not 
related to baseline total cholesterol in non-statin users.
Conclusion: In conclusion, we found that the CETP rs1532624 polymorphism is associ-
ated with cholesterol response to statin therapy in a cohort of elderly subjects in the 
general population.
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introdUCtion
Cardiovascular disease (CVD) is a major health problem and is one of the leading causes 
of death in industrialized countries.1,2 It is a multifactorial complex disease, composed of 
several vascular disorders and many factors contribute to the risk of CVD. One of the ma-
jor risk factors for CVD is high serum cholesterol, especially increased serum low-density 
lipoprotein (LDL).3 Pharmacological interventions, principally lipid-lowering therapy, 
are an essential component of the clinical management of CVD.3-5 The 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, have shown to 
be beneficial for primary and secondary prevention of CVD, due to their cholesterol low-
ering activity.6-11 Statins competitively inhibit HMG-CoA reductase (HMGCR), the rate-
limiting enzyme in the cholesterol biosynthesis pathway. This leads to the upregulation 
of LDL-receptor activity and reduced secretion of apolipoprotein B (apoB)-containing 
lipoproteins from the liver, both of which contribute to lowering of the LDL-cholesterol 
concentration in plasma.12,13 By this mechanism, statins have the potential to protect 
against cardiovascular morbidity and mortality.
Nevertheless, there is a considerable variability between individuals in response to 
statins, in terms of both cholesterol lowering and clinical outcomes, of which the origins 
are poorly understood. A part of this variation may be explained by genetic factors.14,15 
Pharmacogenetics focuses on genetic polymorphisms that influence response to drug 
therapy. Over the past decade, many studies have focused on identifying potential ge-
netic determinants regarding response to statin therapy. Markers that are predictive of 
statin efficacy or the occurrence of statin-related adverse drug reactions could be useful 
in tailoring treatment, based on individual subjects or certain subgroups.
Because statins have an influence on serum cholesterol concentration, single nucleo-
tide polymorphisms (SNPs) in genes involved in the lipid metabolism may be involved in 
the interindividual variability in cholesterol response to statin therapy. In this study, we 
investigated whether common variation in genes involved in lipid metabolism modify 
the effect of statins on total serum cholesterol concentration.
mEthodS
Setting
The Rotterdam Study is a prospective population-based cohort study of chronic diseases 
in the elderly population. From 1990 to 1993, all inhabitants of Ommoord, a district of 
the city of Rotterdam in the Netherlands, aged 55 years or over, were invited to partici-
pate (n=10 278) in the Rotterdam Study I (RS-I). Of them, 78% (n=7983) gave the written 
informed consent, including permission for retrieval of medical records, use of blood 
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and DNA for research purposes, and publication of obtained results. The medical ethics 
committee of the Erasmus Medical Center, Rotterdam, the Netherlands, approved the 
study. Baseline examinations took place from March 1990 through July 1993. Follow-up 
examinations were conducted periodically, every 4–5 years. The cohort was continu-
ously being monitored for major morbidity and mortality through linkage of the Rotter-
dam Study database with general practitioner and municipality records. Furthermore, 
exposure to medication was continuously monitored since 1 January 1991, through fully 
computerized pharmacy records from the seven linked pharmacies in the Ommoord 
district. Information on all dispensed drugs was available in computerized format on a 
day-to-day basis. The data consisted of information on the date of prescribing, the total 
amount of drug units per prescription, the prescribed daily number of units, the product 
name of the drugs and the Anatomical Therapeutic Chemical code. DNA for genotyping 
was available for 6571 (82%) participants from the baseline visit.
Furthermore, in 2000, an extended cohort was enrolled, the Rotterdam Study II (RS-II). 
All inhabitants of Ommoord, aged 55 years or older and not enrolled in the RS-I, were 
invited to participate in this extended cohort (n=5404). Of them, 3011 (67%) entered the 
study and took part in the baseline examination. The second visit for the RS-II took place 
between 2004 and 2005.
Detailed information on design, objectives and methods of the Rotterdam Study has 
been given elsewhere.16,17
Study population
The source population consisted of all participants of the RS-I, who were successfully 
genotyped as part of a large population-based project on genetics of complex traits 
and diseases, financed by the Dutch government through the Netherlands Scientific 
Organization—Large Investments (NWO Groot 175.010.2005.011) (n=5974). The study 
population consisted of all participants of the RS-I, who received a prescription for statin 
therapy in the study period between 1 April 1991 and 1 January 2008, and who had at 
least one serum cholesterol measurement available at any time during the study period 
after prescription of statin therapy (n=554).
outcome definition
In this study, the outcome of interest was cholesterol response to statin therapy. For 
every statin user in the population, the first serum total cholesterol measurement after 
start of prescription of statin therapy was defined as the outcome variable, with the 
date of cholesterol measurement at least 1 week after the prescription date of statin 
therapy. This first cholesterol measurement was considered as a measure of cholesterol 
response to statin therapy. In the Rotterdam Study, serum cholesterol levels are assessed 
at baseline examination and subsequently during follow-up examinations. As of April 
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1997, also fasting total cholesterol levels assessed between follow-up examinations as 
part of patient care were gathered by linkage to the general practitioners’ laboratory 
‘Stichting Artsenlaboratorium Rotterdam en Omstreken’ (Starlab).
Genotyping and SnP selection
At the baseline examination of the Rotterdam Study, blood was taken from which ge-
nomic DNA was extracted, using the salting-out method.18 Microarray genotyping was 
performed in the whole original Rotterdam Study cohort using the Infinium II Human-
Hap550K Genotyping Bead-Chip version 3 (Illumina Inc., San Diego, CA, USA). Genotyp-
ing procedures were followed according to the manufacturer’s protocols. Microarray 
genotyping procedures in the Rotterdam Study have been previously described.19
In this study the selection of SNPs was performed, using a candidate gene approach. 
On the basis of literature13,20,21, we selected 18 genes involved in lipid metabolism. The 
selected genes were HMGCR, squalene synthase (FDFT1), cholesterol 7a hydroxylase (CY-
P7A1), LDL-receptor (LDLR), APOB, apolipoprotein E (APOE), apolipoprotein A-I (APOA1), 
cholesteryl ester transfer protein (CETP), ATP-binding cassette transporter A1 (ABCA1), 
ATP-binding cassette transporter G8 (ABCG8), paraoxonase 1 (PON1), sterol regula-
tory element-binding protein 1 (SREBF1), peroxisome proliferator-activated receptor-d 
(PPARD), peroxisome proliferator-activated receptor-g (PPARG), lipoprotein lipase (LPL), 
hepatic lipase (LIPC), microsomal triglyceride transfer protein (MTP) and leptin recep-
tor (LEPR). Markers were excluded if they deviated significantly from Hardy-Weinberg 
equilibrium (P<1 × 10−4), if they had a low minor allele frequency (MAF<0.05) or if they 
had an SNP call rate <95% within the samples. All SNPs present within the gene area of 
each individual gene ±50 kb were extracted from the data set. This resulted in a data set 
of 667 SNPs in total for the 18 candidate genes together.
Covariables
The following covariates were considered as potential determinants for affecting the 
association between genotype and serum total cholesterol concentration in a popula-
tion only consisting of statin users: age, gender, baseline total cholesterol, high-density 
lipoprotein (HDL)-cholesterol at baseline, average defined daily dose of statin therapy 
and duration of statin use. During the baseline visit at the research center, nonfasting 
blood samples were obtained, and serum lipid parameters of total cholesterol and 
HDL-cholesterol were determined by an enzymatic procedure.22 The prescribed dose of 
statin therapy is given as the average defined daily dose, calculated as the total defined 
daily dose of statin therapy over the total follow-up time divided by the total number 
of days of exposure over the same time period. Duration of statin use is defined as the 
time between the prescription date of statin therapy and the date of first serum total 
cholesterol measurement after at least 1 week of statin therapy.
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Analysis
Differences in baseline characteristics between statin users and the source population 
were tested using a X2-test for binary variables and a t-test for continuous variables. 
Hardy-Weinberg equilibrium was tested using a X2-test.
We performed two statistical analyses in a stepwise approach. First, we investigated 
which of all selected SNPs (n=667) influenced the cholesterol response to statin therapy, 
by using linear regression analysis with Plink version 1.01 (Purcell et al., Boston, MA, 
USA).23 All selected SNPs were tested on total cholesterol concentration after start of 
statin therapy under an additive model, adjusted for age, gender, baseline cholesterol, 
HDL-cholesterol at baseline, statin dose and duration of statin use. To take into account 
the problem of multiple testing, per individual gene, we applied a Bonferroni correction 
for the number of SNPs within the gene region. The Bonferroni P-value was calculated 
by multiplying the observed P-value by the number of SNPs tested for association within 
the gene region. Because a priori candidate genes in the lipid metabolism were selected 
based on literature, Bonferroni correction was performed per individual gene. Selected 
on this Bonferroni P-value, the promising SNPs were also studied in a replication cohort, 
to reduce the chance of reporting a false-positive association. Because our aim was to in-
vestigate polymorphisms that influence cholesterol concentration in response to statin 
therapy, and not polymorphisms that influence cholesterol concentration in general, we 
also performed a linear regression analysis on baseline cholesterol in non-statin users 
to investigate the relationship between each SNP and baseline cholesterol. This linear 
regression was performed on all subjects who had not received any statin at baseline 
and who had a baseline cholesterol measurement available (n=5749).
The SNPs that showed a P<0.1 after Bonferroni correction, and were not significantly 
related to baseline cholesterol, were further analyzed. We tested the remaining SNPs 
in a genotypic model on cholesterol concentration after start of statin therapy, using 
SPSS for Windows software, version 15.0 (SPSS Inc., Chicago, IL, USA). We compared 
cholesterol concentration after start of statin therapy between the different genotype 
categories, whereby we adjusted for age, gender, baseline cholesterol, HDL-cholesterol 
at baseline, statin dose and duration of statin use.
replication
To avoid the reporting of a false-positive association, we repeated the analysis for 
those SNPs that showed a significant effect on cholesterol concentration in response 
to statin therapy in the discovery cohort (RS-I). This replication study was performed 
in an independently collected cohort, the RS-II. The source population for replication 
consisted of all participants in the RS-II, who were successfully genotyped (n=1895). The 
study population consisted of those subjects in the source population who received a 
prescription for statin therapy in the study period between baseline date and 1 January 
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2008, and who had at least one serum cholesterol measurement available at any time 
during the study period at least 1 week after prescription of statin therapy (n=243). 
The outcome variable was cholesterol concentration after start of statin therapy, as 
described earlier. We performed a linear regression analysis, in which both SNPs were 
tested in an additive and a genotypic model. We compared cholesterol concentration 
after start of statin therapy between the different genotype categories, whereby we 
adjusted for age, gender, baseline cholesterol, HDL-cholesterol at baseline, statin 
dose and duration of statin use. Finally, we performed a fixed effect inverse variance 




The baseline characteristics of the source and study population (RS-I) are shown in Table 
1. Overall, the source population consisted of all subjects, of whom genotype data were 
available (n=5974). The mean age in the population was approximately 69.4 years and 
59.4% of the total population were women. For the analysis on cholesterol response to 
statin therapy the study population consisted of all subjects who received statin therapy 
between 1 April 1991 and 1 January 2008 (n=554). For all these 554 statin users, a serum 
cholesterol measurement at least 1 week after start of statin therapy was available. The 
median time between the prescription date of statin therapy and the date of first serum 
total cholesterol measurement was 80 days (interquartile range: 40–174 days), with 
a minimum of 8 days and a maximum of 1068 days. The average defined daily dose 
of statin therapy was 1.12 (SD: ±0.71). Of the different kind of statins, simvastatin was 
prescribed most frequently (n=337, 60.8%), followed by atorvastatin (n=108, 19.5%) and 
pravastatin (n=66, 11.9%).
Cholesterol response
Of all 667 SNPs, only 2 showed evidence for association with cholesterol response to 
statin therapy under an additive model, after Bonferroni correction at a liberal P-value of 
<0.1. The two SNPs that remained under this P-value threshold were the SNP rs1532624 
in the CETP gene (β 0.153, original P-value 0.002, Bonferroni P-value 0.084) and the 
SNP rs533556 in the APOA1 gene (β 0.140, original P-value 0.004, Bonferroni P-value 
0.039). Both SNPs were not related to baseline total cholesterol in non-statin users in the 
discovery cohort (RS-I).
The results of the linear regression analysis on cholesterol concentration after start 
of statin therapy under a genotypic model are shown in Table 2. Subjects with a minor 
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allele of the SNP rs1532624 in the CETP gene showed a higher cholesterol concentra-
tion after start of statin therapy than subjects homozygous for the major allele, the 
reference category. This effect of genotype on cholesterol concentration was borderline 
non-significant for the heterozygous genotype compared with the homozygous major 
allele genotype (β 0.144 mmol/L, P 0.054), and significant for the variant genotype 
compared with the homozygous major allele genotype (β 0.281 mmol/L, P 0.006). In our 
population, the MAF of the rs1532624 SNP was 40.6% (A allele). Subjects with a minor 
allele of SNP rs533556 in the APOA1 gene showed a higher cholesterol concentration 
after start of statin therapy than subjects homozygous for the major allele, the reference 









Age, years (mean±SD) 69.4 ± 9.1 64.5 ± 5.5 64.5 ± 7.1
Gender, n (%)
 – men 2427 (40.6) 232 (41.9) 110 (54.3)
 – women 3547 (59.4) 322 (58.1) 133 (54.7)
Total cholesterol, mmol/L 
(mean±SD)
6.6 ± 1.2 7.6 ± 1.3 5.5 ± 1.1
HDL-cholesterol, mmol/L 
(mean±SD)
1.3 ± 0.4 1.3 ± 0.4 1.3 ± 0.3
Hypertension, n (%) 1997 (34.3) 219 (39.8) –
Smoking, n (%)
 – current 1339 (23.0) 135 (24.7) 56 (23.0)
 – former 2425 (41.7) 258 (47.2) 124 (51.0)
 – never 2046 (35.2) 154 (28.2) 63 (25.9)
Body mass index, kg/m2 
(mean±SD)
26.3 ± 3.7 26.7 ± 3.6 27.9 ± 3.9
Diabetes mellitus, n (%) 631 (10.6) 54 (9.7) –
Heart failure, n (%) 194 (3.2) 11 (2.0) 7 (2.9)
Statin therapy, n (%) –
 – Simvastatin 337 (60.8) 133 (54.7)
 – Pravastatin 66 (11.9) 35 (14.4)
 – Fluvastatin 38 (6.9) 21 (8.6)
 – Atorvastatin 108 (19.5) 52 (21.4)
 – Cerivastatin 5 (0.9) 2 (0.8)
Statin dose, AVDDD (mean±SD) – 1.12 ± 0.71 1.24 ± 0.86
Abbreviations: AVDDD, average defined daily dose; HDL, high-density lipoprotein; n, number; SD, standard 
deviation.
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category. This effect of genotype on cholesterol concentration was significantly differ-
ent for both the heterozygous genotype and the homozygous variant allele genotype, 
compared with the homozygous major allele genotype (β 0.178 mmol/L, P 0.014 and β 
0.246 mmol/L, P 0.021, respectively). In our study population, the MAF of the rs533556 
SNP was 35.5% (A allele). Genotype distributions for the CETP genotype and the APOA1 
genotype are given in Table 3.
replication
The baseline characteristics of the replication sample (RS-II) are shown in Table 1. The 
statins used were comparable between the discovery cohort and the study popula-
tion for replication. Also, the distribution of statin use was comparable between both 
cohorts, with in the replication cohort a median time of 78.5 days (interquartile range: 
40–148 days) between the prescription date of statin therapy and the date of first serum 
total cholesterol measurement, with a minimum of 8 days and a maximum of 1260 days. 
A serum cholesterol measurement after start of statin therapy was available for 385 
statin users. Of these statin users, 239 subjects had genotype data available for the CETP 
polymorphism, and 243 had genotype data available for the APOA1 polymorphism.
Genotype distributions for the CETP and the APOA1 genotypes are given in Table 3. In 
the replication population, the MAF of the CETP rs1532624 SNP was 40.2% (A allele) and 
table 2 Relationship between genotype and cholesterol response among statin users in RS-I
SnP (gene) Genotype number
(%)
Effect genotype on total
cholesterol in mmol/l (95% Ci)
P
rs1532624 (CETP)
Additive model 546 (100) 0.141 (0.045; 0.237) 0.004
Genotypic model CC 191 (35.0) (ref ) –
CA 267 (48.9) 0.144 (−0.002; 0.291) 0.054
AA 88 (16.1) 0.281 (0.081; 0.481) 0.006
rs533556 (APOA1)
Additive model 546 (100) 0.138 (0.041; 0.235) 0.005
Genotypic model CC 230 (42.1) (ref ) –
CA 245 (44.9) 0.178 (0.036; 0.320) 0.014
AA 71 (13.0) 0.246 (0.037; 0.456) 0.021
Abbreviations: APOA1, apolipoprotein A-I; CETP, cholesteryl ester transfer protein; CI, confidence interval; 
SNP, single nucleotide polymorphism.
Effect of CETP and APOA1 genotype on cholesterol concentration after start of statin therapy, using an 
additive and genotypic model. Mean differences in total cholesterol concentration in mmol/L after at least 
1 week of statin use are shown. For both SNPs, genotype CC is homozygous for the major allele, genotype 
CA is heterozygous and genotype AA is homozygous for the variant allele. P-values are adjusted for age, 
gender, baseline cholesterol, HDL-cholesterol at baseline, statin dose and duration of statin use. bold value 
indicates statistically significant association.
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table 3 Genotype frequencies of CETP and APOA1 SNPs
























CC 1890 (31.7) 194 (35.0) 591 (31.5) 83 (34.7)
CA 2935 (49.2) 272 (49.1) 912 (48.6) 120 (50.2)
AA 1142 (19.1) 88 (15.9) 373 (19.9) 36 (15.1)
rs533556 (APOA1)
CC 2589 (43.5) 235 (42.4) 821 (43.3) 92 (37.9)
CA 2677 (44.9) 247 (44.6) 859 (45.3) 119 (49.0)
AA 692 (11.6) 72 (13.0) 214 (11.3) 32 (13.2)
Abbreviations: APOA1, apolipoprotein A-I; CETP, cholesteryl ester transfer protein; SNP, single nucleotide 
polymorphism.
Genotype distributions for the CETP and APOA1 SNPs in the source population and study population, both 
for the discovery cohort and for the replication cohort. For both SNPs, genotype CC is homozygous for the 
major allele, genotype CA is heterozygous, and genotype AA is homozygous for the variant allele.
table 4 Relationship between genotype and cholesterol response among statin users in RS-II (replication)
SnP (gene) Genotype n
(%)





Additive model 239 (100) 0.203 (0.048; 0.359) 0.011
Genotypic model CC 83 (34.7) (ref ) –
CA 120 (50.2) 0.108 (−0.123; 0.339) 0.358
AA 36 (15.1) 0.460 (0.134; 0.785) 0.006
rs533556 (APOA1)
Additive model 243 (100) −0.003 (−0.161; 0.156) 0.975
Genotypic model CC 92 (37.9) (ref ) –
CA 119 (49.0) −0.012 (−0.241; 0.216) 0.915
AA 32 (13.2) −0.002 (−0.339; 0.344) 0.989
Abbreviations: SNP, single nucleotide polymorphism; CETP, cholesteryl ester transfer protein; APOA1, apoli-
poprotein A-I; CI, confidence interval.
Effect of CETP and APOA1 genotype on cholesterol concentration after start of statin therapy, using an ad-
ditive model and a genotypic model. Mean differences in total cholesterol concentration in mmol/L after 
at least 1 week of statin use are shown. For both SNPs, genotype CC is homozygous for the major allele, 
genotype CA is heterozygous and genotype AA is homozygous for the variant allele. P-values are adjusted 
for age, gender, baseline cholesterol, HDL-cholesterol at baseline, statin dose and duration of statin use. 
bold value indicates statistically significant association.
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the MAF of the APOA1 rs533556 SNP was 37.7% (A allele). Both genotype distributions 
were in Hardy–Weinberg equilibrium.
Results of the linear regression analysis on cholesterol concentration after start of 
statin therapy under a genotypic model are shown in Table 4. Subjects with a minor 
allele of the rs1532624 SNP in the CETP gene showed a higher cholesterol concentration 
after start of statin therapy than subjects homozygous for the major allele, the reference 
category. This effect of genotype on cholesterol concentration was significant for the 
variant genotype compared with the homozygous major allele genotype (effect: 0.460 
mmol/L, P 0.006), but not significant for the heterozygous genotype compared with the 
homozygous major allele genotype (effect: 0.108 mmol/L, P 0.358). For the rs533556 
SNP in the APOA1 gene, no significant difference in cholesterol concentration after start 
of statin therapy between the different genotype categories was observed.
The results of the fixed effect inverse variance meta-analysis are shown in Figure 1. 
For the rs1532624 SNP in the CETP gene the β was 0.16 mmol/L (95% CI for β 0.08–0.24 
mmol/L), with a P-value of 1.4 × 10−4. For the rs533556 SNP in the APOA1 gene the β was 
0.10 mmol/L (95% CI for β 0.02–0.18 mmol/L, with a P-value of 0.02.
figure 1 Results of the meta-analysis of the CETP and APOA1 single nucleotide polymorphisms (SNPs)
Fixed effect inverse variance meta-analysis of the effect of the rs1532624 SNP in the CETP gene and the 
rs533556 SNP in the APOA1 gene on cholesterol concentration after start of statin therapy, in the Rotterdam 
Study (RS-I) and an extended cohort of the Rotterdam Study (RS-II). For each study, the β with correspond-
ing 95% CI is reported. (a) rs1532624 in the CETP gene. (b) rs533556 in the APOA1 gene.
Abbreviations: CETP, cholesteryl ester transfer protein; APOA1, apolipoprotein A-I; CI, confidence interval.
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diSCUSSion
In this study, we investigated whether SNPs in genes involved in the lipid metabolism 
modify the relationship between statin therapy and cholesterol response. We showed 
a statistically significant association between the rs1532624 polymorphism, located in 
intron 7 of the CETP gene, and cholesterol response to statin therapy. Subjects with a 
variant allele of the polymorphism showed a significantly smaller cholesterol reduction 
after start of statin therapy. This association was replicated in an independent cohort, 
reducing the chance of a false-positive association. There appears to be a dose–allele 
effect: the cholesterol concentration was on average 0.16 mmol/L higher per additional 
allele. We also demonstrated that subjects with at least one variant allele of the rs533556 
in the APOA1 polymorphism showed a significantly smaller cholesterol reduction after 
start of statin therapy in the discovery sample, however this association failed to repli-
cate.
To the best of our knowledge, the SNP (rs1532624) identified in this study has not 
been described before in the literature in association with cholesterol response to statin 
therapy. Previous pharmacogenetic studies investigated the relationship between 
CETP gene polymorphisms and lipid concentration.24-35 The polymorphism in the CETP 
gene that is most frequently described is the noncoding mutation TaqIB SNP in intron 
1. Several studies investigated the relationship between the TaqIB polymorphism and 
response to statin therapy.25,30,31,33-35 However, these studies used different study popula-
tions and examined different outcomes, for example, serum cholesterol concentrations, 
atherosclerosis progression and CVD outcomes, and the results are not conclusive. None 
of these studies showed a difference between the TaqIB genotype categories in total 
cholesterol concentration after start of statin therapy, the outcome variable we used in 
our study. Fiegenbaum et al.33 showed a greater HDL cholesterol increase for the CETP 
B2B2 homozygotes than for B1B2 and B1B1 subjects (14.1 vs 1.7% and 1.3%, P<0.05) 
in response to simvastatin treatment, but no effect on total cholesterol was seen. De 
Grooth et al.34 investigated the TaqIB polymorphism and change in total cholesterol, 
LDL-cholesterol and HDL-cholesterol, and reduction in nonfatal myocardial infarction 
and coronary heart disease mortality, in response to pravastatin treatment, but no dif-
ference between the genotype categories was shown. We have investigated whether 
the CETP rs1532624 SNP we found in this study was in linkage disequilibrium with the 
CETP TaqIB polymorphism. In our study, the TaqIB polymorphism was not available at 
the Illumina chip, but it was genotyped separately. The R2 between the CETP TaqIB SNP 
and the CETP rs1532624 SNP was 0.88.
The main difference between our study and the previous pharmacogenetic studies 
is the way the SNPs were selected for analysis. Most studies comprised only a few SNPs, 
selected from known candidate genes in the cholesterol or statin metabolism, and 
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known to be related to cholesterol. Although our study also used a candidate gene ap-
proach, we selected 18 genes all involved in the lipid metabolism from the literature. We 
aimed to identify those SNPs that define cholesterol concentration in response to statin 
therapy, and not SNPs that may define cholesterol concentration in general.
In this study, the assumption was made that a response to statin therapy was ob-
served after at least 1 week of statin therapy. It might be argued that this period is too 
short for statins to exert an effect. In clinical trials, often at least a 4-week period of 
statin therapy is taken, before the outcome is measured. In our study, 15.5% of all statin 
users had a first serum total cholesterol measurement between 1 and 4 weeks after the 
prescription date of statin therapy. However, it is unlikely that this results in a bias, as 
the time between the prescription date of statin therapy and the date of first serum 
total cholesterol measurement is likely to be independent of genotype. Inclusion of the 
time between the prescription of statin therapy and the first serum total cholesterol 
measurement in the linear regression analysis did not affect the results. Furthermore, 
when comparing subjects with a short duration of statin therapy use with subjects with 
a long duration of statin therapy use, the mean cholesterol response measurement was 
similar for both the groups.
Regarding the genotype distributions of the CETP polymorphism, given in Table 3, 
both in the discovery cohort and in the replication cohort a difference in genotype 
frequency between the source population and the study population was observed. 
In the study population, a lower frequency of subjects homozygous for the variant 
genotype was observed, and a higher frequency of subjects homozygous for the major 
allele, compared with the source population. An explanation for this difference might 
be that CETP genotype is related to the indication for statin therapy. In our population, 
the CETP genotype was related to HDL-cholesterol: subjects with a variant allele had 
a significantly higher baseline HDL-cholesterol, whereas the baseline total cholesterol 
concentration was equivalent to subjects homozygous for the major allele. Therefore, 
subjects with a variant allele have a better ratio between HDL- and LDL-cholesterol, and 
may be less likely candidates for statin therapy. This may explain the fact that in the 
study population of only statin users we observed fewer subjects homozygous for the 
variant genotype. However, this does not influence the validity of our findings, as our 
study population only consisted of statin users.
Potential limitations of our study should be considered. Selection bias is unlikely as 
missing of blood samples and difficulties with genotyping are not related to CETP and 
APOA1 genotype. Information bias is not likely, as genotype data, data on cholesterol 
measurements, and prescription data of statin therapy were collected prospectively 
without prior knowledge of the aim of the study. We controlled for potential confound-
ing factors such as age, gender, baseline total cholesterol, baseline HDL-cholesterol and 
statin dose in the linear regression analysis, in which we investigated potential effect 
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modification by genotype of the relationship between statin therapy and cholesterol 
response. Furthermore, because statins primarily have their effect on serum LDL-cho-
lesterol concentration, we preferred to consider serum LDL-cholesterol concentrations 
in response to statin therapy as our outcome variable of interest, instead of serum total 
cholesterol concentrations. Because LDL-cholesterol was determined less frequently in 
the Rotterdam Study, we unfortunately could not take this measurement as the outcome 
variable, as we had not enough power because of small sample size. Equally, we had an 
insufficient number of subjects to take Δ cholesterol, the difference between serum cho-
lesterol concentration before and after start of statin therapy, as our outcome variable 
of interest. If we could have taken the Δ cholesterol as our outcome variable, this would 
allow us to include SNPs that were related to both baseline total cholesterol concentra-
tion and serum total cholesterol concentration under statin therapy. For example, we 
had included a polymorphism in the APOE gene, which is one of the most replicated 
statin pharmacogenetic interactions.36-39 In this study, the polymorphism in the APOE 
gene had an effect on serum total cholesterol concentration under statin therapy, but 
was excluded because it was also related to baseline total cholesterol concentration. 
Finally, we could not exclude that we did not find a significant association for some of 
the remaining SNPs, due to a lack of power.
Our study has several strengths. An advantage of the Rotterdam Study is the prospec-
tive ascertainment of risk factors and outcome variables over a relatively long period 
of follow-up, through which extensive information is available for use in the analysis. 
Also, the Rotterdam Study has a population-based character, which reduces the risk of 
selection bias. Another strength of our study is the replication in an independent cohort 
to minimize the chance of reporting a false-positive association, however, the fact that 
our replication sample is collected from the same general population means that the 
replication does not add information on the generalizability to other populations.
In conclusion, we found that the CETP rs1532624 polymorphism was associated with 
total cholesterol concentration in response to statin therapy in a cohort of elderly Eu-
ropean statin users and an independent replication sample in the general population. 
The findings in this study may explain a small part of the interindividual variability in 
cholesterol response to statin therapy, although further research is recommended to 
define the genetic profile that predicts response to statin therapy.
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AbStrACt
Introduction: Recently, minor alleles of two strongly linked polymorphisms in the PPARA 
gene, rs4253728 G>A and rs4823613 A>G, were related to decreased CYP3A4 expression 
and activity. We studied whether they were associated with the cholesterol lowering 
effect of simvastatin.
Methods: We identified 123 incident users with cholesterol measurements before and 
after starting statin therapy in a prospective population-based cohort study. Associa-
tions between PPARA polymorphisms and change in total and low-density lipoprotein 
(LDL)-cholesterol levels were analyzed using linear regression.
Results: The minor G allele of the rs4823613 A>G polymorphism was associated with a 
0.258 mmol/l (95% CI −0.470; −0.046) and a 0.294 mmol/l (95% CI −0.495; −0.093) larger 
reduction in total and LDL-cholesterol, respectively, after starting simvastatin therapy. 
Results were similar for the rs4253728 G>A polymorphism.
Conclusion: The minor alleles of the PPARA rs4253728 and rs4823613 polymorphisms 
are associated with a better total and LDL-cholesterol lowering response to simvastatin, 
possibly through influence on CYP3A4.
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introdUCtion
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are choles-
terol lowering drugs, widely prescribed for the primary and secondary prevention of 
cardiovascular disease.1-4 Statins primarily act by lowering the low-density lipoprotein 
(LDL)-cholesterol concentration. In practice, the treatment goal of statin therapy 
is to reduce the LDL-cholesterol levels below a certain threshold, depending on the 
cardiovascular risk profile of a patient.5,6 Physicians may achieve this goal by monitor-
ing serum cho lesterol levels and adapting the daily dosage accordingly. Nevertheless, 
despite this dose titration, there is still a substantial proportion of patients who do not 
achieve their recom mended goal.7,8 This may have reasons such as noncompliance 
or co-medications interact ing with the drug. Variation in response can also be partly 
explained by genetic factors. SNPs in genes involved in the pharmacoki netics and phar-
macodynamics of statins can interfere with the cholesterol lowering effect.9,10 In previ-
ous years, several SNPs that were associated with differences in cholesterol low ering 
response to statins were discovered in either candidate gene studies or genome-wide 
association studies.9-13
The CYP3A4 enzyme is the main enzyme responsible for the metabolism of simvas-
tatin, whereas there is also a minor contribution of CYP3A5.14-17 In the past few years, 
functional polymorphisms in the CYP3A4 and CYP3A5 gene have been reported that 
influence metabo lizing activity. The minor allele of the recently discovered intron 6 
CYP3A4*22 polymorphism has been associated with decreased CYP3A4 expression and 
function, and with a stronger cholesterol lowering response to simvastatin therapy.18,19 
The more commonly described CYP3A4*1B polymorphism has been associated with a 
decreased reduction in LDL-cholesterol levels in atorvastatin users20, and with a lower 
risk of a dose decrease or a switch to another cholesterol lowering therapy – as proxies 
of an adverse drug reaction – in simvastatin and atorvastatin users.21 CYP3A5*3, the most 
frequent and functionally relevant CYP3A5 polymorphism, has been associated with a 
decreased CYP3A5 expression and a stronger cholesterol lowering response to statin 
ther apy.22,23 The CYP3A4*1B allele is in strong linkage disequilibrium with the CYP3A5*1 
functional allele, and the CYP3A5*3 allele is in strong linkage disequilibrium with the 
CYP3A4*1A allele.24-26
Recently, genetic variation in the peroxisome proliferator-activated receptor alpha 
(PPARA) gene, coding the nuclear receptor PPARα, was discovered as a novel genetic 
determinant influ encing CYP3A4 activity.27 The minor alleles of the strongly linked 
PPARA rs4253728 G>A and rs4823613 A>G polymorphisms were associated with signifi-
cantly decreased CYP3A4 expression and activity. These polymorphisms might there fore 
influence the pharmacokinetics of drugs that are primarily metabolized by the CYP3A4 
enzyme, such as simvastatin. We hypothesized that the minor alleles of the rs4253728 
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G>A and rs4823613 A>G polymorphisms are associated with an increased cholesterol 
lowering response of simvastatin.
In our study, the objective was to investigate whether the minor alleles of the 
rs4253728 G>A and rs4823613 A>G polymorphisms in the PPARA gene were associated 
with response to simvastatin therapy, as assessed by increased serum total cholesterol 
and LDL-cholesterol level reductions after start of therapy in a large population-based 
cohort study. We also investi gated the association in users of other statins to exclude the 
possibility of a pharmacodynamic group effect. Analyses were adjusted for the effect of 
the CYP3A4 and CYP3A5 genotypes.
mEthodS
Setting
The Rotterdam Study is a prospective popula tion-based cohort study of chronic diseases 
in the elderly population. From 1990 to 1993, 7983 inhabitants of the suburb Ommoord 
in Rotter dam, The Netherlands, aged 55 years or older, entered the Rotterdam Study 
(RS-I) and gave written informed consent. Ethical approval was obtained from the 
medical ethical committee of the Erasmus Medical Center, Rotterdam, The Netherlands. 
Participants were invited between 1990 and 1993 and have been continuously fol lowed 
since then. Medication prescription data were obtained from all seven fully computer-
ized pharmacies in the Ommoord suburb. These pharmacies dispense the prescriptions 
of more than 99% of all participants. Information on all filled prescriptions from 1 
January 1991 until 1 June 2008 was available and included infor mation on the product 
name of the drug, the Anatomical Therapeutical Chemical code, the amount dispensed, 
the prescribed dosage regi men and the date of dispensing.28 Further more, in 2000, an 
extended cohort was enrolled, the Rotterdam Study II (RS-II). A total of 3011 inhabitants 
entered the study and have been con tinuously followed since then. Detailed informa-
tion on design, objectives and methods of this study have been described before.29,30
For this study, we used the total cholesterol and LDL-cholesterol assessments from the 
‘Star-Medisch Diagnostisch Centrum’ (Star-MDC), which performs all outpatient labo-
ratory assessments for general practitioners in the Rijnmond area of Rotterdam with 
a poten tial source population of more than 1 million inhabitants. All outpatient total 
cholesterol and LDL-cholesterol assessments from the partici pants of the Rotterdam 
Study between 1 April 1997, the time at which a new computer system was introduced 
at Star-MDC, and 1 June 2008 were obtained.
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Study sample
The study sample consisted of all participants in the Rotterdam Study who were incident 
statin users in the period between 1 April 1997 and 1 June 2008; who had a measurement 
of total and/or LDL-cholesterol level in the period of 180 days before the first prescrip-
tion and in the period between 7 and 180 days following the first prescription; and for 
whom DNA was avail able. Incident statin use was defined as a first dis pensed prescrip-
tion for a particular statin in the database, without prior prescriptions for other statins in 
the period between 1 January 1991 and 1 April 1997. Patients who discontinued statin 
therapy before the first measurement after the start of the study were excluded. Patients 
who were coprescribed fibrates, bile acid sequestrants, nicotinic acids or ezetimibe at 
the time of one of the measurements were also excluded.
outcome
In this study, the outcome of interest was total and LDL-cholesterol response to statin 
ther apy. We analyzed the association between the PPARA rs4253728 G>A and rs4823613 
A>G polymorphisms and reductions in total and LDL-cholesterol level, measured as the 
differ ence in mmol/l between the last measurement before start and the first measure-
ment after start of statin therapy.
Covariables
Age, sex, the level at the last total cholesterol/LDL-cholesterol measurement before start 
of statin therapy, the daily prescribed dose at the time of the first measurement after the 
start of statin ther apy, CYP3A4*22 (intron 6, rs35599367 C>T) genotype and CYP3A5*3 
(rs776746 A>G) geno type were considered as potential confounders or effect modifiers 
for affecting the associa tion between the PPARA polymorphisms and the change in total 
and LDL-cholesterol level. The daily prescribed dose was given in defined daily dose, to 
facilitate direct dose comparisons between drugs from the same pharmacothera peutic 
group. Adjustment for CYP3A4*22 and CYP3A5*3 genotype was done by adjusting for 
the number of minor alleles (additive model) per genotype.
Genotyping & SnP selection
At baseline examination of the Rotterdam Study, blood was taken from which genomic 
DNA was extracted, using the salting-out method.31 Microarray genotyping was per-
formed in both Rotterdam Study cohorts, using the Infinium II HumanHap550K Genotyp-
ing BeadChip version 3 (Illumina Inc., CA, USA). Genotyping procedures were followed 
accord ing to the manufacturer’s protocols. Microar ray genotyping procedures in the Rot-
terdam Study have been previously described.32 The PPARA polymorphisms rs4253728 
G>A and rs4823613 A>G were both genotyped as a tag ging SNP on the Illumina Bead-
Chip. The two polymorphisms were in almost complete linkage disequilibrium (R2 = 0.96).
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Statistical analysis
We investigated the association between genetic variants and serum total and LDL-
cholesterol in all incident simvastatin users, because we expected an association on the 
basis of the pharmacokinetic mechanism via CYP3A4 expression. The association was 
also investigated in incident atorvastatin users, since CYP3A4 is also a contributor to 
the metabolism of atorv astatin, albeit to a lesser extent. Furthermore, we investigated 
this association in all incident statin users combined to exclude a possible pharmaco-
dynamic effect. Potential deviations from Hardy–Weinberg equilibrium were tested 
using a X2 test. A multivariable linear regression model was used to analyze differences 
between the PPARA rs4253728 G>A and rs4823613 A>G genotype groups in change in 
total choles terol and LDL-cholesterol. This was investigated for all statin users combined, 
and for starters with simvastatin and atorvastatin separately. We analyzed both additive 
models, investigating the change in total and LDL-cholesterol level per additive minor 
allele, and categorical models, investigating the change in total and LDL-cho lesterol 
for the heterozygous genotype category and the homozygous minor allele genotype 
cat egory compared with the homozygous major allele genotype category. Multivari-
able linear regression models were also used to analyze diff erences between the PPARA 
rs4253728 G>A and rs4823613 A>G genotypes and baseline total and LDL-cholesterol 
levels, and the diff erences in time from start of simvastatin ther apy and the first total 
cholesterol measurement after the start of therapy. The analyses were per formed using 
SPSS software (SPSS Inc., version 20.0, IL, USA).
rESUltS
We identified 123 incident statin users in the Rotterdam Study (RS-I and RS-II), who had 
a serum cholesterol measurement in the period of 180 days before and in the period be-
tween 7 and 180 days after start of statin therapy, and who had genotype data available 
for the PPARA polymorphisms. The study population consisted of 77 incident simvastatin 
users, 29 incident atorvastatin users, and 17 incident users of other statins (pravastatin: 
eight; fluvastatin: four; cerivastatin: four; and rosuvastatin: one). Baseline characteristics 
of the study population are shown in Table 1.
In the analysis of all incident statin users combined, no significant associations were 
found between the PPARA rs4253728 G>A and rs4823613 A>G polymorphisms and 
change in total and LDL-cholesterol level (Table 2).
We subsequently analyzed incident simvas tatin users separately. In the subgroup of 
77 incident simvastatin users, the minor allele fre quency of the rs4253728 G>A polymor-
phism was 30.5% (A allele), and for the rs4823613 A>G polymorphism the minor allele 
fre quency was 32.5% (G allele). The genotype distributions of both polymorphisms were 
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in Hardy–Weinberg equilibrium (P 0.24 for the rs4253728 G>A polymorphism, P 0.27 for 
the rs4823613 A>G polymorphism; Table 1). No significant differences among genotype 
groups were found when considering the time between the last cholesterol measure-
ment and start of simvastatin therapy or the time between start of simvastatin therapy 
and the first cholesterol measurement. Neither were significant differ ences observed 
in baseline LDL-cholesterol or baseline total cholesterol measurements. The average 
time between start of simvastatin therapy until the first cholesterol measurement was 
51 days for the total cholesterol measure ment (standard deviation [SD] 33 days), and 53 
days for the LDL-cholesterol measurement (SD 34 days). The average decrease in total 
and in LDL-cholesterol levels after start of simvas tatin therapy were 2.1 mmol/l (SD 0.6 
mmol/l) and 2.0 mmol/l (SD 0.7 mmol/l), respectively.
The results of the multivariable linear regres sion analyses on the association between 
the PPARA rs4253728 G>A and rs4823613 A>G polymorphisms and the change in total 
and LDL-cholesterol levels during simvastatin therapy are shown in Table 2. For the 
table 1 Baseline characteristics of the study population
Characteristic
All incident statin users 
(n = 123)
incident simvastatin 
users (n = 77)
incident atorvastatin 













N 54 69 33 44 15 14
Sex (N male, %) 21 (38.9) 35 (36.2) 16 (45.7) 18 (42.9) 3 (20.0) 2 (14.30
Age (years, mean ± SD) 71.1 ± 4.6 71.6 ± 4.9 71.5 ±4.9 71.6 ±5.1 70.7 ± 4.1 70.1 ± 3.8
TOTc before start 
(mmol/L, mean ± SD)
7.09 ±1.01 6.77 ± 1.05 6.92 ± 0.88 6.80 ± 1.11 7.54 ± 1.30 6.77 ± 1.11
LDLc before start 
(mmol/L, mean ± SD)
4.70 ± 1.00 4.51 ± 0.93 4.73 ± 0.89 4.59 ±1.00 4.84 ± 1.29 4.35 ± 0.98
ΔTOTc 
(mmol/L, mean ± SD)
−2.27 ± 0.79 −2.14 ± 0.72 −2.04 ± 0.63 −2.19 ±0.66 −2.94 ± 0.73 −2.51 ± 0.65
ΔLDLc 
(mmol/L, mean ± SD)
−2.04 ± 0.77 −1.97 ± 0.71 −1.91 ± 0.67 −204 ± 0.61 −2.48 ±0.86 −2.21 ± 0.72
Statin dose (mean ± SD)
– at first TOTc 
measurement after start
0.55 DDDb ± 
0.25






11.3 mg ± 
3.5
15.0 ± 5.2
– at first LDLc 
measurement after start








11.3 mg ± 
3.5
15.4 ± 5.2
Abbreviations: DDD, defined daily dosage; TOTc, total cholesterol; LDLc, low-density lipoprotein cholester-
ol; SD, standard deviation. a Baseline characteristics are only shown for the rs4823613 A>G polymorphism 
and not for the rs4253728 G>A polymorphism, because they are almost in complete linkage disequilib-
rium (R2 = 0.96); the AA genotype is the homozygous major allele genotype (reference category). b DDD, 
facilitates direct dose comparisons between drugs from the same therapeutic group. ΔLDLc: Change in 
low-density lipoprotein cholesterol from start of statin therapy; ΔTOTc: Change in total cholesterol from 
start of statin therapy.
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table 2 Association between the PPARA rs4253728 G>A and rs4823613 A>G polymorphisms and total and 
low-density lipoprotein cholesterol reduction during statin therapy – all incident statin users versus inci-
dent simvastatin users versus incident atorvastatin users
Genotype
All incident statin users 
(n = 123)
incident simvastatin users 
(n = 77)
incident atorvastatin 











rs4253728 G>A: total cholesterol
Additive modelc −0.028 (−0.213; 0.157) 0.761 −0.247 (−0.458; −0.035) 0.023 0.224 (−0.111; 0.560) 0.177
Categorical modeld
– GG (ref ) – (ref ) – (ref ) –
– GA 0.070 (−0.145; 0.285) 0.522 −0.189 (−0.437; 0.059) 0.132 0.224 (−0.111; 0.560) 0.177
– AA −0.379 (−0.901; 0.142) 0.152 −0.603 (−1.130; −0.076) 0.026 –e –
rs4253728 G>A: ldl-cholesterol
Additive model 0.067 (−0.157; 0.291) 0.557 −0.253 (−0.458; −0.049) 0.016 0.099 (−0.180; 0.379) 0.461
Categorical model
– GG (ref ) – (ref ) – (ref ) –
– GA 0.096 (−0.181; 0.373) 0.495 −0.165 (−0.410; 0.079) 0.181 0.099 (−0.180; 0.379) 0.461
– AA 0.071 (−0.497; 0.639) 0.804 −0.641 (−1.140; −0.142) 0.013 –e –
rs4823613 A>G: total cholesterol
Additive model −0.011 (−0.189; 0.167) 0.904 −0.258 (−0.470; −0.046) 0.018 0.198 (−0.093; 0.488) 0.170
Categorical model
– AA (ref ) – (ref ) – (ref ) –
– AG 0.054 (−0.166; 0.274) 0.629 −0.207 (−0.454; 0.040) 0.099 0.215 (−0.136; 0.566) 0.213
– GG −0.163 (−0.618; 0.292) 0.479 −0.614 (−1.140; −0.088) 0.023 0.339f (−0.500; 1.178) 0.406
rs4253728 G>A: ldl-cholesterol
Additive model 0.034 (−0.186; 0.253) 0.761 −0.294 (−0.495; −0.093) 0.005 0.019 (−0.222; 0.260) 0.869
Categorical model
– AA (ref ) – (ref ) – (ref ) –
– AG 0.074 (−0.204; 0.352) 0.599 −0.224 (−0.465; 0.016) 0.066 0.150 (−0.126; 0.427) 0.265
– GG −0.007 (−0.547; 0.534) 0.981 −0.672 (−1.154; −0.180) 0.008 −0.337f (−0.977; 
0.303)
0.279
Abbreviations: CI, confidence interval; LDL, low density lipoprotein.
a Full model: adjusted for age, sex, statin dose, cholesterol level before start, CYP3A4*22 genotype and 
CYP3A5*3 genotype. b Average change in total cholesterol and LDL-cholesterol level between the last mea-
surement before start and the first measurement after start of statin therapy. c Number of copies of the mi-
nor allele. d Categorical model with the homozygous major allele genotype as the reference category. e No 
atorvastatin users with the rs4253728 minor allele AA genotype. f One atorvastatin user with the rs4823613 
minor allele GG genotype. bold value indicates statistically significant association.
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PPARA rs4823613 A>G polymorphism, the minor G allele was associated with a trend 
towards a stronger cholesterol response to simvastatin after the start of therapy, as 
reflected by the larger reduction in total and LDL-cholesterol for carriers of the minor 
G allele compared with the homozygous major allele AA genotype. In the full model 
with the homozygous major allele AA genotype as the reference category, the increased 
reduction in total cholesterol was −0.207 mmol/l (95% CI −0.454; 0.040, P 0.099) for the 
heterozygous AG genotype, and −0.614 mmol/l (95% CI −1.140; −0.088, P 0.023) for the 
homozygous minor allele GG genotype. For LDL-cholesterol, the increased reduction 
was −0.224 mmol/l (95% CI −0.465; 0.016, P 0.066) for the heterozygous AG genotype, 
and −0.672 mmol/l (95% CI −1.164; −0.180, P 0.008) for the homozygous minor allele GG 
genotype.
The results of the analyses for the PPARA rs4253728 G>A polymorphism showed simi-
lar significant results as for the rs4823613 A>G polymorphism (Table 2).
We did not find an interaction between the rs4823613 A>G polymorphism and the 
CYP3A4*22 (P-value for interaction term 0.748) or the CYP3A5*3 polymorphism (P-value 
for interaction term 0.624) in the analysis on change in total cholesterol. Also, we did not 
find an interaction between the rs4823613 A>G polymorphism and the CYP3A4*22 (P-
value for interaction term: 0.748) or the CYP3A5*3 poly morphism (P-value for interaction 
term: 0.624) in the analysis on change in LDL-cholesterol. These results were similar for 
the rs4253728 G>A polymorphism. In the full model, both CYP polymorphisms showed 
a non-significant association towards a stronger cholesterol low ering response to simv-
astatin, with a mean β of −0.254 mmol/l for the CYP3A4*22 polymor phism and a mean β 
of −0.319 mmol/l for the CYP3A5*3 polymorphism.
An analysis in the 29 incident atorvastatin users separately showed no significant as-
sociation (Table 2). For atorvastatin, we could not investi gate the association in the dif-
ferent genotype categories, since there was only one atorvastatin user with two minor 
alleles of the rs4823613 A>G polymorphism, and no atorvastatin user with two minor 
alleles of the rs4253728 G>A polymorphism.
diSCUSSion
In this population-based cohort study, the rs4253728 G>A and rs4823613 A>G polymor-
phisms in the PPARA gene were associated with the total and LDL-cholesterol lowering 
effect of simvastatin therapy. For the PPARA rs4253728 G>A polymorphism, the minor 
A allele was associated with a 0.247 mmol/l larger reduction in total cholesterol and 
a 0.253 mmol/l larger reduction in LDL-choles terol. For the PPARA rs4823613 A>G 
polymor phism, the minor G allele was associated with a 0.258 mmol/l larger reduction in 
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total cho lesterol and a 0.294 mmol/l larger reduction in LDL-cholesterol. The association 
disappeared when we considered all incident statin users combined.
This is the first study that demonstrates an association between the strongly linked 
PPARA rs4253728 G>A and rs4823613 A>G polymorphisms and the cholesterol lowering 
effect of simvastatin. The PPARA gene encodes PPARα, which is part of a family of nuclear 
receptors – PPARα, PPARδ and PPARγ –, each encoded by a different gene, and with a 
specific tissue expres sion in which they regulate the transcription of multiple genes. 
PPARα is highly expressed in the liver and is involved in the regulation of lipid metabo-
lism, inflammation and vascular function, and hence interferes with the process of ath-
erogenesis. The effects of PPARα on gene regulation result in an increased high-density 
lipoprotein production by the liver, a decrease in atherogenic LDL-cholesterol levels, a 
decrease in triglyceride levels, and a decreased produc tion as well as an increased clear-
ance of very-low-density lipoprotein. These effects tend to decrease the atherosclerotic 
risk.33-35 Genetic polymorphisms in the PPARA gene have been described and studies 
conducted in rodents and humans have suggested a link between genetic variation in 
the PPARA gene and serum lipid levels and cardiovascular disease.36-42 How ever, only a 
few studies thus far investigated the effect of the rs4253728 G>A and rs4823613 A>G 
polymorphisms. A recent study in Chinese patients with hypercholesterolemia could 
not demonstrate an association between the PPARA rs4823613 A>G polymorphism and 
the change in LDL-cholesterol level after 6 weeks of treat ment with simvastatin 40 mg.43 
Although this study also investigated simvastatin response by determining the differ-
ence in LDL-cholesterol levels before and after start of simvastatin treat ment, in contrast 
with our study the population consists of Asian people with a relatively lower age (55.6 
years). Also, the Rotterdam Study has a population-based setting in which medication 
prescription data are collected through linkage with pharmacies, in contrast with the 
Chinese study in which all patients were treated with 40 mg of simvastatin for 6 weeks. 
Furthermore, genetic structure differs between races and the rs4253728 polymorphism 
is absent in Japanese and Chinese populations. Another study dem onstrated an asso-
ciation between the minor allele of the rs4253728 G>A polymorphism and increased 
triglycerides and apolipopro tein CIII levels in African-Americans but not in Caucasians. 
However, the effect of statin therapy was not investigated.36 No associa tion with total 
cholesterol, LDL-cholesterol or high-density lipoprotein cholesterol levels was found. 
Another study did not find an associa tion between the rs4253728 G>A polymor phism 
and myocardial infarction.37 In our study of only Caucasians, both PPARA poly morphisms 
were not associated with baseline total and LDL-cholesterol levels but only with the 
response to simvastatin.
Based on the results in the study of Klein et al.27, as mentioned in the introduction, and 
in the findings in the current study, a pharmacokinetic mechanism seems to be the most 
plausible explanation for the effect of the PPARA polymorphisms on the cholesterol low-
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ering effect of simvastatin therapy. The CYP3A4 enzyme is involved in the metabolism of 
several statins – simvastatin, atorvastatin, lovastatin and cerivastatin –, with the largest 
effect of CYP3A4 on simvastatin metabolism. A recent study established that the nuclear 
recep tor PPARa directly influenced the expression of CYP3A4.44 In the study of Klein et 
al., the minor alleles of the PPARA rs4253728 G>A and rs4823613 A>G polymorphisms 
were asso ciated with significantly lower CYP3A4 protein expression and enzyme activity 
in vitro.27 Fur ther testing of the rs4253728 G>A polymor phism in atorvastatin-treated 
volunteers con firmed a decrease in atorvastatin metabolism in carriers with two minor 
alleles compared with heterozygous or homozygous major allele carriers. Our results are 
in line with this. The minor alleles of the PPARA rs4253728 G>A and rs48236313 A>G poly-
morphisms signifi cantly decrease the CYP3A4 enzyme activity, leading to a decreased 
simvastatin metabolism and therefore an increased plasma simvastatin concentration. 
Thus, the minor alleles of the PPARA polymorphisms are likely to be associ ated with a 
better cholesterol lowering response to simvastatin therapy. In the study of Klein et al.27, 
the effect of the rs4253728 G>A polymorphism was demonstrated in partici pants using 
atorvastatin, while in our study we did not find an association for incident atorv astatin 
users, neither for all statin users com bined. For atorvastatin, the CYP3A4 enzyme is also 
a contributor to its metabolism. In the study of Klein et al. the decrease in atorvastatin 
metabolism was tested by measuring atorvas tatin-2-hydroxylation, the major metabo-
lite of atorvastatin, after a single-dose of atorvastatin. In our population-based study the 
outcome measure was cholesterol response, derived from clinically driven cholesterol 
measurements from outpatient laboratory assessments. Simv astatin undergoes more 
extensive metabolism by CYP3A4 than atorvastatin, thus inhibition of CYP3A4 by 
co-medication or genetic factors such as the PPARA polymorphisms produces a more 
increased serum simvastatin concentra tion than serum atorvastatin concentration.45,46 
This may explain the fact that in our study, we did find an association in simvastatin 
users, but could not demonstrate an association in atorvastatin users. Atorvastatin users 
with a minor allele had a significantly higher dose than atorvastatin users homozygous 
for the major allele. This would have led to an overestimation of the results in carriers 
of a minor allele, but no association in atorvastatin users was found at all. However, our 
study had too low a power to investigate the association in atorvastatin users, since we 
only had 29 incident atorvastatin users available. Only one user had two minor alleles of 
the rs4823613 A>G polymorphism, and there was no user with two minor alleles of the 
rs4253728 polymorphism. Therefore, an association in atorvastatin users could not be 
excluded and investigating the association in a larger population of atorvastatin users is 
neces sary before definite conclusions can be drawn regarding this association.
Potential biases and limitations in our study should be considered. The PPARA polymor-
phisms were not associated with baseline cholesterol level before start of simvastatin 
therapy. Therefore, it is unlikely that differ ences in cholesterol levels were already pres-
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ent before the start of simvastatin therapy. Genetic variation in the PPARA gene was also 
not associated with plasma lipid levels in the meta-analyses by Teslovich et al.47, a large 
study that revealed 95 loci significantly associ ated with plasma lipid levels. This agrees 
with our finding that the PPARA polymorphisms really influence cholesterol response. 
The effect of statins is already measurable after 1 week of treatment, with the maximum 
effect reached after 4–6 weeks. We included patients with a cholesterol measurement 
7 days after start of statin therapy to prevent potential biases. In response to a choles-
terol measurement in the first 1–4 weeks after start of therapy, adjust ments in therapy 
could have occurred such as a change in dose or switching to another statin. The fact 
that the cholesterol lowering effect during that period has not reached its maxi mum 
would have led to an underestimation of the results, and the actual effect of the PPARA 
polymorphisms on the cholesterol lowering effects of statins is possibly even larger. We 
had a low sample size of only 77 incident sim vastatin users. Despite this limited number 
we found a statistically significant association, indicating that the effect of the PPARA 
poly morphisms on CYP3A4 activity and thus the cholesterol lowering effect of simvas-
tatin might be large. The association was adjusted for the effect of the CYP3A4*22 and 
CYP3A5*3 poly morphisms. Both CYP polymorphisms showed a non-significant associa-
tion towards a stronger cholesterol lowering response, as was expected on the basis of 
previous literature. Unfortu nately, we had insufficient numbers of users of other statins 
other than simvastatin to analyze these statins individually. It would be interest ing to 
investigate whether in our population the PPARA polymorphisms influence CYP3A4 ex-
pression and activity in vitro. Unfortunately, we have no in vitro expression data available 
for this study.
In conclusion, in the Rotterdam Study the strongly linked rs4253728 G>A and 
rs4823613 A>G polymorphisms in the PPARA gene were associated with a stronger total 
and LDL-choles terol lowering response to simvastatin therapy. This is the first study 
that demonstrates an effect of these PPARA polymorphisms on the cholesterol lowering 
effect of simvastatin. With this study, we provide further evidence for the hypothesis 
that the influence of these PPARA polymorphisms on the cholesterol lowering effect of 
simvastatin acts through influence of these polymorphisms on CYP3A4 enzyme activ ity. 
Although these findings are interesting, one might question whether this will lead to 
tailored pharmacotherapy. After all, even if patients with a minor allele have a stronger 
intended choles terol lowering effect, the majority of patients with two major alleles will 
still keep their indi cation for statin therapy. However, they might possibly respond better 
with a higher dose, in which case pharmacogenetics might have clinical consequences.
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fUtUrE PErSPECtivE
We observed that genetic variation in the PPARA gene is associated with a cholesterol 
lowering response to simvastatin. We hypoth esize that this effect appears through influ-
ence of genetic variation in the PPARA gene on CYP3A4 enzyme activity. This might be 
considered as a significant step towards a better management of treatment with drugs 
that are predominantly metabolized by the CYP3A4 enzyme. Since CYP3A4 is one of the 
most important enzymes in drug metabolism, this could be clinically rel evant. Future 
pharmacogenetic studies should focus on the impact of PPARA polymorphisms on the 
response to drugs metabolized by CYP3A4, and should further evaluate whether this 
impact should lead to adjustment of the current treatment guidelines in place for opti-
mization of treatment efficacy and avoidance of drug toxicity. Namely, statin efficacy 
(cholesterol lowering) and the occurrence of adverse drug reactions are both related 
to plasma statin con centrations. According to our hypothesis, one would expect that 
carriers of the minor alleles of the PPARA polymorphisms would have a higher risk of 
statin-induced adverse drug reactions. This would be an interesting topic for further 
research.
In general, the field of statin pharmacogenomics will evolve during the next few years 
and new genetic variation involved in statin response will be discovered through the 




• The CYP3A4 enzyme is the main enzyme responsible for the metabolism of simvastatin.
• Recently, it was discovered that the minor alleles of the two strongly linked poly-
morphisms in the PPARA gene, rs4253728 G>A and rs4823613A>G, decrease CYP3A4 
expression and activity.
• Decreased CYP3A4 activity may result in increased simvastatin plasma levels and 
stronger cholesterol lowering response.
methods
• We analyzed whether these PPARA polymorphisms were associated with a reduction 
in total and low-density lipoprotein (LDL)-cholesterol levels after start of simvastatin 
therapy.
• We adjusted for CYP3A4*22 and CYP3A5*3 genotype, since both polymorphisms 
have been associated with response to statin therapy.
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results: main findings
• The minor G allele of the rs4823613 A>G polymorphism was associated with a 0.258 
mmol/l (95%CI −0.470; −0.046, P 0.018) larger reduction in total cholesterol and a 
0.294 mmol (95% CI −0.495; −0.093, P 0.005) larger reduction in LDL-cholesterol after 
start of simvastatin therapy.
• Categorical analyses demonstrated a −0.614 mmol/l (95% CI −1.140; −0.088; P 0.023) 
larger reduction in total cholesterol and a −0.672 mmol/l (95% CI −1.164; −0.180, 
P 0.008) larger reduction in LDL-cholesterol, for the homozygous minor allele GG 
genotype compared with the reference homozygous major allele AA genotype.
• The results were similar for the strongly linked rs4253728 G>A polymorphism.
• No association was found with all incident statin users combined, to exclude the 
possibility of a pharmacodynamic group effect.
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AbStrACt
Introduction: Recently, the minor allele of the rs13064411A>G polymorphism in the WD 
repeat domain 52 (WDR52) gene was associated with increased statin-induced propro-
tein convertase subtilisin/kexin type 9 (PCSK9) levels, and with low-density lipoprotein 
(LDL)-cholesterol response to statins. PCSK9 promotes LDL-receptor degradation, lead-
ing to increased serum LDL-cholesterol. We investigated whether the polymorphism 
was associated with cholesterol response to statins.
Methods: We identified 1105 current, 322 past, and 4831 never statin users during follow-
up in the prospective population-based Rotterdam Study. Mean delta total, LDL- and 
high density lipoprotein (HDL)-cholesterol levels between current and no current statin 
users with the same number of minor alleles were analyzed using random effect re-
peated measurements. We adjusted for age, sex, number of cholesterol measurements, 
and follow-up time.
Results: Compared to no users with the same genotype, current statin users carrying 
a minor allele showed a statistically significantly lower delta total and LDL-cholesterol 
compared to reference homozygous major allele carriers (total: Δ-0.551 mmol/L [AG+GG] 
vs. Δ-0.732 mmol/L [AA], Pinteraction 5.2 × 10−7; LDL: Δ-0.566 mmol/L [AG+GG] vs Δ-0.720 
mmol/L[AA], Pinteraction 1.8 × 10−5). The effect was stronger in women (Pinteraction: 2.0 × 10−5 
for LDL-cholesterol, 8.0 × 10−6 for total cholesterol) and in high dose users (defined daily 
doses >1.00) (Pinteraction 7.0 × 10−5 for LDL-cholesterol, Pinteraction 0.081 for total cholesterol). 
The polymorphism was not associated with HDL-cholesterol in current statin users, nor 
with total, LDL- and HDL-cholesterol in never statin users.
Conclusion: The minor G allele of the rs13064411 polymorphism, associated with statin-
induced PCSK9-levels, was associated with a decreased LDL- and total cholesterol-
lowering response to statins.
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introdUCtion
The 3-hydroxy-3-methylglutary coenzyme A (HMG-CoA) reductase inhibitors or statins 
are cholesterol lowering drugs, widely prescribed for the primary and secondary pre-
vention of cardiovascular disease. Statins primarily act on serum low density lipoprotein 
(LDL)-cholesterol by interfering with the cholesterol metabolism through inhibition 
of HMG-CoA reductase, the rate-limiting step in the cholesterol metabolism pathway. 
This leads to upregulation of LDL-receptors in the hepatocyte, resulting in an increased 
uptake of LDL-cholesterol from the serum and a decreased serum cholesterol concen-
tration.1-4 In clinical practice, there is a substantial difference between individuals in 
cholesterol lowering response to statin therapy. A part of this variability in response can 
be explained by genetic factors. Several single nucleotide polymorphisms have already 
been discovered that were associated with a modified cholesterol lowering response 
to statin therapy.5-7 For example, the apolipoprotein (APOE) E2 variant has frequently 
been associated with a better LDL-cholesterol lowering response in both candidate and 
genome-wide association studies.8-14
Proprotein convertase subtilisin/kexin type 9, or PCSK9, is involved in the cholesterol 
homeostasis and promotes LDL-receptor degradation. In the liver, PCSK9 binds to the LDL-
receptor and is internalized together with the LDL-receptor. Subsequently, this binding of 
PCSK9 to the LDL-receptor induces modification of LDL-receptor conformation, avoiding 
normal cycling of the LDL-receptor to the plasma membrane and enhancing lysosomal 
degradation. As a result, the number of LDL-receptors at the cell surface of hepatocytes 
is decreased and less LDL-cholesterol is taken up from the serum, with consequently 
a higher serum LDL-cholesterol level.15-17 Serum PCSK9 levels have been shown to be 
positively correlated with both LDL-cholesterol and total cholesterol levels.18-22 Also, it 
was demonstrated that statin therapy increases serum PCSK9 concentrations.19,20,22-26 The 
influence of PCSK9 on cholesterol metabolism and the interaction with statin therapy, 
is of such interest that currently PCSK9-inhibitors are developed as a potential effective 
LDL-cholesterol lowering treatment alone or in combination with statin therapy.27-30
A recent study discovered a polymorphism that was genome-wide significantly (P = 
8.2 × 10−8) associated with statin-induced changes in plasma PCSK9 levels, and modified 
the LDL-cholesterol lowering response to statins.31 The minor allele of the rs13064411 
polymorphism in the WD repeat domain 52 (WDR52) gene was associated with increased 
simvastatin-induced PCSK9 concentrations compared to the homozygous major allele 
genotype. This study was the first one that showed the influence of genetic variation 
on statin-induced changes in serum PCSK9 levels. We aimed to investigate whether this 
polymorphism showed interaction with the effect of statin therapy on serum cholesterol 
measurements. Due to the increased statin-induced PCSK9-levels, statin users carrying 
a minor allele are expected to have an increased LDL-receptor degradation with con-
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sequently less uptake of LDL-cholesterol from the serum into the hepatocytes, thus a 
decreased cholesterol lowering response to statin therapy.
In our study, the objective was to investigate whether the minor allele of the 
rs13064411 polymorphism in the WDR52 gene showed interaction with statin therapy, 
as assessed by a modified effect of the minor allele on serum total, LDL- and high density 
lipoprotein (HDL)-cholesterol levels in statin users compared with non-statin users in a 
large population-based cohort study.
mEthodS
Setting
The current study was performed within the Rotterdam Study, a prospective population-
based cohort study that aims to study the frequency and determinants of diseases in the 
middle-aged and elderly people. The rationale and design of the Rotterdam Study have 
been described in detail previously.32,33 In short, all 10,275 persons aged 55 years and 
over in the Ommoord district of Rotterdam, the Netherlands, were invited to participate. 
Of them, 7,983 (78%) were enrolled between 1990 and 1993 (RS-I). At baseline, all par-
ticipants were interviewed at home and underwent extensive clinical examination at the 
research center. Additional re-examinations took place in 1993-1995, 1997-1999, 2002-
2004, and 2009-2012. In 2000, an extended cohort was enrolled[ when 3011 inhabitants 
entered the study and have been continuously followed since then (RS-II). Furthermore, 
in 2006 a third cohort started (RS-III) including 3932 inhabitants aged 45 years and over. 
The Rotterdam Study has been approved by the medical ethics committee according to 
the Wet Bevolkingsonderzoek: ERGO (Population Study Act: Rotterdam Study), executed 
by the Ministry of Health, Welfare and Sports of the Netherlands. All participants gave 
informed consent to participate in the study and to obtain information from treating 
physicians and pharmacies, separately.
Medication prescription data are continuously obtained from all seven fully computer-
ized pharmacies in the Ommoord district. These pharmacies dispense the prescriptions 
of more than 95% of all participants. Information on all filled prescriptions from 1 Janu-
ary 1991 until 31 January 2012 was available and included information on the product 
name of the drug, the Anatomical Therapeutical Chemical code (ATC-code), the amount 
dispensed, the prescribed dosage regimen and the date of dispensing.34
For this study, we used the total cholesterol, LDL- and HDL-cholesterol assessments 
from the ‘Star-Medisch Diagnostisch Centrum’ (Star-MDC), which performs all outpatient 
laboratory assessments for general practitioners in the Rijnmond area of Rotterdam 
with a potential source population of more than 1 million inhabitants. All outpatient 
cholesterol assessments from the participants of the Rotterdam study between 1 April 
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1997, the time at which a new computer system was introduced at Star-MDC, and 18 
August 2011 were obtained.
Study population
The study sample consisted of all participants in the three cohorts of the Rotterdam 
Study who had at least one cholesterol measurement (total or LDL- of HDL-cholesterol) 
available in the period between 1 January 1997 and 18 August 2011, and for whom 
DNA was available. Participants were excluded if they were prescribed fibrates, bile acid 
sequestrants, nicotinic acids or ezetimibe at the time of one of the measurements. Per 
participant, follow-up started at the date of the first serum cholesterol measurement 
(baseline for the current study).
Exposure to statins
We investigated whether the rs13064411 polymorphism modified the effect of current 
statin use on serum cholesterol levels, by assessing the delta cholesterol between cur-
rent and no current statin users per genotype. Use of statin therapy was obtained from 
dispensing records of fully computerized pharmacies, as described above. Repeated 
prescriptions which were filled within 7 days after ending the previous filled prescription 
were considered as continuous use. If a cholesterol measurement occurred within a pre-
scription period, this contributed to current statin use, and if a cholesterol measurement 
occurred outside a prescription period, this contributed to no current statin use.
outcome
The outcome of interest was serum cholesterol. We investigated whether the polymor-
phism showed significant interaction with response to statin therapy on both serum 
total cholesterol, serum LDL-cholesterol, as well as serum HDL-cholesterol measure-
ments. Cholesterol measurements were derived from the Star-MDC, as described above, 
and were measured in mmol/L.
Covariables
Age, sex, and daily prescribed dose of statin therapy were considered as potential 
confounders or effect modifiers for affecting the association between the rs13064411 
polymorphism and serum cholesterol levels. To compare doses of the different statins, 
the daily dose of statin therapy was expressed in standardized defined daily doses 
(DDD), according to the WHO.34
Genotyping
At the baseline examination of the Rotterdam Study, blood was taken from which ge-
nomic DNA was extracted, using the salting-out method.35 Microarray genotyping was 
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performed in all three Rotterdam Study cohorts, using the Infinium II HumanHap 50K 
Genotyping BeadChip version 3 (Illumina Inc., San Diego, California, USA). Genotyping 
procedures were followed according to the manufacturer’s protocol. During genetic 
quality control, participants with a non-Caucasian background were excluded from the 
genetic dataset. Microarray genotyping procedures in the Rotterdam Study have been 
described previously.36
Statistical analysis
Deviation from Hardy-Weinberg equilibrium was tested using a X2-test. Differences in 
baseline characteristics between the genotype categories were tested for significance 
with a t-test for continuous variables and a X2-test for binary variables.
We used random effect repeated measurements to investigate whether there was sig-
nificant statistical interaction between the rs13064411 polymorphism and current use 
of statin therapy on serum cholesterol measurements.37 Past users were included in the 
group of non-users. Separate analyses were performed for the outcomes total, LDL- and 
HDL-cholesterol. We investigated the mean difference in cholesterol levels in current 
statin users compared to non-statin users with the same number of minor alleles. Analy-
ses were adjusted for age, sex, number of cholesterol measurements per participant, 
and follow-up time. We investigated both additive models, investigating the effect on 
serum cholesterol levels per additive minor allele, and categorical models, investigating 
the effect on serum cholesterol levels for the heterozygous genotype category and the 
homozygous minor allele genotype category compared with the homozygous major 
allele category. In additional analyses, we stratified the population by sex, statin dose, 
and individual statin to see whether the association was different in these categories. In 
sensitivity analyses, we investigated whether there was significant statistical interaction 
between the rs13064411 polymorphism and the daily dose of current statin therapy, 
instead of current use of statin therapy yes/no. Furthermore, in a sensitivity analysis we 
excluded past users of statin therapy.
To investigate whether the polymorphism only interacts with statin therapy on serum 
cholesterol levels, and not influences cholesterol levels in general, we investigated 
whether the polymorphism influences serum cholesterol levels in participants who had 
never used any statin during follow-up. Since the aim of the study was to investigate 
whether the rs13064411 polymorphism showed significant interaction with the choles-
terol lowering effect of statin therapy, it is important to exclude an association between 
the polymorphism and cholesterol levels in general in a population not using statins.
All P-values were two-sided with level of significance of P<0.05. The analyses were 
performed using SPSS software (SPSS Inc., version 21.0, Chicago, Illinois, USA).
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rESUltS
From the three cohorts in the Rotterdam Study, we identified 1,105 participants who 
were current statin users during follow-up, 322 participants who were past statin us-
ers during follow-up, and 4,831 participants who never used statin therapy, who had 
serum cholesterol measurements available, and who had genotype data available for 
the rs13064411 polymorphism. Simvastatin was the most frequently used statin. The 
median number of cholesterol measurements per participant was 4.1 (SD 3.8). The minor 
allele frequency (MAF) of the rs13064411 polymorphism was 14.9%, and the genotype 
distributions of the polymorphism were in Hardy-Weinberg Equilibrium in both statin 
and no statin users (P 0.06 and P 0.18 respectively). Baseline characteristics of the study 
population are shown in table 1.
In the analyses, we compared the effect of the rs13064411 polymorphism on serum 
cholesterol levels in current statin users compared with no current statin users (table 2). 
table 1 Characteristics of the study population






Age, yrs (SD) 68.4 (7.4) 72.0 (8.1)a 63.8 (11.8)b
Sex, N males (%) 491 (44.4%) 139 (43.3%) 2017 (41.8%)b
Baseline total cholesterol, mmol/L, mean (SD) 5.8 (1.1) 5.9 (1.4) 6.0 (1.3)b
Baseline LDL cholesterol, mmol/L, mean (SD) 3.7 (1.2) 3.6 (1.3) 3.6 (1.0)b
Baseline HDL cholesterol, mmol/L, mean (SD) 1.5 (0.4) 1.4 (0.4)a 1.5 (0.4)
Follow-up time, yrs, mean (SD) 7.9 (4.3) 5.4 (4.6)a 4.7 (4.5)b
rs13064411 genotype, n (%)
– homozygous major allele (AA) 778 (70.4%) 233 (72.4%) 3544 (73.4%)
– heterozygous (AG) 288 (26.1%) 79 (24.5%) 1174 (24.3%)
– homozygous minor allele (GG) 39 (3.5%) 10 (3.1%) 113 (2.3%)
Starting dose, DDD, mean (SD) 1.27 (0.8) NA NA
Starting ATC-code NA NA
– simvastatin 612 (55.4%)
– atorvastatin 238 (21.5%)
– pravastatin 138 (12.5%)
– fluvastatin 78 (7.1%)
– rosuvastatin 39 (3.5%)
Abbreviations: yrs, years; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipopro-
tein; DDD, defined daily doses; ATC, Anatomical Therapeutical Chemical; NA, not applicable.
a current statin users differ significantly from never statin users (P<0.05); b current statin users differ signifi-
cantly from past statin users (P<0.05).
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table 2 Delta cholesterol in mmol/L: difference in mean cholesterol levels between current statin users and 
no users with the same number of minor alleles of the rs13064411 polymorphism – statistical interaction 
by genotype on the effect of statins on cholesterol levels














Categorical modeld Categorical modeld
no use – AA 2.66 (0.114) current use – AA 1.94 (0.115) −0.720 (ref ) 4555
no use – AG 2.64 (0.115) current use – AG 2.08 (0.119) −0.566 4.0 × 10−5 1541
no use – GG 2.60 (0.133) current use – GG 2.04 (0.152) −0.565 0.094 162
Dominant modele Dominant modele
no use – AA 2.66 (0.114) current use – AA 1.94 (0.115) −0.620 (ref ) 4555
no use – AG + GG 2.64 (0.115) current use – AG + GG 2.07 (0.119) −0.566 1.8 × 10−5 1703
total cholesterol total cholesterol
Categorical model Categorical model
no use – AA 4.73 (0.107) current use – AA 4.00 (0.109) −0.732 (ref ) 4296
no use – AG 4.72 (0.109) current use – AG 4.16 (0.113) −0.561 6.0 × 10−6 1468
no use – GG 4.78 (0.131) current use – GG 4.31 (0.150) −0.471 0.005 154
Dominant model Dominant model
no use – AA 4.73 (0.107) current use – AA 4.00 (0.109) −0.732 (ref ) 4296
no use – AG + GG 4.73 (0.109) current use – AG + GG 4.18 (0.112) −0.551 5.2 × 10−7 1622
hdl-cholesterol hdl-cholesterol
Categorical model Categorical model
no use – AA 1.47 (0.029) current use – AA 1.51 (0.031) 0.033 (ref ) 3237
no use – AG 1.47 (0.031) current use – AG 1.53 (0.034) 0.056 0.182 1090
no use – GG 1.48 (0.045) current use – GG 1.51 (0.057) 0.028 0.910 121
Dominant model Dominant model
no use – AA 1.47 (0.029) current use – AA 1.51 (0.031) 0.033 (ref ) 3237
no use – AG + GG 1.48 (0.031) current use – AG + GG 1.53 (0.033) 0.052 0.231 1211
Abbreviations: SE, standard error; CI, Confidence Interval; N, number; LDL, low density lipoprotein; HDL, 
high density lipoprotein.
a Delta cholesterol: difference in mean cholesterol levels between current statin users compared to no cur-
rent statin users with the same number of minor G alleles; adjusted for age, sex, number of cholesterol 
measurements per participant, follow-up time. b P-values for the interaction between genotype and current 
statin use on delta cholesterol, with the AA genotype as the reference. c N contains the total number of par-
ticipants: current users + no current users (past and never use). d Categorical model with the homozygous 
major allele AA genotype as the reference category. e Dominant model: effect in participants carrying at 
least one minor G allele compared to the homozygous major allele AA genotype as the reference category.
The degrees of freedom (df ) in the categorical model were 11 for the covariates and 48 for the repeated 
measurements; the df in the dominant model were 9 for the covariates and 48 for the repeated measure-
ments. bold value indicates statistically significant association.
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Current statin users carrying a minor G allele showed a decreased cholesterol lowering 
response compared to the reference homozygous major allele AA carriers, as reflected 
by a smaller delta cholesterol for minor allele carriers. In current users compared to no 
current users with the same number of minor alleles, the mean LDL-cholesterol level 
was 0.720 mmol/L lower in homozygous major allele carriers, 0.566 mmol/L lower in 
heterozygous carriers, and 0.565 mmol/L lower in homozygous minor allele carriers. The 
interaction between the number of minor alleles and current statin use was statistically 
significant for heterozygous carriers (Pint 4.0 × 10−5) but not for homozygous minor allele 
carriers (Pint 0.094), however, it was statistically significant when we combined minor 
allele carriers in the dominant model (Pint 1.8 × 10−5). In current users compared to no 
current users with the same number of minor alleles, the mean total cholesterol levels 
was 0.732 mmol/L lower in homozygous major allele carriers, 0.561 mmol/L lower in 
heterozygous carriers, and 0.471 mmol/L lower in homozygous minor allele carriers. The 
interaction between the number of minor alleles and current statin user was statisti-
cally significant for both heterozygous carriers (Pint 6.0 × 10−6), homozygous minor allele 
carriers (Pint 0.005), as well as for the dominant model (Pint 5.2 × 10−7). For the serum HDL-
cholesterol measurements, no statistically significant interaction was found between 
the polymorphism and current statin use.
In additional analyses we investigated whether the association for LDL- and total 
cholesterol was different if we stratified the current statin users in the population on 
mean dose, compared to all non-current users (figure 1A and 1B), and if we stratified 
the population on sex (figure 1C and 1D). For both LDL- and total cholesterol, the inter-
action between the rs13064411 polymorphism and current statin use was stronger in 
the higher dose category (DDD>1.00) and in women. The difference in effect between 
men and women showed a Pint of 2.0 × 10−5 for LDL-cholesterol and 8.0 × 10−6 for total 
cholesterol. The difference in effect between low dose and high dose users showed a Pint 
of 7.0 × 10−5 for LDL-cholesterol, the Pint for total cholesterol almost reached significance 
(P 0.081).
In analyses in which we stratified on individual statin, the interaction between the 
polymorphism and current statin use remained significant on the LDL- and total choles-
terol measurements for every statin (simvastatin, atorvastatin, pravastatin, fluvastatin, 
rosuvastatin), except for the analyses within fluvastatin users on total cholesterol, pos-
sibly due to low numbers (results not shown).
Table 3 showed the analyses on the association between the rs13064411 polymor-
phism and serum cholesterol levels in participants who never used a statin. In both 
additive and categorical models, the number of minor alleles was not statistically signifi-
cantly associated with both LDL-, total and HDL-cholesterol levels.
In sensitivity analyses, we investigated whether there was statistically significant 
interaction between the polymorphism and the DDD of current statin use. In both the 
80 Chapter 2.3
additive and dominant model, the interaction between the polymorphism and statin 
DDD remained statistically significant for LDL- and total cholesterol, with carriers of a 
minor allele having a smaller delta cholesterol in response to statin therapy than ho-
mozygous major allele carriers. For HDL-cholesterol, again no association was found. 
In a second sensitivity analysis, in which we excluded past users of statin therapy, the 
association remained statistically significant for LDL- and total cholesterol in the addi-
tive and dominant model. The mean delta in cholesterol levels for current statin users 
compared to non-statin users with the same number of minor alleles was similar to the 
main analysis presented in table 2, albeit non-significantly for the categorical model 























































































































































































figure 1 Mean delta in cholesterol levels (in mmol/L) between current statin users and no current statin 
users with the same number of minor alleles of the rs13064411 polymorphism
Abbreviations: LDL, low-density lipoprotein; Pint, P-value for interaction between genotype and statin use in 
the dominant model, with the AA genotype as reference.
Dominant model: effect in participants carrying at least one minor G allele compared to the homozygous 
major allele AA genotype as the reference category. Adjusted for age, sex, number of cholesterol measure-
ments per participant, and follow-up time.
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diSCUSSion
In this population-based cohort study, the rs13064411 polymorphism showed a 
statistically significant interaction with the effect of statin therapy on serum total and 
LDL-cholesterol concentrations. Compared to past and never statin users with the same 
number of minor alleles, current statin users carrying a minor allele showed a mean 
0.154 mmol/L smaller delta LDL-cholesterol and a mean 0.181 mmol/L smaller delta 























































































































































figure 2 Mean delta cholesterol levels (in mmol/L) between current statin users and no current statin users 
with the same number of minor allele of the rs13064411 polymorphism – stratified by sex and statin dose
A: stratified by sex; B: stratified by statin dose.
Abbreviations: DDD, defined daily doses; LDL, low-density lipoprotein; Pint, P-value for the difference be-
tween men/women and low dose/high dose users for the interaction between genotype and statin use on 
cholesterol levels.
Dominant model investigating the effect in participants carrying at least one minor G allele compared to 
the homozygous major allele AA genotype as the reference category; the heterozygous AG genotype and 
homozygous minor allele GG genotype categories were combined due to low number in the GG category. 
Adjusted for age, sex (B), number of cholesterol measurements per participant, and follow-up time.
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was not associated with cholesterol levels in never statin users, which indicates that this 
polymorphism only modifies response to statin therapy.
Theusch et al. showed that the rs13064411 polymorphism was associated with statin-
induced changes in plasma PCSK9 levels and a modified LDL-cholesterol response to 
statin therapy.31 Our study is a first replication in an independent population of this 
new finding by Theusch et al. that the rs13064411 polymorphism was associated with 
inter-individual variation in cholesterol response to statins. In the Rotterdam Study, 
we analyzed whether the polymorphism was associated with a modified response 
of cholesterol levels to statin therapy. The minor G allele is associated with increased 
statin-induced levels of PCSK9, leading to increased LDL-receptor degradation, higher 





beta (95% Ci)b P nc
ldl-cholesterol
Additive modeld – −0.00045 (−0.048; 0.047) 0.985 4831
Categorical modele
AA 2.71 (0.071) (ref ) – 3544
AG 2.73 (0.074) 0.020 (−0.036; 0.076) 0.487 1174
GG 2.62 (0.106) −0.089 (−0.249; 0.071) 0.274 114
total cholesterol
Additive model – 0.034 (−0.019; 0.087) 0.212 4486
Categorical model
AA 4.94 (0.153) (ref ) – 3283
AG 4.97 (0.126) 0.035 (−0.027; 0.098) 0.266 1099
GG 5.00 (0.153) 0.061 (−0.117; 0.240) 0.502 104
hdl-cholesterol
Additive modeld – −0.077 (−0.018; 0.033) 0.557 3347
Categorical modele
AA 1.50 (0.034) (ref ) – 2456
AG 1.51 (0.036) 0.014 (−0.016; 0.045) 0.356 811
GG 1.48 (0.054) −0.012 (−0.098; 0.073) 0.776 80
Abbreviations: SE, standard error; CI, Confidence Interval; N, number; LDL, low density lipoprotein; HDL, 
high density lipoprotein.
a Mean cholesterol levels in mmol/L. b Change in cholesterol levels in minor G allele carriers compared to the 
homozygous major allele AA reference category. c N contains the total number of participants. d Additive 
model: change in cholesterol level per additional minor G allele. e Categorical model: change in cholesterol 
level in never statin users heterozygous and homozygous for the minor allele compared to never statin us-
ers homozygous for the major allele, the reference category. Analyses are adjusted for age, sex, number of 
cholesterol measurements per participant, and follow-up time.
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LDL-cholesterol levels and thus a decreased cholesterol lowering response. Therefore, 
we hypothesized that the rs13064411 polymorphism was associated with increased 
serum LDL and total cholesterol levels. However, in the study by the Theusch et al.31, the 
minor allele of the polymorphism was weakly associated with greater statin-induced 
decreases in plasma LDL-cholesterol levels. Other studies reported that statin-induced 
increase in serum PCSK9 levels led to a stronger LDL-cholesterol reduction during statin 
therapy.19,23-25. This is in contrast with the findings in our study. Other studies are in line 
with our findings and showed that statin-induced increase in PCSK9 levels reduced 
statin efficacy.38,39 Statins lower intracellular cholesterol levels in hepatocytes, with as a 
result upregulation of the activity of transcription factor sterol regulatory element bind-
ing protein-2 (SREBP-2). This leads to gene expression of SREBP-2 target genes, including 
LDL-receptor (LDLR) and PCSK9.16,40 Thus statins induce both LDL-receptor configuration, 
as well as they counteract their therapeutic effect through promoting LDL-receptor deg-
radation via PCSK9. The balance between configuration and degradation determines 
the net effect on the number of LDL-receptors and LDL-concentration, but also depends 
on other factors such as the statin dose or the normal fluctuation in PCSK9 against little 
fluctuation in LDL-cholesterol during the day.41
The rs13064411 polymorphism is located in the WDR52 gene coding for the WDR52 
protein, of whom the function is unknown. Research on other WD-repeat proteins 
indicated that they contain a beta-propeller domain structure and play a role in the 
coordination of several protein interactions.42,43 The WDR52 protein possibly influences 
the effect of PCSK9 on LDL-receptor degradation. The LDL-receptor contains a beta-pro-
peller domain, which is essential for successful directing the LDL-receptor for lysosmal 
degradation by PCSK9.44 An alternative explanation for the genetic variation in response 
is that the polymorphism influences other genes that have their effect on PCSK9 levels. 
Further research is needed to elucidate the mechanism by which the rs13064411 influ-
ences the change in serum PCSK9 levels and response to statin therapy.
We had a large sample size of 5936 participants, of whom 1105 statin users, and in 
total 29,103 LDL- and 30,630 total cholesterol measurements available. In our study, 
we only demonstrated an association on LDL- and total cholesterol levels, and not 
on serum HDL-cholesterol levels. This is in line with previous studies that could not 
demonstrate an association between PCSK9 levels and serum HDL-cholesterol and 
triglycerides.18,19,21 Our results showed a stronger effect of the polymorphism on total 
and LDL-cholesterol levels in women than in men (Pint 8.0 × 10−6 for total cholesterol, 
Pint 2.0 × 10−5 for LDL-cholesterol). The study by Theusch et al.31 showed that women 
had higher serum PCSK9 levels than men at baseline and during statin treatment, but 
no significant sex-difference in statin-induced PCSK9 levels was present. Other studies 
demonstrated that baseline PCSK9 levels were higher in women than in men.20,21,24 A 
sex-difference in the interaction of the rs13064411 polymorphism with the effect of 
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statin therapy on serum cholesterol concentrations, as demonstrated in our study, has 
not been investigated before and needs further replication. Hormone levels might play 
a role, e.g. it is known that estrogen increases LDL receptor levels, while androgens 
diminish this effect.45,46 This sex-difference in genetic effect might also be explained 
by underlying higher baseline serum PCSK9 levels in women. However, since in the 
Rotterdam Study no serum PCSK9 levels are available, we could not investigate this. 
Furthermore, in our study the effect of the polymorphism on LDL- and total cholesterol 
levels was higher in statin users with a DDD>1.00. This makes it more plausible that 
the influence of the rs13064411 polymorphism on statin-induced changes in serum 
cholesterol levels is based on a true-positive finding. Also, the effect on total and LDL-
cholesterol is consistently present in both men and women, in both the low and high 
DDD statin users, and in the different type of statins separately, which further supports 
this finding.
Potential biases and limitations of our study should be considered. The Rotterdam 
Study is a population-based cohort study, in which data is collected prospectively with-
out prior knowledge of the research hypothesis of the current analyses. We used the 
cholesterol measurements requested by general practitioners for healthcare purposes 
and the reasons for the measurements may differ between statin users and non-statin 
users, inducing potential information bias. However, as prescribing physicians were not 
aware of the genotype status, this will not have influenced results. The genetic variant 
was in Hardy-Weinberg equilibrium, thus Mendelian randomization occurred and there-
fore, selection bias was unlikely. We adjusted for potential confounding factors such as 
age, sex and the number of cholesterol measurements per individual. In additional and 
sensitivity analyses, the association remained present, indicating that the association is 
true and not based on a false-positive finding. In the Rotterdam Study, no expression 
data was available for the PCSK9 enzyme. Therefore, we could not investigate whether 
the polymorphism was associated with statin-induced PCSK9 levels, such as in the study 
by Theusch et al. Although non-compliance with statin therapy might have occurred47, 
this would lead to random misclassification and an underestimation of the true effect.
In conclusion, in the Rotterdam Study the rs13064411 polymorphism in the WDR52 
gene was associated with a modified effect of statin therapy on serum LDL- and total 
cholesterol levels. The minor G allele of the polymorphism, with a MAF of 14.9%, was 
associated with a decreased cholesterol lowering response to statins, and this effect 
was stronger in women and in high dose users (DDD>1.00). Currently, PCSK9-inhibitors 
are developed as a potentially effective LDL-cholesterol lowering treatment alone or 
in combination with statin therapy. Considering the potential inter-individual variation 
in response to statin therapy, it may be worthwhile to investigate whether patients 
carrying a minor allele who respond less to statin therapy might benefit from a PCSK9-
inhibitor additional to statin therapy.
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AbStrACt
Introduction: The SLCO1B1 c.521T >C polymorphism is associated with statin plasma 
levels and simvastatin-induced adverse drug reactions. We studied whether the c.521T 
>C polymorphism is associated with dose decreases or switches to other cholesterol 
lowering drugs during simvastatin and atorvastatin therapy, because these events are 
indicators of adverse drug reactions.
Methods: We identified 1939 incident simvastatin and atorvastatin users in the Rot-
terdam Study, a population-based cohort study. Associations were studied using Cox 
proportional hazards analysis. Meta-analysis was performed with data from the Utrecht 
Cardiovascular Pharmacogenetics study.
Results: Simvastatin users with the c.521 CC genotype had a significantly higher risk of 
a dose decrease or switch than users with the TT genotype [hazard ratio (HR) 1.74, 95% 
confidence interval (CI) 1.05; 2.88]. Female sex, age below 70 years, and low starting 
dose were risk factors. In atorvastatin users with starting dose of more than 20 mg, the 
risk of a dose decrease or switch was higher in users carrying a C allele than in users 
with the TT genotype (HR 3.26, 95% CI 1.47; 7.25). In the meta-analysis the association in 
simvastatin users remained, with a significantly higher risk of a dose decrease or switch 
in simvastatin users with two minor alleles (HR 1.69, 95% CI 1.05; 2.73). For atorvastatin 
users no significant association was found.
Conclusion: In simvastatin users in the Rotterdam Study, we demonstrated an association 
between the c.521T >C polymorphism and dose decrease or switching, as indicators of 
adverse drug reactions, and provided risk factors for this association. For atorvastatin, an 
association was found in users with a starting dose of more than 20 mg.
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introdUCtion
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are choles-
terol lowering drugs, prescribed for the primary and secondary prevention of cardio-
vascular diseases.1-4 Statins have a protective effect on cardiovascular morbidity and 
mortality primarily by lowering the low-density lipoprotein cholesterol concentration.5,6 
In general, statins are well-tolerated and safe drugs, although adverse drug reactions do 
occur.7 A common adverse drug reaction is myopathy, which can vary from myalgia to 
life-threatening rhabdomyolysis.8 There is considerable variation between individuals 
in the risk of developing adverse drug reactions during statin therapy. This variation is 
partly explained by genetic factors. Single-nucleotide polymorphisms in genes involved 
in the pharmacokinetics of statins can change the uptake, metabolism, or clearance of a 
particular statin and therefore increase the serum statin concentration and the risk of de-
veloping adverse drug reactions.9,10 Furthermore, there is a dose–response relationship 
in the risk of developing statin-induced adverse reactions, and patient characteristics 
may also contribute to the risk. For example, women are at higher risk of statin-induced 
musculoskeletal adverse reactions.11
The solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene 
encodes the organic anion transporting polypeptide 1B1 (OATP1B1). This influx trans-
porter is mainly expressed on the membranes of hepatocytes and regulates the influx of 
both endogenous and exogenous compounds.12 It is involved in the transport of statins, 
including simvastatin and atorvastatin, into hepatocytes. The rs4149056 c.521T>C minor 
allele in the SCLO1B1 gene alters the OATP1B1 transporter function and statin uptake, 
which increases the serum statin concentration and increases the risk of developing 
adverse drug reactions.12-18
In 2008, the SEARCH Collaborative Group published a genome-wide association (GWA) 
study about the risk of developing myopathy during simvastatin therapy.19 They identi-
fied common genetic variation in the SLCO1B1 gene that was strongly associated with 
an increased risk of simvastatin-induced myopathy. The strongest association was found 
for the SLCO1B1 rs4363657 polymorphism, which was significantly associated genome 
wide with myopathy (P=4 × 10−9), and was in almost complete linkage disequilibrium 
with the c.521T>C polymorphism, which has already been described in the literature 
in relation to statin pharmacokinetics.13,14,17,18 Patients homozygous for the minor allele 
had a 16.9 times higher risk of myopathy than patients with the wild-type genotype.
This GWA study demonstrated an association between the c.521T>C polymorphism 
and myopathy among simvastatin users, but the question is whether this effect is only 
present for simvastatin or also for the other statins. In 2010, Niemi published a paper 
about the role of transporter pharmacogenetics in statin therapy.20 All statins are sub-
strate for the OATP1B1 transporter, but the effect of the c.521T>C polymorphism on the 
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pharmacokinetics of statins differs. This polymorphism exerts its greatest effect on sim-
vastatin, and the effect diminishes according to the sequence pitavastatin, atorvastatin, 
pravastatin, rosuvastatin and fluvastatin, the last one with only a minor effect.
In our study, the objective was to investigate whether the c.521T>C polymorphism 
in the SLCO1B1 gene modifies the risk of adverse drug reactions during simvastatin and 
atorvastatin therapy in the Rotterdam Study and in the Utrecht Cardiovascular Phar-
macogenetics (UCP) study. We assessed whether this polymorphism is associated with 
the occurrence of a dose decrease or a switch to another cholesterol lowering drug, as 
indicators of adverse drug reactions. Our aim was to confirm the previously described 
association between the c.521T>C polymorphism and simvastatin-associated adverse 
drug reactions, and to investigate whether the effect was also present among atorv-
astatin users. We stratified the analyses for sex, age, and dose categories to determine 




The Rotterdam Study is a prospective population-based cohort study of chronic dis-
eases in the elderly population. From 1990 to 1993, 7983 inhabitants (98% White) of the 
suburb of Ommoord in Rotterdam (the Netherlands) aged 55 years or older, participated 
in the Rotterdam Study I (RS-I) and gave written informed consent. Ethical approval was 
obtained from the Medical Ethics Committee of the Erasmus Medical Center (Rotterdam, 
the Netherlands). Baseline examinations took place from March 1990 through July 1993. 
Follow-up examinations were conducted periodically, every 4–5 years. Medication 
prescription data were obtained from the fully computerized pharmacies in the Om-
moord suburb. These pharmacies dispense the prescriptions of more than 99% of all 
participants. Information on all filled prescriptions from 1 January 1991 until 1 June 2011 
was available and included the product name of the drug, the Anatomical Therapeu-
tical Chemical code, the amount dispensed, the prescribed dosage regimen, and the 
date of dispensing.21 Furthermore, in 2000, an extended cohort was enrolled, RS-II. A 
total of 3011 inhabitants entered the study and have been continuously followed since 
then. DNA for genotyping was available for 6571 (82%) participants from RS-I and 2157 
(71.6%) participants from RS-II. Detailed information on design, objectives, and methods 
of the Rotterdam Study have been described previously.22,23
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Study sample
The study population consisted of all participants with at least one filled prescription 
for simvastatin or atorvastatin between 1 January 1991 and 1 June 2011, and for whom 
DNA was available. Follow-up started at the date of the first prescription for simvastatin 
or atorvastatin. Participants were followed until the occurrence of an event as described 
below, the end of the last prescription for simvastatin or atorvastatin, or until the end 
of 3 years of follow-up, whichever came first. In addition, participants were censored 
when they had a gap of at least 180 days between a previous statin prescription and 
the start of a next prescription. A maximum follow-up period of 3 years was chosen 
because the risk of an adverse drug reaction is greater during the first years of therapy, 
and decreases afterwards. To ensure that all participants were incident users and did not 
have a prescription for simvastatin or atorvastatin before 1 January 1991, for which we 
did not have the prescription data, we excluded all simvastatin and atorvastatin users 
with a first prescription before 1 July 1991.
outcome
In this study, the outcome of interest is adverse drug reactions during statin therapy. 
In our database, adverse drug reactions were not registered as such. Therefore, we 
analyzed the occurrence of either a dose decrease or a switch to another cholesterol 
lowering drug as an indicator of an adverse drug reaction or a too strong reduction in 
cholesterol level. The first time during follow-up after start of simvastatin or atorvastatin 
therapy that a patient had a dose decrease or switched to another cholesterol lowering 
drug (statins, fibrates, bile acid sequestrants, nicotinic acid, acipimox, or ezetimibe) was 
considered as an event. If a physician notices an adverse drug reaction, he can proceed 
in two ways. First, the physician can lower the dose of the particular drug, if he considers 
that there is a dose-effect relationship between the drug dose and the adverse drug 
reaction. Second, switching to another cholesterol lowering drug may be considered. 
Therefore, we used both dose decrease and switching as outcome measures, as an 
indicator of a potential adverse drug reaction.
In a previous study by Becker et al.24, the reason for the change in medication was 
retrieved by checking medical patient records of 32 cases, available as of 1 January 1997. 
For this study, we could additionally retrieve the change in medication for 31 cases. Of 
the 63 cases that could be checked in the patient records, 43 cases (68%) had a complaint 
of an adverse drug reaction as reason for the decrease or switch to another cholesterol 
lowering drug, 17 cases (27%) had a too strong reduction in cholesterol level, and three 
cases (5%) switched to another cholesterol lowering drug after a cholesterol measure-
ment; this was most likely due to ineffective drug therapy.
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Covariables
Age, sex, and the prescribed dose of the first prescription for simvastatin or atorvas-
tatin were considered as potential confounders or effect modifiers for the association 
between the SLCO1B1 c.521T>C polymorphism and the occurrence of an event. To com-
pare the doses of atorvastatin and simvastatin, the daily dose of the first prescription 
of statin therapy was expressed in standardized defined daily doses (DDD), according 
to the WHO. The DDD for simvastatin is 30 mg and the DDD for atorvastatin is 20 mg.21
Genotyping and SnP selection
At baseline examination of the Rotterdam Study, blood was taken, from which ge-
nomic DNA was extracted, using the salting-out method.25 Microarray genotyping 
was performed in both Rotterdam Study cohorts using the Infinium II HumanHap550K 
Genotyping BeadChip version 3 (Illumina Inc., San Diego, California, USA). Genotyping 
procedures were followed according to the manufacturer’s protocol. During genetic 
quality control, participants with a non-White background were excluded from the 
genetic dataset. Microarray genotyping procedures in the Rotterdam Study have been 
described previously.26
Since the SLCO1B1 c.521T>C polymorphism was not genotyped as a tagging SNP on 
the Illumina
HumanHap550K Genotyping Beadchip, we selected the genotyped rs1871395 
polymorphism in the SLCO1B1 gene for the analysis. This polymorphism is available 
on the Illumina Beadchip and is in complete linkage disequilibrium with the c.521T>C 
polymorphism (R2=1.0).27
Statistical analysis
Deviation from Hardy–Weinberg equilibrium was tested using a X2-test. Differences in 
baseline characteristics between the genotype categories were tested for significance 
with a t-test for continuous variables and a X2-test for binary variables.
We used Cox proportional hazards models to investigate differences in the incidence 
of the outcome variable between the SLCO1B1 c.521T>C genotypes. We used categorical 
models in which we analyzed the occurrence of events per different genotype catego-
ries, since from the results in the GWA study from the SEARCH Collaborative group the 
greatest effect can be found in the homozygous minor allele genotype. In additional 
analyses, we stratified for sex, age, and the prescribed dose of the first prescription of 
statin therapy, to investigate whether they are risk factors for the outcome. The strati-
fication by age and starting dose was based on the mean value of the covariables in 
the study population, respectively, a mean age of 70.6 years for simvastatin users and 
70.2 years for atorvastatin users, and a mean starting dose of 20 mg (0.67 DDD) for 
simvastatin users and 17.8 mg (0.89 DDD) for atorvastatin users. On the basis of the 
95SLCO1B1 c.521T>C polymorphism and statin-induced ADRs
calculated values in the study population, we used a cut-off point of 20 mg or less (0.67 
DDD) for simvastatin users and 20 mg or less (1.00 DDD) for atorvastatin users. Finally, 
we tested whether we had enough power to test our research hypotheses. The analyses 
were performed using SPSS software (version 20.0; SPSS Inc., Chicago, Illinois, USA).
meta-analysis
We repeated the analyses in an independent cohort, the UCP study. This is a myocardial 
infarction case-control study in patients with hypercholesterolemia and/or hyperten-
sion. Participants from this study were enrolled from the population-based Pharmaco-
Morbidity Record Linkage System (PHARMO, http://www.pharmo.nl), which links drug 
dispensing histories from a representative sample of Dutch community pharmacies to 
the national registration of hospital discharges [Dutch National Medical Registry (LMR)]. 
In PHARMO, complete pharmacy records were available as of 1991, including the day of 
delivery, daily dose, and durations of therapy. Details of this study can be found in earlier 
publications.28,29 The SLCO1B1 rs4149056 c.521T>C polymorphism was genotyped using 
TaqMan allelic discrimination. For this cohort, the same outcome variables, covariates, 
and analysis methods were used as in the Rotterdam Study cohort. The study population 
consists of 98% White participants.
Finally, we performed a fixed effect inverse variance meta-analysis to combine the re-
sults of the original analysis (Rotterdam Study) and the results of the UCP study analysis.
rESUltS
We identified 2080 participants in RS-I and RS-II, who were prescribed simvastatin or 
atorvastatin during follow-up and for whom the SLCO1B1 genotype was available. Of 
these statin users, 141 had a first prescription before 1 July 1991 and were excluded 
from the analysis, finally leading to 1939 statin users eligible for analysis (Table 1). The 
genotype distribution of c.521T>C polymorphism was in Hardy-Weinberg equilibrium (P 
0.055). The minor allele frequency for the c.521T>C polymorphism was 15.5%.
The results of the Cox proportional hazards regression analyses for simvastatin and 
atorvastatin users are shown in Table 2. Among simvastatin users in the Rotterdam 
Study, the c.521T>C polymorphism was significantly associated with the outcome. 
Patients homozygous for the minor allele (CC genotype) had a 1.7 times higher risk of a 
dose decrease or switch to another cholesterol lowering drug than patients with the TT 
genotype [hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.05; 2.88, n=319 events]. 
Among atorvastatin users, we did not find a significant association with the study out-
come (HR 1.49, 95% CI 0.54; 4.10, n=110 events).
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The analyses were stratified for sex, age, and starting dose (Table 3). For simvastatin 
users, female sex, low starting dose of statin therapy (>20 mg), and age below 70 years 
were associated with a higher risk of a dose decrease or a switch to another cholesterol 
lowering drug in patients with the c.521 CC genotype. Women homozygous for the 
minor allele had a more than two-fold higher risk for the outcome than women with 
table 1 Baseline characteristics of 1939 incident statin users in the Rotterdam Study and 637 incident statin 
users in the Utrecht Cardiovascular Pharmacogenetics study
rotterdam Study population 
(original analysis)
UCP study population 
(included in meta-analysis)
Simvastatin 
users (n = 1462)
Atorvastatin 
users (n = 477)
Simvastatin 
users (n = 393)
Atorvastatin 
users (n = 244)
Age [years, mean (SD)] 70.6 (8.2) 70.2 (7.8) 62.3 (9.4) 62.3 (10.3)
Sex [N male (%)] 631 (43.2) 249 (52.2) 296 (75.3) 194 (79.5)
Starting dose [mg, mean (SD)] 20.0 (11.4) 17.8 (13.2) 41.7 (18.9) 45.0 (34.8)
Follow-up [years, mean (SD)] 2.3 (1.1) 2.4 (1.0) 2.3 (1.0) 2.0 (1.0)
Event [n (%)]
total 319 110 88 42
dose decrease 191 (59.9) 80 (72.7) 63 (71.6) 26 (61.9)
switching 128 (40.1) 30 (27.3) 25 (28.4) 16 (38.1)
SLCO1B1 genotype [n (%)]
TT 1058 (72.4) 336 (70.4) 286 (72.8) 179 (73.4)
TC 361 (24.7) 126 (26.4) 99 (25.2) 60 (24.6)
CC 43 (2.9) 15 (3.1) 8 (2.0) 5 (2.0)
Abbreviations: UCP, Utrecht Cardiovascular Pharmacogenetics; SD, standard deviation; SLCO1B1, solute car-
rier organic anion transporter family 1B1.
table 2 The association between the SLCO1B1 c.521T>C polymorphism and dose decrease or switching to 
another cholesterol-lowering drug in simvastatin and atorvastatin users in the Rotterdam Study
Unadjusted hr Adjusted hra 95% Ci P
Simvastatin users (n=1462)b
TT 1.00 (ref ) 1.00 (ref ) – –
TC 0.74 0.77 0.58; 1.02 0.065
CC 1.69 1.74 1.05; 2.88 0.033
Atorvastatin users (n = 477)b
TT 1.00 (ref ) 1.00 (ref ) – –
TC 1.11 1.17 0.77; 1.79 0.454
CC 1.25 1.49 0.54; 4.10 0.445
Abbreviations: HR, hazard ratio; CI, confidence interval; ref, reference.
a Adjusted for age, sex, and starting dose. b Categorical model with the TT genotype as reference. bold value 
indicates statistically significant association.
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the reference genotype (HR 2.18, 95% CI 1.20; 3.96), whereas in men no significant as-
sociation was found (HR 1.10, 95% CI 0.41; 2.99). In the lower age category (<70 years) 
a similar effect was found, with a more than two-fold higher risk in the minor allele 
genotype category (HR 2.14, 95% CI 1.18; 3.89).
For atorvastatin users, we found an association between the c.521T>C polymorphism 
and dose decrease or switching to another cholesterol lowering drug in the highest-
dose category (>20 mg). We combined the heterozygous and homozygous minor allele 
genotype categories for this analysis, since the number of events in patients with minor 
variant alleles was too small (two events). Patients in this category with at least one 
table 3 The association between the SLCO1B1 c.521T>C polymorphism and dose decrease or switching to 
another cholesterol-lowering drug in simvastatin and atorvastatin users in the Rotterdam Study – stratified 
for sex, starting dose, and age
Unadjusted hr Adjusted hra 95% Ci P
Stratified by sexb
Men
Simvastatin (n = 631) CC vs TT 1.15 1.10 0.41; 2.99 0.851
Atorvastatin (n = 249) CC vs TT 1.25 1.39 0.43; 4.52 0.580
Women
Simvastatin (n = 831) CC vs TT 2.00 2.18 1.20; 3.96 0.010
Atorvastatin (n = 228) CC vs TT 1.11 1.59 0.21; 11.83 0.653
Stratified by starting doseb
Lower starting dose ≤ 20 mg
Simvastatin (n = 1142) CC vs TT 1.87 1.83 1.06; 3.16 0.029
Atorvastatin (n = 406) CC vs TT 1.12 1.21 0.38; 3.90 0.746
Higher starting dose > 20 mg
Simvastatin (n = 320) CC vs TT 1.02 1.12 0.27; 4.65 0.877
Atorvastatin (n = 71) TC + CC vs TTc 3.67 3.26 1.47; 7.25 0.004
Stratified by ageb
Age < 70 years
Simvastatin (n = 722) CC vs TT 2.14 2.14 1.18; 3.88 0.012
Atorvastatin (n = 252) CC vs TT 0.84 0.81 0.11; 5.91 0.835
Age ≥ 70 years
Simvastatin (n = 690) CC vs TT 0.98 0.98 0.36; 2.66 0.971
Atorvastatin (n = 225) CC vs TT 1.50 1.73 0.53; 5.69 0.364
Abbreviations: HR, hazard ratio; CI, confidence interval.
a Adjusted for age and starting dose for the analysis stratified by sex; adjusted for age and sex for the analy-
sis stratified by starting dose; adjusted for sex and starting dose for the analysis stratified by age. b Categori-
cal model comparing the homozygous minor allele genotype (CC genotype) with the reference category 
(TT genotype. c The TC and CC genotype categories are combined since the number of cases with two mi-
nor alleles (CC genotype) was too small (two cases, one event). bold value indicates statistically significant 
association.
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minor allele (TC+CC genotypes) showed a more than three-fold higher risk for a dose 
decrease or switch compared with the reference TT genotype category (HR 3.26, 95% 
CI 1.47; 7.35).
In simvastatin users, the power was 100.0% to find an HR of 2.0 and the power was 
87.8% to find an HR of 1.5, whereas for atorvastatin users the power was 90.0% to find 
an HR of 2.0 and 51.7% to find an HR of 1.5.
meta-analysis
The baseline characteristics of the UCP study sample are shown in Table 1. Within the 
UCP study, we identified 393 incident simvastatin users and 244 incident atorvastatin 
users eligible for the analysis. The genotype distribution of the c.521T>C polymorphism 
was in Hardy–Weinberg equilibrium (P 0.89), and the minor allele frequency was 14.5%.
The results of the Cox proportional hazards regression on dose decrease or switching 
in the UCP study are shown in Table 4. Within the UCP study, the c.521T>C polymorphism 
was not associated with dose decrease or switching.






Simvastatin users (n = 393)a
TT 1.00 (ref ) 1.00 (ref ) – –
TC 0.78 0.74 0.45; 1.24 0.259
CC 1.26 1.38 0.34; 5.71 0.653
Atorvastatin users (n = 244)a
TT 1.00 (ref ) 1.00 (ref ) – –
TC or CCb 0.96 0.97 0.68; 1.40 0.871





Simvastatin and atorvastatin users (n = 3576)
CC (n = 71) vs TT (n=1859) 0.454 1.57 1.02; 2.42 0.220
Simvastatin users (n = 1855)
CC (n = 51) vs TT (n = 1344) 0.526 1.69 1.05; 2.73 0.244
Atorvastatin users (n = 721)
TC + CC (n = 206) vs TT (n = 515) 0.066 1.07 0.82; 1.40 0.137
Abbreviations: UCP, Utrecht Cardiovascular Pharmacogenetics; HR, hazard ratio; CI, confidence interval; ref, 
reference; SE, standard error.
a Categorical model with the TT genotype as reference. b The TC and CC genotype categories are combined 
since the number of cases with two minor alleles (CC genotype) was too small. c Adjusted for age, sex, and 
starting dose. bold value indicates statistically significant association.
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In simvastatin users the power was 83.3% to find an HR of 2.0 and the power was 
44.5% to find an HR of 1.5, while for atorvastatin users the power was 56.0% to find an 
HR of 2.0 and 29.0% to find an HR of 1.5.
The results of the fixed effect inverse variance meta-analysis are shown in Table 4. For 
simvastatin users, compared with the reference homozygous major allele genotype, the 
heterozygous genotype was associated with a significantly lower risk of a dose decrease 
or switching to another cholesterol lowering drug (HR 0.76, β – 0.270, 95% CI 0.60; 0.98), 
and the homozygous minor allele genotype was significantly associated with a higher 
risk of the outcome (HR 1.69, β 0.526, 95% CI 1.05; 2.73).
For atorvastatin users in the UCP study the number of patients with two minor alleles 
was too low, and therefore we combined the heterozygous and homozygous minor 
allele genotype in the meta-analysis of atorvastatin users. For atorvastatin users, no sig-
nificant association was found. When we combined simvastatin users and atorvastatin 
users, the heterozygous genotype showed no significant association with the outcome 
(HR 0.86, β – 0.156, 95% CI 0.70; 1.05), whereas patients homozygous for the minor allele 
showed a significantly higher risk of the outcome (HR 1.57, β 0.454, 95% CI 1.02; 2.42).
diSCUSSion
The c.521T>C polymorphism in the SLCO1B1 gene is associated with a higher risk of a 
dose decrease or switch to another cholesterol lowering drug during simvastatin thera-
py. These changes in medication are indicators of adverse drug reactions or too strong 
reductions in plasma cholesterol concentration. In simvastatin users, the determinants 
female sex, low starting dose (≤20 mg), and age under 70 years were associated with 
a higher risk of these events. In atorvastatin users, we found a significant association 
among patients with a high dose (>20 mg) at first prescription. In a meta-analysis in 
which we combined the original Rotterdam Study results and the results from an inde-
pendent cohort, the UCP study, the association in simvastatin users remained.
In this study, we demonstrated that the SLCO1B1 c.521 CC genotype is associated with 
a higher risk of a dose decrease or switch, as indicators of adverse drug reactions, associ-
ated with simvastatin therapy, but in the group of all atorvastatin users there was no as-
sociation. The question remains whether this association is mainly present for simvastatin 
therapy, or whether the polymorphism also significantly influences the risk of adverse 
drug reactions associated with other statins, in particular atorvastatin. For simvastatin 
therapy, it is established that the variant genotype of the polymorphism is associated 
with a higher risk of simvastatin-induced adverse drug reactions.11,19,30,31 Although it has 
been demonstrated that the c.521T>C minor allele is associated with higher serum statin 
plasma concentrations for all statins except for fluvastatin20, previous studies did not 
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show an effect of this polymorphism on atorvastatin associated adverse drug reactions. 
Voora et al.11 demonstrated a significant association of the polymorphism with adverse 
drug reactions during simvastatin therapy, and patients showed the same trend during 
atorvastatin therapy, but the association did not reach statistical significance. Santos et 
al.32 could not find a significant association of the c.521T>C polymorphism with myalgia 
or abnormal creatinine kinase values among atorvastatin users. In the study by Brunham 
et al.30, the SLCO1B1 c.521T>C polymorphism was significantly associated with myopa-
thy in simvastatin users, whereas for atorvastatin users no significant association was 
found. In our study, we demonstrated a significant association between the SLCO1B1 
polymorphism and the risk of the outcome in atorvastatin users with a starting dose 
of more than 20 mg and with at least one minor allele. These results suggest that there 
may be an association with the SLCO1B1 polymorphism in high-dose atorvastatin users, 
although other studies did not find an association. However, all studies found an odds 
ratio above one for the association with adverse drug reactions among atorvastatin 
users, but the number of cases was lower than in our study. As shown in our results 
above, we had sufficient power to test our main hypotheses. Another explanation for 
our finding might be that the high-dose atorvastatin group contains mainly too strong 
reductions in cholesterol levels instead of adverse drug reactions, which were treated by 
decreasing the dose subsequently. For the majority of cases, we could not distinguish 
between the underlying reasons for the medication change. However, the majority of 
the events were due to adverse drug reactions.
Whether the association between the c.521T>C polymorphism and adverse drug 
reactions is present for all statins remains to be determined. The effect of the c.521T>C 
polymorphism on serum statin concentration is greater for simvastatin than for atorv-
astatin20, but despite this difference, our study was able to detect a pharmacogenetic 
interaction for atorvastatin with the outcome. Since the serum statin concentration is 
potentially related to the risk of adverse drug reactions, one would expect the effect 
of the c.521T>C polymorphism on the risk of developing adverse drug reactions to be 
greater in high-dose atorvastatin users as compared with low-dose users. This finding 
is also corroborated by results from the SEARCH study.19 They found a greater risk of 
simvastatin in the 80 mg daily SEARCH study, compared with the 40 mg daily Heart 
Protection Study replication. Furthermore, simvastatin and atorvastatin are not only 
transported by the OATP1B1 transporter; other OATP transporters also contribute 
to their uptake. Atorvastatin is also a substrate for the OATP2B1 transporter whereas 
simvastatin is not.33 This may indicate that atorvastatin is a less important substrate for 
the OATP1B1 transporter than simvastatin, and therefore the c.521T>C polymorphism 
also has a more important effect in simvastatin users than in atorvastatin users, and an 
effect for atorvastatin can only be seen in high-dose users. Furthermore, in our study the 
power was lower for atorvastatin compared with simvastatin. However, in the UCP study 
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we did not have enough power to investigate this association, and replication of the 
finding in atorvastatin users in an independent population is necessary.
In simvastatin users, the heterozygous genotype showed a non-significant decreased 
association with dose decrease and switching, with an HR of 0.77. We could not explain 
this association, and it is in contrast with previous findings from the literature and prob-
ably due to chance. In the analysis in the UCP study cohort, in which the same methods 
were used as in the original analysis, we could not demonstrate an association for sim-
vastatin and atorvastatin users. However, the number of statin users in the UCP study 
was only one-third of those from the Rotterdam Study, and consequently we had sub-
stantially less power to demonstrate an association. Furthermore, among atorvastatin 
users it was not possible to investigate the association in the homozygous minor allele 
genotype category separately because of too low numbers, while based on the results in 
the Rotterdam Study and the results of the SEARCH collaborative group the greatest ef-
fect can be found in that category. Nevertheless, in the meta-analysis of the two studies 
combined, the association in the homozygous minor allele genotype category was still 
significant for simvastatin, and for simvastatin and atorvastatin combined.
In the Rotterdam Study, among simvastatin users, women showed an approximately 
two-fold higher risk for a dose decrease or switch to another cholesterol lowering drug. 
No significant association was found in men. The biological mechanism for this difference 
is unclear, but our findings are consistent with previous studies that showed an effect 
of sex. Voora et al.11 investigated the association between the c.521T>C polymorphism 
and statin-induced adverse drug reactions and showed that female sex was associated 
with a higher risk of statin-induced adverse drug reactions, in simvastatin, atorvastatin, 
and pravastatin users. Niemi et al.34 demonstrated that women carrying the variant al-
lele of the c.521T>C polymorphism had a higher serum pravastatin concentration than 
men carrying the variant allele. In the participants of the SEARCH trial, the relative risk 
of myopathy was higher in women.19 In a recent study, women homozygous for the 
minor allele of the c.521T>C polymorphism showed a significantly greater decrease in 
total cholesterol compared with men.35 It is possible that the OATP1B1 transporter is 
more strongly expressed in women than in men, resulting in the effect of the c.521T>C 
polymorphism being stronger in women. Furthermore, statins are not only dependent 
on the OATP1B1 transporter for their uptake; other transporters also play a role. It is 
possible that another uptake transporter has a lower activity in women, through which 
the OATP1B1 transporter plays a more important role and therefore the effect of the 
c.521T>C polymorphism is more pronounced. Differences between men and women 
in transporter expression have been described previously. The ATP-binding cassette B1 
(ABCB1) transporter, for example, has a lower expression in women than in men.36
We found an age difference in the risk of the events for simvastatin, with a significant 
effect in the younger age category (<70 years) and no significant association in the 
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older age category (≥70 years). Possibly, the older age group is a more selective group 
of simvastatin users who are relatively healthier. This group reached the older age cat-
egory, whereas the more diseased patients had already died. Furthermore, in the older 
population other factors, such as a decrease in liver and renal function and a change in 
body composition, may be of more importance in the risk of developing adverse drug 
reactions, making the effect of pharmacogenetics lower.37-39 Another explanation might 
be that the OATP1B1 transporter expression is influenced by age. For example, this has 
been described for the P-glycoprotein transporter expression.40
We found a significant association between the c.521T> C polymorphism and the out-
come in simvastatin users in the lower-dose category (≤20 mg), and in atorvastatin users 
in the high-dose category (>20 mg). There is a dose–response relationship in the risk of 
developing statin-induced adverse drug reactions. A possible explanation is that physi-
cians are more careful in prescribing statins to patients with risk factors for myopathy 
(high-risk patients), and therefore start with a lower dose in these patients. For example, 
a physician starts with a lower dose in a female patient with impaired liver function.
Potential biases in our study should be considered. Omission of blood samples and 
difficulties with genotyping were completely random and not related to the c.521T>C 
genotype. The results of our study are consistent with previous studies on this topic. In 
the medical patient records, we could not retrieve the reasons for all dose decreases or 
switches and assumed that these events were associated with increased serum statin 
levels resulting in adverse drug reactions. The majority of the checked events were due 
to adverse drug reactions. Only in a minority of the cases was the cause of the event too 
strong cholesterol lowering or ineffective drug therapy. Furthermore, we missed events 
caused by adverse drug reactions, since we did not consider, for example, patients who 
stopped statin therapy due to adverse drug reactions. This may have resulted in less 
power of the study but will not change the effect size. We explicitly did not choose 
discontinuation of treatment as an indicator of an adverse drug reaction, since dis-
continuation of statins could be related to many reasons, such as noncompliance, the 
disappearance of the indication over time, the patient reaches a certain age, and the 
preventive effect becomes too small. Noncompliance frequently occurs in the case of 
statin therapy; in a previous study it was demonstrated that 53% of new users of statin 
therapy discontinued therapy within 2 years.41 The risk of information or selection bias is 
unlikely since the Rotterdam Study is a population-based cohort study, in which data are 
collected prospectively without prior knowledge of the aim of this study. In the analysis, 
we controlled for potential confounding factors such as age, sex, and starting dose of 
the prescribed statin therapy. Although we had 1939 statin users available and we had 
the option of stratifying the analysis by age, sex, and starting dose, in some categories 
we lost power because of small sample size.
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In conclusion, our study provides further evidence for the role of the SLCO1B1 c.521T>C 
polymorphism in simvastatin-associated adverse drug reactions. We demonstrated an 
association between the c.521T>C polymorphism and dose decrease or switching, as 
indicators of adverse drug reactions, among simvastatin users, and describe risk fac-
tors that increase the risk for these events. In addition, in atorvastatin users we found 
an association between the c.521T>C polymorphism and dose decrease or switching 
among users with a starting dose of more than 20 mg. For simvastatin users with the 
homozygous minor allele genotype, female sex, age under 70 years, and a low starting 
dose (<20 mg) were risk factors for the outcome. Our findings suggest that in patients 
carrying two minor alleles of the c.521T>C polymorphism, an alternative statin instead 
of simvastatin, or a cholesterol lowering drug from a different drug group, may be a 
reasonable first choice in the treatment of hypercholesterolemia.
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AbStrACt
Introduction: Genetic variation has been shown to influence statin response in terms 
of lowering LDL-cholesterol. The recently discovered CYP3A4*22 allele (defined as 
rs35599367) has been shown to affect statin-induced LDL-cholesterol lowering. Our 
objective was to investigate whether this polymorphism modifies the risk reduction for 
myocardial infarction (MI) by statins.
Methods: We analyzed the interaction between the *22 minor allele and statin use in 
the independent Utrecht Cardiovascular Pharmacogenetics study and Rotterdam Study, 
using logistic and Cox regression models.
Results: In total, 771 MI cases and 6131 controls were included in the analyses. There 
was no effect of the CYP3A4*22 allelic status in the studies separately, nor when the 
estimates from both studies were combined (interaction odds ratio: 1.27, 95% CI 0.73; 
2.21; P 0.40 for carriers of the minor T-allele).
Conclusion: We found no association of the CYP3A4*22 minor allele (rs35599367) with 
the effectiveness of statins in reducing MI risk.
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introdUCtion
Statins are widely prescribed to reduce plasma LDL-cholesterol (LDL-C), and by this ac-
tion reduce the risk for cardiovascular disease (CVD). Statins act by inhibiting HMG-CoA 
reductase, the rate-controlling enzyme in the cholesterol biosynthesis pathway.1 The 
response to statin therapy shows a degree of interindividual variability influenced by 
genetic variation and environmental factors. Based on a variety of selection criteria, a 
whole range of candidate genes and SNPs have been associated with the lipid-lowering 
response to statins.2 Due to several factors (e.g., small samples, differences in analysis 
methods and preference to publish new results), results have rarely been replicated.
One way to reduce false-positive findings in addition to using stringent criteria for 
claiming associations is to investigate well-characterized SNPs with effects on gene 
expression or protein function. This method is especially relevant in pharmacogenet-
ics, where the biologic pathway involved (e.g., enzymes metabolizing the drug and the 
proteins that the drug targets) is known, at least to a degree.
Lovastatin, simvastatin and atorvastatin are all extensively metabolized on the first 
pass through the liver, primarily by cytochrome P450 isoform CYP3A4, which leads to a 
systemic availability of 5-10%.3 A change in CYP3A4 activity is expected to be associated 
with a change in the metabolism of the drug, which may in turn affect systemic statin 
levels. Several genetic variants in the CYP3A4 gene have been described, but none of 
these have explained a large proportion of the variability in CYP3A4 enzyme activity. 
Recently, a SNP (rs35599367, CYP3A4*22) in the CYP3A4 gene was reported to be as-
sociated with reduced CYP3A4 enzyme expression and activity and increased response 
to statin therapy.4 In separate studies, this SNP was associated with reduced CYP3A4 
activity, resulting in an increased lipid-lowering response to simvastatin5, tacrolimus 
pharmacokinetics6, and an increased risk of delayed graft function.7
While the association of rs35599367 with CYP3A4 activity and a lipid-lowering re-
sponse to statins has been replicated, it is unknown whether this SNP also affects the 
relative risk reduction for cardiovascular events.8 Here, we aimed to investigate whether 
this SNP in intron 6 of CYP3A4 modifies the risk-lowering effect of statins on myocardial 
infarction (MI) in two large population-based studies.
mEthodS
We assessed the association of rs35599367 with statin effectiveness in reducing MI risk 
in two separate data sets, the Utrecht Cardiovascular Pharmacogenetics (UCP) study and 
the Rotterdam Study. The study setup has been described for both the UCP study9 and 
the Rotterdam Study10,11, and will be described briefly here (for further information, see 
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Supplementary Methods). The UCP study was approved by the Medical Ethics Commit-
tee of the University Medical Center Utrecht, The Netherlands, and participants gave 
written informed consent to the researcher allowing them to collect, store and analyze 
their DNA material. The Rotterdam Study was approved by the Medical Ethics Commit-
tee according to the Wet Bevolkingsonderzoek: ERGO (Population Study Act: Rotterdam 
Study), executed by the Ministry of Health, Welfare and Sports of The Netherlands. At 
baseline of the Rotterdam Study, participants gave written informed consent for the 
researchers to use their DNA for research purposes.
We included 1483 individuals from the UCP study and 5484 individuals from the Rot-
terdam Study. From this total of 6967 individuals ( Table 1), 771 subjects were MI cases. 
This gave us a power of 80% to detect a SNP-statin interaction odds ratio (OR) of 0.5, and 
a power of 8% to detect an interaction OR of 0.92, both at a P-value of 0.05.
the UCP study
The UCP study participants were enrolled from the population-based Pharmaco-
Morbidity Record Linkage System (PHARMO) System, which links drug-dispensing 
histories from a representative sample of Dutch community pharmacies to the national 
registration of hospital discharges. Patients who received a prescription for an antihy-
pertensive drug and/or had hypercholesterolemia (prescription for a cholesterol lower-
ing drug or total cholesterol >5.0mmol/l) were selected from the PHARMO database 
for pharmacogenetic studies on antihypertensive drugs and statins. From this cohort, 
patients hospitalized for MI (International Classification of Diseases [ICD]-9 code 410) 
were included as cases if they were registered in the PHARMO database for at least 1 
year. Controls were selected using risk set sampling and if they met the same eligibility 
criteria as the cases but had not developed a MI. Coded pharmacy records were used 
to ascertain exposure to statins and other drugs. Self-reported data on covariates (e.g. 
smoking, hypertension and diet, among others) were assessed using questionnaires. We 
used conditional logistic regression for analysis, with cases matched to controls based 
on age and sex. Analyses were corrected for BMI, use of antihypertensive medication, 
family history of CVD and smoking. Analyses were performed using R (version 3.0.212).
the rotterdam study
The Rotterdam Study is a prospective, population-based cohort study of chronic diseases 
in the general population. At baseline between 1990 and 1993, all persons aged 55 years 
and over in the Ommoord district of Rotterdam, the Netherlands, were invited to partici-
pate. Participants have been continuously followed since then during follow-up rounds 
(1993–1995, 1997–1999, 2002–2004 and 2009–2012). Medication-dispensing data 
were obtained from all seven fully computerized pharmacies in the Ommoord suburb. 
Information on the presence and occurrence of MI is available through collaboration 
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with the general practitioners in the study area13. In order to control for confounding, 
analyses were corrected for age, sex, family history of CVD, hypertension, current and 
past smoking status, BMI, use of antihypertensives, serum total and HDL-cholesterol 
levels and the presence of type 2 diabetes mellitus. Cox proportional hazard regression 
analyses were used, and all analyses were performed using SPSS software (SPSS, Inc., 
version 20.0, IL, USA).
table 1 Baseline characteristics by case-control status










Males 216 (78.5%) 879 (78.4%) 1b 264 (55.2%) 1852 (37.0%) <0.0001
Age 62.25 (9.68) 62.19 (9.45) 0.9219b 68.54 (7.58) 69.33 (9.17) 0.033
BMI 27.65 (9.36) 26.98 (9.45) 0.2343 26.42 (3.44) 26.27 (3.75) 0.408
Familial history of CVD 164 (59.6%) 595 (53.1%) 0.0382 282 (60.8%) 2588 (53.2%) 0.002
Current smoker 176 (64.0%) 452 (40.3%) <0.0001 130 (27.2%) 1103 (22.0%) <0.0001
Use of statins 126 (45.8%) 595 (53.0%) 0.0364 69 (14.7%) 899 (17.9%) 0.562
Use of antihypertensives 161 (58.5%) 621 (55.3%) 0.3817 149 (31.2%) 1273 (25.4%) 0.010
Total cholesterol 
(mmol/L)
NA NA NA 6.84 (1.18) 6.61 (1.23) <0.0001
HDL-cholesterol 
(mmol/L)
NA NA NA 1.25 (0.33) 1.37 (0.37) <0.0001
Hypertension NA NA NA 214 (44.8%) 1599 (32.7%) 0.066
Diabetes patients NA NA NA 67 (14.1%) 715 (14.3%) 0.237
Genotypes
CC (n, %) 247 (89.9%) 1006 (89.7%) NA 413 (87.1%) 4412 (88.1%) NA
CT (n, %) 25 (9.09%) 107 (9.54%) NA 60 (12.6%) 586 (11.7%) NA
TT (n, %) 3 (1.09% 8 (0.71%) NA 1 (0.21%) 12 (0.24%) NA
Statin type n (%) dosec n (%) dosec
Simvastatin (C10AA01) 421 (49.0%) 1.48 (0.80) NA 627 (64.8%) 1.18 (0.73) NA
Pravastatin (C10AA03) 99 (11.5%) 1.50 (0.59) NA 106 (11.0%) 0.94 (0.58) NA
Fluvastatin (C10AA04) 23 (2.7%) 0.93 (0.55) NA 47 (4.9%) 0.90 (0.46) NA
Atorvastatin (C10AA05) 271 (31.5%) 2.10 (1.47) NA 162 (16.7%) 1.48 (0.91) NA
Cerivastatin (C10AA06) 5 (0.6%) 1.30 (0.45) NA 11 (1.1%) 1.16 (0.41) NA
Rosuvastatin (C10AA07) 41 (4.8%) 1.28 (0.61) NA 15 (1.5%) 1.12 (0.71) NA
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein; ATC, Ana-
tomical Therapeutical Chemical Code.
Categorical data are presented as n (%), while continuous data are presented as mean (standard deviation).
a P-value from t-test (continuous variables) or X2-tests (categorical variables). b Analyses were matched by 
sex and age; cases and controls are therefore very similar for these variables. c Defined daily doses given as 
mean dose (standard deviation).
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Statin use & case definition
For this study, participants with more than 180 cumulative defined daily dosages (DDDs) 
of total use of statins were considered to be users, while participants with less than 
180 cumulative DDDs were considered to be nonusers. An exposure of 180 DDDs was 
chosen as the cumulative statin exposure necessary to exert a protective effect on MI. 
Participants that developed a MI (ICD-9 code 410) during follow-up were defined as a 
case, whereas controls did not develop a MI during follow-up.
Genotyping
For both studies, genotyping was carried out using TaqMan® (Applied Biosystems, CA, 
USA) genotyping assays (catalog identifier: C_59013445_10) on the ABI PRISM® 7500 
Fast Real-Time PCR Systems (Applied Biosystems), according to manufacturer instruc-
tions.
Statistical analysis
Analyses were performed separately for both data sets, consisting of logistic regression 
analysis for the UCP study and Cox proportional hazards regression analysis for the 
Rotterdam Study. A SNP–statin interaction in the regression model was used to assess 
the influences of the SNP on statin efficacy. The SNP–statin interaction analyses were 
investigated in all statins combined, and second, only in statins that are metabolized by 
CYP3A4, which include simvastatin, atorvastatin, lovastatin and cerivastatin. Estimates 
from both studies were combined using inverse-variance meta-analysis. Due to the low 
minor allele frequency (6%), a dominant genetic model was used. QUANTO was used 
for the power analyses.14 A Hardy–Weinberg equilibrium p-value of <0.01, calculated 
with the exact test15 due to low genotype counts, was considered to be an indication 
of problems with the genotyping. We performed two sensitivity analyses: one in 
which only patients using statins at the date of MI (or corresponding date for matched 
controls) were considered as being exposed, and one in which start and end dosages 
were stratified by genotype in order to investigate whether the genotype group with a 
theoretically stronger statin effect was titrated towards lower dosages.
rESUltS
A total of 771 MI cases and 6131 controls were eligible for the analysis (Table 1). Cases 
in the UCP study (n = 275) more frequently had a familial history of CVD and smoked 
more frequently than controls in this study. Cases in the Rotterdam Study (n = 474) also 
had a familial history of CVD more frequently than controls, and had increased rates of 
hypertension and use of blood pressure-lowering medication. Compared with the par-
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ticipants in the Rotterdam Study, participants in the UCP study were younger and more 
frequently males. Genotype distributions were similar in both studies, and rs35599367 
was in Hardy–Weinberg equilibrium in both studies.
Statins were protective for MI in the UCP study (OR 0.66, 95% CI 0.49; 0.89, Supple-
mentary Table 1) and in the Rotterdam Study (OR 0.95, 95% CI 0.71; 1.27, Supplementary 
Table 2). Statins were more protective in the Rotterdam Study, but not in the UCP study, 
when only current users were considered (sensitivity analysis; Supplementary Tables 3 & 
4). The CYP3A4*22 polymorphism had no main effect on the risk for MI (i.e., no SNP effect 
without considering an interaction with statins), with the OR in the UCP study being 0.98 
(95% CI 0.63; 1.53, P 0.93) and the OR in the Rotterdam Study being 1.15 (95% CI 0.87; 
1.52, P 0.32).
SnP-statin interaction
In both the UCP study and the Rotterdam study, there was no evidence of a SNP-
statin interaction (Table 2). In the UCP study, the adjusted interaction OR of 0.94 (95% 
CI 0.37;2.40) indicated a slightly higher statin benefit in carriers of the minor T-allele. 
However, in the Rotterdam Study, the interaction effect estimator was above 1 (adjusted 
interaction OR 1.48, 95% CI 0.75; 2.94), indicating less benefit. When the estimates from 
table 2 Interactions between statin exposure and rs35599367 and the risk of myocardial infarction





CC no statin exposure 135 476 Reference value
Statin exposure 112 530 0.75 (0.56; 1.01)
Ct/tt no statin exposure 14 50 Reference value
Statin exposure 14 65 0.70 (0.17; 2.99) 0.94 (0.37; 2.40)
rotterdam Study
CC no statin exposure 356 3618 Reference value
Statin exposure 57 794 0.86 (0.63; 1.19)
Ct/tt no statin exposure 49 493 Reference value
Statin exposure 12 105 1.19 (0.55; 2.54) 1.48 (0.75; 2.94)
meta-analysis
CC no statin exposure 491 4094 Reference value
Statin exposure 169 1324 0.80 (0.65; 0.99)
Ct/tt no statin exposure 63 543 Reference value
Statin exposure 26 170 1.06 (0.54; 2.09) 1.27 (0.73; 2.21)
Abbreviations: OR, odds ratio; CI, confidence interval.
a Values are from unadjusted conditional logistic regression for the UCP study (adjusted models cannot be 
calculated in all strata). b Adjusted values for both data sets.
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both studies are combined, the interaction OR was 1.27 (95% CI 0.73; 2.21), with a P-value 
of 0.40. SNP-statin interaction analyses in which we only con sidered the statins that 
are metabolized by CYP3A4 (i.e., simvastatin, atorvastatin, cerivastatin and lovas tatin) 
showed results similar to the analysis with all statin users combined (Supplementary 
Table 5); the overall interaction OR was 1.21 (95% CI 0.66; 2.22, P 0.54) in this analysis. An 
additional sensitivity analysis showed that there was no effect of genotype on end dos-
ages of statins in the UCP study or in the Rotterdam Study (Supplementary Tables 6 & 7).
diSCUSSion
Here, we examined the functional SNP rs35599367 in CYP3A4, coding for the *22 iso-
form, and its rela tionship with the effectiveness of statins in terms of reducing the risk 
for MI. Although this study pres ents a ‘negative’ result in that we did not find an as-
sociation, the result is still of interest. We showed that the rs35599367 polymorphism in 
the metaboliz ing CYP3A4 enzyme, with a known and replicated association with either 
necessary dose4 or LDL-C reduction with a standard dose5, is not associated with the 
clinical outcome MI.
The SNP under investigation was linked to a 0.34 mmol/l stronger lipid-lowering 
response for rs35599367 minor T-allele carriers when compared with non-carriers. Be-
cause stronger reductions in LDL-C correspond to further reductions in the incidence of 
cardiovascular events (relative risk of 0.78 per mmol/l of LDL-C reduction16), we hypoth-
esized that this SNP is associated with bet ter statin effectiveness. When considering the 
effect the T-allele has on the lipid-lowering response, we expected an interaction OR 
of 0.92 for the clinical outcome. When assuming a 22% reduction of cardio vascular risk 
through normal statin-induced LDL-C lowering, this translates to a 28% risk reduction 
for carriers of one or more minor T-alleles. The size of the difference made it reasonable 
to search for the clinical effect of this polymorphism in observational studies.
There may be several reasons for not finding an association of rs35599367 with statin 
effectiveness. The most probable explanation seems to be that the effect on LDL-C re-
sponse is too small to affect clini cal outcome. While our study had a statistical power of 
80% for detecting a SNP–statin interaction OR of 0.5, it had much less power for detect-
ing a smaller effect (i.e., an interaction OR of 0.92). The power to find an interaction of 
this size was 8%, emphasiz ing the difficulty of finding small effects on clinical benefit, 
even in large studies. However, if the associa tion can only be found in an extremely large 
dataset, the clinical relevance of the interaction is uncertain. Secondly, we have analyzed 
the data from two sepa rate studies, each with their own study design. For example, the 
studies demonstrated different values regarding the effectiveness of statins. However, 
by adjusting for specific covariates in both studies, we showed a protective effect of 
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statins, and it is unlikely that the SNP–statin interaction was influenced by confound-
ing, because the prescribing physicians had no knowledge of the genetic information. 
Another possible reason for not finding an effect is that the drug dosage is titrated for 
a particular reduction of LDL-C, thus negating any potential clinical effect. However, we 
did not see any difference between the genotype groups regarding dosages of statins. 
Lastly, it cannot be excluded that in a different population (e.g., of Asian ancestry), this 
SNP might have a larger effect. This is not uncommon in (pharmaco)genet ics, but we 
were unable to study this with the current Caucasian data sets.
The strengths of this study are that we used two separate studies with an accurate 
measure of drug use and a well-defined outcome, being that of MI. Both studies 
separately did not show an interaction, nor was there an effect when the data from both 
studies were combined. The current sample size was larger than that of the previous 
studies4,5, which investigated 235 and 80 statin users, respectively, in terms of LDL-C 
outcome. Here, with 771 cases and 4713 controls, we could not show an effect on risk 
reduction for MI.
In two population-based studies, we could not dem onstrate any effect of modifica-
tion of the CYP3A4 rs35599367 polymorphism on the effectiveness of statins in reducing 
the risk for MI. Although this polymorphism has been shown to influence other clinical 
outcomes, this study suggests a limited value of genotyping patients for this specific 
polymorphism in order to improve the clinical effectiveness of statins on MI.
fUtUrE PErSPECtivE
To date, several polymorphisms have been found to affect responses to statin therapy 
based on achieving reduced LDL-C. A further increase in the number of loci associated 
with LDL-C response could probably be achieved with larger studies using genome-
wide association study methodologies, although large num bers of statin users would 
be required in order to effec tively conduct such studies. The main problem with statin 
pharmacogenetics is that using these findings to improve clinical effectiveness has not 
been very suc cessful. When more loci are identified, a dosing algo rithm based on the 
whole collection of SNPs influenc ing statin response might improve effectiveness. Given 
the existing findings in this field, it seems unlikely that genotyping an incident statin 





• The response to statin therapy shows a degree of interindividual variability, which is 
influenced by genetic variation and environmental factors.
• Statins are extensively metabolized on the first pass through the liver, primarily by 
cytochrome P450 isoform CYP3A4.
• The CYP3A4*22 isoform (defined as rs35599367) was associated with lower CYP3A4 
expression and activity and increased response to statin therapy, based on LDL-
cholesterol lowering. It is unclear whether this polymorphism has effects on the 
reduction of cardiovascular events by statin use.
Patients & methods
• We analyzed the association of rs35599367 with clinical effectiveness of statins in 
two separate data sets, the Utrecht Cardiovascular Pharmacogenetics (UCP) study 
and the Rotterdam Study.
• A total of 771 myocardial infarction cases and 6131 controls were included in the 
analyses.
results & conclusion
• There was no effect of CYP3A4*22 in either of the studies separately, nor when the 
estimates from both studies were combined (interaction odds ratio 1.27, 95% CI 0.73 
– 2.21, P 0.40 for carriers of the minor T-allele).
• Although this polymorphism has been shown to influence other clinical outcomes, 
this study suggests a limited value of genotyping patients for this specific poly-
morphism in order to improve the clinical effectiveness of statins in prevention of 
myocardial infarction.
All supplementary files can be found via:
http:// www.futuremedicine.com/doi/suppl/10.2217/pgs.14.90
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Statins effectively lower LDL-cholesterol levels in large studies and the observed inter-
individual response variability may be partially explained by genetic variation. Here we 
perform a pharmacogenetic meta-analysis of genome-wide association studies (GWAS) 
in studies addressing the LDL-cholesterol response to statins, including up to 18,596 
statin-treated subjects. We validate the most promising signals in a further 22,318 statin 
recipients and identify two loci, SORT1/CELSR2/PSRC1 and SLCO1B1, not previously iden-
tified in GWAS. Moreover, we confirm the previously described associations with APOE 
and LPA. Our findings advance the understanding of the pharmacogenetic architecture 
of statin response.
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introdUCtion
The 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
also known as statins, are widely prescribed and are highly effective in the management 
and prevention of cardiovascular disease. Statin therapy results in a lowering of low-
density lipoprotein cholesterol (LDL-C) levels by up to 55%1 and a 20–30% reduction 
of cardiovascular events.2 Despite the clinical efficacy of statins in a wide range of pa-
tients2, interindividual variability exists with regard to LDL-C-lowering response as well 
as efficacy in reducing major cardiovascular events.3 The suggestion that some of this 
variability may be due, in part, to common pharmacogenetic variation is supported by 
previous studies that have identified genetic variants associated with differential LDL-C 
response to statin therapy.4-6
A small number of genome-wide association studies (GWAS) have previously identi-
fied loci associated with statin response on a genome-wide level. A GWAS in the JUPI-
TER trial identified three genetic loci, ABCG2 (rs2199936), LPA (rs10455872) and APOE 
(rs7412), that were associated with percentage LDL-C reduction following rosuvastatin 
therapy.7 In the CARDS and ASCOT studies, single nucleotide polymorphisms (SNPs) 
at LPA (rs10455872) and APOE (rs445925 and rs4420638) were associated with LDL-C 
response to atorvastatin treatment.8 A combined GWAS in three statin trials identified 
a SNP within CLMN (rs8014194) that is associated with the magnitude of statin-induced 
reduction in plasma cholesterol.9 However, two other GWAS identified no genetic deter-
minants of LDL-C response to statin therapy at a genome-wide significant level.6,10 On 
the basis of these studies, as well as previous candidate gene studies4,6, the only genetic 
variants that have been consistently identified to be associated with variation in LDL-C 
response to statin therapy, irrespective of statin formulation, are located at or nearby 
APOE and LPA. To determine whether additional loci may influence LDL-C response to 
statins, we formed the Genomic Investigation of Statin Therapy (GIST) consortium and 
conducted a pharmacogenetic meta-analysis using GWAS data sets from randomized 
controlled trials (RCTs) and observational studies. We identify two loci not previously 
identified in GWAS, SORT1/CELSR2/PSRC1 and SLCO1B1. In addition, we confirm the as-
sociations within the APOE and LPA genes. These findings will extend the knowledge of 
the pharmacogenetic architecture of statin response.
mEthodS
Study populations
The meta-analysis was conducted in the GIST consortium, which includes data from 8 
randomized controlled statin trials (RCTs) and 11 prospective, population-based studies. 
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The initial analysis (first stage) was performed in 8,421 statin-treated subjects from 6 
RCTs (ASCOT, CARDS, CAP, PRINCE, PROSPER and TNT) and 10,175 statin-treated subjects 
from 10 observational studies (AGES, ARIC, BioVU, CHS, FHS, GoDARTS I, GoDARTS II, 
Health ABC, HVH and MESA). Further investigation (second stage) was performed in 
21,975 statin-treated subjects from two randomized trials (HPS and JUPITER) and one 
observational study (Rotterdam Study). Six SNPs were additionally genotyped in the 
Scandinavian participants of the ASCOT study. The details of the first- and second-stage 
studies can be found in the Supplementary Tables 1 and 2 and Supplementary Notes 1 
and 2.
Subjects
Response to statin treatment was studied in statin-treated subjects only and not in those 
treated with placebo. Subjects included in the observational studies’ analysis should 
be treated with statins and have LDL-C measurements before and after start of statin 
treatment. Subjects of reported or suspected non-European ancestry were excluded. All 
participants gave written informed consent and the study was approved by all institu-
tional ethics committees.
outcome measurements
The response to statin treatment was defined as the difference between the natural log-
transformed on- and off-treatment LDL-C levels. The beta of the corresponding regres-
sion thus reflects the fraction of differential LDL lowering in carriers versus non-carriers 
of the SNP. For observational studies, the on-treatment LDL-C levels were taken into 
account for all kinds of prescribed statins, at any dosage, for any indication and for at 
least 4 weeks before measurement. Characteristics of on- and off-treatment LDL-C levels 
and statins used in each study are shown in Supplementary Table 2. For each individual, 
at least one off-treatment LDL-C measurement and at least one on-treatment LDL-C 
measurement were required. When multiple on- or off-treatment measurements were 
available, the mean of the cholesterol measurements was used. Subjects with missing 
on- or off-treatment measurements were excluded, with the exception of the GoDARTS 
cohorts for which missing off-treatment LDL-C levels were estimated using imputation 
methods (Supplementary Note 2). In the HPS, proportional LDL-C response was defined 
by the changes in natural log lipid levels from the screening visit before starting statin 
therapy to the randomization visit.6
Genotyping and imputation
Genotyping, quality control, data cleaning and imputation were performed indepen-
dently in each study using different genetic platforms and software as outlined in 
Supplementary Table 4. In all studies, genotyping was performed using Illumina, Af-
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fymetrix or Perlegen genotyping arrays, and MACH, Impute or BIMBAM software was 
used for imputation.
GwAS analysis
Each study independently performed the GWAS on the difference between natural 
log-transformed on- and off-treatment LDL-C levels. To control for possible associations 
with off-treatment LDL-C levels, analyses were adjusted for the natural log-transformed 
off-treatment LDL-C level. An additive genetic model was assumed and tested using 
a linear regression model. For imputed SNPs, regression analysis was performed onto 
expected allele dosage. Analyses were additionally adjusted for age-, sex- and study-
specific covariates (for example, ancestry principal components or country). Analyses 
in the observational studies were, if available, additionally adjusted for the statin dose 
by the natural logarithm of the dose equivalent as defined in Supplementary Table 3. 
This table shows the dose equivalent per statin type; dividing the statin dosage of an 
individual by the dose equivalent shown in Supplementary Table 3 will give the adjusted 
statin dosage.
Quality control and meta-analysis
Centrally, within each study, SNPs with MAF <1% or imputation quality <0.3 were 
excluded from the analysis. QQ-plots were assessed for each study to identify between-
study differences (Supplementary Fig. 1). The software package METAL was used for 
performing the meta-analysis (http://www.sph.umich.edu/csg/abecasis/Metal/index.
html). A fixed effects, inverse variance weighted approach was used. Using an inverse 
variance weighted meta-analysis will give smaller weights to studies with large SE. To 
correct for possible population stratification, genomic control was performed by adjust-
ing the within-study findings and the meta-analysis results for the genomic inflation 
factor.
Second stage
SNPs with P values <5 × 10−4 in the first-stage meta-analysis were selected for further 
investigation in a second stage. A maximum of two SNPs per locus were selected, based 
on statistical significance, except for the APOE locus, for which all genome-wide sig-
nificant associated SNPs were selected for validation. A total of 246 SNPs, within 158 
independent loci, were selected for the second stage, which was performed in the JUPI-
TER trial, HPS study and the Rotterdam Study, which all had GWAS data and response to 
statin treatment available. For 2 of the 246 SNPs, a proxy was used in the JUPITER trial, 
and 31 SNPs were not available, nor was a proxy SNP. HPS provided data on 151 directly 
genotyped SNPs from GWAS and IPLEX experiments, including 48 of the requested SNPs 
and 103 proxy SNPs (R2> 0.8). Analysis in HPS was not adjusted for ln baseline LDL-C 
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levels. In addition, the number of subjects with data varied from SNP-to-SNP and ranges 
from ~4,000 for variants with GWAS data to ~18,000 for some candidate genes. Results of 
the first and second stage were combined using fixed effects, inverse variance weighted 
meta-analysis and analyzed by METAL. As a third stage, six SNPs with P values 5 × 10−8 < 
P < 5 × 10−7 in the combined meta-analysis were selected for additional genotyping in 
the Scandinavian participants of the ASCOT study. Kaspar assays were designed for four 
of the SNPs using the KBioscience Primerpicker software, and oligos were provided by 
Intergrated DNA technologies (http://eu.idtdna.com/site). Full Kaspar methodology is 
available from LGC SNP genotyping (http://www.lgcgenomics.com/genotyping/kasp-
genotypingreagents/). Two SNPs (rs981844 and rs13166647) were genotyped using 
Taqman assays supplied by Life Technologies (http://www.lifetechnologies.com/uk/en/ 
home.html) using the standard Taqman protocol. Results of the additional genotyping 
were combined with results from the first and second stages using a fixed effects, inverse 
variance weighted meta-analysis and analyzed by METAL.
determination of changes in ldl subfractions
LDL subclasses were analyzed as described previously29 using non-denaturing gradi-
ent gel electrophoresis of fasting plasma samples taken at baseline and after 6 weeks 
of simvastatin 40 mg per day (CAP study, n = 579) or 12 weeks of pravastatin 40 mg 
per day (PRINCE study, n = 1,284). Aliquots of 3.0ml of whole plasma were mixed 1:1 
with a sampling buffer of 20% sucrose and 0.25% bromophenol blue. Electrophoresis 
of samples and size calibration standards was performed using 2–14% polyacrylamide 
gradients at 150V for 3 h following a 15-min pre-run at 75 V. Gels were stained with 
0.07% Sudan black for 1h and stored in a 0.81% acetic acid, 4% methanol solution 
until they were scanned by computer-assisted densitometry for determination of ar-
eas of LDL IVb (22.0–23.2 nm), LDL IVa (23.3–24.1nm), LDL IIIb (24.2–24.6 nm), LDL IIIa 
(24.7–25.5nm), LDL IIb (25.6–26.4 nm), LDL IIa (26.5–27.1nm) and LDL I (27.2–28.5 nm). 
The cholesterol concentrations of the subfractions (mg/dL plasma) were determined by 
multiplying percent of the total stained LDL area for each subfraction by the LDL-C for 
that sample. For genetic association analyses, subfractions were grouped into large LDL 
(LDL IIa), medium LDL (LDL IIb), small LDL (LDL IIIa) and very small LDL (LDL IIIb+Iva+IVb) 
as described previously.18 A generalized estimating equation method was used to test 
the association of log change with the interaction of the four SNPs by LDL subfraction.
Effect of off-treatment ldl-C
Effects of genetic variation on treatment response as measured by on-treatment LDL-C 
could be mediated through effects on the off-treatment LDL-C. To evaluate whether 
genetic on-treatment LDL-C likely reflects residual effect on off-treatment LDL-C, it is 
necessary to adjust for the off-treatment LDL-C levels and to correct the maximum likeli-
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hood estimate of the adjusted effect of genotype on on-treatment value for the noise in 
off-treatment values (the noise is both random measurement error and intra-individual 
variation in usual LDL-C). This analysis was only carried out in CARDS in which multiple 
baseline measurements were available. From the rules of path analysis, we calculated 
the direct effect γ of genotype on an on-treatment trait value as β − αδ (1 − ρ)/ ρ, where 
β is the coefficient of regression for on-treatment trait value on genotype adjusted for 
measured off-treatment value, α is the coefficient of regression of baseline LDL on geno-
type, ρ is the intraclass correlation between replicate measurements of off-treatment 
values and δ is the coefficient of regression for on-treatment value on observed off-
treatment value8. For these calculations, we used ρ = 0.8 as a plausible value for the 
intraclass correlation based on the within-person correlation in LDLC values taken over 
two off-treatment visits in CARDS. The interaction of candidate SNPs with statin versus 
placebo allocation was assessed in the JUPITER trial, since this study was not involved in 
the first-stage meta-analysis. Regression models were applied to the combined popula-
tion of statin- and placebo-treated subjects by including extra terms encoding placebo 
allocation and the product of placebo allocation with SNP minor allele dose.7
GwCA using Genome-Complex trait Analysis
There may be multiple causal variants in a gene and the total variation that could be 
explained at a locus may be underestimated if only the most significant SNP in the region 
is selected. To identify independent SNPs, we ideally can perform a conditional analysis, 
starting with the top associated SNP, across the whole genome followed by a stepwise 
procedure of selecting additional SNPs, one by one, according to their conditional P 
values. Such a strategy would allow the discovery of more than two associated SNPs at a 
locus. To identify independent SNPs across the genome-wide data, we used an approxi-
mate conditional and joint analysis approach implemented in Genome-Complex Trait 
Analysis (GCTA) software (http://www.complextraitgenomics.com/software/gcta/). We 
used summary-level statistics from the first- and second-stage-combined meta-analysis 
and LD corrections between SNPs estimated from CARDS GWAS data. SNPs on different 
chromosomes or more than 10Mb distant are assumed to be in linkage equilibrium. The 
model selection process in GCTA starts with the most significant SNP in the single-SNP 
meta-analysis across the whole genome with P-value <5 × 10−7. In the next step, it calcu-
lates the P-values of all the remaining SNPs conditional on the top SNP that have already 
been selected in the model. To avoid problems due to colinearity, if the squared multiple 
correlations between a SNP to be tested and the selected SNP(s) is larger than a cut-off 
value, such as 0.9, the conditional P-value for that SNP will be set to 1. Select the SNPs with 
minimum conditional P-value that is lower than the cut-off P-value. Fit all the selected 
SNPs jointly in a model and drop the SNPs with the P value that is greater than the cut-off 
P value. This process is repeated until no SNPs can be added or removed from the model.
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Pathway analysis and construction of a statin response network
Genes showing evidence of association (based on direct association or LD (HapMap CEU 
R2 >0.8)) were reviewed for evidence of involvement in statin response at a pathway 
level using GeneGo Metacore (Thomson Reuters (portal.genego.com)). A statin re-
sponse network was constructed in two stages. First, all genes with a literature-reported 
involvement in statin response (based on Medical Subject Headings (MeSH)) were 
identified using GeneGo MetaCore (Supplementary Data 3). Second, these genes were 
combined with all genes in associated loci (including genes in LD) and a network was 
constructed based on direct interactions only. By including direct interactions only, we 
created a conservative network of direct gene interactions that have been consistently 
linked to statin response in the literature.
eQtl analysis
LDL-C-associated index SNPs (246 SNPs) were used to identify 1,443 LD proxy SNPs dis-
playing complete LD (R2 = 1) across four HapMap builds in European ancestry samples 
(CEU) using the SNAP tool (http://www.broadinstitute.org/mpg/snap/). The primary 
index SNPs and LD proxies were searched against a collected database of expression 
SNP (eSNP) results, including the following tissues: fresh lymphocytes30, fresh leuko-
cytes31, leukocyte samples in individuals with Celiac disease32, whole-blood samples33-36, 
lymphoblastoid cell lines (LCL) derived from asthmatic children37,38, HapMap LCL from 
three populations39, a separate study on HapMap CEU LCL40, additional LCL population 
samples41-43 (Mangravite et al., unpublished), CD19+ B cells44, primary phytohaemag-
glutinin-stimulated T cells41, CD4+ T cells45, peripheral blood monocytes44,46,47, CD11+ 
dendritic cells before and after Mycobacterium tuberculosis infection48, omental and 
subcutaneous adipose33,43,49, stomach49, endometrial carcinomas50, ER+ and ER− breast 
cancer tumour cells51, brain cortex46,52,53, prefrontal cortex54,55, frontal cortex56, temporal 
cortex53,56, pons56, cerebellum53,56, three additional large studies of brain regions includ-
ing prefrontal cortex, visual cortex and cerebellum, respectively57, liver49,58,59, osteo-
blasts60, ileum49,61, lung62, skin43,63 and primary fibroblasts.41 Micro-RNA QTLs were also 
queried for LCL64 and gluteal and abdominal adipose.65 The collected eSNP results met 
the criteria for association with gene expression levels as defined in the original papers. 
In each case where a LDL-C-associated SNP or proxy was associated with a transcript, 
we further examined the strongest eSNP for that transcript within that data set (best 
eSNP), and the LD between the best eSNP and GIST-selected eSNPs to estimate the 
concordance of the LDL-C and expression signals.
Statin response connectivity map analysis
The Connectivity Map (Cmap) data set is available at the Broad Institute (www.broadin-
stitute.org/cmap) and contains more than 7,000 expression profiles representing 1,309 
Meta-analysis of GWAS of LDL-cholesterol response to statins 127
compounds used on five different cultured human cancer cell lines (MCF7, ssMCF7, 
HL60, PC3 and SKMEL5). We selected (prostate tumour-derived) PC3 cells as they showed 
the most responsiveness to statins at a genome-wide level. Four statins were included 
in our analysis, including pravastatin, atorvastatin, simvastatin and rosuvastatin. PC3 
Instance reference files for each statin treatment were extracted (as defined by Lamb 
et al.12), that is, a treatment associated to its control pair. Transcripts were considered to 
show evidence of differential expression with a fold change >2. A fold change >1.5 was 
considered to be suggestive of differential expression only.
Exploration of functional impact among directly and indirectly associated variants
Genes and variants across all LDL-C-associated loci were investigated for evidence of 
functional perturbation using a range of bioinformatics tools and databases. Variants 
showing LD (CEU R2 >0.8) with associated variants were explored for impact on coding 
gene function using Annovar66 and regulatory function using a combination of Hap-
loReg67 and Regulomedb68, which both draw on comprehensive data from the Encyclo-
pedia of DNA Elements (ENCODE)69 and the NIH Roadmap Epigenomics consortium70. 
Building on the functional annotation, we also identified variants that were shown to 
mediate eQTLs. Genes in associated loci were also used to query the NIH connectivity 
map for evidence of differential expression in PC3 cell lines treated with pravastatin, sim-
vastatin and rosuvastatin. By combining a wide range of functional data and pathway 




The GIST consortium includes 6 RCTs (n = 8,421 statin recipients) and 10 observational 
studies (n = 10,175 statin recipients) that participated in the first stage (see Methods; 
Supplementary Tables 1 and 2; Supplementary Notes 1 and 2). To search for genetic 
variants associated with differential LDL-C response to statin therapy, each study in-
dependently performed a GWAS among statin users, using the difference between the 
natural log-transformed LDL-C levels on- and off-treatment as the response variable (see 
Methods).
The first-stage meta-analysis identified three loci, including 13 SNPs, that attained ge-
nome-wide significance (P<5 × 10−8) for association with LDL-C response to statin treat-
ment (Fig. 1; Table 1). The most significant association was for a SNP on chromosome 19, 
at APOE (rs445925, minor allele frequency (MAF) 0.098, β −0.043, SE 0.005, P 1.58 × 10−18; 
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tional 4.3% increase per allele in LDL-C lowering effect compared with non-carriers. The 
second strongest association was with a SNP at LPA on chromosome 6 (rs10455872, MAF 
0.069, β 0.041, SE 0.006, P 1.95 × 10−11; Fig. 2b), indicating a 5.9% smaller LDL-C lowering 
per minor allele for carriers of the SNP compared with non-carriers. Associations at both 
loci have previously been described.7,8 A third genome-wide significant association was 
found with a SNP at RICTOR on chromosome 5 (rs13166647, MAF 0.230, β −0.253, SE 
0.046, P 4.50 × 10−8), although genotypes for this SNP were only available in two studies 
within the first stage (n = 2,144).
Second-stage meta-analysis
We selected 246 SNPs with P <5 × 10−4 from 158 loci for further investigation in three 
additional studies comprising up to 22,318 statin-treated subjects (see Methods; 
Supplementary Tables 1 and 5; Supplementary Note 3). This second stage confirmed the 
genome-wide significant associations between variations within the APOE and LPA loci 
and LDL-C response, as observed in the first stage (Table 1; Supplementary Fig. 2; Sup-
plementary Table 5). In addition, SNPs at two new loci with P values between 6.70 × 10−7 
and 2.26 × 10−6 in the first phase were shown to be significantly associated with statin-
induced LDL-C lowering after statin treatment in the total combined meta-analysis at 
a genome-wide level: SORT1/CELSR2/PSRC1 (rs646776, β −0.013, SE 0.002, P 1.05 × 10−9 
and rs12740374, β −0.013, SE 0.002, P 1.05 × 10−9; Fig 2c) and SLCO1B1 (rs2900478, β 
figure 1 Results of the GWAS meta-analysis
Manhattan plot presenting the −log10 P-values from the combined meta-analysis (n = 40,914) on LDL-C 
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figure 2 Regional association plots of the genome-wide significant associations with LDL-C response after 
statin treatment
The plots show the genome-wide significant associated loci in the combined meta-analysis (n = 40,914), 
the APOE locus (a), the LPA locus (b), the SORT1/CELSR2/PSRC1 locus (c) and the SLCO1B1 locus (d) (gener-
ated using LocusZoom (http://genome.sph.umich.edu/wiki/LocusZoom)). The RefSeq genes in the region 
are shown in the lower panel. P-values were generated using linear regression analysis.
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0.016, SE 0.003, P 1.22 × 10−9; Fig 2d), indicating an additional 1.5% increase per allele 
in LDL-C lowering effect for carriers of the SORT1/CELSR2/PSRC1 SNP and a 1.6% smaller 
LDL-C lowering per minor allele for carriers of the SLCO1B1 SNP.
The six next-ranked SNPs with P values just below 5 × 10−8 in the combined meta-
analysis, including the two SNPs at RICTOR (rs13166647 and rs13172966), were selected 
for additional genotyping in the Scandinavian ASCOT participants (see Methods). None 
of these six SNPs reached genome-wide significance after this additional genotyping 
(Supplementary Table 6). Therefore, our overall genome-wide significant findings were 
the SNPs at APOE, LPA, SORT1/CELSR2/PSRC1 and SLCO1B1.
Subfraction analyses
To extend our results for the novel GWAS finding SORT1/CELSR2/PSRC1, we performed 
additional association analyses, using measurements of cholesterol levels in four LDL 
subfractions (large, medium, small and very small) from two of the trials in GIST, CAP and 
PRINCE (Table 2; see Methods). The minor allele of SORT1 rs646776 was associated with 
greater statin-induced reductions in levels of all LDL subfractions, and there was a non-
significant trend for larger effect sizes and greater statistical significance for lowering 
of small and very small LDL (Table 2). In contrast, the APOE SNP associated with greater 
LDL-C response to statins (rs445925) showed a small and nonsignificant association 
with change in very small LDL (Table 2). For the minor allele of rs2900478 (SLCO1B1), the 
borderline significant association with smaller magnitude of LDL-C reduction showed a 
trend for preferential association with larger versus smaller LDL subfractions. The lack 
of association of rs10455872 (LPA) with changes in LDL subfractions is consistent with 
evidence discussed below that this locus affects levels of lipoprotein(a) (Lp(a)) and not 
table 2 Associations of the minor alleles of rs646776, rs445925, rs2900478 and rs10455872 with changes in 












beta SE P beta SE P beta SE P beta SE P
ldl-C total −0.023 0.008 0.003 −0.046 0.018 0.008 0.010 0.005 0.04 0.032 0.019 0.09
large ldl-C −0.028 0.014 0.042 −0.075 0.029 0.009 0.020 0.008 0.01 0.036 0.031 0.23
medium ldl-C −0.027 0.015 0.075 −0.079 0.032 0.012 0.016 0.009 0.07 0.010 0.034 0.77
Small ldl-C −0.047 0.018 0.009 −0.071 0.037 0.050 0.002 0.010 0.83 −0.024 0.039 0.54
very small ldl-C −0.034 0.009 0.00006 −0.022 0.017 0.202 0.001 0.005 0.90 0.008 0.019 0.67
Abbreviations: S.E., standard error; LDL-C, low-density lipoprotein cholesterol; MAF, minor allele frequency.
a Change: ln (on treatment) – ln (baseline) models adjusted for log (baseline variable), age, sex, body mass 
index, smoking(y/n) and study (CAP versus PRINCE). Betas and P values were assessed using a generalized 
estimating equation method.
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LDL particles. Using generalized estimating equations, we tested the association of log 
change in each of the LDL subfractions with interactions of the four SNPs. For very small 
LDL, the association with the rs646776 minor allele was significantly different from that 
of the other minor alleles (P 0.03 after adjustment for multiple testing).
Effects of off-treatment ldl-C
To demonstrate that our findings for LDL-C response to statin treatment are unlikely to 
be explained through associations with baseline LDL-C levels, we performed a number 
of additional analyses (see Methods). First, Supplementary Table 7 shows regression 
coefficients for baseline-adjusted and measurement noise-corrected estimates of the 
direct effect of genotype on on-treatment LDL-C at the strongest SNPs in the GIST 
meta-analysis (P <1 × 10−8), which were available in the CARDS data set. Correcting our 
effect size estimate further and modeling measurement noise at baseline reduced the 
apparent effect only slightly for all the markers, suggesting that there is little effect of 
measurement noise. Next, within the JUPITER trial, additional analyses were performed 
to determine whether there was an interaction between LDL-C change and statin or 
placebo allocation. Supplementary Table 8 shows significant P values for interaction (all 
<5 × 10−2) for SNPs at the four genome-wide significant loci in the GIST meta-analysis, 
also suggesting that genetic effects on baseline LDL-C as manifested in the placebo 
group contribute at most only in part to genetic effects on LDL-C response in the statin 
group.
Genome-wide Conditional Analysis
To investigate whether there were multiple SNPs within any gene and multiple loci as-
sociated with differential LDL-C lowering to statin therapy, we performed a conditional 
analysis across the genome using the summary statistics of the combined meta-analysis. 
The results of the Genome-Wide Conditional Analysis (GWCA; see Methods; Supplemen-
tary Table 9) showed 14 SNPs independently associated with statin response and these 
explained ~5% of the variation in LDL-C response to statin treatment. Of the 14 inde-
pendent SNPs, 6 were genome-wide significant in the combined GWAS meta-analysis 
(Supplementary Table 5).
Previous findings
In Supplementary Table 10, we performed a look-up in our GWAS meta-analysis for SNPs 
previously described in the literature (NHGRI Catalogue11 of Published GWAS and Candi-
date gene studies) to be associated with statin response, besides the loci associated at a 
genome-wide level in the current study. None of these SNPs was associated with statin 
response in our GWAS after correcting for multiple testing.
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functional analyses
Functional characterization of the 246 SNPs selected for the second stage was per-
formed using a range of bioinformatics tools (see Methods). A total of 420 expression 
quantitative trait loci (eQTL) associations were identified across a wide range of tissues 
(Supplementary Data 1), which comprised 67 independent gene eQTL associations. 
Eleven genes, including APOE, SORT1, CELSR2 and PSRC1, showed eQTLs in liver, which 
considering its primary role in mediating statin-induced LDL reduction may be particu-
larly relevant to statin response. Putative gene eQTLs were combined with genes anno-
tated to variants in linkage disequilibrium (LD) with LDL-C response-associated variants, 
resulting in a list of 185 candidate gene loci, defined by 2,681 SNPs (Supplementary Data 
2 and 3). To identify statin responsive genes among the candidate loci, gene expression 
data measured in response to statin treatment in a range of cell lines was retrieved from 
the Connectivity Map resource12 (see Methods). Five genes (APOE, BRCA1, GRPEL1, ADRB2 
and ETV1) showed convincing evidence of statin responsiveness on the basis of greater 
than twofold differential expression in response to statin treatment. Eight genes showed 
suggestive evidence (1.5- to 2-fold change; TOMM40, SREBP1, PSRC1, BCL3, BCAM, ANK3, 
SIVA1 and RANBP9; Supplementary Data 3).
Finally, involvement in statin response was investigated at a pathway level using 
GeneGo Metacore (Thomson Reuters13). Briefly, 87 literature-reported genes linked 
to statin response were combined with the 185 candidate gene loci reported here 
(Supplementary Data 3). A conservative network of direct interactions was constructed 
between query genes (Supplementary Data 4). The network included 24 genes located 
in the LDL-C-associated loci (Supplementary Fig. 4). Collectively, our functional and 
pathway analysis confirms a strong biological and functional role in statin response 
for several strongly associated gene loci, including APOE/TOMM40/PVRL2 and SORT1/
CELSR2/PSRC2.
diSCUSSion
We have performed a meta-analysis of GWAS including more than 40,000 subjects, 
investigating genetic variants associated with variation in LDL-C lowering on statin 
treatment independent from associations with baseline LDL-C. We identified four loci 
at genome-wide significance, including the previously identified APOE and LPA, and the 
novel GWAS loci SORT1/CELSR2/PSRC1 and SLCO1B1.
Nine SNPs in the APOE gene region reached genome-wide significance for LDL-C 
response. The minor allele of the lead SNP rs445925, which is a proxy for the apoE ε2 
protein variant defining SNP rs741214, was associated with a larger LDL-C-lowering 
response to statins compared with carriers of the major allele. The magnitude and direc-
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tion of the effect size was similar to previously reported findings for the rs445925 variant 
in the GWAS study performed in CARDS and ASCOT8 and of the SNP rs7412 in JUPITER.7 
Since the apoE ε2 protein results in increased hepatic cholesterol synthesis, it may also 
predispose to stronger inhibition of cholesterol synthesis by statin treatment.8,10
Three independent SNPs at LPA were significantly associated with LDL-C response 
to statins. The minor G allele of the lead SNP rs10455872 was associated with smaller 
LDL-C reduction than the major allele. This result was similar to the previous GWAS find-
ings for this SNP in the JUPITER trial and the combined ASCOT and CARDS study.7,8 The 
rs10455872 SNP was strongly associated with the KIV-2 copy number variant in Lp(a), 
which encodes variability in apo(a) size and is responsible for ~30% of variance in Lp(a) 
levels.8,15 Furthermore, rs10455872 was shown to be strongly associated with plasma 
Lp(a) levels.16 Standard assays of LDL-C, as well as the Friedewald formula, include cho-
lesterol that resides in Lp(a).6,8 Carriers of this LPA variant are characterized by higher 
Lp(a) levels and a larger proportion of their measured LDL-C resides in Lp(a) particles.8,10 
Since statin therapy does not reduce the number of Lp(a) particles17, their presence at-
tenuates the measured LDL-C response to statins.
Two SNPs at SORT1/CELSR2/PSRC1 (rs646776 and rs12740374) on chromosome 1p 
were associated with an enhanced statin LDL-C response. A similar association was pre-
viously observed in a large candidate gene study in HPS6; however, we demonstrate this 
finding now first at a genome-wide significance level. The minor allele of rs12740374 has 
been shown to generate a binding site for the transcription factor C/EBPa.18 Transcrip-
tion results in upregulation of hepatic expression of three genes at this locus, SORT1, 
CELSR2 and PSRC118, which we also showed in our eQTL analysis (Supplementary Data 1). 
Of these, SORT1 is most notable, in that it encodes the multifunctional intracellular traf-
ficking protein sortilin, which has been shown to bind tightly to apoB.19 Sortilin-induced 
lowering of plasma LDL-C results from two mechanisms: reduced secretion of apoB-con-
taining precursors, and, perhaps of greater importance, increased hepatic LDL uptake 
via binding to sortilin at the cell surface, with subsequent internalization and lysosomal 
degradation.19 Notably, the minor allele of rs646776 is preferentially associated with 
lower levels of small and very small LDL (Table 2), suggesting that sortilin is of particular 
importance for regulating levels of these particles.18 Smaller LDL subfractions have been 
shown to be relatively enriched in particles with reduced LDL receptor binding affinity 
and cellular uptake20, a property that may contribute to their associations with increased 
risk for cardiovascular disease.21 This property may also underlie the diminished efficacy 
of statins for reduction of these particles (Supplementary Fig. 3)22, since statins act to 
reduce LDL-C levels to a large extent by increasing LDL receptor expression as a result 
of upregulation of the transcription factor SREBP2, whereas SORT1 is not regulated by 
this mechanism. Hence, the greater statin-mediated reduction of LDL-C among carriers 
of the rs646776 minor allele could be attributed to relative depletion of LDL particles 
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dependent on sortilin for clearance and hence a residually greater proportion of those 
LDL particles whose uptake is more dependent on the LDL receptor than on sortilin.
Notably, the strong association of rs646776 with statin-induced reductions in small 
and very small LDL particles contrasts to the weaker associations of changes in these 
particles with rs445925, likely the result of differing mechanisms underlying the effects 
of these SNPs on statin response. As noted above, rs445925 is a proxy for the SNP defining 
the apoE ε2 protein variant that is thought to predispose to heightened statin response 
as a result of greater statin inhibition of cholesterol synthesis and hence upregulation of 
SREBP and LDL receptor activity.
The SLCO1B1 rs2900478 minor allele was associated with a smaller LDL-C reduction in 
response to statin treatment. SLCO1B1 encodes the organic anion-transporting polypep-
tide OATP1B1 and facilitates the hepatic uptake of statins.23 SNP rs2900478 is in strong 
LD (R2 = 0.89) with rs4149056, which represents the Val174Ala substitution resulting in 
complete loss of function. In the HPS trial, which used simvastatin, this candidate gene 
SNP was associated with a 1% lower LDL-C reduction per allele.6 Single-dose studies 
have shown that the observed area under the curve of plasma level of active simvastatin 
after a dose of 40 mg was 221% higher in rs4149056 CC homozygotes compared with 
rs4149056 TT homozygotes, as compared with atorvastatin 20 mg (144% higher for CC 
versus TT) and rosuvastatin 40 mg (117% higher for CC versus TT).24 This finding results 
from the slower hepatic uptake of statins caused by the genetic variant, which would 
also be expected to result in a reduction in the cholesterol lowering effect.25 In a GWAS 
of the genetic risk factors for simvastatin-induced myopathy, SLCO1B1 showed the 
strongest association.25 Homozygous carriers of the SLCO1B1 variant had a 16.9 times 
higher risk for myopathy compared with non-carriers. This might have led to a decrease 
in study medication adherence, and consequently a decreased effect on LDL-C in car-
riers of this SNP. In addition, previous analysis in the GoDARTS study showed that the 
effect of the SLCO1B1 gene on statin efficacy was abolished after removal of individuals 
who showed signs of intolerance.26
GWCA identified three independent loci in the APOE gene region and two loci in the 
LPA gene region (Supplementary Table 9). GWCA also showed several other loci with P 
<5 × 10−8 that were not GWAS significant on single-SNP analysis (HGD, RNF175, ISCA1L-
HTR1A, GLIS3-SLC1A1, LOC100128657, NKX2-3-SLC25A28 and PELI2). These findings will 
require replication in independent, larger data sets. The significant SNPs in the GWCA 
analysis explained ~5% of the variation in LDL-C response to statin treatment. Whether 
this 5% is clinically relevant should be investigated by other studies. For example, it 
would be of interest to investigate whether this differential LDL-C lowering is also as-
sociated with differential event reduction by statin treatment.
In the current study, we combined the results of 6 randomized clinical trials and 
10 observational studies in the first stage. This approach resulted also in combining 
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several types of statins, since different statins were studied in the trials and within the 
observational studies (Supplementary Table 2). This, and the variation in statin dos-
age during follow-up for an individual, is a limitation of the current study, since, for 
example, the impact of the SLCO1B1 variant on statin pharmacogenetics is known to be 
highly dependent on statin type and dose.24,27 To overcome this limitation, the individual 
study analyses were adjusted for statin dose. Dividing the actual statin dose given by 
the statin-specific dose equivalent (Supplementary Table 3) gives the statin-adjusted 
equivalent based on the daily dosages required to achieve a mean 30% LDL-C reduction. 
Using this table, we made the different statin dosages and types comparable within the 
studies. To correct for between-study variance, we used a fixed effect meta-analysis with 
inverse variance weighting. Since we observed that the SLCO1B1 gene was genome-
wide significantly associated with LDL lowering, this highlights the thoroughness of our 
analytical approach, in which the analyses were correctly adjusted for the type and dose 
of statins used (Supplementary Table 3). Moreover, a comparison of the estimates of 
the SNPs between the RCTs (where there are no intra-individual differences in dosages) 
with the estimates of the SNPs in the observational studies showed large homogeneity 
between the estimates in the various study designs (Supplementary Fig. 2), indicating 
that our adjustment for dosage seems to be sufficient within this study.
Another possible limitation of the current study is the influence of the identified 
genetic variants on baseline LDL-C levels. In pharmacogenetic studies investigating 
the LDL-C-lowering response to statins, it is important to eliminate the effect of as-
sociation between the genetic variant and baseline LDL-C levels, since those findings 
may confound the response to treatment associations. Previous large GWAS studies 
have shown strong associations between baseline LDL-C levels and genetic variants in 
SORT1/CELSR2/PSRC1, APOE and LPA.28 To eliminate those possible confounding effects, 
our response to treatment analyses were adjusted for baseline LDL-C levels. In addition, 
additional analysis in CARDS and JUPITER suggests no or little influence of genetic as-
sociations with baseline LDL-C on the genetic effects on LDL-C-lowering response.
In conclusion, this study is the largest meta-analysis of GWAS for LDL-C response to 
statin therapy conducted to date. Our results demonstrate that apart from the previ-
ously identified APOE and LPA loci, two new loci, SORT1/CELSR2/PSRC1 and SLCO1B1, also 
have a modest but genome-wide significant effect on LDL-C response. The minor alleles 
of the APOE rs445925 and SORT1/CELSR2/PSRC1 rs646776 SNPs were associated with a 
larger statin response, whereas the minor alleles of the LPA rs10455872 and SLCO1B1 
rs2900478 SNPs were associated with a smaller statin response. Our findings advance 
the understanding of the pharmacogenetic architecture of statin response.
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AbStrACt
Introduction: Non-alcoholic fatty liver or hepatic steatosis is considered the hepatic 
manifestation of the metabolic syndrome. Statins are often used by patients with meta-
bolic syndrome, but their effect in steatosis is not well established. We aimed to study 
the association between statins and the presence of steatosis.
Methods: In the population-based Rotterdam Study, 2578 subjects underwent liver 
ultrasonography and had prescription data available. In a cross-sectional design, we 
investigated the effect of current, past, and duration of statin use. Logistic regression 
analyses were adjusted for age, sex, and other known risk factors.
Results: The prevalence of steatosis was 35.3%. We identified 631 current and 359 past 
statin users. In multivariable analyses, current statin use >2 years was associated with 
a significantly lower steatosis prevalence (OR 0.43, 95% CI 0.19; 0.96). Stratification by 
mean body mass index showed that this association was stronger in patients with body 
mass index ≥27.5 (OR 0.30, 95% CI 0.11; 0.81 for current use >2 years), while in patients 
with body mass index <27.5 the association was non-significant.
Conclusion: Within the Rotterdam study, in patients with body mass index ≥27.5 current 
use of statins for >2 years was associated with a lower prevalence of steatosis.
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introdUCtion
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of serum alanine 
aminotransferase (ALT) elevation and of chronic liver disease in Western countries. The 
term NAFLD encompasses a spectrum of disease activity, ranging from simple hepatic 
steatosis or non-alcoholic fatty liver (NAFL), to non-alcoholic steatohepatitis (NASH) 
and NASH cirrhosis, which may lead to a decreased liver function, hepatocellular car-
cinoma, and liver failure.1-3 NAFLD is considered as the hepatic manifestation of the 
metabolic syndrome. It is frequently associated with dyslipidemia, with elevated serum 
triglycerides and low-density lipoprotein (LDL)-cholesterol, and a decrease in serum 
high-density lipoprotein (HDL)-cholesterol.1-5 Furthermore, NAFLD has been associated 
with the risk of incident cardiovascular disease (CVD), independently of the components 
of the metabolic syndrome, and the major cause of death in NAFLD is CVD.2,5-10
Statins interfere with cholesterol metabolism in the liver by inhibiting HMG-CoA re-
ductase, the rate-limiting enzyme of the cholesterol synthesis pathway. This leads to up-
regulation of LDL receptors in the liver, increased uptake of circulating LDL-cholesterol, 
and subsequently to a decrease in LDL-cholesterol concentration. Besides this reduction 
in LDL-cholesterol, statins are effective in lowering of the triglyceride concentration 
and modestly effective in raising the HDL-cholesterol concentration.11-16 Statins are 
beneficial in the prevention of CVD with an approximately 20% relative risk reduction on 
mortality and major cardiovascular events in persons free of CVD.17,18 In general, statins 
are well-tolerated and safe drugs.19
Statins are frequently used for several indications such as dyslipidemia, type 2 diabe-
tes mellitus, and in patients at high risk of CVD.20 There is some discussion as to whether 
statins are safe and effective in NAFLD, and whether they worsen hepatic steatosis, 
despite improvement of serum lipid concentration.21-25 Clarification of this topic is im-
portant, since due to the co-existence of dyslipidemia and NAFLD, and a higher risk of 
CVD mortality in NAFLD patients, these patients will often be treated with statins for the 
primary and secondary prevention of CVD.
In the present study, the objective was to investigate whether statin therapy is associ-
ated with the presence of NAFL, considering both current and past use of statin therapy, 
and duration of statin therapy, in a large prospective cohort study in community-dwell-
ing elderly. In an extended analysis, we investigated whether the association between 
the use of statin therapy and NAFL was modified by body mass index (BMI) because 




The Rotterdam Study is a prospective population-based cohort study of chronic diseases 
in the elderly population. From 1990 to 1993, 7983 inhabitants of the suburb Ommoord 
in Rotterdam, the Netherlands, aged 55 years or older, participated in the Rotterdam 
Study (RS-I) and gave written informed consent. Ethical approval was obtained from the 
Medical Ethical Committee of the Erasmus Medical Center, Rotterdam, the Netherlands. 
Baseline examinations took place from March 1990 through July 1993. Follow-up exami-
nations were conducted periodically, every 4–5 years. In 2000, an extended cohort was 
enrolled, the Rotterdam Study II (RS-II). Three-thousand-eleven inhabitants entered the 
study and have been continuously followed since then. Furthermore, in 2006, a younger 
cohort was enrolled, the Rotterdam Study III (RS-III), containing 3932 inhabitants aged 
45 years or older. Abdominal ultrasonography was added to the core protocol at the fifth 
survey of the Rotterdam Study (February 2009–February 2012), which constitutes the 
baseline survey for the present study.
Medication dispensing data were obtained from the fully computerized pharmacies 
in the Ommoord suburb. Information on all filled prescriptions from 1 January 1991 
until 1 December 2011 was available and included information on the product name 
of the drug, the Anatomical Therapeutical Chemical code, the amount dispensed, the 
prescribed dosage regimen and the date of dispensing.26
Detailed information on design, objectives and methods of the Rotterdam Study has 
been described before.27,28
Study population
The study population consisted of all participants with complete data on the extensive 
interview and clinical examination at the fifth survey of the Rotterdam Study (Febru-
ary 2009–February 2012). The clinical examination included a fasting blood sample, 
abdominal ultrasonography, and anthropometric assessment. Medication prescription 
data on the use of statin therapy was avail-able until 1 December 2011. Therefore, all 
participants with an interview and clinical examination date after 1 December 2011 
were excluded.
Exposure to statins
For every prescription of a statin, the duration was calculated by dividing the number 
of dispensed tablets by the prescribed daily number. Repeated prescriptions which 
were filled within seven days after ending a previous one, were considered as one single 
episode of continuous use. At the date of ultrasonography, every cohort participant was 
classified into the following mutually exclusive categories: ‘current use’ if the ultrasonog-
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raphy was performed within a prescription episode; ‘past use’ if the patient had been 
treated with statins in the past but did not use statins on the day of ultrasonography; 
‘non-use’ meant that the participant had not used statins at all during the study period. 
The prescribed daily dose of statin therapy was expressed in standardized defined daily 
doses (DDD), according to the World Health Organization.26
outcome
The outcome of interest was the presence of NAFL, assessed by abdominal ultrasonog-
raphy in all study participants. Abdominal ultrasonography was performed by certified 
and experienced technicians on a Hitachi HI VISION 900. Images were stored digitally 
and re-evaluated by a hepatologist with more than ten years experience in ultrasonog-
raphy. The diagnosis and grading of fatty liver was determined according to the protocol 
by Hamaguchi et al.29 Severity of fatty liver was classified as ‘no fatty liver’ (score 0–1), 
‘mild fatty liver’ (score 2–3), or ‘moderate to severe fatty liver’ (score 4–6). Individuals 
with any of the following possible secondary causes of fatty liver were excluded from 
the analyses: (1) current excessive alcohol consumption or a history of excessive alcohol 
consumption, (2) positive HBsAg or anti-HCV, and (3) use of pharmacological agents 
historically associated with fatty liver (i.e. amiodarone, corticosteroids, methotrexate, 
and tamoxifen).
Covariables
To control for confounding, we adjusted the analyses for age, sex, prescribed dose of 
statin therapy, serum total cholesterol level, number of ethanol consumptions weekly, 
presence of type2 diabetes mellitus, the individual components of the metabolic 
syndrome, presence of CVD in history, and use of fibrates or other cholesterol lowering 
medication. CVD in history was defined as a myocardial infarction (MI), percutaneous 
transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), heart 
failure, carotid desobstruction, cerebrovascular accident (CVA), or a transient ischemic 
attack (TIA) in the history.30-32 Information on covariables was obtained by an interview 
at home, laboratory measurements, and anthropometric assessments at the research 
center. The interview was designed to obtain data concerning demographics, medical 
history, co-morbid conditions, smoking behaviour, physical activity, and alcohol con-
sumption.
Fasting blood samples were collected on the morning of ultrasound examination. 
Blood lipids, serum glucose, ALT, aspartate aminotransferase (AST), gamma-glutamyl-
transferase (GGT), alkaline phosphatase (ALP), and total bilirubin were measured using 
automatic enzymatic procedures (Roche Diagnostics GmbH, Mannheim, DE). HbsAg and 
anti-HCV antibodies were measured by automatic immunoassay (Roche Diagnostics 
GmbH, Mannheim, DE).
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Anthropometric measurements were performed by well trained nurses. Waist and hip 
circumference were measured in centimeters. BMI was calculated as the weight (in kg) 
divided by height (in m2). The average of two blood pressure measurements, obtained 
at a single visit in sitting position after a minimum of 5 min rest, was used for analysis. 
Presence of type 2 diabetes mellitus was defined as the use of glucose-lowering drugs, 
a non-fasting glucose level of more than 11.0 mmol/L, or a fasting glucose level of more 
than 6.9 mmol/L. The metabolic syndrome was defined according to the following 
criteria: (1) abdominal obesity, defined as a waist circumference in men >102 cm (40 
in.) and in women >88 cm(35 in.), (2) serum triglycerides ≥150 mg/dL (1.7 mmol/L), (3) 
serum HDL-cholesterol <40 mg/dL (1.0 mmol/L) in men and <50 mg/dL (1.3 mmol/L) 
in women, (4) blood pressure ≥130/85 mmHg or drug treatment for elevated blood 
pressure, (5) elevated fasting glucose ≥100 mg/dL (5.6 mmol/L) or drug treatment for 
hyperglycaemia. Although this is according to Adult Treatment Panel III criteria, use of 
cholesterol lowering drugs was not used as a criteria because of the research objec-
tive.33,34
Statistical analysis
Differences in the distributions of characteristics between statin users and non-statin 
users were tested for significance with a t-test (means) for continuous variables and a 
Wilcoxon rank sum test (medians) for categorical variables. We used logistic regression 
analysis to investigate the association between statin therapy and the presence of NAFL. 
We considered both current, past, and never use of statin therapy, as well as the duration 
of current and past use. Duration of use was distinguished a priori, based on the median 
duration of past and current use in the population: a cut-off point of 2 years for past 
use and a cut-off point of a half year for current use. To investigate the effect of longer 
duration of use, also current use for >2 years was investigated. In an extended analysis, 
we stratified the population by the mean BMI. In this analysis, we investigated the as-
sociation between statin therapy and the presence of NAFL in participants with BMI 
<27.5 and in participants with BMI ≥27.5. We performed a sensitivity analysis in which 
we excluded all NAFL patients with ‘mild fatty liver’ at ultrasonography. Furthermore, we 
performed a sensitivity analysis on the outcome steatosis defined by the noninvasive 
Fatty Liver Index (FLI) according to the definition by Bedogni et al.35, including BMI, waist 
circumference, GGT, and triglycerides. According to Bedogni et al. a FLI ≥60 can be used 
to rule in hepatic steatosis.
Statistical analyses were performed using SPSS software (SPSSInc., version 20.0, Chi-
cago, IL, USA).
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rESUltS
baseline characteristics
In total, 3205 participants underwent abdominal ultrasonography. Three hundred 
ninety-four participants were excluded because of the presence of potential secondary 
causes of fatty liver (excessive alcohol consumption (n = 255), positive HBsAg (n = 3) 
or anti-HCV (n = 24), use of pharmacological agents historically associated with fatty 
liver (n = 121)). Of these 2811 remaining participants, 2578 had information on statin 
dispensing data available and were eligible for the analysis. Differences in characteris-
tics between statin users and non-statin users are shown in Table 1. Of the 2578 study 
participants, 1588 (61.6%) had never used any statin, 631 (24.5%) were current users of 
statin therapy and 359(13.9%) were past users of statin therapy. The prevalence of NAFL 
was 35.3%; 134 participants (5.2%) had ‘mild fatty liver’ and 776 participants (30.1%) had 
‘moderate to severe fatty liver’.






Age (mean, years) 76.8 ± 5.5 76.2 ± 6.2 0.014
Gender, male (n, %) 423 (42.7%) 604 (38.0%) 0.018
Serum total cholesterol (mean±SD, mmol/L) 4.9 ± 1.1 5.7 ± 0.9 <0.0001
Serum HDL-cholesterol (mean±SD, mmol/L) 1.3 ± 0.3 1.5 ± 0.4 <0.0001
Serum LDL-cholesterol (mean±SD, mmol/L) 2.6 ± 1.0 3.5 ± 0.8 <0.0001
Serum triglycerides (mean±SD, mmol/L) 1.6 ± 0.8 1.3 ± 0.6 <0.0001
Serum ALT (mean±SD, mmol/L) 21.6 ± 11.3 19.5 ± 10.2 <0.0001
Serum AST (mean±SD, mmol/L) 26.8 ± 10.4 25.7 ± 7.0 0.004
NAFL (n, %) 404 (40.8%) 506 (31.9%) <0.0001
Ethanol use (drinks/week) 3.6 ± 3.7 3.8 ± 3.8 0.30
Body mass index (mean±SD, kg/m2) 27.9 ± 4.3 27.1 ± 4.2 <0.0001
Hypertension (n, %) 960 (97.0%) 1440 (90.7%) <0.0001
Waist circumference (mean±SD, cm) 94.5 ± 12.3 91.2 ± 11.8 <0.0001
Insulin resistance (HOMA-IR >3) (n, %) 520 (52.5%) 537 (33.8%) <0.0001
Type 2 diabetes mellitus (n, %) 251 (26.0%) 125 (8.1%) <0.0001
Metabolic syndrome (n, %) 519 (52.4%) 515 (32.4%) <0.0001
Cardiovascular disease in history (n, %) 428 (43.2%) 164 (10.3%) <0.0001
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; NAFL, non-alcoholic fatty liver; HOMA-IR, Homeostasis Model of Assess-
ment-Insulin Resistance.
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Statin therapy and the prevalence of nAfld
The results of the logistic regression analysis on the association between the use of 
statin therapy and NAFL are shown in Table 2. In this analysis, current and past use of 
statin therapy were compared with never use as the reference category, and duration 
of use was considered by dividing current and past use into categories with different 
durations of use, based on the median duration of use.
In the multivariable analysis, adjusted for age and sex, ever use of statin therapy 
(including current and past use) was associated with a higher prevalence of NAFL (OR 
1.51, 95% CI 1.28; 1.78, P < 0.001) compared with never use, whereas this association 
disappeared when the analysis was adjusted for all co-variables (full model: OR 1.06, 
95% CI 0.82; 1.73, P 0.648).
When we analyzed ever use as a categorical variable, dividing past use into two catego-
ries (>2 year past use and ≤2year past use), and current use into three categories (≤half 
year current use, >half year – ≤2 year current use, >2 year current use), and adjusted for 
all covariables, past use of statin therapy was not significantly associated with NAFL (OR 
table 2 Association between the use of statins and the presence of non-alcoholic fatty liver
Current + past vs. never usea or beta 95% Ci P n
Crude analysesb
Additive model 1.51 0.411 1.28; 1.78 <0.0001 2578
Categorical model
never use 1.00 (ref ) – – 1588
>2 years past use 1.69 0.523 1.24; 2.30 0.001 189
1 days to ≤2 years past use 1.75 0.559 1.27; 2.41 0.001 170
>1 day to ≤half year current use 1.41 0.340 1.10; 1.80 0.007 326
>half year to ≤2 years current use 1.53 0.425 1.17; 2.01 0.002 256
>2 years current use 0.81 −0.209 0.43; 1.55 0.526 49
Adjusted analysesc
Additive model 1.06 0.060 0.82; 1.73 0.648 2578
Categorical model
never use 1.00 (ref ) – – 1588
>2 years past use 1.34 0.292 0.92; 1.94 0.125 189
1 days to ≤2 years past use 1.14 0.131 0.76; 1.70 0.520 170
>1 day to ≤half year current use 0.77 −0.267 0.49; 1.20 0.239 326
>half year to ≤2 years current use 0.80 −0.227 0.51; 1.26 0.328 256
>2 years current use 0.43 −0.843 0.19; 0.96 0.040 49
Abbreviations: OR, odds ratio; CI, confidence interval; N, number of participants.
a In all analyses, never use is the reference category. b Adjusted for age and sex. c Adjusted for age and sex, 
statin dose, total cholesterol level, number of ethanol containing drinks per week, type 2 diabetes mellitus, 
individual components of the metabolic syndrome, cardiovascular disease in history, and use of fibrates or 
other cholesterol-lowering drugs. bold value indicates statistically significant association.
Statins and the prevalence of NAFLD 153
1.34, 95% CI 0.92; 1.94, P 0.125 for >2 year past use; OR 1.14, 95% CI 0.76; 1.70, P 0.520 
for ≤2 year past use). Only current use for more than 2 years was significantly associated 
with a lower prevalence of NAFL (OR 0.77, 95% CI 0.49; 1.20, P 0.239 for ≤half year current 
use; OR 0.80, 95% CI 0.51; 1.26, P 0.328 for >half year – ≤2 year current use; OR 0.43, 95% 
CI 0.19; 0.96, P 0.040 for >2 year current use).
Fig. 1 shows the results of the logistic regression analysis on the association between 
the use of statin therapy and NAFL stratified by BMI. Stratification by BMI was based on 
the mean BMI in the population (27.44 kg/m2) and the population was stratified by BMI 
<27.5 and BMI ≥27.5. In participants with BMI ≥27.5, current use of statin therapy for 
more than two years was significantly associated with a lower prevalence of NAFL and 
this association was stronger than for the non-stratified analyses (Table 2). There was a 
trend towards a lower prevalence of NAFL the longer statin therapy was used (OR 0.66, 
95% CI 0.38; 1.17, P 0.153 for ≤half year current use; OR 0.58, 95% CI 0.32; 1.05, P 0.071 
for >half year– ≤2 year current use; OR 0.30, 95% CI 0.11; 0.81, P 0.017 for >2 year cur-
rent use). Past use of statin therapy was not significantly associated with the prevalence 
of NAFL in participants with BMI ≥27.5. In participants with BMI <27.5, the association 
between statin therapy and a lower prevalence of NAFL was not present.
We performed sensitivity analyses in which we excluded all NAFL participants with 












































































figure 1 Association between the use of statins and the presence of non-alcoholic fatty liver in participants 
with body mass index <27.5 (A) and in participants with body mass index ≥27.5 (B)
Abbreviations: BMI, body mass index; OR, odds ratio; CI, confidence interval; yrs, years.
In all analyses, never use is the reference category. Analyses are adjusted for age and sex, statin dose, total 
cholesterol level, number of ethanol containing drinks per week, type 2 diabetes mellitus, individual com-
ponents of the metabolic syndrome, cardiovascular disease in history, and use of fibrates or other choles-
terol lowering drugs.
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‘moderate to severe fatty liver’, the association between current use statin therapy >2 
years and the lower prevalence of NAFL remained (OR 0.42, β −.862, 95% CI 0.18; 0.98, 
P 0.045). In a second additional sensitivity analysis the outcome measure was FLI ≥60 
(steatosis) vs. FLI <60, based on the noninvasive calculation of the FLI. In this analysis, 
there was a trend for an association between current use of statin therapy and a lower 
prevalence of NAFL, albeit non-significantly. However, the number of participants in the 
categories were smaller than in the original analysis (n = 24 in statin users >2 years with 
BMI≥27.5).
discussion
In this cross-sectional analysis in a large population-based prospective study, current 
use of statin therapy for more than 2 years was significantly associated with an approxi-
mately two times lower prevalence of NAFL. This association was only found in patients 
with a BMI ≥27.5, who showed an approximately three times lower prevalence of NAFL 
with more than 2 years current use of statin therapy.
It has been hypothesized that statins may exacerbate or worsen NAFLD despite 
an improvement in serum lipid levels. Statins may increase de novo cholesterol and 
fatty acid synthesis through induction of transcription factor sterol response regulatory 
element-binding protein-2 (SREBP-2) that activates genes involved in the synthesis of 
cholesterol, fatty acids, triglycerides and the LDL receptor.36,37 Furthermore, by inhibi-
tion of HMG-CoA reductase, the number of hepatic LDL receptors increases, leading 
to an enhanced uptake of LDL-cholesterol.13 Both effects might increase hepatic fatty 
infiltration and thereby exacerbate or worsen NAFLD. Conversely, the effect of statins 
might be beneficial as well, both by their most widely known lipid-lowering function, as 
well as through their pleiotropic effects acting on other mechanisms than the HMG-CoA 
reductase pathway, independent of their cholesterol lowering effect. Anti-inflammatory 
and immunomodulatory effects, anti-oxidant effects, and an improvement of the en-
dothelial function are examples of pleitropic effects of statins.38 Although the exact 
pathogenesis of NAFLD is currently not clarified and probably many factors contribute, 
insulin resistance, lipid abnormalities and chronic inflammation are considered to be 
the central pathway for the development of diseases related to obesity such as NAFLD 
and CVD.1,39,40
Similar to our results, no association between ever use of statins and NAFLD was 
demonstrated in a cross-sectional analysis in the Dallas Heart Study.7 That such a crude 
exposure measure can lead to non-differential misclassification and bias towards the 
null hypothesis, is known.41 However, we demonstrated a protective effect of >2 years 
current statin use and the prevalence of NAFL. We were able to distinguish between 
current and past users, and adjust for statin dose, in contrast with other studies which 
mostly obtained medication data by questionnaire. Our findings are supported by stud-
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ies on the effect of statin therapy on hepatic histology by liver biopsy, showing that 
statin therapy was associated with improvement in liver steatosis.5,42,43 Although studies 
have suggested that statins might induce hepatic injury, statin therapy was infrequently 
associated with acute or chronic liver failure, and significant injury from statins is rare.21-25 
In February 2012, the Food and Drug Administration (FDA) approved important safety 
label changes for statins to remove the need for routine periodic monitoring of liver 
enzymes in patients taking statins.44 Furthermore, recent reviews from literature support 
our findings and clearly showed the safety of statins in NAFLD, and demonstrated that 
statins may lead to a reduction in the extent of hepatic steatosis.45-47
It seems plausible that statins may protect against NAFLD by their favourable effect 
on blood lipids. In our study, in patients with a BMI ≥27.5 who were current statin us-
ers for more than 2 years, statins showed a strong protective association with NAFL, 
while inpatients with a BMI <27.5 no protection could be demonstrated. The metabolic 
syndrome is the most important risk factor for NAFLD, and the individual components 
of the metabolic syndrome are all related to obesity.1 Furthermore, overweight people 
are more likely to have a disturbed lipid profile. The accumulation of lipids in the hepa-
tocytes, mainly triglycerides, is essential for the development of NAFLD.1 Statins also 
exert their effect on serum triglycerides, with a mean reduction of 10–30% in serum 
triglycerides concentration.13-15 Furthermore, obesity is associated with inflammation48, 
and anti-inflammatory effects of statins might play a protective role.
This is the first observational study on this topic with continuous information on 
medication data, whereby past, current and duration of use was investigated. Another 
strength of the study was that we were able to adjust our analyses for a history of CVD, 
whereas no other studies did control for this. Adjustment for CVD is important to mini-
mize confounding by indication. Since statin therapy is mainly prescribed for the primary 
and secondary prevention of CVD, and previous studies suggest a strong link between 
NAFLD and CVD, independently from the metabolic syndrome8,9, the prevalence of 
NAFLD may also be higher in patients who use statins for CVD. When no adjustment 
is made for a history of CVD in the analyses, one may not detect or underestimate a 
potential favourable effect of statin therapy on NAFLD.
However, also some potential limitations and biases in our study should be consid-
ered. The risk of information or selection bias is unlikely, since the Rotterdam Study is a 
population-based cohort study, in which data are collected prospectively without prior 
knowledge of the aim of this study. A ‘healthy user’ effect seems unlikely because in that 
case ever use would also have been associated with a lower prevalence of NAFL. We 
investigated whether participants in the statin user categories differ from non-users in 
change in BMI or fasting serum glucose over time, thus whether life-style modifications 
might have played a role in the demonstrated association. No statistically significant 
differences between the groups were present. In the analysis, we controlled for potential 
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confounding factors such as dose of the prescribed statin therapy and a history of car-
diovascular disease. In the present study, the diagnosis and severity of hepatic steatosis 
was assessed by ultrasonography. Ultrasonography may be less sensitive than more 
advanced imaging techniques such as CT/MRI, since ultrasonography is not appropriate 
for the detection of less than 30 percent steatosis. However, Hernaez et al.49 showed 
that ultrasonography is comparable with other imaging modalities in the detection of 
NAFLD with an acceptable sensitivity of 80–100%. Ultrasonography is especially insensi-
tive in the detection of mild steatosis. However, in a sensitivity analysis in patients with 
moderate to severe fatty liver (mild fatty liver patients excluded), the investigated as-
sociation remained. Unfortunately, no histology was available in this population-based 
study, and therefore we could not investigate the effect of statin therapy on hepatic 
histology by liver biopsy. Finally, we had only a very low number of users of cholesterol 
lowering medication other than statins, such as ezetimibe, to investigate the effect of 
these drugs in NAFL patients.
In conclusion, we did not demonstrate an overall association between current and past 
use of statin therapy and the presence of NAFL in this large population-based cohort 
study. However, current use of statin therapy for more than two years was significantly 
associated with a lower prevalence of NAFL, and this association was even stronger in 
patients with a BMI ≥27.5. We think that this protective association warrants further 
investigation through replication in an independent cohort. In the meantime, and given 
the association between NAFLD and CVD, lipid lowering treatment with statins may be 
considered in the treatment of NAFLD patients.
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AbStrACt
Introduction: Statins or HMG-CoA reductase inhibitors decrease cholesterol production. 
Because cholesterol is a precursor of the testosterone biosynthesis pathway, there is 
some concern that statins might lower serum testosterone levels. Our objective was to 
investigate the association between use of statins and serum testosterone levels in men.
Methods: We used a cross-sectional design within the prospective population-based 
Rotterdam Study. We included 4166 men with total testosterone, non-SHBG-bound 
testosterone, and medication dispensing data available. Multivariable linear regression 
analysis was used to compare differences in serum testosterone levels (nmol/L) between 
current, past, and never statin users. We considered dose and duration of use. Analyses 
were adjusted for age, body mass index, cardiovascular disease history, diabetes mel-
litus, hypertension, and estradiol levels.
Results: We identified 577 current (mean age 64.1 years), 148 past (mean age 64.6 years), 
and 3441 never (mean age 64.6 years) statin users. Adjusted for all covariables, current 
statin use 1–≤6 months and >6 months was significantly associated with lower total 
testosterone levels compared to non-users (β −1.24, 95%CI −2.17; −0.31 and β −1.14, 
95%CI −2.07; −0.20 respectively). Current use 1–≤6 months was also associated with 
significantly lower non-SHBG-bound testosterone levels (β −0.42, 95%CI −0.82; −0.02). 
There was a trend towards lower testosterone levels at higher statin doses, both for total 
(Ptrend 2.9 × 10−5) and non-SHBG-bound testosterone (Ptrend 2.0 × 10−4). No association 
between past statin use and testosterone levels was found.
Conclusion: We showed that current use of statins was associated with significantly 
lower serum total and non-SHBG-bound testosterone levels. Clinical relevance of the 
association should be further investigated.
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introdUCtion
Statins or HMG-CoA reductase inhibitors are widely used cholesterol lowering drugs 
which are effective in the primary and secondary prevention of cardiovascular disease 
(CVD).1-3 They competitively inhibit HMG-CoA reductase, mainly in the liver, which is the 
rate-limiting enzyme in the cholesterol biosynthesis pathway. By inhibiting this choles-
terol biosynthesis, the number of low-density lipoprotein (LDL) receptors in the hepatic 
membrane is increased. This leads to increased serum uptake of LDL-cholesterol, and 
thus a decrease in serum cholesterol concentration.4
Testosterone is the main circulating androgenic hormone in men with important 
effects on libido, bone mass, fat distribution, muscle mass, strength and production 
of blood cells and sperm.5,6 It is synthesized in the testes, and this process requires a 
continuous supply of cholesterol, which can be derived from plasma, mostly originating 
from the liver, or from de novo production within the gland.7 In contrast, women have 
in general 8 to 9 times lower levels of serum total testosterone; the hormone here also 
plays a role in sexual function and libido.8 Circulating testosterone in men is for 40-65% 
bound to sex hormone-binding globulin (SHBG), which regulates the serum concentra-
tion of testosterone and its transport to target tissues. SHBG has a high binding affin-
ity for testosterone and the serum concentrations of total testosterone and SHBG are 
strongly correlated. In contrast, the non-SHBG-bound fraction of testosterone, which is 
considered to be bioactive, is barely associated with the serum SHBG concentration.9-11 
This indicates that non-SHBG-bound testosterone, rather than total testosterone plays 
an important role in maintaining equilibrium in the negative feedback of the hypothal-
amo-pituitary-testicular axis and in other androgenic effects.
Since statins decrease cholesterol biosynthesis, and cholesterol is the precursor of 
testosterone, there is some concern whether statins might impair testosterone produc-
tion. Statins decrease serum availability of the substrate cholesterol, in vitro studies 
showed that statins decrease cholesterol production in testicular Leydig cells12, or 
inhibit enzymes within the testosterone biosynthesis pathway (e.g. 17β-hydroxysteroid 
dehydrogenase).13 A lower testosterone level due to statins may be undesired in men 
with already low testosterone levels, since it may lead to symptoms such as a decrease 
in mood, libido, muscle strength, or bone mineral density. The 2013 American guidelines 
for cardiovascular disease prevention lowered the threshold for treatment with statins 
and widened the target population.14 Furthermore, the prevalence of diseases such 
as type 2 diabetes mellitus (T2DM) and CVD is increasing.15,16 Therefore, the already 
substantial use of statins in clinical practice may further increase, and this might come 
along with an increase in non-beneficial effects of statins.17 Consequently, it is important 
to elucidate whether statins decrease serum testosterone levels, and more specifically 
non-SHBG bound testosterone, as potential undesired effect of their use.
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In this large population-based cohort study, our objective was to investigate whether 
the use of statins was associated with decreased serum levels of total and non-SHBG-
bound testosterone in male persons aged 45 years or older.
mEthodS
Setting and Study Population
This research was conducted within the Rotterdam Study, a prospective population-
based cohort study, which aims to examine the frequency and determinants of diseases 
in middle-aged and elderly people. The rationale and design of the Rotterdam Study 
have been described previously.18,19
In short, at start, all 10,275 persons aged ≥55 years in the Ommoord district of Rot-
terdam, the Netherlands, were invited to participate. Of them, 7,983 (78%) were enrolled 
between 1990 and 1993 (RS-I). At baseline, participants underwent extensive clinical 
examination at the research center. Participants have been followed during up to four 
follow-up rounds (1993-1995, 1997-1999, 2002-2004, 2009-2012). In 2000, an extended 
cohort was enrolled (RS-II), in which 3,011 inhabitants aged ≥55 years entered the study 
and are continuously followed since then. Furthermore, in 2006, a third cohort started 
(RS-III) including 3,932 inhabitants aged ≥45-54 years at enrollment.
The Rotterdam Study has been approved by the medical ethics committee according 
to the Wet Bevolkingsonderzoek: ERGO (Population Study Act: Rotterdam Study), ex-
ecuted by the Ministry of Health, Welfare and Sports of the Netherlands. All participants 
gave informed consent to participate in the study and to obtain information from treat-
ing physicians and pharmacies, separately.
All three cohorts of the Rotterdam study were considered in the current research, 
including a study population aged 45 years or over. The study population consisted of 
all male participants of the Rotterdam Study (n=4,255), for whom a serum total testos-
terone measurement was available, for whom a serum non-SHBG-bound testosterone 
concentration could be calculated, and for whom medication dispensing data were 
available. As most of the women in the Rotterdam Study are postmenopausal and have 
very low testosterone levels, we expected that any potential effect of statins could 
probably only be demonstrated in males or would not be clinically relevant in females. 
Therefore, we restricted our study population to only male participants.
outcome assessment
Our outcomes of interest were the serum levels of total testosterone and non-SHBG 
-bound testosterone. Serum hormone data were assessed from laboratory measure-
ments during the third visit of the first cohort (RS-I-3, 1997-1999), first visit of the second 
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cohort (RS-II-1, 2000-2001), and the first visit of the third cohort (RS-III-1, 2006-2008). 
Serum levels of non-SHBG-bound testosterone were used as a measure of bioactive 
testosterone.
Exposure assessment
The exposure of interest was the use of statin therapy. Medication dispensing data were 
obtained from all seven fully computerized linked pharmacies in the Ommoord district. 
Information on all filled prescriptions from January 1st 1991 until February 1st 2012 was 
available and included information on the product name of the drug, the Anatomical 
Therapeutical Chemical Code (ATC-code), the amount dispensed, the prescribed dose 
regimen and the date of dispensing.20 For every dispensing of a statin, the duration of 
use (prescription episode) was calculated by dividing the number of dispensed tablets 
by the prescribed daily number. Repeated prescriptions, which were filled within 7 days 
after ending the previous filled prescription, were considered as continuous use.
At the date of the testosterone measurement, every participant was classified into 
mutually exclusive categories: ‘Current use’ if the measurement occurred within a pre-
scription episode, ‘Past use’ if the participant previously stopped using statins, or ‘Never 
use’ if the participant had not used statins during the study period. Current and past 
statin users were further stratified into 5 categories according to the duration of expo-
sure to statins: current use ≤1 month, current use >1 to ≤6 months, and current use >6 
months; past use >6 months, and past use ≤6 months since the end of the last prescrip-
tion episode. The 6-month cut-off was applied based on the median duration of current 
and past use in the population. To facilitate direct dose comparisons between drugs 
from the same therapeutic drug group, the daily dose of statin therapy was expressed in 
'Defined Daily Doses' (DDD).20
Analytical determinations
All steroids and SHBG were estimated in the same serum sample obtained from blood 
taken in the morning in the fasting state. Testosterone, dehydroepiandrosterone (DHEA) 
and DHEA sulphate (DHEAS) were measured simultaneously with a LC-MS/MS method 
using the CHS™ MSMS Steroids Kit (Perkin Elmer, Turku, Finland). The Steroids Kit uses a 
combined solvent extraction and protein precipitation method with acetonitrile contain-
ing the deuterated internal standards 2H5-testosterone, 2H6-DHEA and 2H6-DHEAS. The 
internal standard underwent processing identical to the analytes. The chromatographic 
separation was performed on a Waters® (Milford, MA, USA) Acquity™ UPLC HSS T3 1.8 µm 
column (diameter 1 mm, length 10 cm) and in-line filter frit 0.2 µm with an acetonitrile/
MeOH gradient. A Waters XEVO-TQ-S system equipped with an ESI source operating in 
the electrospray positive mode was used for quantitation. The lower limits of quantita-
tion for testosterone, DHEA and DHEAS were 0.07, 2.2 and 24.7 nmol/L, respectively. 
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Non-SHBG-bound testosterone was calculated according to the method of Södergard 
et al.21, using previously described equations9 assuming a fixed albumin level of 40 g/L. 
SHBG, estradiol and insulin were measured using a Cobas 8000 Modular Analyzer (Roche 
Diagnostics GmbH, Mannheim, Germany). Fasting total cholesterol was measured on a 
cobas c702 system (Roche Diagnostics GmbH,Mannheim, DE).
Covariables
Variables were considered as potential confounders or effect modifiers influencing the 
association between the use of statins and serum testosterone levels, based on their 
clinical relevance or confounding effect in the analysis (a variable that changed the es-
timate >10% was considered as a confounder).22-24 Our selected confounders were: age, 
body mass index (BMI), a history of CVD, T2DM, hypertension, and serum estradiol levels. 
Testosterone is known to decrease with increasing age and BMI. CVD, hypertension and 
T2DM are conditions associated with lower testosterone levels. Estradiol changed the 
estimate >10% and is also correlated with testosterone and SHBG. Furthermore, analy-
ses were adjusted for the prescribed DDD of statin therapy.
In addition, we investigated whether additional adjustment for insulin, total choles-
terol, DHEA, and DHEAS influenced the association between SHBG and testosterone, 
and investigated whether these variables were effect modifiers or intermediates. Insulin 
influences SHBG levels that are strongly correlated with total testosterone, total choles-
terol and DHEA are part of the pathway from cholesterol to testosterone, and DHEAS is 
a metabolite of DHEA.
BMI was calculated as the weight (in kg) divided by height-squared (in m2). CVD in 
history was defined as the occurrence of a myocardial infarction (MI), percutaneous 
transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), 
heart failure, carotid desobstruction, cerebrovascular accident (CVA), or transient isch-
emic attack (TIA) before the date of testosterone measurement.25-27 T2DM was defined 
as a current prescription for an oral glucose-lowering drug or insulin (ATC-code A10). 
Hypertension was defined as blood pressure higher than 140/90 mmHg or a current 
prescription for an antihypertensive agent (ATC-code C02, C03, C07, C08 or C09).20
Statistical analysis
Kolmogorov-Smirnov tests were used to test the normality of the distribution of the 
parameters. Correlations between variables were tested using Pearson’s correlation 
method for normally distributed data, and Spearman’s correlation method for non-
normally distributed data. Differences in characteristics between current, past and never 
statin users were tested using unpaired two-sided Student’s T-test for normally distrib-
uted parameters and Mann-Whitney U-test for non-normally distributed parameters.
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In a cross-sectional design, we investigated the association between use of statins 
and serum total and non-SHBG-bound testosterone levels, using multivariable linear 
regression analysis to adjust for confounders. Non-normally distributed data were log 
transformed in these analyses. First, we compared current and past use of statin therapy 
on serum testosterone levels, with never use as the reference category. In a second 
analysis, we considered duration of statin use (current use ≤1 month, >1-≤6 months and 
>6 months; past use ≤6 and >6 months), and investigated the effect of duration of use 
on serum testosterone levels, with never use as the reference category. Furthermore, 
we investigated whether additional adjustment for insulin, total cholesterol, DHEA, and 
DHEAS influenced this association, and investigated whether these variables were effect 
modifiers or intermediates.
In an additional analysis, we investigated whether the association between statins and 
testosterone levels was dose-dependent. We stratified the DDD of statin therapy into 
tertiles, and compared current and past use of statins with never use in each stratum.
A sensitivity analysis was performed in participants without CVD, to investigate 
whether associations are constant in men without CVD. Another sensitivity analysis 
was performed re-allocating most recent past users (within 14 days) from ≤6 months 
past use into the current use category. This was done because we believed that patients 
recently exposed to statins might still be affected by the drug (i.e. carry-over effect).
Statistical analyses were performed using SPSS software (SPSS Inc., version 21.0, 
Chicago, Illinois, USA). All p-values are two-sided and were considered statistically 
significant if p<0.05.
rESUltS
In total, 4,255 male participants with a serum total testosterone measurement, a calcu-
lated serum non-SHBG-bound testosterone measurement, and medication dispensing 
data were available. Since we analyzed complete case sets, 89 (2%) of 4,255 participants 
were excluded due to incomplete data on covariables. Of all 4,166 eligible male partici-
pants in the study population, 577 (14%) were current statin users and 148 (3.5%) were 
past statin users. Characteristics of current, past and never users are shown in Table 1. 
All hormone levels were non-normally distributed in the population and were therefore 
log transformed in the analyses. Compared to never users, current and past users had 
a significantly higher BMI and a higher prevalence of CVD, T2DM and hypertension. 
Furthermore, current statin users had significantly higher serum insulin and estradiol 
levels, and significantly lower levels of SHBG, DHEA, DHEAS and cholesterol. Both cur-
rent and past statin users had significantly lower mean total (current users 13% ↓, past 
users 9% ↓) and non-SHBG-bound (current users 8% ↓, past users 7% ↓) testosterone 
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levels compared to never users. The majority of current statin users used simvastatin 
(n = 345, 59.8%), followed by atorvastatin (n = 112, 19.4%), pravastatin (n = 68, 11.8%), 
fluvastatin (n = 34, 5.9%), and rosuvastatin (n = 18, 3.1%).
In multivariable linear regression analysis, after adjustment for all covariables, current 
use of statins was associated with statistically significantly lower total testosterone levels 
compared to never use, with a beta of −1.18 nmol/L (95%CI −1.96; −0.40, P 0.003). Past 
statin use was not significantly associated with lower total testosterone levels compared 
to never use (β −0.79, 95% CI −1.70; 0.12, P 0.089) (Table 2). When duration of use was 
considered, >1 to ≤6 months current use and >6 months current use were associated 
with statistically significantly lower total testosterone levels, compared to never use 








Age (mean±SD, years) 64.1 ± 8.1 64.6 ± 7.9 64.6 ± 9.7
BMI (mean±SD, kg/m2) 28.1 ± 3.9a 28.0 ± 4.1b 26.8 ± 3.5
CVD in history (n, %) 179 (31.0%)a 39 (26.4%)b 115 (3.3%)
T2DM (n, %) 100 (17.3%)a 24 (16.2%)b 18 (5.4%)
Hypertension (n, %) 298 (51.9%)a 72 (49.0%)b 896 (26.0%)
Total T (median, IQR, nmol/L) 14.8 (11.5 – 18.8)a 15.5 (12.0 – 19.9)b 17.0 (13.3 – 21.4)
Non-SHBG-bound T (median, IQR, nmol/L) 8.1 (6.6 – 9.9)a 8.2 (6.8 – 9.7)b 8.8 (7.2 – 10.6)
Insulin (median, IQR, pmol/L) 90 (63 – 136)a 90 (62 – 137)b 71 (49 – 101)
Estradiol (median, IQR, pmol/L) 105 (79 – 132)a 97 (75 – 122)b 99 (77 – 126)
SHBG (median, IQR, nmol/L) 40 (31 – 52)a 42 (33-57)b 46 (35 – 58)
DHEA (median, IQR, nmol/L) 8 (6 – 14)a 8 (6 – 14)b 10 (6 – 15)
DHEAS (median, IQR, μmol/L) 2.44 (1.43 – 3.90)a 2.48 (1.49 – 3.87)b 2.81 (1.73 – 4.31)
Total cholesterol (median, IQR, mmol/L) 4.69 (4.14 – 5.32)a 5.47 (4.70 – 6.31)b 5.59 (4.96 – 6.20)
Duration of current use (mean±SD, days) 190.8 ± 185.3 – –
Statin DDD (mean±SD) 1.6 ± 1.2 – –
Type of statin – –
 – Simvastatin (C10AA01) 345 (5.8%)
 – Pravastatin (C10AA03) 68 (11.8%)
 – Fluvastatin (C10AA04) 34 (5.9%)
 – Atorvastatin (C10AA05) 112 (19.4%)
 – Rosuvastatin (C10AA07) 18 (3.1%)
Abbreviations: SD, standard deviation; T, testosterone; IQR, interquartile range; BMI, body mass index; CVD,
cardiovascular disease; T2DM, type 2 diabetes mellitus; SHBG, sex hormone-binding globulin; DHEA,
dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; DDD, defined daily doses.
a Current users/b Past users are statistically significantly different from never users (P<0.05).
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(β −1.24, 95%CI −2.17; −0.31, P 0.009 for >1 to ≤6 months current use; β −1.14, 95%CI 
−2.07; −0.20, P 0.017 for >6 months current use). For the past use categories and ≤1 
month current use, no significant association with serum total testosterone levels was 
found (Table 2).
In the multivariable analyses on non-SHBG-bound testosterone levels, current statin 
use was associated with lower non-SHBG-bound testosterone levels compared to never 
table 2 Multivariable linear regression on the association between use of statin therapy and serum total 
and non-SHBG-bound testosterone levels
beta (SE)a 95% Ci P n
total testosterone
Current – Past – Never useb
never use (ref ) – – 3441
current use −1.18 (0.40) −1.96; −0.40 0.003 577
past use −0.79 (0.47) −1.70; 0.12 0.089 148
Current and past use categoriesc
never use (ref ) – – 3441
≤1 month current use −1.13 (0.71) −2.52; 0.26 0.111 78
>1 – ≤6 months current use −1.24 (0.47) −2.17; −0.31 0.009 288
>6 months current use −1.14 (0.48) −2.07; −0.20 0.017 226
≤6 months past use −1.17 (0.62) −2.39; 0.05 0.061 81
>6 months past use −0.35 (0.67) −1.67; 0.97 0.600 67
non-ShbG-bound testosterone
Current – Past – Never use
never use (ref ) – – 3441
current use −0.35 (0.17) −0.68; −0.01 0.042 577
past use −0.26 (0.20) −0.65; 0.13 0.191 148
Current and past use categories
never use (ref ) – – 3441
≤1 month current use −0.29 (0.30) −0.89; 0.31 .341 78
>1 – ≤6 months current use −0.42 (0.20) −0.82; −0.02 .039 288
>6 months current use −0.29 (0.21) −0.70; 0.11 .153 226
≤6 months past use −0.34 (0.27) −0.87; 0.18 .200 81
>6 months past use −0.17 (0.29) −0.73; 0.40 .563 67
Abbreviations: β, beta; SE, standard error; CI, confidence interval; SHBG, sex hormone-binding globulin.
a Analyses are adjusted for age, body mass index, history of cardiovascular disease, diabetes mellitus, hy-
pertension, estradiol level, and statin dose. b Current and past use of statin therapy compared to never use 
as the reference category. c Current and past use categories: the 1-month current use cut-off was applied to 
investigate whether statins exert an effect already after 1 month of therapy; the 6-month current and past 
use cut-off was applied based on the median duration of current and past use in the population. bold value 
indicates a statistically significant association.
170 Chapter 3.2
use (β −0.35, 95%CI −0.68; −0.01, P 0.042). Past statin use was not significantly associated 
with lower non-SHBG-bound testosterone levels compared to never use (β −0.26, 95% 
CI −0.65; 0.13, P 0.191) (Table 2). When duration of use was considered, >1 to ≤6 months 
current use was associated with statistically significantly lower non-SHBG-bound testos-
terone levels with a beta of −0.42 (95%CI −0.82; −0.02, P 0.039). For the other past and 
current use categories, no significant association was found (Table 2).
We investigated whether other hormones and total cholesterol were intermediates 
in the association between statins and testosterone levels. Additional adjustment for 
insulin and DHEAS did not change the results importantly. Additional adjustment for 
total cholesterol and DHEA showed the largest effects on the associations, and reduced 
the magnitude of the effect. Additional adjustment for total cholesterol showed a beta 
of −0.97 (95%CI −1.75; −0.18, P 0.015) for total testosterone and a beta of −0.25 (95%CI 
−0.58; 0.90, P 0.151) for non-SHBG-bound testosterone for current use, instead of the 
original betas of −1.18 and −0.35 respectively. Additional adjustment for DHEA showed 
similar results as for total cholesterol adjustment. (Results not shown).
Moreover, we stratified statin DDD in tertiles to investigate whether a higher statin 
dose was associated with a stronger testosterone lowering effect. As shown in Figure 1, 
there was a trend towards a stronger testosterone lowering effect at a higher statin dose, 
both for total testosterone (P for trend 2.9 × 10−5) and non-SHBG-bound testosterone (P 













































































figure 1 Multivariable linear regression of the association between tertiles of dosage of statin therapy in all 
current users and serum total and non-SHBG-bound testosterone levels
Abbreviations: SHBG, sex hormone-binding globulin; CI, confidence interval; DDD, defined daily doses.
A: Total Testosterone; B: Non-SHBG-bound Testosterone.
Tertiles of statin drug dosage compared to never use as the reference category. Analyses are adjusted for 
age, body mass index, history of cardiovascular disease, diabetes mellitus, hypertension, and estradiol level.
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ated with betas of −1.17 (95%CI −2.00; −0.35, P 0.005) and −1.89 (95%CI −2.75; −1.03, 
P 1.7 × 10−5) nmol/L of lower serum total testosterone, respectively, when compared to 
never users. For non-SHBG-bound testosterone, current statin use in the mid and high 
dosage tertiles was associated with betas of −0.44 (95%CI −0.79; −0.09, P 0.015) and 
−0.85 (95%CI −1.21; −0.48, P 6.0 × 10−6) nmol/L, respectively, when compared to never 
users.
In a sensitivity analysis, we excluded all participants with a history of CVD (8% of the 
population). Current users again showed significantly lower total testosterone levels (β 
−1.12, SE 0.43, P 0.048). The effect estimate for current users on lower non-SHBG-bound 
testosterone levels was similar to the original analysis, although non-significant (β −0.29, 
SE 0.27, P 0.125). For past statin use, again no association was found.
In an additional sensitivity analysis, we re-allocated 23 participants from ≤6 months 
past use to current use. These patients were the most recent past users (they had stopped 
statins ≤14 days before testosterone assessment). Results showed no significant asso-
ciation of past use with lower total and non-SHBG-bound testosterone levels. Current 
users again showed a stronger and more significant association with total testosterone 
levels (β −1.31, 95%CI −2.06; −0.56, P 0.001) and non-SHBG-bound testosterone levels (β 
−0.42, 95%CI −0.74; −0.10, P 0.011), than never users (Table 3). When past users within 
30 days were re-allocated to current use (40 participants re-allocated), the results were 
similar to the 14 days re-allocation (Results not shown).
table 3 Sensitivity analysis: multivariable linear regression on the association between use of statin therapy 
and serum total testosterone levels – recent past users reallocated
beta (SE)a 95% Ci P n
total testosterone
Current – Past – Never useb
never use (ref ) – – 3441
current use −1.31 (0.38) −2.06; −0.56 0.001 600
past use −0.49 (0.50) −1.47; 0.49 0.331 125
non-ShbG-bound testosterone
Current – Past – Never use
never use (ref ) – – 3441
current use −0.42 (0.16) −0.74; −0.10 0.011 600
past use −0.12 (0.21) −0.54; 0.30 0.569 125
Abbreviations: β, beta; SE, standard error; CI, confidence interval; SHBG, sex hormone-binding globulin.
a Analyses are adjusted for age, body mass index, history of cardiovascular disease, diabetes mellitus, hyper-
tension, estradiol level, and statin dose. b Current and past use of statin therapy compared to never use as 
the reference category. bold value indicates a statistically significant association.
172 Chapter 3.2
diSCUSSion
In this cross-sectional population-based study, we showed that current use of statins 
was associated with statistically significantly lower levels of serum total and non-SHBG-
bound testosterone in males. We demonstrated that the magnitude of the decrease 
in testosterone was directly proportional to the dosage of statin therapy. Considering 
duration of statin use, the association between current statin use and lower testosterone 
levels was present after at least 1 month current use. For past use, no association was 
found with testosterone levels.
As far as we know, there are five cross-sectional studies in the literature that studied 
the association between statins and testosterone levels. Three studies are in line with 
our findings on total testosterone levels and showed that statins were associated with 
lower total testosterone levels28-30, while two showed no association at all31,32. The stud-
ies which showed lower total testosterone levels demonstrated a difference of 1.5, 1.6 
and 3.0 nmol/L, respectively, while in our study mean total testosterone levels were 
2.2 nmol/L lower in current users compared to never users. Three of these five studies 
also investigated free testosterone, of which two did not find an association29,31 and 
one showed significantly lower free and bioavailable testosterone levels30. Bioavailable 
testosterone levels were 1.0 nmol lower in statin users than in non-users[30], while in 
our study mean non-SHBG-bound testosterone levels were 0.7 nmol/L lower in current 
users than in never users. Advantages of our study compared with these studies are that 
one did not adjust for potential confounders29, another had only 25 statin users32, only 
one study had statin dosage30, while in none of these studies duration of therapy was 
analyzed. Moreover, one study was conducted only in patients consulting for erectile 
dysfunction30, while in another exclusively T2DM patients were selected29.
Similarly, placebo controlled randomized trials studied total testosterone levels before 
and after statin therapy. A recent meta-analysis including 5 such trials concluded that 
current statin therapy (4 weeks – 3 months) induced a decrease in total testosterone of 
−0.66 nmol/L in men.33
Theoretically, there are several mechanisms by which statins may inhibit testosterone 
production. The main one is by inhibiting HMG-CoA reductase in the testis.12 By operat-
ing in the testis, statins consequently suppress de novo cholesterol production, impairing 
the substrate source for the testosterone biosynthesis pathway. The second mechanism 
is by decreasing serum cholesterol concentrations, and therefore cholesterol uptake by 
the testis, which could, again, limit its availability and impact on testosterone produc-
tion. A third mechanism is by directly inhibiting other enzymes in the testosterone bio-
synthesis pathway.13 An alternative theory for the decrease in testosterone levels is that 
statin users have increased insulin levels, because these patients often have metabolic 
syndrome, and statins themselves may increase insulin levels.34 Insulin suppresses SHBG 
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production in the liver35,36, with consequently lower total testosterone levels, because 
free testosterone levels are kept constant in response to the decrease in SHBG levels.9
The impact of statins as testosterone lowering drugs has been criticized37 and several 
arguments were used. First, a decrease of −0.66 nmol/L, as shown in the recent meta-
analysis33, is a small mean decrease in total testosterone level. Second, in literature there 
is a poor correlation between the use of statins and symptoms such as decreased libido 
or muscle strength, which questions the clinical relevance of this decrease. However, 
there is a variability in response to statins and some patients might be more vulnerable 
to statins and will have a stronger decrease.38 A modest average decrease in a popu-
lation might hide a substantial decrease in a handful of individuals and in those with 
an already low testosterone, it might be clinically meaningful. Moreover, even modest 
effects on a population-based scale may gain more relevance now that statin therapy is 
increasingly used. For instance, application of the adapted American guidelines on male 
participants of the Rotterdam Study would imply that nearly all elderly men (i.e. 96.4%) 
should be prescribed statins.39 This corroborates to the idea that adverse reactions to 
statins, e.g. a testosterone lowering effect, deserve attention. In our study, additional 
adjustment for total cholesterol or DHEA attenuated the association between statins 
and lower testosterone levels, while DHEAS and insulin showed no important effect. 
Both cholesterol and DHEA are substrates for testosterone formation, and attenuation 
of the association through additional adjustment supports the hypothesis that statins 
lower testosterone through reducing cholesterol. Also, DHEA is a reflection of adrenal 
steroid production, and suppression of DHEA may suggest an effect on adrenal ste-
roidogenesis.40 Moreover, when the decrease in testosterone levels is clinically relevant, 
statin users can become eligible for testosterone replacement therapy (TRT). However, 
evidence as to whether TRT is associated with an increase in cardiovascular events is 
controversial, since a first meta-analysis41 on RCTs supported the association, while a 
reviewing second meta-analysis42 did not.
Our study is cross-sectional, because regular assessment of serum testosterone levels 
is very unusual in a population-based setting. Nevertheless, we were able to study dura-
tion of use to establish a temporal relationship. Current use for >1 to ≤6 months and >6 
months showed a significantly lower total testosterone level. The first month of therapy 
was investigated separately to gain insight into how testosterone levels behave during 
the beginning of statin use. During the first month, the testosterone lowering effect was 
non-significant and less strong than for the other current use categories, suggesting that 
more time is needed to induce a complete effect on testosterone levels. For >1 to ≤6 
months of statin use, non-SHBG-bound testosterone levels decreased in parallel with 
total testosterone. However, for the > 6 months statin users, non-SHBG-bound testoster-
one levels also showed a negative beta which was, however, not significant. As described 
in the introduction, non-SHBG-bound testosterone is driving the negative feedback 
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mechanism of the hypothalamo-pituitary-gonadal axis to keep its concentration con-
stant. Possibly, in long-term statin users, the setpoint has adapted to the effect of statins 
on testosterone lowering, as a compensatory effect to prevent the levels of bioactive 
non-SHBG-bound testosterone to fall. This might explain why we could not demonstrate 
an effect of long-term statin use on the levels of bioactive non-SHBG-bound testosterone.
The magnitude of the association between current statin use and lower serum total 
and non-SHBG-bound testosterone was stronger at a higher statin doses. This is in line 
with what is expected, and strengthens our finding. Some misclassification of exposure 
may have occurred in very recent past users who may actually be current users who took 
a drug holiday or be subject to a carry-over effect after stopping the drug. In sensitivity 
analyses, the association was strengthened for current users, which supports the pos-
sibility of some misclassification of exposure.
Strengths and potential limitations should be considered. The Rotterdam Study is a 
large prospective population-based cohort study with extensive data collection. For in-
stance, we were able to consider statin dose and were the first study that considered the 
effect of duration of statin use. Furthermore, we accounted for potential confounding 
variables (e.g. T2DM, hypertension and CVD). Compared to other cross-sectional stud-
ies, we managed not only to overcome potential flaws, but also to further extend and 
strengthen the analysis. We adjusted for confounding by indication which potentially 
plays a role since diseases such as CVD and T2DM are independently associated with 
lower testosterone levels.43
A strength is that we measured total testosterone, DHEA and DHEAS by LC-MS/MS. Al-
though we measured estradiol by electrochemiluminescence immunoassay, the method 
used has been standardized via ID-GC/MS. In the Rotterdam Study no direct measure-
ment of free testosterone by equilibrium dialysis was performed. Instead, we calculated 
non-SHBG-bound testosterone using the formula by Sodergard et al.20 Results of both 
types of estimations of free testosterone yielded highly correlated results.44 Ideally, the 
study should be performed longitudinally with several testosterone assessments over 
time. However, this is very unusual in a population-based setting. Unfortunately, we 
had too low numbers of current statin users to investigate the association in users of 
the different types of statins separately. However, we expected a class effect of statins 
on testosterone lowering. This study supports the hypothesis that statins lower testos-
terone through cholesterol lowering, and thus all statins will show this effect. Analyses 
of the association between current statin use and testosterone levels showed a similar 
direction of the effect (negative beta) for all statins separately. However, the association 
only remained significant for the association of total testosterone in simvastatin users, 
due to decreased power because of sample size.
In conclusion, our study showed that current use of statin therapy is associated with 
significantly lower serum total and non-SHBG-bound testosterone levels after adjust-
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ment for important confounders. Given the large number of statin-treated males and 
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AbStrACt
Introduction: When studying the causal effect of drug use in observational data, marginal 
structural modeling (MSM) can be used to adjust for time-dependent confounders that 
are affected by previous treatment. The objective of this study was to compare tradi-
tional Cox proportional hazard models (with and without time-dependent covariates) 
with MSM to study causal effects of time-dependent drug use.
Methods: The example of primary prevention of cardiovascular disease (CVD) with 
statins was examined using up to 17.7 years of follow-up from 4,654 participants of the 
observational prospective population-based Rotterdam Study. In the MSM model, the 
weight was based on measurements of established cardiovascular risk factors and co-
morbidity.
Results: In general, we could not demonstrate important differences in results from the 
Cox models and MSM. Results from analysis on duration of statin use suggested that 
substantial residual confounding by indication was not accounted for during the period 
shortly after statin initiation.
Conclusion: In conclusion, although on theoretical grounds MSM is an elegant technique, 
lack of data on the precise time-dependent confounders, such as indication of treat-
ment or other considerations of the prescribing physician jeopardizes the calculation of 
valid weights. Confounding remains a hurdle in observational effectiveness research on 
preventive drugs with a multitude of prescription determinants.
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introdUCtion
Increasingly, comparative effectiveness research is performed using data from large 
health care databases on drug utilization and clinical outcomes. Such databases have 
traditionally been utilized to study rare adverse drug reactions and prescription patterns 
in unselected populations. It is imperative that these health care databases contain 
accurate and complete information on drug use, clinical outcomes, and relevant covari-
ates. However, because the consequences of invalid findings can be substantial, also 
proper methods for statistical analysis need to be employed to estimate causal effects.1
Observational studies with information on drug use at baseline only (e.g. based on 
interviews at enrollment) may have substantial misclassification of exposure during 
follow-up. Drug use is in most circumstances a time-varying determinant since discon-
tinuation, change in dosage, or switching to another drug is common. To circumvent 
this, we previously proposed a method based on a Cox model for the analysis of drug 
use as a time-dependent determinant.2 Nonetheless, effect estimates may be biased 
because some risk factors which change during follow-up may have been influenced by 
preceding drug use, and in the presence of a time-dependent risk factor for the event 
of interest which also predicts subsequent drug use. Both conditions will hold when a 
time-dependent covariate is simultaneously (1) a reason for prescribing (often termed 
‘confounding by indication’3); (2) influenced by the drug treatment under study; and 
(3) a potential cause of the outcome of interest. This can be adjusted for by marginal 
structural modeling (MSM), in which drug-outcome associations can be modeled with 
the drug as a time-dependent determinant, along with adjustment for time-dependent 
confounding through the application of weights. In short, all observations are assigned 
a weight based on the inverse of the conditional probability of receiving observed 
treatment.4,5 However, there is limited experience with the application of such MSMs in 
observational studies with complete data on drug use during follow-up and a multitude 
of treatment determinants. This is unfortunate as the method may be valuable for the 
rapidly increasing number of observational studies on the effectiveness of drug use in 
health care databases which serve as a basis for decision making or initiation of clinical 
trials.
The objective of this study was to investigate whether MSM produces different risk 
estimates from more traditional Cox models with and without time-dependent covari-
ates in observational (i.e. nonrandomized) data with detailed information on medica-
tion use, clinical outcomes, and relevant covariates. We used data from the prospective 
population-based Rotterdam Study to examine the example of primary prevention of 




The current study was performed within the Rotterdam Study, a prospective population-
based cohort study in the general population. The rationale and design of the Rotterdam 
Study have been described in detail elsewhere.6,7 In short, all 10,275 persons aged 55 
years and over in the Ommoord district of Rotterdam, the Netherlands, were invited to 
participate. Of them, 7,983 (78 %) were enrolled between 1990 and 1993. At baseline, all 
participants were interviewed at home and 7,085 underwent extensive clinical examina-
tion at the research center. We additionally used data from re-examinations that took 
place in 1993–1995, 1997–1999, and 2002–2004.
The Rotterdam Study has been approved by the medical ethics committee according 
to the Wet Bevolkingsonderzoek: ERGO (Population Screening Act: Rotterdam Study), 
executed by the Ministry of Health, Welfare and Sports of the Netherlands.
Study population
We excluded all participants who did not visit the research center at baseline, were 
80 years or older, and those with established CVD, diabetes mellitus, or statin use at 
baseline. Prevalent CVD was defined as a history of myocardial infarction (MI), heart 
failure, stroke, transient ischemic attack (TIA), or coronary-, carotid-, or abdominal aortic 
revascularization. Diabetes mellitus at baseline was defined as filling a prescription ac-
cording to the pharmacy dispensing records for oral glucose lowering drugs or insulin 
before the baseline examination. Statin use at baseline was defined as filling a prescrip-
tion according to pharmacy records for statins or if the participant reported statin use 
during the interview.
drug exposure
Medication dispensing data were obtained from all seven fully computerized pharmacies 
in the Ommoord district. Information on all filled prescriptions from 1 January 1991 until 
1 February 2012 were available and included information on the product name of the 
drug, the WHO Anatomical Therapeutical Chemical (ATC) code8, the amount dispensed, 
the prescribed dosage regimen, and the date of dispensing.6,7 We excluded participants 
who filled a first prescription of statins prior to 1 April 1991 in order to ensure that all 
participants were incident users and did not use statins before. We used the ATC codes 
C10AA and C10B for statins; C02 (antihypertensives), C03 (diuretics), C07 (b-blockers), 
C08 (calcium channel blockers) or C09 (renin-angiotensin system modifying agents) for 
blood pressure lowering medication; and A10 for oral glucose-lowering medication and 
insulin.8
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For every dispensing of a statin, the duration of use was calculated by dividing the 
number of dispensed tablets by the prescribed daily number. Repeated prescriptions 
which were filled within 7 days after ending the previous filled prescription were consid-
ered as continuous use. At each month during follow-up, every participant was classified 
into mutually exclusive categories: ‘ever use’ if the participant had filled a prescription 
for statins during this month or at any point during follow-up prior to this month; ‘never-
use’ if the participant had not used statins during the study period leading up to that 
month. We did not distinguish between current use and past use of statins since we did 
not have good determinants for discontinuation available and thereby assumed that 
any participant starting statins during follow-up remained exposed thereafter (‘inten-
tion to treat’). We considered duration of statin use by dividing the total number of days 
of statin use into mutually exclusive categories of cumulative use: first month of use, 
cumulative use equals 31 days to 365 days, cumulative use for more than 365 days.
Cardiovascular outcomes
Information on the presence and occurrence of CVD is available through collaboration 
with the general practitioners in the study area. Methods of data collection and defini-
tions of cardiovascular outcomes in the Rotterdam Study have been described in detail 
previously.9-11
For the present analysis, we used two different combined clinical endpoints as out-
come of interest. First, we considered ‘hard’ atherosclerotic cardiovascular endpoints, 
defined as the first occurrence of any of the following events: fatal or nonfatal MI, non-
hemorrhagic stroke, or atherosclerotic CVD death. Second, we extended this definition 
by including all strokes and arterial revascularization procedures (defined as a surgical 
or percutaneous coronary, carotid revascularization, or abdominal aortic surgery). Physi-
cians prescribe statins to those whom are expected to benefit most from statins during 
their remaining lifespan12 which carry similar considerations as the patient selection 
for arterial revascularization procedures. Heart failure and TIA were not considered as 
endpoints, but if one of these events occurred during follow-up, the participant was 
censored since statin use after the occurrence of such an event could not be considered 
as primary prevention of CVD.
Covariables
The variables age, sex, current smoking status, systolic blood pressure, and serum level 
of total cholesterol were considered in the analysis. This was based on the variables used 
in the risk charts used for cardiovascular risk management in clinical practice: the Euro-
pean Society of Cardiology guidelines on CVD prevention.13 Besides these established 
cardiovascular risk factors, we additionally considered body mass index (BMI) in kg/m2, 
family history of premature MI (first degree relative aged <65 years), level of highest 
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education attained as a measure of socioeconomic status14, incident non-skin cancer (n 
= 1,327) and chronic obstructive pulmonary disease (COPD) at baseline as measures of 
co-morbidity, and use of blood pressure lowering medication.
Statistical analysis
Throughout the analysis we used pooled logistic regression models using generalized 
estimating equations with each person-month of follow-up as a separate observation. 
This was done to emulate time-dependent Cox proportional hazards models with the 
ability to incorporate time-dependent weighing of the observations.15,16
We compared three different models. First, we used a Cox proportional hazards model 
with statin use during follow-up as a time-dependent exposure (including categories 
based on the cumulative duration of use) (model I). This analysis was adjusted for the 
baseline values of age, sex, smoking status, systolic blood pressure, total cholesterol, 
BMI, level of education, incident non-skin cancer, COPD, and the use of blood pressure 
lowering medication.
In the second time-dependent Cox proportional hazards model (model II), we in-
cluded statin use during follow-up as a time-dependent exposure, as well as updated 
variables for the potential confounding variables. At every monthly interval, the values 
for the covariates smoking status, systolic blood pressure, total cholesterol level, and 
BMI were updated to the most recent visit of the Rotterdam Study research center. Use 
of blood pressure lowering medication, based on pharmacy records, and incident non-
skin cancer were also included as a time-dependent covariate. Furthermore, model II 
was adjusted for age, sex, level of education, and COPD at baseline.
Last, we used a marginal structural Cox proportional hazards model (model III) to adjust 
for time-dependent confounding by indication.17 To adjust for time-dependent con-
founding by indication, all observations are weighted by the inverse of the conditional 
probability of the observed status of statin use, based on variables that are considered to 
influence the initiation of statins: age, sex, smoking status, systolic blood pressure, total 
cholesterol, BMI, level of education, incident non-skin cancer, COPD, and use of blood 
pressure lowering medication. We used stabilized weights as described by Hernán et al.4,17 
The range and distribution of the stabilized weights used in model III are visualized in Fig. 1 
(mean 1.012; median 0.996). At every monthly interval, the time-dependent measures of 
the covariates used to compute the weights were updated to the values from the most 
recent visit to the Rotterdam Study research center. The regression model was adjusted 
for the baseline values of the covariates in model I. Statin use was included as a categori-
cal time-dependent exposure based on the cumulative duration of use. Adjustment for 
follow-up time was done by including dummy variables for the tertiles of follow-up time 
(<43 months, ≥43-<98 months, and ≥98 months, respectively). Model III was based on a 
previously published SAS macro (statistical code available in the online supplement).17
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In a sensitivity analysis we excluded observations with extreme stabilized weights 
(<0.01th and >99.99th percentile in line with Cook et al.18; <0.044 and >17.756, respec-
tively,) in order to assess the impact of these observations on the results.
For the present study, follow-up started at 1 April 1991 or the date of clinical examina-
tion when enrolled later. The end of the follow-up was 1 January 2009. Since we aimed 
to study primary prevention of CVD in accordance with the European and American 
guidelines13,19, participants were followed until the date of any cardiovascular event, 
the date of first dispensing of oral blood glucose lowering drugs or insulin, the 80th 
birthday, or the last date of data collection, whichever came first.
Missing values for one or more of the covariates at baseline were present in 105 (2.3 %) 
participants. These were handled by single imputation using an expectation-maximiza-
tion algorithm.20 Throughout follow-up we used last observation carried forward for all 
confounders. All measures of association are presented with 95% confidence intervals 
(95% CIs). We used the level of significance of P<0.05. The analyses were performed us-
ing SAS version 9.3 (SAS Institute Inc., Cary, NC, U.S.).
figure 1 Distribution of stabilized weights for the marginal structural model (model III)
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The baseline characteristics of the study population are presented in Table 1. A total of 
4,654 participants were eligible for the analysis. During up to 17.7 years of follow-up, 583 
participants initiated statin therapy. At the end of follow-up, 378 (64.8 %) participants 
that initiated statin therapy were still using statins. Out of the 3,795 person-months of 
follow-up after initial statin dispensing, 2,697 person-months were covered by statin 
dispensing, corresponding to a 71.1 % coverage of person-time exposed to ‘ever statin 
use’. The mean duration of cumulative use was 4.6 years. A total of 510 ‘hard’ atheroscle-
rotic CVD and 655 ‘extended’ atherosclerotic CVD endpoints occurred. The follow-up and 
reasons for ending follow-up for the present study are presented in Table 2.
In the first Cox regression model with time-dependent statin use (model I), ever use 
of statins was significantly associated with a lower risk of the hard CVD endpoint (HR 
0.68, 95% CI 0.47; 1.00), but it was not significantly associated with the extended CVD 
endpoint (HR 1.19, 95% CI 0.89; 1.61). These results are shown in Table 3 and Table 4 
respectively. When we divided use of statins into categories based on the cumulative 
duration of use, in the analysis on the hard CVD endpoint, use of statins for more than 
1 year was significantly associated with a lower risk of hard CVD with a HR of 0.50 (95% 
CI 0.31; 0.82) (Table 3). This association could not be demonstrated in the analysis on 
the extended endpoint. In this analysis however, cumulative statin use for 1–30 days 
table 1 Characteristics of the study population at baseline (1990-1993)
Characteristic Study population (n = 4,654)
Age, years (mean, SD) 66.3 (6.7)
Men (n, %) 1,835 (39.4%)
BMI, kg/m2 (mean, SD) 26.3 (3.6)
Current smoking (n, %) 1,135 (24.4%)
Systolic blood pressure, mmHg (mean, SD) 138 (22)
Hypertension (n, %) 2,387 (51.3)
Total cholesterol, mmol/L (mean, SD) 6.7 (1.2)
HDL-cholesterol, mmol/L (mean, SD) 1.3 (0.4)
COPD (n,%) 180 (3.9%)
Use of blood pressure lowering drugs (n, %) 1006 (21.6%)
 – Diuretics (n, %) 389 (8.4%)
 – β-blockers (n, %) 524 (11.3%)
 – Calcium channel blockers (n, %) 172 (3.7%)
 – ACE-inhibitors (n, %) 194 (4.2%)
 – Other blood pressure lowering drugs (n, %) 44 (0.9%)
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index; HDL, high-density lipoprotein; 
COPD, chronic obstructive pulmonary disease.
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and cumulative statin use for 31–365 days were associated with a significantly increased 
risk of CVD with HRs of 3.73 (95% CI 1.51; 9.21) and 2.82 (95% CI 1.73; 4.61), respectively 
(Table 4).
The analyses of the time-dependent Cox regression model (model II) with both statin 
therapy and covariates updated during follow-up showed similar results compared to 
model I on the association between use of statins and both CVD endpoints (Tables 3; 4).
In the Cox proportional hazards MSM analyses (model III), ever use of statins was 
associated with a lower hard CVD risk. However, this association was not statistically 
significant (HR 0.89, 95% CI 0.5; 1.43). When distinguishing categories of the cumulative 
duration of use, use of statins for more than 1 year was significantly associated with 
a lower risk of hard CVD (HR 0.57, 95% CI 0.33; 0.99) (Table 3). For the extended CVD 
endpoint, ever use of statins was not significantly associated with CVD (HR 1.05, 95% 
table 2 Details regarding the indications for end of follow-up and amount of follow-up (1991–2009)
Cvd events
Total CVD (n, %) 655 (14.1%)
 – Coronary heart disease (n, %) 353 (7.6%)
  – Myocardial infarction (n, %) 199 (4.3%)
  – Coronary artery bypass grafting (n, %) 43 (0.9%)
  – Percutaneous coronary intervention (n, %) 50 (1.1%)
  – Coronary death (n, %) 61 (1.3%)
 – Cerebrovascular disease (n, %) 268 (5.8%)
  – Non-hemorrhagic stroke (n, %) 231 (5.0%)
  – Hemorrhagic stroke (n, %) 36 (0.8%)
  – Carotid revascularization (n, %) 1 (0.0%)
 – Abdominal aortic surgery (n, %) 28 (0.6%)
 – Other atherosclerotic CVD mortality (n, %) 6 (0.1%)
indications for censoring follow-up
Last date of data collection (n, %) 1,170 (25.1%)
Non-atherosclerotic death (n, %) 421 (9.0%)
80th birthday (n, %) 1,695 (36.4%)
First dispensing of glucose-lowering medication or insulin (n, %) 314 (6,7%)
Diagnosis of heart failure (n, %) 245 (5.3%)
Diagnosis of cerebrovascular transient ischemic attack (n, %) 154 (3.3%)
follow-up
Total, pys 44,065
Median (interquartile range), years 9.8 (4.8–15.0)
incidence
Crude incidence rate (95% CI), per 1,000 pys 14.9 (13.7–16.0)
Abbreviations: CVD, cardiovascular disease; pys, person-years; CI, confidence interval.
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CI 0.67; 1.64). When we divided statin use into categories, use of statins for more than 
1 year was significantly associated with a lower risk of CVD (HR 0.70, 95% CI 0.15; 0.99). 
Use of statins in the first month after initiation and between 31 days and 1 year after 
start was significantly associated with a higher risk of CVD, with HRs of 4.36 (95% CI 1.17; 
16.28) and 2.47 (95% CI 1.25; 4.87), respectively (Table 4). After exclusion of observations 
with extreme weights, results from the MSM analyses did not markedly change, albeit 
table 3 Cox regression and MSM analyses for the association between statin use and the occurrence of 
hard atherosclerotic CVD
ncases pys i. first time-dependent 
Cox regression modela




hr (95% Ci; P-value)
iii. mSmc
model
hr (95% Ci; P-value)
Ever use versus never used
Never use 476 40,326 1.00 (ref ) 1.00 (ref ) 1.00 (ref )
Ever use 34 3,739 0.68 (0.47; 1.00, 0.048) 0.69 (0.48; 1.00, 0.050) 0.89 (0.55; 1.43, 0.627)
duration of usee
Never use 476 40,326 1.00 (ref ) 1.00 (ref ) 1.00 (ref )
1-30 days use 4 201 1.77 (0.44; 7.16, 0.425) 1.63 (0.40; 6.69, 0.495) 4.50 (0.86; 23.5, 0.074)
31-365 days use 11 825 1.15 (0.51; 2.62, 0.736) 1.09 (0.48; 2.48, 0.831) 2.00 (0.77; 5.18, 0.154)
≥366 days use 19 2,714 0.50 (0.31; 0.82, 0.006) 0.51 (0.31; 0.83, 0.007) 0.57 (0.33; 0.99, 0.045)
We used pooled logistic regression models using generalized estimating equations with each person-
month of follow-up as a separate observation. This was done to emulate time-dependent Cox proportional 
hazards models with the ability to incorporate time-dependent weighting of the observations.15,16 ‘Hard’ 
atherosclerotic CVD is a composite endpoint of fatal and nonfatal myocardial infarction, stroke, and ath-
erosclerotic CVD death.
Abbreviations: MSM, marginal structural model; CVD, cardiovascular disease; Ncases, number of CVD cases; 
pys, person-years of observed follow-up; HR, hazard ratio; CI, confidence interval; ref, reference; BMI, body 
mass index; COPD, chronic obstructive pulmonary disease.
a First time-dependent Cox regression model: statin use during follow-up as time-dependent variable; ad-
justed for the baseline values age, sex, BMI, smoking status, systolic blood pressure, total cholesterol, use of 
blood pressure lowering drugs, presence of COPD, incident non-skin cancer, and level of education.
b Second time-dependent Cox regression model: statin use during follow-up as time-dependent variable; 
adjusted for the updated values of BMI, smoking status, systolic blood pressure, total cholesterol level (up-
dated at every monthly interval to the most recent visit of the Rotterdam Study) and adjusted for age, sex, 
use of blood pressure lowering drugs at baseline, presence of COPD, incident non-skin cancer, and level of 
education.
c MSM: exposure and adjustment is the same as for the first time-dependent Cox regression model. All 
observations are weighted by the inverse of the conditional probability of the observed status of statin use, 
based on variables that are considered to influence the initiation of statins: age, sex, smoking status, systolic 
blood pressure, total cholesterol, BMI, level of education, incident non-skin cancer, COPD, and use of blood 
pressure lowering medication.
d Ever use of statins versus never use of statins at the occurrence of a cardiovascular event.
e Use of statins divided in categories based on the duration of cumulative use: first month of use of statins, 
cumulative use of statins equals more than 31 days to 1 year, cumulative use of statins for more than 1 year.
bold value indicates statistically significant association.
Comparing a MSM with Cox models on time-varying statin use in the primary prevention of CVD 191
the HRs for the extended endpoint in the 1–30 days and 31–365 days of use categories 
were no longer statistically significant (data not shown).
table 4 Cox regression and MSM analyses for the association between statin use and the occurrence of 
atherosclerotic CVD (extended endpoint including arterial revascularization procedures)
ncases pys i. first time-dependent 
Cox regression modela




hr (95% Ci; P-value)
iii. mSmc
model
hr (95% Ci; P-value)
Ever use versus never used
Never use 586 40,326 1.00 (ref ) 1.00 (ref ) 1.00 (ref )
Ever use 69 3,739 1.19 (0.89; 1.61, 0.241) 1.10 (0.84; 1.45, 0.499) 1.05 (0.67; 1.64, 0.836)
duration of usee
Never use 586 40,326 1.00 (ref ) 1.00 (ref ) 1.00 (ref )
1-30 days use 7 201 3.73 (1.51; 9.21, 0.004) 3.11 (1.24; 7.76, 0.015) 4.36 (1.17; 16.28, 0.028)
31-365 days use 26 825 2.82 (1.73; 4.61, <0.0001) 2.47 (1.52; 4.01, <0.001) 2.47 (1.25; 4.87, 0.009)
≥366 days use 36 2,714 0.86 (0.59; 1.27, 0.452) 0.79 (0.55; 1.14, 0.205) 0.70 (0.15; 0.99, 0.047)
We used pooled logistic regression models using generalized estimating equations with each person-
month of follow-up as a separate observation. This was done to emulate time-dependent Cox propor-
tional hazards models with the ability to incorporate time-dependent weighting of the observations.15,16 
‘Extended’ atherosclerotic CVD is a composite endpoint of fatal and nonfatal myocardial infarction, stroke, 
atherosclerotic CVD death, and arterial revascularization procedures defined as surgical or percutaneous 
coronary revascularization, abdominal aortic surgery, or carotid revascularization.
Abbreviations: MSM, marginal structural model; CVD, cardiovascular disease; Ncases, number of CVD cases; 
pys, person-years of observed follow-up; HR, hazard ratio; CI, confidence interval; ref, reference; BMI, body 
mass index; COPD, chronic obstructive pulmonary disease.
a First time-dependent Cox regression model: statin use during follow-up as time-dependent variable; ad-
justed for the baseline values age, sex, BMI, smoking status, systolic blood pressure, total cholesterol, use of 
blood pressure lowering drugs, presence of COPD, incident non-skin cancer, and level of education.
b Second time-dependent Cox regression model: statin use during follow-up as time-dependent variable; 
adjusted for the updated values of BMI, smoking status, systolic blood pressure, total cholesterol level (up-
dated at every monthly interval to the most recent visit of the Rotterdam Study) and adjusted for age, sex, 
use of blood pressure lowering drugs at baseline, presence of COPD, incident non-skin cancer, and level of 
education.
c MSM: exposure and adjustment is the same as for the first time-dependent Cox regression model. All 
observations are weighted by the inverse of the conditional probability of the observed status of statin use, 
based on variables that are considered to influence the initiation of statins: age, sex, smoking status, systolic 
blood pressure, total cholesterol, BMI, level of education, incident non-skin cancer, COPD, and use of blood 
pressure lowering medication.
d Ever use of statins versus never use of statins at the occurrence of a cardiovascular event.
e Use of statins divided in categories based on the duration of cumulative use: first month of use of statins, 
cumulative use of statins equals more than 31 days to 1 year, cumulative use of statins for more than 1 year.
bold value indicates statistically significant association.
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In this study, we compared MSM and traditional Cox regression models using empirical 
data on time-varying statin use in the primary prevention of CVD as an example. We 
investigated whether the use of MSM to estimate the causal effect of time-dependent 
drug use in the presence of time-dependent confounders, produces different relative 
risk estimates from traditional Cox proportional hazards models with and without time-
dependent covariates. In general, we could not demonstrate important differences 
between these different analyses.
marginal structural modeling of time-dependent drug use
Efficacy of drugs is tested in double-blind randomized clinical trials. However, the ho-
mogeneous characteristics of patients in clinical trials differ substantially from those of 
patients in a real-life setting.21-24 Therefore, effectiveness in a real-life setting requires 
observational studies, ideally in unselected populations. The chance of confounding by 
(contra) indication in observational studies is well-recognized and generally dealt with 
by adjustment for the (contra) indication.25 Hernán et al.17 pointed out that such adjust-
ment may be flawed in the presence of time-varying confounders that are influenced 
by the drug under study. As a potential remedy, they proposed a model to adjust for 
time-dependent confounding in observational studies by weighting of the observations 
with the inverse conditional probability of receiving their observed treatment.4,17
Marginal structural modeling resembles the use of propensity scores in which the 
baseline probability of being treated is used to deal with potential confounding by in-
dication by matching, stratification, or adjustment on score at baseline.26 On theoretical 
grounds, MSM is a more valid approach than the use of baseline propensity scores, since 
MSM allows for taking into account time-dependent confounders that are affected by 
prior treatment.
However, propensity scores are increasingly used in observational (comparative) 
effectiveness research27, whereas MSM is still less frequently encountered in pharmaco-
epidemiological literature.28,29
In 2000, Hernán et al.17 published a seminal study on the use of MSM in studying 
causal effects of drugs in observational data. They investigated the effect of zidovudine 
on survival 0f human immunodeficiency virus (HIV)-positive men using data from an 
observational cohort study. They demonstrated an important difference between 
the unadjusted model and the weighted MSM with adjustment for time-dependent 
confounders. In the unadjusted model, zidovudine was spuriously associated with an 
increased risk of death, while the weighted MSM showed a significantly reduced mortal-
ity rate ratio for zidovudine. In our study, a 32% CVD risk reduction with the Cox model 
with time-dependent statin use decreased to 11% with MSM. The study by Hernán et al. 
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differs from our study on several aspects. First, they investigated treatment by specialists 
for a disease entity with a very strictly defined indication for initiation of zidovudine, 
namely CD4+ lymphocyte count in the case of HIV positivity30, while in our study the 
indication to start statins for primary prevention of CVD is far less stringent and pre-
scribing of statins is mostly initiated by general practitioners on the basis of the global 
cardiovascular risk profile and expected merits of treatment.12,13 Second, once a patient 
with HIV starts on zidovudine, this will generally be continued indefinitely since con-
tinued treatment is necessary for survival. Opposite, statins can be used intermittently 
and are far less crucial for survival, and may therefore be more frequently discontinued 
because of non-adherence to therapy or perceived adverse reactions such as myalgia. 
Discontinuation frequently occurs in the case of statin therapy, a previous study demon-
strated that 53 % of new users of statins discontinued within 2 years.31
In line with our results, previous MSM studies on statin effectiveness in observational 
data reported small differences between the unweighted risk estimates and the weight-
ed risk estimates.32,33 A recent literature review of application of MSMs in pharmaco-
epidemiology summarized discrepancies between HRs from conventional regression 
analysis and MSM.28 Of the 14 studies that directly compared the HRs from different 
regression techniques, only six studies concluded that the MSM results differed from 
the conventional analysis. Another recent literature review on the use of MSM estimated 
that in only 40 % of the studies the effect estimates from MSMs materially differed from 
results from conventional models.29 In all, this indicates that there is often insufficient 
information on the time-dependent confounding of treatment, or that the influence of 
time-varying confounding is small.4,17
Confounding by indication of statin treatment
Current guidelines on prevention of CVD recommend clinicians to start statins in 
persons without established CVD, but with a high global absolute CVD risk.13,19 These 
recommendations are based on large randomized clinical trials that demonstrate a 
25% risk reduction on the occurrence of major cardiovascular endpoints and 14% 
risk reduction in all-cause mortality in persons free of CVD.34 There is no substitute for 
randomized clinical trials since proper randomization minimizes the risk of confound-
ing in such studies.35 This was recently confirmed by Danaei et al.32 who emulated a 
hypothetical randomized trial using observational data. They demonstrated that there 
was substantial confounding by indication for statins in primary prevention of CVD. In 
line with our results, the HRs during the initial months after statin initiation suggest a 
non-beneficial effect of statin use on CVD endpoints. This seems to indicate that there 
was still substantial unmeasured confounding by indication which was not accounted 
for, such as due to symptoms of angina.
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limitations
Potential limitations of our study should be considered. First, we did not observe a large 
difference in effect estimates between the results from the Cox model without time-
dependent covariates (model I) and the Cox model with time-dependent covariates 
(model II). A possible explanation for this could be that the changes in cardiovascular 
risk factors and other potential confounders we evaluated do not materially relate to 
the probability of initiating statin treatment, i.e. for our particular research question no 
or only a limited degree of time-dependent confounding by indication was present. The 
observed increased risk in the category 1–30 days of statin use also argues that other 
factors may be of greater importance for statin prescription in everyday clinical practice, 
besides measurements of established cardiovascular risk factors. Therefore, other time-
dependent predictors, such as more detailed measures of the burden of co-morbidity 
and frailty or symptoms like angina or intermittent claudication, may be more appro-
priate indicators of both statin initiation and subsequent prognosis. Also, information 
on the confounders was updated at 4–5 year time intervals during follow-up visits of 
the Rotterdam Study. As a consequence, some participants had only a small number of 
updates on the time-dependent covariates. A density plot of the weights used in model 
III showed a steep curve, with a 5th and 95th percentile of 0.824 and 1.194, respectively 
(Fig. 1), indicating that the weights carried a limited amount of information. Next, in 
the MSM analysis we made an attempt to model weights for statin initiation. Since use 
of statins is frequently discontinued it would be useful to also compute weights for 
discontinuation of treatment to more adequately deal with potential confounding by 
contra-indication. Furthermore, we conducted an ‘intention to treat’ analysis because 
information on determinants for statin discontinuation, such as adverse drug reactions 
or patient preferences are not available in the Rotterdam Study. This may have affected 
our estimates given that one third of the participants in our study who started statins 
discontinued treatment during follow-up (71.1 % coverage of exposed person-time). 
Last, we did not take into account the differences in equivalent statin dose used or 
changes in dosage over time.36
Conclusions
Although, on theoretical grounds, MSM is an elegant statistical technique to adjust for 
time-dependent confounding by indication, the absence of knowledge about detailed 
confounder status on a daily basis may be a hurdle to the use of MSM in real-life popu-
lation-based cohort studies. Even if drug use is registered on a daily basis, the absence 
of data on time-dependent confounders, such as the precise prescription indication or 
other treatment considerations jeopardizes the calculation of the actual valid weights. 
Confounding by indication remains a hurdle in observational effectiveness research on 
preventive drugs with a multitude of prescription determinants.
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Introduction: Non-alcoholic fatty liver disease (NAFLD), or hepatic steatosis, is consid-
ered as the hepatic manifestation of the metabolic syndrome. Previous cross-sectional 
studies suggested an association between higher serum sex hormone-binding globulin 
(SHBG) levels and a lower prevalence of NAFLD. Our aim was to investigate whether 
serum SHBG levels, measured in a population with a very low probability of steatosis at 
baseline, were associated with the development of NAFLD during follow-up.
Methods: In the population-based Rotterdam Study, 632 men and 1132 women had 
a fatty liver index (FLI) below 60 (very low probability of steatosis) and a serum SHBG 
measurement available at baseline, and underwent liver ultrasonography after a mean 
follow-up period of 11 years. In multivariable logistic regression analysis, we investigated 
the association between SHBG levels in nmol/L and NAFLD incidence. In an additional 
analysis, we selected participants with a FLI<30 (no steatosis).
Results: In men and women with FLI<60, higher baseline SHBG levels were significantly 
associated with a lower incidence of NAFLD during follow-up, after adjustment for total 
testosterone level and other co-variables. The odds ratio per SD increase in SHBG was 
0.64 (95%CI 0.46; 0.89) in men and 0.78 (95%CI 0.64; 0.94) in women. Analyses in partici-
pants with FLI<30 showed similar effect estimates, although non-significant.
Conclusion: Higher SHBG levels were independently associated with a lower risk of de-
veloping NAFLD after around 11 years follow-up. This study showed evidence that SHBG 
might be an early biomarker for the development of NAFLD.
SHBG as an early biomarker for NAFLD 203
introdUCtion
Non-alcoholic fatty liver disease (NAFLD) or hepatic steatosis is a condition in which 
fat is accumulated in hepatocytes. It encompasses a spectrum of disease activity, rang-
ing from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH) and NASH 
cirrhosis, which may finally lead to a decreased liver function, liver failure, and hepato-
cellular carcinoma.1-3 NAFLD is considered the hepatic manifestation of the metabolic 
syndrome and its prevalence increases, especially in developed countries.1,4 NAFLD is 
frequently associated with dyslipidemia, obesity, and type 2 diabetes mellitus (T2DM), 
and has been associated with an increased risk of incident cardiovascular disease (CVD), 
independently of the components of the metabolic syndrome.1-3,5,6 The pathogenesis of 
NAFLD is not completely clear, but insulin resistance, hyperlipidemia and inflammation 
are considered to play a major role in NAFLD development.1,7,8
Sex hormone-binding globulin (SHBG) is a glycoprotein that is mostly produced in the 
liver.9 Serum SHBG binds to sex steroid hormones, regulates the serum concentration 
of these circulating hormones and their transport to target tissues. SHBG has a high 
binding affinity for testosterone and the serum concentrations of total testosterone and 
SHBG are strongly correlated.10-12 Previous studies have shown that low serum SHBG 
levels were associated with the metabolic syndrome, insulin resistance and T2DM, and 
the risk of incident CVD.13-16 Furthermore, low serum SHBG levels were associated with 
an increased prevalence of NAFLD in previous cross-sectional studies.17-20
Serum testosterone levels are also linked to obesity, insulin resistance, and the meta-
bolic syndrome15,16,21, and previous studies also suggested an association between serum 
testosterone levels and NAFLD.19,20,22-24 Whether serum SHBG levels contribute to the de-
velopment of NAFLD, and whether this effect is independent of testosterone, is unclear. 
Studies on this association were relatively small, were performed cross-sectionally, and 
further longitudinal research is needed before conclusions on the role of SHBG in the 
development of NAFLD can be drawn.
In this large prospective population-based cohort study, the aim was to investigate 
whether higher serum SHBG levels at baseline were associated with a lower risk of devel-
oping NAFLD during follow-up, independent of testosterone levels. Thereby, we aimed 





The current study was performed within the Rotterdam Study, a prospective population-
based cohort study that aims to study the frequency and determinants of diseases in the 
middle-aged and elderly people. The rationale and design of the Rotterdam Study have 
been described in detail previously.25,26 In short, all 10,275 persons aged 55 years and 
over in the Ommoord district of Rotterdam, the Netherlands, were invited to participate. 
Of them, 7,983 (response rate 78%) were enrolled between 1990 and 1993 (RS-1). At 
baseline, all participants were interviewed at home and underwent extensive clinical 
examination at the research center. Additional re-examinations took place in 1993-1995, 
1997-1999, 2002-2004, and 2009-2012. In 2000, an extended cohort was enrolled, when 
3011 inhabitants (response rate 67%) aged 55 years and over entered the study (RS-II). 
The Rotterdam Study has been approved by the medical ethics committee according 
to the Wet Bevolkingsonderzoek: ERGO (Population Screening Act: Rotterdam Study), 
executed by the Ministry of Health, Welfare and Sports of the Netherlands. All partici-
pants gave informed consent to participate in the study and to obtain information from 
treating physicians and pharmacy records, separately.
Study sample
We aimed to investigate whether serum SHBG levels could serve as an early biomarker 
for the development of NAFLD. Therefore, we created a longitudinal component and 
selected a population with a very low probability of steatosis at baseline (as measured 
by a Fatty Liver Index [FLI] of <6027), with a SHBG measurement available at baseline, 
and investigated whether these participants developed NAFLD after years of follow-up 
(Figure 1). In the Rotterdam Study data for calculation of the FLI were available from the 
third visit of the first cohort (RSI-3, March 1997 – December 1999) and first visit of the 
second cohort (RSII-1, February 2000 – December 2001) onwards. These visits constitute 
the baseline survey for the current study (Figure 1). The FLI is a noninvasive measure to 
predict hepatic steatosis and was calculated according to the formula by Bedogni et 
al.27, including triglycerides, body mass index (BMI), gamma-glutamyltransferase (GGT), 
and waist circumference. For every participant, a FLI at baseline was calculated. Accord-
ing to Bedogni et al., a FLI≥60 can be used to rule in hepatic steatosis, and a FLI<30 
can be used to rule out hepatic steatosis. In our previous study using Rotterdam Study 
data, we have validated the use of FLI to predict NAFLD as measured by ultrasound 
with an area under the receiver operating characteristic curve of 0.81, a sensitivity of 
92% and 64% and a specificity of 49% and 82% when using a cut-off of FLI >60 and <30, 
respectively.28 Hence, participants with a FLI<60 were included in the study population, 
to create a study population with a very low probability of having hepatic steatosis at 
SHBG as an early biomarker for NAFLD 205
baseline. In a second analysis, we selected only participants with no steatosis (FLI<30) 
at baseline.
Exposure assessment
The exposure of interest was serum SHBG level. At baseline of this study during the 
center visit (RSI-3, RSII-1), fasting blood samples were collected. Serum SHBG levels were 
measured using double antibody radioimmunoassays (Diagnostic Systems Laboratories, 
Inc., Webster, TX) and expressed in nmol/L.
outcome assessment
The outcome of interest was NAFLD, assessed by abdominal ultrasonography in all study 
participants. Abdominal ultrasonography was added to the core protocol at the fi fth 
survey of the fi rst cohort and the third survey of the second cohort of the Rotterdam 
Study (RS-I-5, February 2009 – January 2011; RS-II-3, February 2011 – February 2012) 
(Figure 1). Abdominal ultrasonography was performed by certifi ed and experienced 
ultrasonographists on a Hitachi HI VISION 900. Images were stored digitally and re-
figure 1 Overview of the assessment of the exposure and the outcome during follow-up of the Rotterdam 
Study
Abbreviations: RS, Rotterdam Study; SHBG, sex hormone-binding globulin; NAFLD, non-alcoholic fatty liver 
disease
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evaluated by a hepatologist with more than ten years experience in liver ultrasonogra-
phy. The diagnosis and grading of fatty liver was determined according to the protocol 
by Hamaguchi et al.29 Severity of fatty liver was classified as ‘no fatty liver’ (score 0-1), 
‘mild fatty liver’ (score 2-3), or ‘moderate to severe fatty liver’ (score 4-6). Individuals with 
any of the following possible secondary causes of fatty liver were excluded from the 
analyses: 1) current excessive (i.e. more than 14 drinks per week) alcohol consumption 
or a history of excessive alcohol consumption, 2) positive HBsAg or anti-HCV, and 3) use 
of pharmacological agents associated with fatty liver (i.e. amiodarone, corticosteroid, 
methotrexate, and tamoxifen).
Medication prescription data were obtained from all seven fully computerized phar-
macies in the Ommoord district. Information of all filled prescriptions from January 1st 
1991 until January 31st 2012 was available and included information of the product 
name of the drug, the Anatomical Therapeutical Chemical Code (ATC-code), the amount 
dispensed, the prescribed dosage regimen and the date of dispensing.30
Covariables
To control for confounding, we adjusted for the following baseline variables: age; sex; 
BMI; waist circumference; number of alcoholic drinks weekly; hypertension or use of 
blood pressure lowering drugs; diabetes mellitus; Insulin resistance, as assessed by the 
Homeostasis Model of Assessment – Insulin Resistance (HOMA-IR); history of CVD; use 
of statins; serum levels of total testosterone, estradiol, dehydroepiandrosterone sulfate 
(DHEAS), high-density lipoprotein (HDL)-cholesterol, and triglycerides. Furthermore, we 
adjusted for follow-up time, i.e. the time between the date of the SHBG measurement 
and the date of the abdominal ultrasonography.
Information on covariables was obtained by an interview at home, laboratory mea-
surements, and anthropometric assessments at the research center. The interview was 
designed to obtain data concerning demographics, medical history, co-morbid condi-
tions, smoking behaviour, physical activity, and alcohol consumption. Anthropometric 
measurements were performed by well-trained research assistants. Waist circumference 
was measured in centimeters. BMI was calculated as the weight (in kg) divided by height 
(in m2). The average of two blood pressure measurements, obtained at a single visit in 
sitting position after a minimum of 5 minutes rest, was used for analysis. A blood pres-
sure below 130/95 mmHg was defined as hypertension. The HOMA-IR was calculated 
as: fasting glucose (mmol/L) x fasting insulin (mU/L)/22.5.31 Blood lipids (HDL, total 
cholesterol, triglycerides), serum alanine aminotransferase (ALT), and GGT were mea-
sured using automatic enzymatic procedures (Roche Diagnostics GmbH, Mannheim, 
DE). Low-density lipoprotein (LDL)-cholesterol was calculated with the Friedewald 
formula, using total cholesterol, HDL-cholesterol and triglycerides (<4.5 mmol/L).32 
HbsAg and anti-HCV antibodies were measured by automatic immunoassay (Roche 
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Diagnostics GmbH, Mannheim, DE). Serum levels of total testosterone, estradiol, and 
DHEAS were measured using radioimmunoassays (Diagnostic Systems Laboratories, 
Inc., Webster, TX). Serum blood measurements were measured at the same date of 
serum SHBG measurement. CVD in history was defined as a myocardial infarction (MI), 
percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft-
ing (CABG), heart failure, carotid desobstruction, cerebrovascular accident (CVA), or 
transient ischemic attack (TIA) in the history.33-35 Diabetes mellitus developed before the 
date of liver ultrasonography was defined as a dispensing of ATC code A10, oral glucose 
lowering medication and insulin, at baseline. Use of blood pressure lowering medication 
was defined as a dispensing of ATC codes C02 (miscellaneous antihypertensives), C03 
(diuretics), C07 (β-blockers), C08 (calcium channel blockers) or C09 (rennin-angiotensin 
system modifying agents) at baseline. Use of statins was defined as a dispensing of ATC 
code C10AA or C10B at baseline.
Statistical analysis
Baseline characteristics of the study population were stratified by sex, because normal 
values for serum SHBG differ between men and women.
We used multivariable logistic regression models, with relative risks expressed as odds 
ratios (ORs), to investigate the association between serum SHBG levels and the risk of 
developing NAFLD (yes/no), and adjusted for all potential confounding covariables. 
All analyses were stratified by sex. SHBG levels were expressed in sex-specific standard 
deviations (SDs). We investigated the association between an increase in serum SHBG 
levels and the incidence of NAFLD during follow-up. This is a cumulative incidence over 
a mean follow-up period of 11 years under the assumption that participants have a very 
low probability of steatosis at baseline. The cumulative incidence was calculated as the 
number of NAFLD cases that occurred during follow-up divided by the number of par-
ticipants at risk at baseline. First, participants with a FLI<60 at baseline were investigated 
on the risk of NAFLD during follow-up. Subsequently, this association was investigated 
in an additional analysis in participants with a FLI<30 at baseline. In a sensitivity analysis, 
we excluded participants with mild steatosis on ultrasonography, since ultrasonogra-
phy is less sensitive for the detection of mild steatosis. We investigated the association 
between serum SHBG levels and ‘moderate to severe fatty liver’ vs no fatty liver, using 
multivariable logistic regression analyses.
All analyses were performed complete case, using SPSS software (SPSS Inc., version 
21.0, Chicago, Illinois, USA).
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rESUltS
In total, we identified 632 men and 1,132 women with a FLI<60 and a serum SHBG 
measurement at baseline, who underwent ultrasonography during follow-up. Baseline 
characteristics of the study population are shown in Table 1. Compared to women, men 
had a significantly lower BMI but higher waist circumference, more frequently a his-
tory of CVD, consumed more alcoholic drinks weekly, and used more frequently statins 
(P<0.05). Furthermore, men had a significantly lower total and HDL cholesterol levels, 
and higher serum levels of ALT and GGT, compared to women (P<0.05)
The mean follow-up time between the SHBG measurement at baseline and the NAFLD 
ultrasonography during follow-up was 11 years (minimum 9 years, maximum 15 years) 
(Figure 1). The incidence of NAFLD was 23.6% for men and 26.1% for women.
Serum SHBG levels at baseline were significantly lower in NAFLD patients than in non-
NAFLD patients, both for men (mean 44.0 [SD 15.3] vs mean 52.3 [SD 19.3] respectively, 
table 1 Baseline characteristics of the present study
Characteristic men (n = 632) women (n = 1132)
Age (mean, years) 65.6 (5.9) 65.2 (6.0)
Body mass index (mean±SD, kg/m2) 24.9 (2.1) 25.5 (3.0)
Waist circumference (mean±SD, cm) 91.9 (6.5) 84.6 (8.4)
Hypertension (n, %) 596 (94.3%) 1051 (92.8%)
Cardiovascular disease (n, %) 126 (19.9%) 109 (9.6%)
Diabetes Mellitus (n, %) 39 (6.1% 69 (6.0%)
HOMA-IR (mean±SD) 2.8 (2.1) 2.9 (3.0)
Alcohol consumption (drinks/week) 6.2 (6.2) 3.8 (4.6)
Use of statins (n, %) 141 (22.3%) 206 (18.2%)
Serum total cholesterol (mean±SD, mmol/L 5.0 (1.0) 5.7 (1.0)
Serum HDL cholesterol (mean±SD, mmol/L 1.4 (0.4) 1.7 (0.4)
Serum LDL cholesterol (mean±SD, mmol/L) 3.1 (0.9) 3.5 (1.0)
Serum triglycerides (mean±SD, mmol/L) 1.2 (0.5) 1.2 (0.6)
Serum ALT (mean±SD, mmol/L) 20.6 (0.4) 18.9 (10.3)
Serum GGT (mean±, mmol/L) 30.6 (29.0) 25.7 (26.4)
Serum fasting glucose (mean±SD, mmol/L) 5.7 (0.9) 5.6 (1.1)
Serum fasting insulin (mean±SD, pmol/L) 63.8 (54.1) 64.3 (34.9)
Serum total testosterone (mean±SD, nmol/L) 18.8 (5.7) 0.9 (1.1)
Serum estradiol (mean±SD, pmol/L) 105.9 (37.2) 49.5 (63.1)
Serum DHEAS (mean±SD, nmol/L) 3016.7 (1591.3) 1865.7 (1075.4)
Abbreviations: SD, standard deviation; HOMA-IR, Homeostasis Model of Assessment – Insulin Resistance; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; GGT, gamma-glutamyltransferase; DHEAS, dehydroepiandrosterone sulfate.
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P 1.3 × 10−7) and women (mean 57.5 [SD 28.4] vs mean 73.5 [SD 31.4] respectively, P 
3.0 × 10−15). Furthermore, in men, NAFLD patients had statistically significantly lower 
total testosterone levels at baseline than non-NAFLD patients.
Over a mean follow-up period of 11 years, 152 out of 632 men and 299 out of 1,132 
women at risk developed NAFLD, corresponding with a cumulative incidence of 24.1% 
and 26.4%, respectively. The results of the multivariable logistic regression analysis on 
the association between serum SHBG levels and the incidence of NAFLD are shown in 
Table 2. For men, the mean SHBG-level was 50.3 nmol/L (with sex-specific SD 18.7); for 
women, the mean SHBG level was 69.3 nmol/L (with sex-specific SD 31.4). Adjusted for 
all covariables, in participants with FLI<60 at baseline, higher SHBG levels were asso-
ciated with a lower incidence of NAFLD during follow-up. In men, per SD increase in 
serum SHBG levels the OR for NAFLD was 0.64 (95%CI 0.46; 0.89, P.008). In women, per 
SD increase in serum SHBG levels the OR for NAFLD was 0.78 (95%CI 0.64; 0.94, P.011).
In a second analysis, we selected 229 men and 642 women with a FLI<30 at baseline. 
In this population, for men the mean SHBG level was 55.5 nmol/L (sex-specific SD 19.7), 
and for women the mean SHBG level was 76.9 nmol/L (sex-specific SD 31.0). The results 
of the multivariable logistic regression analysis between SHBG levels and incidence of 
NAFLD in participants with a FLI<30 at baseline were similar to the results of the analy-
table 2 The relative risk of NAFLD per SD increase in serum SHBG levels – stratified by sex
mean ShbG level and sex-specific Sd mean (nmol/l) Sd n
within participants with fli<60 at baseline
Men 50.3 18.7 632
Women 69.3 31.4 1132
within participants with fli<30 at baseline
Men 55.5 19.7 227
Women 76.9 31.0 634
logistic regression analyses or (95% Ci)a beta (SE) P
within participants with fli<60 at baseline
Men 0.64 (0.46; 0.89) −0.45 (0.17) 0.008
Women 0.78 (0.64; 0.94) −0.25(0.10) 0.011
within participants with fli<30 at baseline
Men 0.59 (0.33; 1.07) −0.52 (0.23) 0.084
Women 0.81 (0.60; 1.07) −0.22 (0.15) 0.139
Abbreviations: NAFLD, non-alcoholic fatty liver disease; SD, standard deviation; SHBG, sex hormone-bind-
ing globulin; N, number of men/women; OR, odds ratio; CI, confidence interval; SE, standard error.
a Adjusted for: age; body mass index; waist circumference; number of alcoholic drinks weekly; hyperten-
sion; diabetes mellitus; HOMA-IR; history of cardiovascular disease; use of statins; serum levels of total tes-
tosterone, estradiol, dehydroepiandrosterone sulfate, high-density lipoprotein cholesterol, triglycerides; 
time between SHBG measurement and steatosis echo.
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ses in participants with FLI<60 at baseline, albeit not statistically significant anymore. 
In men, the OR for NAFLD was 0.59 (95%CI 0.33; 1.07, P.084), and in women the OR for 
NAFLD was 0.81 (95%CI 0.60; 1.07, P.139) (Table 2).
In a sensitivity analysis, we excluded participants with mild fatty liver at ultrasonog-
raphy, and investigated the association between serum SHBG levels and incidence of 
‘moderate to severe fatty liver’. In both men and women, the association between higher 
SHBG levels and a lower incidence of NAFLD remained present. In men with FLI<60, 
per SD increase in serum SHBG levels the OR was 0.70 (95%CI 0.50; 0.99, P.043), and in 
women with FLI<60, per SD increase in serum SHBG levels the OR was 0.72 (95% CI 0.58; 
0.90, P.004) (Results not shown).
diSCUSSion
In this population-based cohort study, we demonstrated that higher SHBG levels in a 

































































































figure 2 Differences in baseline values of SHBG and total testosterone between patients with and without 
NAFLD during follow-up
Abbreviations: SD, standard deviation; CI, confidence interval; SHBG, sex hormone-binding globulin; TT, 
total testosterone.
A: Baseline values in men; B: Baseline values in women.
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lower risk of developing NAFLD during follow-up. This association was present in both 
men and women and independent of serum levels of total testosterone.
Previous cross-sectional studies also showed an inverse association between serum 
SHBG levels and the presence of NAFLD. One study showed that serum SHBG levels were 
associated with a statistically significantly lower prevalence of biopsy-proven NAFLD 
in postmenopausal women, after adjustment for age, BMI and waist circumference.19 
Others showed that serum SHBG levels decreased with increasing fatty liver disease 
severity in type 2 diabetes patients, after adjustment for total testosterone and other 
confounding factors.17 Hua and colleagues showed that low serum SHBG levels were 
associated with NAFLD after adjustment for total testosterone and other covariables in 
patients with type 2 diabetes mellitus.18 Other studies also showed an inverse associa-
tion between serum SHBG levels and hepatic steatosis20 and amount of liver fat.36,37
A role of SHBG in the development of NAFLD has been discussed in literature. How-
ever, a convincing explanation has not been revealed yet, and possibly SHBG is not more 
than a biomarker for the development of NAFLD. The pathogenesis of NAFLD is cur-
rently not completely clarified, but insulin resistance, hyperlipidemia, and inflammation 
play a role. Insulin resistance leads to accumulation of fat in hepatocytes through both 
lipolysis and hyperinsulinemia.1,38 Hepatic lipogenesis and the accumulation of lipids in 
the hepatocytes, especially triglycerides, is essential for the development of NAFLD.1,7,8,39 
A previous study demonstrated that a decrease in liver fat, independent from a change 
in total body fat and visceral adiposity, was associated with an increase in SHBG levels 
during a lifestyle intervention37, and another study found an association between in-
creased intrahepatic fat and decreased SHBG levels.40 Furthermore, a study showed that 
monosaccharides (fructose, glucose) induced hepatic lipogenesis, and this subsequently 
reduced hepatic SHBG gene expression and SHBG production.41 Otherwise, insulin has 
shown to inhibit SHBG production in the liver in vivo and vitro.42,43 Insulin resistance with 
hyperinsulinemia is often present in conditions such as the metabolic syndrome, type 2 
diabetes mellitus, and obesity.1,8,44 Both hepatic lipogenesis and increased insulin levels 
could thus affect the hepatic SHBG production, and subsequently decrease serum SHBG 
levels. In line with this, in our study serum SHBG levels were negatively correlated with 
triglycerides levels, positively correlated with HDL cholesterol, and negatively correlated 
with fasting insulin and the HOMA-IR.
The association between serum SHBG levels and the presence of NAFLD has only 
been investigated in cross-sectional studies, but in this study type reverse causation 
cannot be excluded, and it is difficult to draw firm conclusions about temporal associa-
tions.17-19 In our analyses, we created a longitudinal component by only including those 
participants who had a FLI<60 at the moment of the baseline serum measurements. 
Abdominal ultrasonography for detection of NAFLD was performed 9-15 years after the 
serum measurement (Figure 1). This enabled us to study the effect longitudinally, since 
212 Chapter 5.1
there was a mean period of 11 years in which participants with initially a low probability 
of having steatosis based on the FLI (FLI<60, according to Bedogni et al.27) could develop 
steatosis on abdominal ultrasonography. Analyses in participants with FLI<30 at baseline 
showed similar estimates as for the association in participants with FLI<60, albeit non-
significantly probably due to low numbers. Our results suggest that a low SHBG level 
can be considered as an early biomarker for the development of NAFLD. Although no 
steatosis could be established according to the FLI, a measure which has shown to agree 
with steatosis detection with SteatoTest and abdominal ultrasound45, the serum levels of 
SHBG have already decreased significantly. The association between SHBG and NAFLD 
remained present after adjustment for testosterone, estradiol, and other hormones. This 
indicates that especially SHBG could serve as a biomarker for later NAFLD development. 
Furthermore, another advantage of the current study compared to other studies on this 
topic, is that we included 1764 participants in the analysis, while other studies on this 
topic were performed in smaller populations (40 to 279 participants).
However, also some potential biases and limitations in our study should be consid-
ered. The risk of information bias or selection bias is unlikely, since the Rotterdam Study 
is a population-based cohort study, in which data are collected prospectively without 
prior knowledge of the research hypothesis in this study. We adjusted for potential con-
founding factors which could interfere in the association between SHBG levels and the 
incidence of NAFLD, such as BMI and serum triglycerides levels. The change in these fac-
tors during follow-up was not significantly different for the participants that developed 
steatosis compared to those that did not develop steatosis. The diagnosis and severity of 
NAFLD was assessed by abdominal ultrasonography. Ultrasonography may be less sensi-
tive than more advanced imaging techniques such as CT/MRI, since ultrasonography is 
not appropriate for the detection of less than 30 percent steatosis. However, Hernaez 
et al.46 showed that ultrasonography is comparable with other imaging modalities in 
the detection of NAFLD with an acceptable sensitivity of 80-100%. Furthermore, in a 
sensitivity analysis in patients with moderate to severe fatty liver, the investigated asso-
ciation remained statistically significant present in both men and women. Unfortunately 
no pathology was available in this population-based study, and therefore we could not 
investigate the effect of serum SHBG levels on hepatic histology. Only one study on this 
topic was performed in 22 biopsy-proven NAFLD patients and demonstrated an inverse 
association between serum SHBG levels and biopsy-proven NAFLD.19
In conclusion, in this large prospective population-based cohort study, higher serum 
levels of SHBG were independently associated with a lower risk of developing NAFLD 
after more than ten years follow-up. This study demonstrates evidence that SHBG might 
be an early biomarker for the development of NAFLD, however, future longitudinal stud-
ies are needed to determine whether SHBG could indeed be used in clinical practice as 
a sensitive predictor of NAFLD.
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Worldwide, cardiovascular disease (CVD) is a public health challenge, and therefore 
a large focus is on prevention and better treatment of CVD.1-4 Cholesterol-lowering 
statins have proven to be beneficial in the primary and secondary prevention of CVD.5-7 
They have a broad spectrum of indications, ranging from hypercholesterolemia and 
other forms of dyslipidemia, to type 2 diabetes mellitus (T2DM), a history of a previous 
vascular event, and as a new potential indication inflammatory (rheumatic) diseases.5-9 
Meta-analyses on large clinical trials showed a risk reduction by statins of approximately 
25% on the occurrence of major cardiovascular endpoints in persons free from CVD 
(primary prevention)5-7, and a risk reduction of 20% on the occurrence of major cardio-
vascular endpoints in patients with a history of vascular disease.7 Therefore, statins have 
definitely entered daily clinical practice, and their use is expected to increase even more 
with a widening of therapeutic indications.10 However, current pharmacotherapy may 
not be optimal for all patients, and individuals may not respond adequately to statins. 
This ranges from a lack of therapeutic effect to the occurrence of adverse drug reac-
tions (ADRs), and can have several underlying reasons. Insight into why people do not 
respond adequately to statins might improve clinical practice, can partly avoid these 
events, and may finally lead to tailored drug therapy.11,12
This thesis contains several pharmaco-epidemiological studies investigating the 
use of statins in an ageing population. We investigated genetic variants that modified 
response to statins; considered unintended effects of the use statins in clinical practice; 
and investigated methodological aspects of studying drug effectiveness in observa-
tional studies. Last, in a separate study we investigated sex hormone-binding globulin 
(SHBG) levels as early biomarker for non-alcoholic fatty liver disease (NAFLD).
In this section, the main findings will be discussed and placed in a broader perspective. 
We will discuss methodological issues, the consequences of widespread use of statins 
in clinical practice, and the implementation of pharmacogenetics in clinical practice 
including recommendations for future research.
mAin findinGS
Genetic factors modifying statin response
Individual variation in drug response is an important clinical problem and is influenced 
by factors such as patient’s overall health status and prognosis (e.g. age, renal or he-
patic failure), severity of disease for which the drug is given, potential interaction of 
co-medication with the drug, quality of drug prescribing, patient’s compliance with 
prescribed therapy, and genetic profile.13
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In clinical practice, a treatment goal of statin therapy is to reduce serum low den-
sity lipoprotein (LDL)-cholesterol levels below a certain threshold, depending on the 
cardiovascular risk profile of a patient.14,15 Statins lower LDL-cholesterol with a mean 
reduction of 25-55%, but are also effective in lowering triglycerides (mean reduction 10-
30%) and modestly increase high-density lipoprotein (HDL)-cholesterol (mean increase 
5-15%).16-19 Two large meta-analyses of randomized controlled trials (RCTs) showed that 
per 1 mmol/L decrease in LDL-cholesterol, the average risk reduction in major cardio-
vascular events is just over 20%.7,20 In clinical practice, physicians may achieve the LDL 
treatment goal by monitoring serum cholesterol levels and adapting the daily dosage 
accordingly. Nevertheless, despite this dose titration, there is still a substantial number 
of patients who do not achieve their recommended goal, which can be explained by 
genetic variation.21,22
Genetic polymorphisms in protein coding regions of the DNA (exons) may change 
the amino acid sequence in a protein, resulting in decreased or increased activity of 
the protein, e.g. metabolizing enzymes, influx or efflux transporters. Genetic polymor-
phisms in non-coding regions of the DNA (introns) may change gene expression and 
transcription, resulting in higher or lower protein concentrations. The net result of these 
effects can be an increased or decreased drug effectiveness.23 For example, a genetic 
polymorphism may decrease the activity of an influx transporter that regulates the up-
take of a particular drug from the serum into a target organ. The decreased activity of 
the transporter increases the serum concentration of the drug. Since there is a direct 
relationship between serum concentration and the risk of developing ADRs, the net 
effect of the polymorphism is a combination of decreased activity in combination with 
an increased risk of ADRs.
In chapter 2, we investigated the influence of genetic variation on statin efficacy and ef-
fectiveness, i.e. on the cholesterol lowering response to statins, the risk of statin-induced 
ADRs, and the primary clinical outcome myocardial infarction (MI).
In three candidate gene studies we investigated whether genetic polymorphisms 
modified the cholesterol lowering response of statins, whereby we aimed to confirm pre-
vious plausible biological mechanisms. In chapter 2.1, we investigated genetic variation 
in genes involved in lipid metabolism. Because statins act on the cholesterol pathway, 
genetic variation in these genes is likely involved in the variability in cholesterol response 
to statins. In this candidate-gene approach, we created a hypothesis-free component by 
testing all polymorphisms in these genes, while most candidate-gene studies comprise 
only a few polymorphisms which are already described in relation to cholesterol and 
statin metabolism. Furthermore, the interaction between a polymorphism and choles-
terol response to statins should not be explained by an effect of the polymorphism on 
cholesterol levels itself. We showed that two polymorphisms were associated with a 
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smaller reduction in total cholesterol after start of statin therapy: rs1532624 in the cho-
lesteryl ester transfer protein (CETP) gene and rs533556 in the apolipoprotein A-I (APOA1) 
gene. Only the finding for the CETP polymorphism was replicated in an independent 
population. The CETP rs1532624 polymorphism was not described before in association 
with statin response. However, it was in linkage (R2 0.88) with the non-coding TaqIB poly-
morphism in the CETP gene, which is frequently described in relation with cholesterol 
response to statins.24-29 The non-replication of the finding for the APOA1 polymorphism 
could be explained by a false positive association in the discovery cohort, or fewer num-
bers (decreased power) in the replication cohort of 243 participants. However, in the 
meta-analysis of both cohorts the association for the APOA1 polymorphism remained 
significant. Further investigation of these polymorphisms in an independent population 
seems worthwhile, particularly on LDL-cholesterol, the primary target of statins, or to 
investigate delta cholesterol, the difference between serum cholesterol before and after 
start of statins. In our study, we had insufficient numbers to investigate these outcomes.
The cytochrome P450 (CYP) 3A4 enzyme is the main enzyme responsible for the 
metabolism of simvastatin, whereas there is also a minor contribution of CYP3A5. The 
CYP3A4 enzyme contributes to a lesser extent to the metabolism of atorvastatin, lovas-
tatin, and cerivastatin.30-33 Several functional polymorphisms in the CYP3A4 and CYP3A5 
enzymes have been described that influence their metabolizing activity, and changed 
the cholesterol response to statins. The CYP3A4*22 and CYP3A5*3 polymorphisms have 
been associated with a stronger cholesterol lowering response to statin therapy34-37, 
while the CYP3A4*1B polymorphism has been associated with a decreased cholesterol 
lowering response to statin therapy.38-41 A study by Klein and colleagues discovered 
novel genetic variation in the peroxisome proliferator-activated receptor alpha (PPARA) 
gene that influenced CYP3A4 enzyme expression and activity.42 The minor alleles of the 
strongly linked rs4253728 G>A and rs4823613 A>G polymorphisms were associated 
with significantly decreased CYP3A4 expression and activity in vitro and in vivo, and 
might therefore influence the pharmacokinetics of simvastatin. In the study described 
in chapter 2.2, we therefore hypothesized that the minor alleles of both polymorphisms 
were associated with a stronger cholesterol lowering response to simvastatin, since 
decreased metabolism of simvastatin would lead to an increased simvastatin concen-
tration, and thus to increased availability to exert its effect. Results indeed showed a 
stronger total and LDL-cholesterol lowering effect of simvastatin in minor allele carriers 
of the polymorphisms, and this effect was independent of the CYP3A4*22 and CYP3A5*3 
polymorphisms. We performed the first study that demonstrated this effect, and con-
firmed the previous finding by Klein and colleagues on a pharmacokinetic mechanism.42 
Their in vivo study was performed in atorvastatin users, and showed a decreased atorv-
astatin metabolism for homozygous minor allele carriers compared to major allele car-
riers. Although in our study we could not demonstrate an association in 29 atorvastatin 
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users, probably due to low power, an association could not be excluded. Atorvastatin 
undergoes less extensive metabolism by CYP3A4 than simvastatin, thus inhibition of 
CYP3A4 enzyme activity and expression by the PPARA polymorphisms affects serum 
atorvastatin concentration to a lesser extent.43,44
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase by statins 
leads to upregulation of LDL receptors in the hepatocytes, consequently an increased 
uptake of LDL-cholesterol and a decreased serum LDL concentration.45-47 Proprotein 
convertase subtilisin/kexin type 9 (PCSK9) binds to the LDL receptor and promotes its 
degradation, resulting in a decreased uptake of LDL and a higher serum LDL-cholesterol 
concentration.48-50 Statins have shown to increase PCSK9 concentrations, and thereby 
counteract their own mechanism of action.51-57 A recent genome-wide association study 
(GWAS) was the first to show genetic variation that modified statin-induced PCSK9 
concentrations. The minor allele of the rs13064411 polymorphism was significantly 
associated with increased simvastatin-induced PCSK9 concentrations.58 In chapter 
2.3, we therefore hypothesized that statin users carrying a minor allele would have 
increased LDL receptor degradation with consequently less uptake of LDL-cholesterol 
from the serum into the hepatocytes and a decreased cholesterol lowering response 
to statins. We confirmed this hypothesis and our study serves as a first replication in 
an independent population of the new GWAS finding. The rs13064411 polymorphism 
showed significant effect modification of the total and LDL-cholesterol lowering re-
sponse by statins, with minor allele carriers having a decreased response. This effect was 
stronger in women and in users of a high dose of statins. No association was found for 
HDL-cholesterol, which is in line with previous literature. Also, the polymorphism did 
not influence cholesterol levels in general in participants who had never used statins, 
which indicates that this polymorphism indeed modifies response to statin therapy. The 
dose-response effect, the consistent findings in the different type of statins separately, 
and confirmation in sensitivity analyses, makes it more plausible that the association is 
based on a true-positive finding. Nevertheless, replication of our findings is desirable, 
especially since previous studies show contradictory results on increased PCSK9 levels 
and increased51,53,54,56,58 or decreased59,60 statin efficacy on serum cholesterol levels. The 
research question would be even more specifically addressed, if we had serum PCSK9 
levels available in the Rotterdam Study, to directly link the polymorphism to PCSK9 
levels, and subsequently PCSK9 levels to statin response. However, this information was 
not available in our study.
In general, statins are well-tolerated and safe drugs, although ADRs do occur. The most 
common ADR is myopathy, which can vary from myalgia to life-threatening rhabdomy-
olysis.61 In chapter 2.4, we investigated whether the rs4149056 c.521T>C polymorphism 
in the solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene 
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modified the risk of developing statin-induced ADRs. In a GWAS, the minor allele of this 
polymorphism was associated with an increased risk of simvastatin-induced myopathy.62 
Patients carrying two minor alleles had a 16.9 times higher risk of myopathy compared 
to homozygous major allele carriers. The SLCO1B1 gene encodes a hepatic influx trans-
porter – organic anion transporting polypeptide 1B1 (OATP1B1) – that transports statins 
into hepatocytes.63 The SLCO1B1 rs4149056 minor allele is associated with an altered 
transporter function and increased serum statin concentration, with a subsequently 
increased risk of developing ADRs.63-68 In the Rotterdam Study, no data on myopathy 
was available, and we therefore considered the occurrence of either a dose decrease or 
a switch to another cholesterol lowering drug as an indicator of an ADR or a too strong 
reduction in cholesterol level. Within the Rotterdam Study, we confirmed the previous 
finding from the GWAS and thereby provided further evidence for the role of this poly-
morphism in adverse reactions to simvastatin. The association failed to replicate within 
the independent Utrecht Cardiovascular Pharmacogenetics (UCP) study, but remained 
present in a meta-analysis of both studies combined. For atorvastatin, we only found an 
association in users with a higher starting dose of more than 1.00 standardized defined 
daily doses. The question remains whether there is a class effect, or that the association 
is only present for simvastatin. A class effect is most likely, since the rs4149056 minor 
allele was associated with higher serum statin concentrations for all statins except for 
fluvastatin.69 Also, the minor allele was associated with atorvastatin concentration to a 
lesser extent than simvastatin concentration69, and other transporters may contribute 
to atorvastatin and not simvastatin uptake such as the OATP2B1 transporter.70 This 
makes atorvastatin a less important substrate for the OATP1B1 transporter, and might 
explain why we only found an association in high-dose atorvastatin users. Ideally, we 
had directly used myopathy or alternatively serum creatinine kinase (CK) measurements 
as outcome measure. However, this was not possible in the Rotterdam Study. Although 
our outcome measure was less precise, we were able to retrieve the reasons for dose 
decreases or switches in medical patient records from general practitioners. The major-
ity of the events were due to ADRs or too strong cholesterol lowering, and in a minority 
(5%) due to ineffective drug therapy. Besides lowering the dose or prescribing another 
cholesterol lowering drug, the statin may also be stopped once an ADR occurs. We 
explicitly did not choose discontinuation of treatment as an indicator of ADRs, since this 
is a heterogeneous outcome measure which could also relate to reasons such as non-
adherence (non-compliance) to therapy, or disappearance of the indication over time.
The risk of MI is indirectly influenced by statins via cholesterol lowering, but is also 
influenced by underlying diseases, such as hypertension and T2DM. The heterogeneity 
represented by the underlying mechanism of the outcome MI affects the probability of 
detecting a gene-statin treatment interaction, and requires more power than with an 
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intermediate endpoint.71 However, an advantage of considering a hard clinical endpoint 
as outcome is that it directly allows for evaluation of the effect of a polymorphism on 
statin effectiveness in reducing the risk, as opposed to a surrogate parameter such as 
LDL-cholesterol reduction. In chapter 2.5, we could not demonstrate significant effect 
modification by the CYP3A4*22 polymorphism on the effect of statins in reducing the risk 
of MI, neither in the independent UCP study and Rotterdam Study separately, nor in a 
meta-analysis of the two studies combined. The CYP3A4*22 polymorphism (rs35599367) 
has previously been associated with a stronger cholesterol lowering response to 
statins in two independent studies34,35, but its association with cardiovascular events 
was never investigated.72 Minor allele carriers had a 0.34 mmol/L stronger cholesterol 
lowering compared to homozygous major allele carriers, and stronger reductions in 
LDL-cholesterol correspond to further reductions in the incidence of cardiovascular 
events.20 A 1 mmol/L decrease in cholesterol leads to a 21-22% risk reduction in major 
cardiovascular events, and this translates to a 28% risk reduction in carriers of a minor 
allele.20 Therefore, this polymorphism seemed an interesting candidate to investigate 
on the outcome MI. One reason for not finding an association is that the effect on LDL-
cholesterol may be too small to affect clinical outcome while we had too low power to 
detect an association. Another potential reason is heterogeneity of the UCP study and 
Rotterdam Study. It could not be explained by titration of the statin dose below a certain 
LDL threshold since there were no differences between the genotypes in statin start and 
end dosages.
Besides these candidate studies, we also investigated the cholesterol lowering response 
to statins in a GWAS, a hypothesis-free approach without a priori thought of the underly-
ing genetic variation involved. The Genomic Investigation of Statin Therapy (GIST) con-
sortium is a collaboration in which both RCTs and observational studies participate, and 
aimed to discover genetic factors that modified the effect of statins on total, LDL- and 
HDL-cholesterol. The Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium was formed to facilitate GWAS meta-analyses and replication 
opportunities among multiple large and well-phenotyped longitudinal population-
based cohort studies.73 For the GIST-consortium analyses, the observational studies 
came mostly from the CHARGE consortium, one of which is the Rotterdam Study. In a 
pharmacogenetic meta-analysis of GWAS, described in chapter 2.6, including in total 
18,596 statin users (6 RCTs and 10 observational studies), genetic variation modifying 
the delta LDL-cholesterol lowering response to statins was investigated. The most prom-
ising signals were further validated in 22,318 statin users (2 RCTs and 1 observational 
study, the Rotterdam Study). Two loci at Sortilin 1 (SORT1)/Cadherin EGF LAG seven-pass 
G-type receptor 2 (CELSR2)/Proline-Serine-rich coiled-coil 1 (PSRC1) and SLCO1B1 were 
newly discovered. Furthermore, previously described associations with Apolipoprotein 
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E (APOE) and Lipoprotein, Lp(a) (LPA) were confirmed74,75, the only two loci that have 
nowadays consistently been identified to be associated with variation in LDL-cholesterol 
response to statins in both GWAS and candidate-gene studies.74-77 Genetic variation 
in SORT1 and APOE was associated with a stronger LDL-lowering response to statins, 
genetic variation in LPA and SLCO1B1 was associated with a decreased LDL-lowering 
response to statins, independent of baseline LDL-cholesterol. Additional functional and 
pathway analyses confirmed a strong biological and functional role in statin response 
for several strongly associated gene loci, including APOE/TOMM40/PVRL2 and SORT1/
CELSR2/PSRC2. In general, with this largest meta-analysis of GWAS on LDL-lowering 
response to statins conducted to date, we advanced the understanding of the pharma-
cogenetic architecture of statin response.
A connection between the candidate-gene study in chapter 2.4 and this GWAS in 
chapter 2.6 can be made. The SLCO1B1 rs2900478 polymorphism, which resulted from 
the meta-analysis of GWAS and was associated with a smaller reduction in LDL-choles-
terol, is in strong linkage disequilibrium with the rs4149056 polymorphism (R2 0.89), 
which is associated with an increased risk of statin-induced ADRs. The minor allele of 
rs4149056 was previously associated with increased serum statin concentrations63,64,66, 
and with a smaller LDL-cholesterol reduction in response to simvastatin in candidate 
gene studies.77,78 Thus, besides the conclusion that this polymorphism is associated 
with an increased risk of statin-induced ADRs due to increased statin serum concentra-
tions62,78,79, it is also associated with a decreased efficacy. The decreased uptake of statins 
into hepatocytes by the OATP1B1 uptake transporter is expected to result in decreased 
cholesterol lowering.62 An alternative explanation is that the increased number of ADRs 
in patients carrying a minor allele might lead to decreased statin adherence, and conse-
quently decreased measured efficacy on a population-based scale.
Unintended effects of the use of statins in clinical practice
Statins are frequently used in clinical practice, and with the increasing prevalence of 
chronic diseases such as CVD and T2DM, the number of patients using statins will in-
crease even more. Although, these drugs are prescribed because of their well-proven 
beneficial effect, one should not ignore potential ADRs that may occur. In chapter 3, we 
investigated unintended effects of the use of statins in daily practice. Possibly, statins 
have beneficial effects on diseases for which currently no therapeutic indication exists, 
or otherwise, have adverse effects that raise questions as to whether the risk-benefit 
balance is acceptable to allow the widespread use of these drugs in clinical practice.
In chapter 3.1, we investigated the association between statins and the prevalence of 
NAFLD. NAFLD, or hepatic steatosis, is considered as the hepatic manifestation of the 
metabolic syndrome, independently of the components of the metabolic syndrome. 
Also, CVD is the major cause of death in patients with NAFLD.80-83 NAFLD patients often 
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have dyslipidemia, and therefore these patients frequently have an indication for statin 
therapy. Given the association between NAFLD and CVD, these drugs may be beneficial 
in these patients. However, there is some concern as to whether statins are safe and ef-
fective in NAFLD, and whether they may exacerbate or worsen hepatic steatosis despite 
improvement in lipid profile.84-88 In the Rotterdam Study, we provided further evidence 
for the safe use of statins in NAFLD patients. We did not find an overall association 
between current and past use of statins and NAFLD prevalence. In patients with a body 
mass index (BMI) ≥27.5, current use of statins for more than two years was significantly 
associated with an approximately three times lower NAFLD prevalence. Our study adds 
further to the field since we performed the first study that distinguished between the 
effects of current and past use, and adjusted for statin dose. In contrast, other studies 
mostly obtained medication data by questionnaire, which gives no insight into duration 
of use and thereby leads to non-differential misclassification. Obesity is a strong and 
independent risk factor for NAFLD. We could not give a clear explanation for the finding 
in only patients with a high BMI but it seems plausible that in this high-risk group a 
beneficial effect is most clearly visible. The exact pathogenesis of NAFLD is currently not 
clarified. Insulin resistance, lipid abnormalities and chronic inflammation are considered 
to be central in the development of diseases related to obesity such as NAFLD and 
CVD.80,89,90 The accumulation of lipids, especially triglycerides, is essential for the devel-
opment of NAFLD.80 Statins might protect against NAFLD through their lipid-lowering 
effect, but also through their pleiotropic effect such as their anti-inflammatory and im-
munomodulatory effects.91 Since these factors are more explicit in obese individuals, a 
protective effect of statins may be more pronounced.
In chapter 3.2, we demonstrated a non-beneficial effect of statins, since current statin 
use was significantly associated with lower total and bioactive non-SHBG-bound testos-
terone levels in males. Testosterone is synthesized in the testes, and this process requires 
a continuous supply of cholesterol.92 Since statins decrease cholesterol levels, and 
cholesterol is a precursor of testosterone, statins may also decrease serum testosterone 
levels. This hypothesis was further based on theoretical mechanisms that statins lower 
testosterone levels by direct inhibition of HMG-CoA-reductase in the testis93, by lower-
ing the serum cholesterol level and thereby decrease cholesterol uptake by the testis, 
and by direct inhibition of other enzymes in the testosterone pathway.94 Our finding 
that statins significantly lowered total and non-SHBG-bound testosterone was further 
supported by the finding that the magnitude in decrease was directly proportional to 
the dosage of statin therapy. Overall, in current statin users the mean decrease in total 
and non-SHBG-bound testosterone was −1.18 and −0.35 nmol/L, respectively. A recent 
meta-analysis of 5 RCTs showed a mean decrease of −0.66 nmol/L in total testosterone 
level.95 One might question the clinical relevance of such a small decrease. Testosterone 
is biologically important for mood, libido, muscle strength, and protects against osteo-
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penia, however, poor correlation exists between testosterone level and symptoms.96 
Nevertheless, a modest average decrease in a population might hide a substantial 
decrease in a handful of individuals with stronger response, and in those with an already 
low testosterone level. Therefore, this association might be clinically meaningful on a 
population-based scale, since statins are increasingly recommended and consequently 
used in nowadays practice.
Estimating the effect of time-dependent statin use in observational studies
Unlike constant characteristics such as sex and genetic constitution, drug exposure is 
essentially a time-varying determinant. In observational studies, effect estimates may 
be biased in the presence of a time-dependent covariable which is simultaneously 1) a 
reason for prescribing or dose-changing (often termed ‘confounding by indication’97), 2) 
influenced by the drug treatment under study, and 3) a potential cause of the outcome of 
interest.98,99 In chapter 4, we investigated whether the use of a marginal structural model 
(MSM) to estimate the causal effect of time-dependent drug use in the presence of time-
varying confounders, produces different relative risk estimates from traditional Cox 
proportional hazard models with and without time-dependent covariables. Currently, 
there is limited experience with the application of the MSM method in observational 
studies with complete data on drug use during follow-up and a multitude of treatment 
determinants. In our study, we used observational data from the Rotterdam study and 
investigated the use of statins for the primary prevention of CVD. In the Cox models 
with time-dependent statin use, and with and without time-dependent covariables, we 
demonstrated a 31% and 32% risk reduction respectively in ever statin users on athero-
sclerotic CVD (composite endpoint of fatal and nonfatal MI, stroke, and atherosclerotic 
CVD death). This risk decreased to a 11% risk reduction with MSM, in which all observa-
tions were weighted by the inverse of the conditional probability of the observed status 
of statin use. Three main conclusions could be made on the basis of the results. First, we 
could not observe a large difference in effect estimates between the results from the Cox 
model with time-dependent covariables and the Cox model without time-dependent 
covariables. A possible explanation for this could be that the changes in cardiovascular 
risk factors and other potential confounders we evaluated do not materially relate to 
the probability of initiating statin treatment, i.e. for our particular research question no 
or only a limited degree of time-dependent confounding by indication may have been 
present. Second, we could not demonstrate important differences in risk estimates from 
the MSM compared to the traditional Cox proportional hazards models. This is similar to 
results from other MSM studies on statin effectiveness in observational studies100,101, and 
general literature about the application of MSMs.102,103 Last, we concluded that in our 
MSM analysis, we were not able to deal with all confounding factors, and there was still 
substantial unmeasured confounding by indication in the initial period after statin initia-
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tion which was not accounted for. Possibly, other factors may be of greater importance 
for statin prescription in everyday clinical practice, or the design and data of the Rot-
terdam Study provide insufficient information for an adequate MSM analysis. This topic 
on estimating drug effectiveness and time-dependent drug use in observational studies 
will be further discussed in the ‘Methodological considerations’ part of this discussion.
ShbG level as a biomarker for nAfld
SHBG is a glycoprotein which is mostly produced in the liver and regulates the serum 
concentration of sex steroid hormones. SHBG has a high binding affinity for testos-
terone, and the serum concentrations of total testosterone and SHBG are strongly 
correlated.104,105 Previous cross-sectional studies suggested an association between 
low serum SHBG levels and an increased NAFLD prevalence.106-109 In these studies, it is 
difficult to draw firm conclusions about temporal associations and reverse causation 
cannot be excluded. It is therefore unclear whether SHBG contributes to the develop-
ment of NAFLD. Also, studies showed an association between serum testosterone levels 
and NAFLD107,109-112, and it should be unraveled whether the association between SHBG 
and NAFLD is independent of testosterone. A potential role of SHBG in the development 
of NAFLD has been discussed, such as interference with hepatic lipogenesis and the 
influence of insulin resistance.113-116 However, a convincing explanation has not been 
revealed yet. In the Rotterdam Study, we created a longitudinal component by select-
ing a population with a very low probability of steatosis (defined as fatty liver index 
(FLI) <60) and a serum SHBG measurement available at baseline, and investigated 
whether these participants developed NAFLD over a mean follow-up time of 11 years. 
We demonstrated that higher SHBG levels at baseline were associated with a lower risk 
of developing NAFLD during follow-up, both in men and women and independent of 
serum total testosterone levels. Sensitivity analyses in participants with FLI <30 showed 
similar effect estimates and supported our findings. Our study provided evidence for 
the assumption that low SHBG level might be considered as an early biomarker for the 
development of NAFLD. Although steatosis could not be established yet according to 
the FLI, a measure which has shown to agree with steatosis detection with SteatoTest 
and abdominal ultrasound117, serum levels of SHBG have already decreased significantly. 
Future longitudinal studies should determine whether SHBG could indeed be used in 
clinical practice as a sensitive predictor of NAFLD.
widESPrEAd USE of StAtinS in CliniCAl PrACtiCE
Currently, CVD is the leading cause of death worldwide.1 The aging population and 
population growth will contribute to a further increase in the number of patients with 
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coronary heart disease (CHD).118 Furthermore, the increase in number of people with 
overweight due to food overconsumption will increase the prevalence of metabolic 
diseases such as T2DM and NAFLD, both diseases with CVD as important cause of death. 
Therefore, prevention of CVD is of utmost importance and could be achieved through 
lifestyle interventions or through pharmacotherapy with different classes of drugs, as 
described in the introduction of this thesis. Guidelines on primary prevention of CVD 
recommend clinicians to treat persons without established CVD, but with an increased 
global absolute risk of future CVD with lipid-lowering therapy.17,119-121 These recommen-
dations are based on large clinical trials that demonstrated an approximately 25% risk 
reduction on the occurrence of major cardiovascular endpoints (nonfatal MI, coronary 
death, stroke, coronary revascularization) and 14% risk reduction in all-cause mortal-
ity in persons free of CVD.5-7 In 2013, the US guidelines were substantially changed by 
lowering the cutoff for indication for statin treatment for primary prevention. While in 
the Adult Treatment Panel III (ATP-III) guidelines the threshold for statin therapy starts 
at a 20% risk of CHD, this recommendation was lowered to a 7.5% risk on hard athero-
sclerotic CVD in the new American College of Cardiology/American Heart Association 
(ACC/AHA) guidelines.119 A recent study showed that application of the new guidelines 
on participants of the Rotterdam Study would imply that in 96.4% of men and 65.8% 
of women treatment with statins is recommended, while in an additional 3.3% of men 
and 14.2% of women treatment should be considered.10 This would imply that in only 
a few men (0.3%, n = 6, of 1894 men in this study population) and in the minority of 
women (20.0%, n = 462, of 2315 women in this study population) no treatment with 
statins is needed.10 Strictly following the ACC/AHA guidelines would have a large impact 
on healthcare expenditure but also raise questions. Should statins be considered as 
the new wonder drugs, similar to what was initially said about the polypill strategy, a 
combination of drugs in one pill that should be prescribed to everyone aged 55 years 
and older to prevent CVD, which was published in 2003?122 Should statins be used as 
widespread as our water from the tap? Until we find an attractive new pharmacothera-
peutic panacea against the consequences of our increasingly luxurious way of life?
Nowadays, the benefits of statins on cholesterol lowering and CVD prevention are well-
established on the basis of large clinical trials with an average 22% risk reduction per 1 
mmol/L decrease in LDL-cholesterol.6,20 Epidemiological studies have shown a log-linear 
association between cholesterol concentration and CVD risk, with no flattening of the 
curve at lower serum cholesterol levels. It seems therefore attractive to decrease LDL-
cholesterol levels as much as possible. Clinical trials showed also benefit in patients 
with lower-than-average cholesterol levels, with a risk reduction proportional to the 
magnitude of the achieved cholesterol reduction, which seemed to be largely indepen-
dent of the starting cholesterol level.18,20,123 Consequently, the treatment threshold for 
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LDL-cholesterol was lowered over the years. Moreover, intensive treatment regimens 
with higher statin dosages of e.g. 80 mg simvastatin or atorvastatin also showed one 
fifth reduction in major vascular events123,124, and these higher dosages did not lead to 
a significant increase in non-vascular deaths.123-125 Additionally, a large meta-analysis of 
27 RCTs showed that LDL-cholesterol reduction with statins in individuals with a 5-year 
risk of major vascular disease of less than 10%, significantly and safely reduced the risk 
of major vascular events, both in those with and without a previous history of vascular 
disease.7 The proportional reduction was at least as big in the two lowest risk categories 
(<5% and ≥5-<10%, with RR 0.62 and 0.69 per 1 mmol/L decrease in LDL respectively) 
as in the higher risk categories (≥20%-<30% and ≥30%, with RR 0.81 and 0.79 per 1 
mmol/L decrease in LDL respectively). From an efficacy point of view, these findings 
seemed to justify the widespread use of statins in clinical practice for a broader indica-
tion. Nevertheless, one should be aware that a 20% risk reduction in people with an 
already low 5-years risk of CVD, does not add much benefit on the absolute risk of CVD, 
and in these people the number needed to treat to prevent one CVD event is high.126 In 
the meantime, therapy may lead to unintended adverse effects. Also, it is hardly known 
what individual reassuring thoughts about the benefits of life-long statin treatment 
will do to the ability of individuals to exert self-discipline regarding their daily fat and 
carbohydrate intake. A drug which is healthy in individuals can still be toxic to societal 
tenacity.127
Increased use of statins and more intensive treatment regimens raises concerns about 
the occurrence of ADRs. Although statins are generally recognized as well-tolerated and 
safe drugs, myopathy may occur, and in its severe form this may lead to life-threatening 
rhabdomyolysis.61,128 Intensive treatment regimens have not shown to increase myopa-
thy substantially129, except for simvastatin 80 mg daily.62 In this large SEARCH trial, the 
excessive number of myopathy cases with 80 mg simvastatin was four per 1000 per year 
in the first year of treatment, and decreased to one per 1000 per year thereafter. The 
latter is still ten times more common than the relatively low incidence of one per 10,000 
patients with 20-40 mg simvastatin daily. About a fifth developed rhabdomyolysis, and 
this number might even be higher in daily clinical practice since the trial participants 
were monitored thoroughly, which resulted in earlier detection and timely prevention 
of rhabdomyolysis.62 However, the myopathy cases were largely confined to minor allele 
carriers of the rs4149056 polymorphism in the SLCO1B1 gene, which was also associated 
with statin-induced ADRs in our study described in chapter 2.4. More than 60% of the 
myopathy cases in patients using 80 mg simvastatin could be attributed to the minor 
C allele, and in theory, this genetic variation could be detected before treatment initia-
tion. These minor allele carriers may be treated with newer, more potent statins (e.g. 
80 mg atorvastatin, 20-40 mg rosuvastatin, daily) or a combination of a standard dose 
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statin with another cholesterol lowering drug, without increasing the risk of myopathy 
substantially.
Moreover, statins have been associated with elevated liver enzymes, and studies sug-
gested that statins might induce hepatic injury and worsen hepatic steatosis. However, 
statins were rarely associated with acute or chronic liver failure or significant liver in-
jury.84-88 In February 2012, the Food and Drug Administration approved important safety 
label changes for statins to remove the need for routine periodic monitoring of liver 
enzymes in patients taking statins.130 Concerning hepatic steatosis, our study described 
in chapter 3.1 showed no overall association between use of statins and NAFLD preva-
lence, and longer duration of use was even associated with a lower NAFLD prevalence 
in patients with a high BMI. Studies with pathological data including liver biopsy and 
recent literature reviews showed a rather beneficial effect by showing a reduction in the 
extent of hepatic steatosis in statin users.131-136
Third, statins have been associated with an increased risk of new onset T2DM in meta-
analyses of RCTs137,138 and observational studies.139-141 The mechanism is currently not 
clarified, but a recent study discovered the interesting finding that this increase in risk is 
partly explained by inhibition of HMG-CoA reductase.142 As a consequence, this adverse 
effect of statins, inherent to their primary mechanism, seems to be partly unavoidable. 
Other mechanisms proposed were a detrimental effect on glucose mechanism via an 
effect of statins on the glucose-transporter 4143, an increase in insulin resistance144-146, or 
blocking of calcium channels in the β-cells of the pancreas and consequently reduced 
insulin secretion.147 Nevertheless, the increase in T2DM risk in statin users corresponded 
to only a slight increase in T2DM in absolute terms. It did not outweigh the reduction 
in major cardiovascular events, implying that clinical decision-making should not be 
changed for patients with an indication for statins for moderate to high CVD risk or 
existing CVD.138,148 However, it might question the use of statins at low CVD risk.
Furthermore, as described previously in literature and in our study in chapter 3.2, use of 
statins was associated with lower levels of both total and non-SHBG bound testosterone. 
Given the important biological role of testosterone, the increased use of statins, and the 
fact that this decrease might be substantial in individuals with stronger response or an 
already low testosterone, this might be clinically relevant.
Last, besides the risk-benefit balance, judgments about the appropriateness of the 
widespread use of statins, especially in patients at lower risk of major cardiovascular 
events, depends also on the cost-effectiveness.149
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mEthodoloGiCAl ConSidErAtionS
Study setting and design
The studies described in this thesis were all embedded in the prospective population-
based Rotterdam Study. The Rotterdam Study started in 1990 in the suburb Ommoord 
in Rotterdam, when 7,983 participants aged 55 years and older were enrolled in the 
first cohort (RS-I). In 2001, a second cohort started including 3,011 participants aged 55 
years and older (RS-II), and in 2006, a third cohort started including 3,932 participants 
aged 45 years and older. The overall response rate (number of enrolled participants 
divided by the number of invited eligible inhabitants) over the three cohorts was 72.0%. 
Detailed medication dispensing data is available on a daily basis through linkage with 
computerized pharmacies in the Ommoord suburb. Furthermore, the cohort is con-
tinuously monitored for major morbidity and mortality through linkage with general 
practitioner’s records. Detailed information on design, objectives and methods of the 
Rotterdam Study has been described before.150,151
The Rotterdam Study has several advantages. Detailed information and follow-up 
data is available on many covariables, which were measured with standardized meth-
ods and over a relatively long period of follow-up. The population-based character of 
the Rotterdam study reduces the risk of selection bias, and the only inclusion criteria 
besides residing in the Ommoord suburb is age. The prospective ascertainment of risk 
factors and outcome variables without prior knowledge of the aim of the research 
hypotheses of studies, minimizes information bias. The data from general practitioners 
are of great value since it contains detailed information on disease but, for example, 
also determinants of prescribing can be figured out. In our study described in chapter 
2.4 on the SLCO1B1 rs4149056 polymorphism and statin-induced ADRs, we used these 
general practitioners’ records to retrieve the reason for a dose decrease of statin therapy 
or switch to another cholesterol-lowering drug, since these events were considered as 
indicators of ADRs or too strong reductions in cholesterol level. By checking these re-
cords, we were able to validate our outcome measure. Moreover, the detailed pharmacy 
data on every day of follow-up enabled us to investigate the effects of dose and duration 
of use, and limited non-differential (random) misclassification of exposure. In addition, 
differential (non-random) misclassification is restricted through prospective gathering 
of complete drug dispensing data. In studies that assessed drug information at baseline 
on the basis of an interview or during repeated rounds of cross-sectional measuring, the 
risk of information bias is increased because so-called ‘recall bias’ may lead to differential 
misclassification and biased risk estimates. People with severe disease tend to have a 
better recall of drug exposure data than healthy controls.152 Although non-compliance 
with statin therapy could have occurred153, this would have led to random misclassifica-
tion and underestimation of the true effect.
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A potential limitation of the Rotterdam Study is that the cohort includes mostly white 
(99% Caucasian) individuals aged 45 years and older, which limits external validity. The 
generalizability of our findings to younger and non-Caucasian populations remains 
doubtful. With reference to our genetic studies, it has been suggested that at older age 
the effect of genetics is less important and other factors such as a change in body com-
position and organ function may contribute more to differences in drug response.154-156 
Also, genetic structure differs between races, e.g. the rs4253728 polymorphism de-
scribed in chapter 2.2 is not present in Chinese and Japanese populations. Moreover, in 
the Rotterdam Study, information on ADRs is not collected on a structural basis.
A frequently encountered problem in genetic studies is power, which depends on 
sample size, magnitude of the effect of the polymorphism on drug response, propor-
tion of cases exposed to the drug of interest, and the minor allele frequency (MAF) 
of a gene variant. To increase power and limit the risk of both false positive and false 
negative results, it is important to collaborate with researchers from other studies to 
increase sample size. The GWAS in chapter 2.6 was performed in 19 independent studies 
with in total over 40,000 statin users. However, in some of our candidate gene studies 
samples size may be limited. To prevent non-valid results, findings were validated in an 
independent population (2.1, 2.4, 2.5), or we confirmed previously well-characterized 
genetic findings/mechanisms from literature (2.2, 2.3, 2.4). Although, in two studies an 
association failed to replicate (2.1, 2.4), it remained present in a meta-analysis.
In chapter 2.1, we selected one – most significant – polymorphism per candidate gene. 
There can be multiple causal variants in a gene and the total variation explained by a 
locus may be underestimated. Although we found two polymorphisms in two different 
genes associated with statin response, this study would have been further strengthened 
if we had used a method described in chapter 2.6. A conditional analysis, starting with 
the top associated polymorphism across the whole genome, followed by a stepwise 
procedure in which one by one additional polymorphisms are selected, according to 
their conditional P-values, would allow the discovery of more polymorphisms at a locus.
Omission of blood samples for genetic data and difficulties with genotyping were 
completely random and not related to genotype status. Patient and prescribing physician 
are both unaware of the patient’s genetic profile. Also, the modified response to a drug 
caused by genetic variation in the pharmacokinetic and pharmacodynamic pathway of 
the drug is only present once a drug is administered to the body. Genetic variation at 
baseline will therefore be random. This can be referred to as Mendelian randomization, 
a method that enables to investigate causal effects in observational data in the presence 
of confounders, as long as first use of a drug is taken into consideration as switching 
between drugs with a similar indication can lead to confounding (by contra-indication). 
It assumes that the genotype is assigned randomly and population genotype distribu-
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tion is unrelated to confounders. The genotype acts as an instrument for the exposure 
of interest and only affects the outcome indirectly via its effect on the exposure.157,158 
In all our genetic studies, polymorphisms were in Hardy-Weinberg equilibrium, thus 
Mendelian randomization occurred and selection bias was therefore unlikely.
The studies described in chapter 2.2 and 2.3 could have been further strengthened 
with the use of expression data, since in both studies the hypothesis was based on a 
previous finding in literature between genetic variation and altered expression of an 
enzyme. Unfortunately, these data were not available in the Rotterdam Study.
Our outcome measure NAFLD in chapter 3.1 and 5.1 was assessed by ultrasonography, 
while the gold standard for NAFLD detection is liver biopsy. In the population-based 
Rotterdam Study, it would have been unethical to study participants with this invasive 
diagnostic technique, and therefore hepatic histology data were not available. More-
over, ultrasonography may be less sensitive to detect NAFLD than more advanced imag-
ing techniques such as CT/MRI, since ultrasonography is not appropriate for detection 
of less than 30 percent steatosis. However, in a previous study, ultrasonography was 
similar to other imaging modalities in NAFLD detection with an acceptable sensitivity of 
80-100%.159 Also, in both of our studies, exclusion of patients with mild steatosis did not 
affect the associations.
In two studies (chapter 2.2 and 2.3), we used laboratory measurements from the ’Star-
Medisch Diagnostic Centrum’ (Star-MDC), which performs all outpatients laboratory 
assessments for general practitioners in the Rotterdam Rijnmond area with a potential 
source population of more than 1 million inhabitants. Reasons for the laboratory mea-
surements requested by general practitioners for healthcare purposes may have dif-
fered between statin users and non-statin users, inducing a potential information bias. 
However, we used these measurements in genetic studies, and as prescribing physicians 
were not aware of the genotype status, this will not have influenced our results.
measuring drug effectiveness in observational studies
The efficacy of a drug is defined as how well the drug achieves its intended effect under 
optimal circumstances, often on a secondary endpoint such as serum cholesterol or 
blood pressure. The effectiveness of a drug is defined as how well the drug achieves its 
intended effect in a real-life setting, mostly on a primary endpoint such as stroke or car-
diovascular mortality. Often, a discrepancy exists between efficacy and effectiveness, and 
the drug does not perform as expected in everyday clinical practice. The efficacy of drugs 
is tested in double-blind RCTs, in which the randomization and blinding minimizes the 
risk of selection bias and confounding.160 However, the homogeneous characteristics of 
patients in these trials differ substantially from those of patients in a real-life setting.161-164 
Moreover, outside the controlled setting of trials, dose adjustments, non-compliance, and 
discontinuation frequently occur over time. Therefore, effectiveness research requires 
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observational studies, ideally in unselected populations, to reflect a more real-life setting 
and to enhance the generalizability of the results. Comparative effectiveness research 
(CER) is defined by the Institute of Medicine committee as ‘the generation and synthesis 
of evidence that compares the benefits and harms of alternative methods to prevent, 
diagnose, treat, and monitor a clinical condition, or improve the delivery of care. The 
purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make 
informed decisions that will improve health care at both the individual and population 
levels’.165 In short, it compares existing health care interventions with the question which 
treatment works best, for whom, and under what circumstances.
Increasingly, CER on drug utilization and clinical outcomes is performed in large 
health care databases, but besides above mentioned value and advantages, these 
observational studies are subject to bias and confounding. It is assumed that these 
databases contain accurate and complete information on drug use, clinical outcomes, 
and relevant covariables. As mentioned previously, drug exposure is essentially a time-
varying determinant. Observational studies with drug use available at baseline only, 
may lead to substantial differential and non-differential misclassification of exposure 
during follow-up, with as a consequence non-valid effect estimates. To reduce this mis-
classification, drug exposure should precisely be defined by dividing drug use during 
follow-up into mutually exclusive episodes of non-use, past use and current use per 
individual. Previously, a method was proposed based on a Cox model for the analysis 
of drug use as a time-dependent determinant.152 Unfortunately, effect estimates may 
be biased in the presence of time-varying confounding: some risk factors which change 
during follow-up may have been influenced by preceding drug use, and in the presence 
of a time-dependent risk factor for the event of interest which also predicts subsequent 
drug use. Both conditions will always be the case when a time-dependent co-variable is 
simultaneously 1) a reason for prescribing or dose-changing (often termed ‘confound-
ing by indication’97); 2) influenced by the drug treatment under study; and 3) a potential 
risk factor for the outcome of interest.98,99 For example, serum LDL-cholesterol is a 
time-varying confounder in the association between statins and MI risk. Confounding 
by indication arises from the fact that patients who are prescribed a certain drug have a 
different (mostly poorer) prognosis than people who are not prescribed that drug. The 
indication for the drug is a risk factor for the outcome under study, and the association 
between drug exposure and outcome is erroneously attributed to the drug, while in 
fact the underlying disease (indication for the drug) explains the association.166 Ways to 
deal with this in observational studies is to study the association in patients who receive 
different treatments for the same underlying disease status, or to adjust for the indica-
tion. However, such adjustment may remain insufficient in the presence of time-varying 
confounders that influence the drug under study.
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In its routine definition, a confounder is assumed to precede and to be independently 
associated with exposure, to be a risk factor for the outcome, and not to be a step in 
the causal pathway between exposure and outcome.166 In the case of time-varying con-
founding, the confounder is both associated with past and future exposure.98,99 Analyses 
with the presence of time-varying confounders are complex in several ways. First, since 
the time-varying confounder is affected by past exposure and independently predicts 
outcome, it acts as an intermediate for the effect of past exposure on the outcome. We 
would not want to adjust for intermediates when estimating the total effect, but other-
wise we have to adjust for the confounder because it may confound future exposure and 
outcome. Second, the time-varying confounder is affected by past exposure and other 
covariables that also predict outcome, then adjusting for this confounder may create 
selection bias99. In the example in chapter 4 with use of statins for primary prevention of 
CVD, several analytical methods can induce biased results: examining the unadjusted ef-
fect of baseline statin use; examining the unadjusted effect of time-updated statin use; 
controlling for baseline covariables; and controlling for time-dependent covariables. 
The unadjusted estimate of baseline statin use will be biased since statin users more fre-
quently have comorbidities associated with increased CVD risk. Therefore, they differ in 
baseline risk from non-statin users, and statins will be falsely associated with increased 
CVD risk. Furthermore, baseline statin use does not take into account changes in dose 
and duration of therapy over time. This is accounted for in the unadjusted time-updated 
statin use analysis, but still has the problem of differences in baseline risk. Controlling for 
baseline co-variables also gives biased effect estimates because it ignores the fact that 
covariables frequently change over time and may be influenced by statin therapy. Con-
trolling for the time-updated values of co-variables, such as serum cholesterol, will still 
give biased estimates of the effect of statins, since statins protect against CVD (mostly) 
by lowering serum cholesterol, and hereby we would control for an intermediate which 
is in the pathway between statins and CVD. Because the consequences of invalid findings 
can be substantial, adequate methods for statistical analysis need to be employed to 
estimate causal effects and overcome this time-varying confounding.167 Methods to deal 
with this are G-estimation of structural accelerated failure time modeling, G-estimation 
of structural cumulative failure time modeling, and inverse probability weighted estima-
tion of MSM.168 In MSM, which was used in chapter 4, all observations are assigned a 
weight based on the conditional probability of receiving observed treatment.169 This 
resembles the use of propensity scores, but differs in the sense that with propensity 
scores only the probability of being treated is used. To deal with confounding by indica-
tion, matching, stratification, or adjustment on propensity score is performed.170
As described in our study chapter 4, and in previous MSM studies, it remains difficult to 
deal completely with time-varying confounding and still substantial unmeasured con-
founding by indication remains present. Furthermore, a lack of difference between tradi-
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tional Cox proportional hazard models and MSM is described. In general, on theoretical 
grounds MSM is an elegant statistical technique to adjust for time-varying confounding 
by indication. However, the absence of knowledge about detailed confounder status 
on a daily basis may be a hurdle to the use of MSM in real-life population-based cohort 
studies. Even if drug use is registered on a daily basis, the absence of data on time-
dependent confounders, such as the precise prescription indication or other treatment 
considerations jeopardizes the calculation of the actual valid weights. Confounding by 
indication remains a hurdle in observational effectiveness research on preventive drugs 
with a multitude of prescription determinants.
CliniCAl imPlEmEntAtion And fUtUrE dirECtionS: PErSonAlizEd 
mEdiCinE
Genetic variation influencing statin response, and treatment response in general, has 
been investigated with different techniques. From the hypothesis-based candidate 
gene studies, hypothesis-generating GWAS, to more recently ‘next-generation sequenc-
ing’, such as whole-genome sequencing (investigates the complete DNA sequence) and 
exome sequencing (investigates the protein-coding regions of the genome).171-174 GWAS 
have succeeded in discovering common gene variants (MAF>~ 5 %), but with often 
very small effect sizes, weak correlations with neighbouring variants, and infrequently 
tracking of the causal variant. Whole-genome analyses are expected to increase the dis-
covery of causal variants and to unravel rare genetic variants with larger impact on drug 
response.175 Next-generation sequencing also considers other genetic variation besides 
single nucleotide polymorphisms, such as insertions, deletions and copy number varia-
tions. These are not well captured with a GWAS approach. To completely understand the 
genetic profile that predicts drug response, the field of pharmacogenetics bridges with 
the fields of epigenomics (investigates change in gene expression that occurs without 
a change in DNA sequence, such as DNA methylation), transcriptomics (investigates the 
expression levels of mRNA), proteomics (investigates the structure and function of the 
entire range of proteins expressed by a genome), and metabolomics (investigates the 
metabolites in a cell, tissue, organ, or organism).
Insight into underlying genetic variation that predicts treatment response has two main 
purposes. First, it generates insight into underlying biological mechanisms that facilitates 
the discovery and development of new targets for drug therapy. Genetic mutations in 
PCSK9 were discovered to influence cholesterol metabolism, and nowadays, large clinical 
trials from pharmaceutical companies investigate the effect of PCSK9 inhibitors as choles-
terol lowering drugs for monotherapy or in combination with statins.176-179 Second, drug 
response ranges from therapeutic effect to the risk of developing ADRs. Insight into the 
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genetic profile that predicts drug response may help to identify patients with inadequate 
response, may optimize drug effectiveness and safety, and may reduce the utilization and 
costs of daily health care. This may ultimately lead to clinical decision making based on 
patient’s genetic profile: ‘tailored pharmacotherapy’ or ‘personalized medicine’. However, 
the genetic studies described in this thesis, and pharmacogenetic findings in general, do 
not have direct clinical implications. Although many polymorphisms are already discov-
ered that modify drug response, the clinical application of pharmacogenetics is lagging 
behind. Nowadays in the Netherlands, pharmacogenetics-based (dose) recommenda-
tions are developed for only a few dozen of drugs.180 Several hurdles and future steps 
have to be taken before genotype-guided clinical decision making can be applied. The 
main reason for limited clinical implementation is lack of evidence that genetic testing 
leads to improvement in clinical outcomes. Genetic variation may lead to a decreased 
cholesterol response to statins, but the effect may be too small to be relevant. For ex-
ample, in chapter 2.2, minor allele carriers of two PPARA polymorphisms had a better 
cholesterol lowering response to statins. Although this is interesting, it will not directly 
lead to tailored pharmacotherapy. After all, even if patients with a minor allele have a 
stronger intended cholesterol lowering effect, the majority of patients with two major 
alleles will still keep their indication for statins. Nevertheless, homozygous major allele 
carriers might respond better with a higher dose – or with a PCSK9-inhibitor in future 
practice –, in which case pharmacogenetics might have clinical consequences. Moreover, 
response to drugs is not likely based on a single polymorphism or gene, but more likely 
relies on the combination of or interaction between several polymorphisms in different 
genes.181 Therefore, future research should focus on combinations of polymorphisms, e.g. 
by considering haplotypes (a combination of polymorphisms on a single chromatid that 
is inherited together), by performing pathway analyses, or by using a genetic risk score 
approach. If more loci are identified, a dosing algorithm based on the whole collection 
of polymorphisms influencing statin response may predict and improve statin effective-
ness. Third, discovered genetic associations failed to replicate or results are contradic-
tory.182 To avoid false-positive associations and to clarify current contradictions, findings 
should be replicated in independent populations. To achieve this, large meta-analyses 
of independent studies in a consortium, such as the CHARGE consortium, are needed. 
Future research should prioritize the search for and set up of adequate databases for 
genetic research. Fourth, although decreased over recent years, the costs of genetic test-
ing are still higher than simply routinely monitoring of patient’s blood (e.g. cholesterol 
levels for statin efficacy, CK levels for statin toxicity), and titrate the dose accordingly. 
Last, other factors influencing drug response, such as a decrease in liver and renal func-
tion and change in body composition with increasing age, may be of more importance 
in drug response and overrule the effect of pharmacogenetics. However, investigating 
genetic associations and their interaction with patient characteristics might be relevant.
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In the end, one might question whether genotyping for tailoring therapy will be 
broadly implemented in clinical practice. Possibly, it will be confined to a small selection 
of polymorphisms with large clinical consequences in selected groups of patients. Al-
though this might seem a somewhat negative appraisal, it does not mean that pharma-
cogenetic research is a waste of time, effort and resources. It provided us with important 
scientific insights into underlying biological mechanisms involved in drug metabolism 
and action. Hopefully, future findings will make it possible that each individual receives 
treatment based on his own genetic profile, and thereby increase treatment efficacy, 
reduce the risk of drug toxicity, and minimize costs of health care. However, before we 
reach that point, there is still a long way to go.
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Cardiovascular disease (CVD) is an important cause of morbidity and mortality world-
wide. The increasing incidence and prevalence of CVD constitutes a considerable dis-
ease burden and major health challenge for prevention and treatment. CVD frequently 
co-exists with other diseases such as type 2 diabetes mellitus (T2DM) and non-alcoholic 
fatty liver diseases (NAFLD), which are both strongly related to the metabolic syndrome. 
The 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors or statins are 
cholesterol-lowering drugs that are beneficial in the primary and secondary prevention 
of CVD. With an approximately 20-25% reduction of the risk of major cardiovascular 
endpoints, these drugs have definitely entered daily clinical practice, and their use is 
expected to increase even more with a widening of therapeutic indications. However, 
current pharmacotherapy may not be optimal for all patients, and some individuals may 
not respond adequately to statins. This inadequate response may consist of a lack of 
therapeutic effect or the occurrence of adverse drug reactions (ADRs), and can have 
several underlying reasons. Insight into why people do not respond adequately to 
statins might improve clinical practice, can partly avoid these events, and may finally 
lead to tailored drug therapy. Moreover, in 2013, the American guidelines on primary 
prevention of CVD lowered the threshold for the indication for statin treatment, and 
thereby widened the target population for these already frequently prescribed drugs. 
This might have implications for current clinical practice, since prescribers should not 
ignore the potential risk of overtreatment or unintended effects that may go with this 
increased use. 
Chapter 1 describes the current state of knowledge on the pharmacogenetics of 
response to cardiovascular drug therapy, written some years ago at the beginning of 
this PhD-project. Subsequently, in this thesis we focused on the pharmacogenetic epi-
demiology of statins in an ageing population. We describe genetic factors that modify 
the response to statins, whereby we discovered new genetic variation and validated 
previous findings from genome-wide research and other relevant literature on the phar-
macogenetics of statins. Furthermore, we describe unintended effects of the use of 
statins in clinical practice, and methodological approaches to estimate statin effective-
ness in observational studies.
All studies described in this thesis are embedded in the Rotterdam Study, a prospec-
tive population-based cohort study among 14,926 inhabitants of Ommoord, a suburb of 
Rotterdam, aged 45 years and older.
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Genetic factors modifying statin response
In chapter 2, we investigated genetic variation that modified the efficacy and effective-
ness of statins, and their risk of ADRs in clinical practice. We used the genome-wide 
association study (GWAS) approach to discover new genetic markers without a priori 
hypothesis of the underlying genetic variation, and the candidate gene approach to 
replicate genetic variation that has previously been associated with a modified statin 
response or occurred in a pathway that relates to statin pharmacokinetics. In three 
candidate gene studies, we investigated the influence of genetic polymorphisms on 
the cholesterol-lowering response to statins. In chapter 2.1, we investigated the role 
of genetic variation in genes involved in the cholesterol metabolism. We selected 
polymorphisms in these genes based on a hypothesis-free approach, and subsequently 
tested the most promising ones in a candidate gene analysis. We showed that two poly-
morphisms in two different genes, rs1532624 in the cholesteryl ester transfer protein 
(CETP) gene and rs533556 in the apolipoprotein A-I (APOA1) gene, were associated 
with a decreased cholesterol lowering response to statin therapy. The association for 
the CETP polymorphism was subsequently replicated in an independent population. 
Moreover, in chapter 2.2, we were the first study that demonstrated that two strongly 
linked polymorphisms in the peroxisome proliferator-activated receptor alpha (PPARA) 
gene, rs4253728 and rs4823613, were associated with a stronger cholesterol lowering 
response to statins. Thereby, we confirmed a pharmacokinetic mechanism which was 
previously discovered, namely that these two polymorphisms were associated with 
significantly decreased cytochrome P450 3A4 (CYP3A4) enzyme expression and activity. 
In chapter 2.3, we performed a first replication of a recent finding that the rs13064411 
polymorphism was associated with increased statin-induced serum proprotein conver-
tase subtilisin/kexin type 9 (PCSK9) concentrations, and cholesterol response to statins. 
PCSK9 binds to the low-density lipoprotein (LDL-) receptor, and subsequently promotes 
the receptor for degradation. We showed that the rs13064411 polymorphism was as-
sociated with a decreased cholesterol lowering response to statins, and this effect was 
stronger in women and in users of a high dose of statins.
In general, statins are safe and well-tolerated drugs, although a common ADR is my-
opathy, which can vary from myalgia to life-threatening rhabdomyolysis. In chapter 2.4, 
we confirmed the previously described association between the rs4149056 c.521T>C 
polymorphism in the solute carrier organic anion transporting polypeptide (SLCO1B1) 
gene and an increased risk of developing ADRs to statins. A previous GWAS showed that 
patients carrying two minor alleles had a 16.9 times higher risk of simvastatin-induced 
myopathy than patients carrying two major alleles. Within simvastatin users in the Rot-
terdam Study, we demonstrated that the rs4149056 polymorphism was associated with 
an increased risk of a dose decrease or switch to another cholesterol lowering drug, 
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as indicators for ADRs. For atorvastatin users, an association was found in users with a 
starting dose of more than 1.00 standardized defined daily doses.
The risk of myocardial infarction (MI) is indirectly influenced by statins via cholesterol 
lowering, but is also influenced by underlying diseases, such as hypertension and T2DM. 
The heterogeneity in causal risk factors for a hard clinical endpoint such as MI, may af-
fect the probability of detecting one specific gene-statin interaction and may therefore 
require more power than with an intermediate endpoint. The CYP3A4*22 polymorphism 
was previously associated with a stronger cholesterol lowering response to statins. 
Based on the magnitude of its effect on cholesterol, this polymorphism seemed a good 
candidate to investigate on the outcome MI. However, in chapter 2.5, we could not 
demonstrate significant effect modification by the CYP3A4*22 polymorphism on the 
effect of statins in reducing the risk of MI, neither in the independent UCP study and 
Rotterdam Study separately, nor in a meta-analysis of the two studies.
Besides candidate gene studies, in chapter 2.6 we investigated the LDL-cholesterol 
lowering response to statins in a GWAS, as part of the GIST consortium including more 
than 40,000 statin users in both randomized controlled trials and observational studies. 
In this large pharmacogenetic meta-analysis, two loci at Sortilin 1 (SORT1) and SLCO1B1 
were newly discovered to be associated with a stronger, and decreased LDL-cholesterol 
lowering response to statins, respectively. Furthermore, previously described associa-
tions with Apolipoprotein E (APOE) and Lipoprotein, Lp(a) (LPA) were confirmed, that 
showed a respectively stronger and decreased LDL-cholesterol lowering response.
Unintended effects of the use of statins in clinical practice
Statins are increasingly prescribed in clinical practice and although relatively safe, 
prescribers should not ignore potential ADRs that may occur. Chapter 3 investigated 
unintended effects of the use of statins in daily practice. Possibly, statins have beneficial 
effects on diseases for which currently no therapeutic indication exists. In chapter 
3.1, we did not find an overall association between current and past use of statins and 
NAFLD prevalence. In patients with a body mass index (BMI) ≥27.5, current use of statins 
for more than two years was significantly associated with an approximately three times 
lower NAFLD prevalence. With our study we provide further evidence for the safe use 
of statins in NAFLD patients. Since these patients frequently have dyslipidemia, and 
the major cause of death in NAFLD patients is CVD, statins may be beneficial. On the 
other hand, statins might have adverse effects that raise questions as to whether the 
risk-benefit balance is acceptable to allow the widespread use of these drugs in clinical 
practice. In chapter 3.2 we demonstrated a non-beneficial effect of statins. Current use 
of statins was associated with lower total and (bioactive) non-sex hormone-binding 
globulin (SHBG)-bound testosterone levels in males. Statins decrease cholesterol pro-
duction, and cholesterol is a precursor in the testosterone biosynthesis pathway. This 
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association should be further investigated but might be clinically relevant, given the 
important biological role of testosterone, the increased use of statins, and the fact that a 
modest average decrease in a population might hide a substantial decrease in a handful 
of individuals and in those with an already low testosterone level.
Estimating the effect of time-dependent statin use in observational studies
Drug exposure is essentially a time-varying determinant. In observational studies, effect 
estimates may be biased in the presence of a time-dependent co-variable which is si-
multaneously 1) a reason for prescribing or dose-changing (often termed ‘confounding 
by indication’), 2) influenced by the drug under study, and 3) a potential cause of the 
outcome of interest. A method to deal with this time-varying confounding is marginal 
structural modeling (MSM), in which all observations are assigned a weight based on the 
conditional probability of receiving the observed treatment. In chapter 4, we compared 
MSM and traditional Cox proportional hazard models with and without time-dependent 
covariables using empirical data on time-varying statin use in the primary prevention 
of CVD. First, we could not observe a large difference in effect estimates between the 
results from the Cox models with and without time-dependent covariables. Second, we 
could not demonstrate important differences in risk estimates from MSM compared to 
the Cox models. Last, in our MSM, there was still substantial unmeasured confounding 
by indication in the initial period after statin initiation which was not accounted for. 
In general, although on theoretical grounds MSM is an elegant technique, lack of data 
on the precise time-dependent confounders, such as indication of treatment or other 
considerations of the prescribing physician jeopardizes the calculation of valid weights. 
Confounding remains a hurdle in observational effectiveness research on preventive 
drugs with a multitude of prescription determinants.
ShbG level as a biomarker for nAfld
In chapter 5, we provided evidence for the assumption that a low serum SHBG level 
might be considered as an early biomarker for the development of NAFLD. In addition 
to previous cross-sectional studies, we created a longitudinal component by selecting at 
baseline a population with a very low probability of steatosis (defined as fatty liver index 
<60) and a serum SHBG measurement available, and investigated whether these partici-
pants developed NAFLD over a mean follow-up time of 11 years. We demonstrated that 
higher SHBG levels at baseline were associated with a lower risk of developing NAFLD 
during follow-up.
Conclusions
Finally, in chapter 6 we discussed the main findings of this thesis and placed them in 
a broader perspective. We discussed methodological issues, speculated about the con-
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sequences of widespread use of statins in clinical practice, and the implementation of 
pharmacogenetics in daily practice.
Overall, in this thesis we have provided more insight into the use of statins in an ageing 
population. Statins are expected to be used even more frequently in clinical practice, i.e. 
through widening of the indication for statins, the aging population and the increasing 
prevalence of welfare diseases associated with dyslipidemia and an increased CVD risk. 
Future research should investigate the consequences of this increased use for daily clini-
cal practice. Hopefully, there will be a future role for genotype-based clinical decision 





Hart- en vaartziekten (HVZ) zijn een belangrijke oorzaak van ziekte en sterfte wereldwijd. 
De toename in de incidentie en prevalentie van HVZ is een groot gezondheidsprobleem 
en vormt een grote uitdaging voor preventie en behandeling. HVZ gaan vaak samen 
met andere ziekten zoals type 2 diabetes mellitus (T2DM) en niet-alcoholische lever-
vervetting, twee aandoeningen die beide sterk geassocieerd zijn met het metabool 
syndroom.
De 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase remmers, oftewel statines, 
zijn cholesterol-verlagende geneesmiddelen, die werkzaam zijn in de primaire en secun-
daire preventie van HVZ. Met circa 20 tot 25 procent afname in het risico op belangrijke 
cardiovasculaire eindpunten zijn deze geneesmiddelen niet meer weg te denken uit de 
huidige klinische praktijk. Er wordt verwacht dat het gebruik van statines alleen maar 
verder toe zal nemen, met een uitbreiding van therapeutische indicaties, zoals inflam-
matoire reumatische ziekten. Echter, in de klinische praktijk reageert niet iedere patiënt 
optimaal op statines, haalt bijvoorbeeld het beoogde therapiedoel niet of krijgt vaker 
bijwerkingen op statines. Dit kan verschillende oorzaken hebben. Inzicht in de vraag 
waarom mensen niet adequaat op statines reageren, kan de klinische praktijk verbete-
ren en het optreden van verminderde effectiviteit en bijwerkingen deels vermijden. Dit 
kan uiteindelijk leiden tot het voorschrijven van geneesmiddelen afgestemd op de in-
dividuele patiënt of bepaalde patiëntengroepen, zogenaamde ‘personalized medicine’. 
Daarnaast is in de Amerikaanse richtlijnen voor primaire preventie van HVZ in 2013 de 
drempel voor het instellen van een behandeling met statines verlaagd, en daarbij de 
populatie vergroot, die in aanmerking komt voor deze reeds frequent voorgeschreven 
medicijnen. Dit heeft implicaties voor de huidige klinische praktijk. Voorschrijvers 
mogen niet het potentiële risico op overbehandeling of andere onbedoelde effecten 
negeren dat kan samengaan met deze toename in gebruik.
hoofdstuk 1 beschrijft de huidige kennis over de farmacogenetica van verschillende 
cardiovasculaire geneesmiddelen. Dit is een aantal jaren geleden geschreven aan het 
begin van het PhD-project. Vervolgens richtte het proefschrift zich op de farmacoge-
netische epidemiologie van statines in een ouder wordende populatie. We beschrijven 
genetische factoren die de reactie op statines beïnvloeden, waarbij we nieuwe gene-
tische variatie ontdekten en eerdere bevindingen van genoombreed onderzoek en 
andere relevante literatuur over de farmacogenetica van statines valideerden. Verder 
beschrijven we in dit proefschrift onbedoelde effecten van het gebruik van statines in 
de klinische praktijk, en behandelen we methodologische benaderingen om effectiviteit 
van statines in observationele studies te onderzoeken.
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Alle studies beschreven in dit proefschrift zijn uitgevoerd binnen het Erasmus Rot-
terdam Gezondheid Onderzoek (Rotterdam Study), een prospectief observationeel 
bevolkingsonderzoek onder 14,926 inwoners van Ommoord, een deelgemeente van 
Rotterdam, in de leeftijd van 45 jaar en ouder.
Genetische factoren die de respons op statines beïnvloeden
In hoofdstuk 2 onderzochten we genetische variatie die de werkzaamheid en doelma-
tigheid van statines, en het risico op bijwerkingen in de klinische praktijk beïnvloeden. 
Met gebruik van genoombrede associatiestudies (GWAS) wilden we nieuwe genetische 
markers ontdekken zonder een a priori hypothese over de onderliggende genetische 
variatie. Met behulp van de kandidaatgen benadering wilden we genetische variatie 
repliceren, die eerder geassocieerd was met een veranderde respons op statines of die 
zich in een ‘pathway’ bevindt die een rol speelt in de farmacokinetiek van statines. In 
drie kandidaatgen studies onderzochten we de invloed van genetische polymorfismen 
op de cholesterolverlagende respons van statines. In hoofdstuk 2.1 onderzochten we 
de rol van genetische variatie in genen die betrokken zijn bij het cholesterol metabo-
lisme. We selecteerden polymorfismen in deze genen gebaseerd op een hypothese-
vrije benadering, en testten vervolgens de meest belovende polymorfismen in een 
kandidaatgen analyse. We toonden aan dat twee polymorfismen in twee verschillende 
genen, rs1532624 in het cholesterol ester transfer protein (CETP) gen en rs533556 in 
het apolipoprotein A-I (APOA1) gen, waren geassocieerd met een verminderde choles-
terolverlagende reactie op statines. We repliceerden de associatie voor het CETP poly-
morfisme vervolgens in een onafhankelijke populatie. Verder geven we in hoofdstuk 
2.2 de eerste studie weer, die aantoonde dat twee sterk gelinkte polymorfismen in het 
peroxisome proliferator-activated receptor alpha (PPARA) gen, rs4253728 en rs4823613, 
waren geassocieerd met een sterker cholesterolverlagend effect van statines. Daarbij 
bevestigden we een farmacokinetisch mechanisme dat eerder was ontdekt, namelijk dat 
deze twee polymorfismen waren geassocieerd met significant verlaagde cytochroom 
P450 3A4 (CYP3A4) enzym expressie en activiteit. In hoofdstuk 2.3 repliceerden we als 
eerste de resultaten uit een recente studie, namelijk dat het rs13064411 polymorfisme 
was geassocieerd met toegenomen statine-geïnduceerde serum proprotein convertase 
subtilisin/kexin type 9 (PCSK9) concentraties, en cholesterolrespons op statines. PCSK9 
bindt de low-density lipoprotein (LDL) receptor, en bevordert vervolgens de afbraak van 
de receptor. We toonden aan dat het rs13064411 polymorfisme was geassocieerd met 
een afgenomen cholesterolrespons op statines, en dit effect was sterker bij vrouwen en 
bij gebruikers van een hogere dosis statines.
Over het algemeen zijn statines veilige geneesmiddelen die goed worden verdragen, 
hoewel myopathie een veel voorkomende bijwerking is. Myopathie kan variëren van 
spierpijn (myalgie) tot rhabdomyolyse, een levensbedreigende overmatige afbraak 
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van spierweefsel. In hoofdstuk 2.4 bevestigden we de eerder beschreven associatie 
tussen het rs4149056 c.521T>C polymorfisme in het solute carrier organic transporting 
polypeptide (SLCO1B1) gen en een toegenomen risico op bijwerkingen van statines. Een 
eerdere GWAS toonde aan dat patiënten met twee minor allelen (de variant, het minst 
voorkomende allel in de populatie) een 16.9 maal hoger risico hadden op simvastatine-
geïnduceerde myopathie dan patiënten met twee major allelen. Bij gebruikers van sim-
vastatine in de Rotterdam Study toonden we aan dat het rs4149056 polymorfisme was 
geassocieerd met een toegenomen risico op een dosis verlaging of het switchen naar 
een ander cholesterolverlagend geneesmiddel, als indicatoren voor een bijwerking. Bij 
gebruikers van atorvastatine vonden we een toegenomen risico bij gebruikers van een 
hoge startdosering.
Het risico op een myocard infarct (MI) wordt indirect beïnvloed door statines via het 
verlagen van cholesterol maar wordt ook beïnvloed door onderliggende ziekten zoals 
hypertensie en T2DM. De heterogeniteit in causale risicofactoren in het geval van een 
harde klinische uitkomst zoals MI kan de kans op het detecteren van een specifieke 
gen-statine interactie beïnvloeden, en kan daardoor meer power vereisen dan in het 
geval van een tussenliggend eindpunt zoals cholesterol. Het CYP3A4*22 polymorfisme 
was eerder geassocieerd met een sterkere cholesterolverlagende reactie op statines. 
Gezien de grootte van het effect van het polymorfisme op cholesterolconcentraties, 
leek dit polymorfisme een geschikte kandidaat om te onderzoeken op de uitkomstmaat 
MI. Echter, in hoofdstuk 2.5 konden we geen significante effect modificatie door het 
CYP3A4*22 polymorfisme aantonen van statines op het risico op MI, noch in de UCP 
study en Rotterdam Study apart, noch in een meta-analyse van de twee studies samen.
Naast kandidaatgen studies, onderzochten we in hoofdstuk 2.6 de cholesterolverla-
gende respons op statines in een GWAS, als onderdeel van het GIST consortium dat meer 
dan 40,000 statinegebruikers omvat in zowel gerandomiseerde gecontroleerde studies 
als in observationele studies. In deze grote farmacogenetische meta-analyse werden 
twee loci op Sortilin 1 (SORT1) en SLCO1B1 ontdekt die waren geassocieerd met een 
sterkere en verminderde LDL-cholesterolverlagende respons op statines. Verder werden 
eerder beschreven associaties met Apolipoprotein E (APOE) en Lipoprotein, Lp(a) (LPA) 
bevestigd, die een respectievelijk sterkere en verminderde LDL-cholesterolverlagende 
respons vertoonden.
onbedoelde effecten van het gebruik van statines in de klinische praktijk
Statines worden steeds meer voorgeschreven in de klinische praktijk en hoewel deze 
geneesmiddelen relatief veilig zijn, mogen voorschrijvers niet het potentiële risico op 
bijwerkingen negeren. In hoofdstuk 3 onderzochten we onbedoelde effecten van 
het gebruik van statines in de dagelijkse praktijk. Mogelijk hebben statines gunstige 
effecten op ziektes waarvoor op dit moment geen therapeutische indicatie bestaat. 
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In hoofdstuk 3.1 vonden we geen associatie tussen huidig gebruik van statines en 
de prevalentie van non-alcoholische leververvetting. Ook bleek er geen associatie te 
zijn tussen gebruik van statines in het verleden en non-alcoholische leververvetting. In 
patiënten met een body mass index (BMI) ≥27.5 was huidig gebruik van statines voor 
een periode van meer dan twee jaar geassocieerd met significante, ongeveer drie maal 
lagere prevalentie van non-alcoholische leververvetting. Met onze studie leveren we 
verder bewijs voor het veilige gebruik van statines in patiënten met non-alcoholische 
leververvetting. Aangezien deze patiënten frequent dyslipidemie hebben, en de be-
langrijkste doodsoorzaak in deze patiënten HVZ is, kan het gebruik van statines gunstig 
zijn. Aan de andere kant kunnen statines bijwerkingen veroorzaken, hetgeen altijd de 
vraag moet oproepen of de balans werkzaamheid/schadelijkheid het wijdverspreide 
gebruik van deze geneesmiddelen in de klinische praktijk rechtvaardigt. In hoofdstuk 
3.2 toonden we een ongunstig effect van statines aan. Huidig gebruik van statines was 
geassocieerd met lagere totaal en (bioactief ) niet-gebonden testosteronconcentraties 
bij mannen. Statines verlagen de cholesterolproductie, en cholesterol is een voorloper in 
de testosteron biosynthese ‘pathway’. Deze associatie moet verder worden onderzocht 
maar kan klinisch relevant zijn, gezien de belangrijke biologische rol van testosteron, 
het toegenomen gebruik van statines, en het feit dat een relatief kleine daling op po-
pulatieniveau een substantiële daling kan maskeren bij een handvol individuen en bij 
diegenen met een al lage testosteronspiegel.
het schatten van het effect van tijdsafhankelijk statinegebruik in observationele 
studies
Blootstelling aan geneesmiddelen is in principe een over de tijd variërende determi-
nant. In observationele studies kan er vertekening (bias) zijn van effectschattingen 
indien er een tijdsafhankelijke covariabele aanwezig is die gelijktijdig 1) een reden is 
voor voorschrijven of een verandering in dosering (vaak ‘confounding by indication’ 
genoemd), 2) wordt beïnvloed door het geneesmiddel dat bestudeerd wordt, 3) een 
onafhankelijke oorzaak kan zijn van de uitkomst van de studie. Een methode om met 
deze tijdsafhankelijke confounding om te gaan is ‘marginal structural modeling (MSM)’, 
waarbij alle observaties een gewicht toegewezen krijgen gebaseerd op de conditionele 
kans op het krijgen van de geobserveerde behandeling. In hoofdstuk 5 vergeleken we 
MSM en traditionele Cox proportionele hazard modellen met en zonder tijdsafhanke-
lijke covariabelen, met gebruik van empirische data over tijdsafhankelijk statinegebruik 
voor de primaire preventie van HVZ. Allereerst konden we geen groot verschil aantonen 
in effectschattingen tussen de resultaten van de Cox modellen met en zonder tijdsaf-
hankelijke covariabelen. Ten tweede konden we geen belangrijke verschillen aantonen 
in risicoschattingen van MSM vergeleken met de Cox modellen. Als laatste, bij de MSM 
methode was er nog steeds substantiële niet-gemeten ‘confounding by indication’ in 
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de eerste periode na het starten van een statine, waar geen rekening mee kon worden 
gehouden. In het algemeen kan geconcludeerd worden dat, hoewel op theoretische 
gronden MSM een elegante techniek is, gebrek aan data over de precieze tijdsafhan-
kelijke confounders, zoals de indicatie voor behandeling of andere overwegingen van 
de voorschrijvende arts, een obstakel vormt bij het berekenen van valide gewichten. 
Confounding blijft een lastig probleem bij observationeel doelmatigheidsonderzoek 
naar preventieve medicijnen met een veelvoud aan determinanten van voorschrijven.
ShbG als een biomarker voor nAfld
In hoofdstuk 5 leveren we bewijs voor de hypothese dat een lage serumwaarde van 
‘Sex Hormone-Binding Globulin’ (SHBG) kan worden overwogen als een vroege bio-
marker voor het ontwikkelen van NAFLD. In aanvulling op eerdere cross-sectionele 
studies creëerden we een longitudinale component door op baseline een populatie te 
selecteren met een erg lage kans op steatose (gedefineerd als een ‘fatty liver index’ <60) 
die een serum SHBG meting beschikbaar had. We onderzochten of deze deelnemers 
non-alcoholische leververvetting ontwikkelden over een gemiddelde follow-up periode 
van 11 jaar. We toonden aan dat hogere SHBG concentraties op baseline waren geas-
socieerd met een lager risico op het ontwikkelen van non-alcoholische leververvetting 
gedurende follow-up.
Conclusies
Als laatste bediscussieerden we in hoofdstuk 6 de belangrijkste bevindingen van 
dit proefschrift en plaatsten we deze in een breder perspectief. We bediscussieerden 
methodologische aspecten, speculeerden over de consequenties van het wijdverspreid 
gebruik van statines in de klinische praktijk, en de implementatie van farmacogenetica 
in de dagelijkse praktijk.
Concluderend, in dit proefschrift leverden we meer inzicht in het gebruik van statines 
in een ouder wordende populatie. Er wordt verwacht dat het gebruik van statines in de 
klinische praktijk alleen maar verder zal toenemen, onder andere door het verbreden 
van de indicatie voor statines, de vergrijzende populatie en de toename in prevalentie 
van welvaartsziekten die geassocieerd zijn met dyslipidemie en een toegenomen risico 
op HVZ. Toekomstig onderzoek moet de gevolgen voor de klinische praktijk van deze 
toename in gebruik onderzoeken. Mogelijk is er een toekomstige rol voor klinische be-
sliskunde gebaseerd op het genotype met statinetherapie toegespitst op de behoeften 
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